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Abstract  
 
Adequate iodine intake during pregnancy is essential to maintain optimal maternal 
thyroid function which is crucial for fetal neurodevelopment. Though, globally, iodine 
deficiency is considered to be the single, most important, preventable cause of brain 
damage, many pregnant women are still iodine-deficient.  
 
The research work presented in this thesis aimed to investigate several aspects of maternal 
iodine nutrition, including:  (i) the determinants of iodine status in pregnancy; ii) the effect 
of advancing gestation on urinary-iodine concentration which is the most commonly-used 
biomarker of population iodine-status; iii) the usefulness of serum thyroglobulin as a 
functional biomarker of longer-term iodine nutrition in pregnancy; iv) the effect of 
maternal iodine deficiency in pregnancy, as measured in multiple spot-urine samples, on 
child cognition; v) the effect of iodine supplementation of mildly-to-moderately iodine-
deficient pregnant women on thyroid function and child cognition. 
 
In the first study, data from three European birth-cohorts were used. Milk and dairy 
products were found to be an important, common, dietary determinant of iodine status in 
pregnancy; cohort-specific determinants were also identified. In the second study, three 
spot-urine iodine measurements from each trimester were used in longitudinal analysis 
which showed an increase in urinary-iodine concentration across pregnancy. The third 
study showed that thyroglobulin was negatively associated with urinary-iodine 
concentration in an iodine-sufficient and a mildly iodine-deficient pregnant population; 
this suggested that thyroglobulin could be used as a complementary indicator of 
population iodine status. In the fourth study, iodine deficiency at multiple gestational 
time-points was associated with lower non-verbal intelligence quotient in children at 8 
years. In the final study, evidence of the effects of iodine supplementation of mildly-to-
moderately iodine-deficient pregnant women on thyroid function and child cognition was 
reviewed systematically; the results highlighted the lack of good-quality evidence from 
randomised-controlled trials to support recommendations for iodine supplementation in 
pregnancy in these areas. Public-health strategies aimed at educating pregnant women 
and women of childbearing age on the importance of iodine and the ways that they can 
meet iodine requirements through diet are needed. An accurate assessment of iodine 
status in pregnancy would be valuable for public-health monitoring and future research.  
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Chapter 1                                    
Introduction 
 
1.1 Motivation for research project 
“On a worldwide basis, iodine deficiency is the single most important preventable 
cause of brain damage.” World Health Organisation (WHO) (WHO 2007a) 
 
Although micronutrients are needed only in small amounts in the body, their lack can 
have severe consequences for the health and development of populations worldwide 
(WHO 2019). According to the WHO, iodine, along with vitamin A and iron, is one of 
the most important micronutrients for global public health (WHO 2019). 
 
Iodine is an essential nutrient in the first 1000 days of life (Velasco et al. 2018). As a 
crucial component of the thyroid hormones, it is required for optimal fetal brain 
development (Williams 2008) and iodine deficiency is one of the main causes of impaired 
cognitive development in children (WHO 2007a). Although the brain undergoes a long 
period of development and specialisation and a degree of brain plasticity has been well-
documented (Stiles and Jernigan 2010), the developing brain is particularly vulnerable to 
intrauterine and early-life nutritional deficits, which can have long-term effects 
(Georgieff 2007). Brain development begins in the third week after conception and 
represents a chain of developmental processes that unfold over time (Stiles and Jernigan 
2010), therefore even minor changes in the early developmental events might have 
consequences for later development (Isaacs and Oates 2008). This highlights the 
importance of studying maternal diet during pregnancy (e.g., iodine nutrition), through 
its influence on early brain development, as an important predictor of offspring cognitive 
function later in life. 
 
Poor child cognitive development might have implications for both individuals and 
populations. Neurodevelopmental deficits in early childhood may result in poorer school 
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performance and limited career opportunities later in life (Piccolo et al. 2016). 
Furthermore, a slight decrease in population average intelligence quotient (IQ) has an 
effect on economic growth (e.g., an increase in population average IQ by one point was 
associated with an annual increase of 0.11% in gross domestic product per person) (Jones 
and Schneider 2006). 
 
Considering the importance of adequate iodine intake in pregnancy for optimal brain and 
neurological development of the offspring, the research work presented in this thesis 
aimed to investigate various aspects of maternal iodine nutrition during pregnancy and 
was motivated by the scientific knowledge gaps discussed in this introductory chapter.  
 
 
1.2 Scientific context and research gaps 
1.2.1 Iodine as a chemical element  
Iodine is a chemical element in the group of halogens (Periodic Group VII) (Martinez and 
Perez 2012). As a result of its high electronegativity, elemental iodine always forms 
diatomic structures, with two joined iodine atoms sharing electrons (i.e., shown as I2). 
Iodine is very reactive and for that reason it is never found in its pure form in nature, but 
rather as an iodide ion in a configuration with other elements forming iodates (Martinez 
and Perez 2012). 
 
1.2.2 Iodine in the environment  
Iodine is widely present in the environment, however its distribution is uneven 
(Zimmermann 2011). The majority of iodine is found in the oceans, as a result of large 
amounts having leached from surface soils by rain, snow or glaciations, which were then 
carried by rivers and floods to the oceans (Hess 2013). Surface soils are, therefore, 
depleted from iodine (e.g., median soil iodine concertation worldwide is 5 µg/g but it can 
vary from 1 to 150 µg/g) (Hess 2013). One of the main routes by which iodine from the 
oceans is transferred back to the land is by evaporation into the atmosphere in the form 
of volatile organic iodine, which is then deposited onto soils and surface water and 
incorporated into plants and animals (Preedy et al. 2009). Although some of the iodine is 
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transferred back to the land, this return is insufficient to compensate for the initial loss, 
resulting in a relatively low iodine content in soils and drinking water (Hess 2013). 
 
1.2.3 Physiology and functions of iodine in the body  
1.2.3.1 Iodine metabolism  
After ingestion, dietary iodine is reduced to iodide and more than 90% is rapidly absorbed 
in the stomach and small intestine (Zimmermann et al. 2008). Dietary iodide together 
with iodide resulting from peripheral thyroid-hormone breakdown (by deiodination) 
constitute the extrathyroidal pool of inorganic iodide (Glinoer 2004). This circulating 
iodide pool is in an equilibrium with the thyroid gland and the kidneys (Glinoer 2004).  
 
The body of a healthy adult contains approximately 15-20 mg of iodine, with the majority 
(70-80%) concentrated in the thyroid gland (Hess 2013). When iodine intake is sufficient, 
around 10 to 30% of the absorbed iodine (as iodide) is actively transported from the 
circulation to the follicular cells of the thyroid gland (i.e., the thyrocytes) against a 
concentration gradient (i.e., iodine trapping) via the transmembrane protein 
sodium/iodide symporter (NIS) (Braverman and Cooper 2012). In healthy non-pregnant 
adults with sufficient iodine intake, the thyroid traps around 80 µg iodine/day (55 µg from 
dietary origin and 25 µg from thyroid-hormone catabolism) for thyroid hormone 
production (Glinoer 2004). After the thyroid iodine requirements are met, more than 90% 
of the ingested iodine is excreted in the urine by the kidneys, with insignificant amounts 
lost in the faeces (around 15 µg) and sweat (Institute of Medicine US Panel on 
Micronutrients 2001). Most of the knowledge of iodine metabolism and the estimation of 
the average iodine requirements are derived from iodine turnover and thyroidal iodine 
uptake studies with radioactive isotopes of iodine (particularly 131I) (Institute of Medicine 
US Panel on Micronutrients 2001), with only a few small-scale iodine balance studies 
conducted in the 1960s (Harrison et al. 1965; Dworkin et al. 1966; Vought and London 
1967; Harrison 1968), one of which was in a small sample of five pregnant women 
(Dworkin et al. 1966).These balance studies have serious limitations (e.g., risks of iodine 
contamination and the use of crude techniques for iodine measurement).  
 
In normal conditions, iodine metabolism is in an equilibrium (i.e., iodine intake 
approximates the amount of iodine excreted) and the intrathyroidal iodine stores are 
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maintained (Glinoer 2004). If iodine intake becomes inadequate, the thyroid adapts 
mainly by upregulating its iodide trapping mechanism, however this is not sufficient to 
maintain thyroid hormone production and the thyroid starts using its iodine stores 
(Glinoer 2004); if adequate iodine intake is not restored, this would result in a progressive 
depletion of the thyroidal iodine stores and a negative iodine balance. 
1.2.3.2 Iodine metabolism in pregnancy  
Pregnancy may not represent a steady-state of iodine metabolism (intake vs excretion) 
(Glinoer 2004). A number of physiological changes that occur at different time-points 
during gestation can alter the pre-conception steady-state discussed in Section 1.2.3.1 
(Glinoer 2004); changes include increased renal iodide clearance, increased synthesis of 
thyroid hormones (e.g., the amount of iodine needed for thyroid-hormone production 
increases from 80 µg/day pre-pregnancy to 120 µg/day in pregnancy) and increased 
transfer of iodide and thyroid hormones from the mother to the fetus (Glinoer 2004; 
Delange 2007). These changes lead to an increased thyroidal activity during pregnancy, 
especially if iodine intake was inadequate pre-pregnancy and the iodine stores are already 
low (Glinoer 2004).  
1.2.3.3 Function in thyroid hormone synthesis  
In the thyroid, iodine is required for the synthesis of the thyroid hormones 
triiodothyronine (T3) and thyroxine (T4) (Zimmermann et al. 2008). Thyroid hormone 
synthesis has been described extensively in the literature (Braverman and Cooper 2012; 
Hess 2013). Briefly, after iodide is actively transported into the thyrocytes, it is oxidised 
by the enzyme thyroid peroxidase (TPO) in the presence of hydrogen peroxide (H2O2) 
and it simultaneously binds to specific tyrosyl residues within the thyroid-specific 
glycoprotein thyroglobulin (Tg) (i.e., organification). This process results in the 
production of the thyroid hormone precursors – monoiodotyrosine (MIT) and 
diiodotyrosine (DIT). The coupling of these precursors within Tg is catalysed by TPO 
and results in the formation of the thyroid hormones T3 (one MIT and one DIT) and T4 
(two DIT residues). The mature Tg molecule, stored extracellularly in the colloid of 
thyroid follicles, contains one third of its iodine in the form of thyroid hormones and the 
rest is stored as the inactive precursors MIT and DIT. To release the hormones into the 
circulation, the Tg molecule enters the follicular cells (i.e., the thyrocytes) by endocytosis, 
where Tg-proteolysis and release of thyroid hormones from the Tg molecule is initiated. 
Once the process is completed, T3 and T4 are released into the circulation, where they 
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mainly bind to plasma transport proteins (e.g., thyroid hormone-binding globulin, 
transthyretin and albumin). In the target tissues, T4 is converted to T3, which is the 
biologically active form. The inactive precursors are not released into the circulation and 
their iodine content is recycled by deiodinase enzymes within the thyroid gland. 
1.2.3.4 Regulation of thyroid function  
Thyroid homeostasis is maintained by the hypothalamic-pituitary-thyroid axis (HPT axis) 
using a negative feedback mechanism (Lingvay and Holt 2011). Thyroid hormone 
production is mainly driven by thyroid-stimulating hormone (TSH), which is a 
glycoprotein hormone secreted by the anterior pituitary (Zoeller et al. 2007). TSH 
increases the trapping of iodide in the thyroid, Tg breakdown and stimulates the synthesis 
and release of thyroid hormones in the blood (Hess 2013). In high concentrations, the 
thyroid hormones inhibit the secretion of TSH directly from the pituitary and also 
indirectly by inhibiting the release of thyrotropin-releasing hormone (TRH) from the 
hypothalamus (Lingvay and Holt 2011; Costa-e-Sousa and Hollenberg 2012). The thyroid 
gland also has autoregulatory mechanisms in response to iodide availability, which are 
used to maintain thyroid hormone stores and occur without a detectable change in TSH 
(Lingvay and Holt 2011); the efficiency of iodide transport into the thyroid is improved 
when iodide concentration in the circulation is low and vice versa when the concentration 
is too high (e.g., in iodine excess).  
1.2.3.5 Function of thyroid hormones 
Regulation of gene expression through binding of T3 to nuclear thyroid hormone receptors 
(THRs) is the main mechanism behind the biological effects of thyroid hormones 
(Lingvay and Holt 2011). The main isoforms of THRs include THRα1, THRβ1 and 
THRβ2; all THRs are widely distributed in cells, except THRβ2, which is specific to the 
brain (Lingvay and Holt 2011). Thyroid hormones are involved in brain and neurological 
development (e.g., neurogenesis, neuronal migration, dendritic branching, synapse 
formation and myelination) (Williams 2008). Additionally, they are important for the 
regulation of metabolism, skeletal development and linear growth (Hess 2013).  
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1.2.4 Dietary iodine sources and requirements 
1.2.4.1 Dietary sources of iodine  
Iodine cannot be generated endogenously and it must be supplied through the diet 
(Braverman and Cooper 2012). As most iodine is found in the oceans (in a concentration 
of about 50 µg/L) (Zimmermann et al. 2008), the richest natural food sources of iodine 
are fish (Haldimann et al. 2005) and seaweed (Yeh et al. 2014).  The iodine content of 
fish varies by fish type [e.g., white fish contains more iodine that oily fish (Dahl et al. 
2004)]. Seaweed iodine concentration is also highly variable and some species (e.g., 
kombu) are a very concentrated source of iodine (Yeh et al. 2014) and can provide 
excessive amounts (Bouga and Combet 2015). The native iodine content of most other 
foods and beverages is relatively low (Hess 2013). As discussed previously in Section 
1.2.2, the iodine concentration of soils is low and for that reason plant-based foods 
generally have low iodine content (Haldimann et al. 2005).  
 
Iodine concentration of foods, however, is also affected by various farming practices that 
can result in an increase in the native iodine content of foods (e.g., use of iodine-
containing compounds in irrigation, fertilisers and livestock feed, use of iodophores for 
cleaning milking equipment) (Zimmermann et al. 2008). For instance, milk has a low 
natural iodine content but as a consequence of various dairy-farming practices, including 
the use of iodine-supplemented cattle-feed and iodophor disinfectants for teat-cleaning 
and sterilising milking equipment, it has a relatively-high iodine content due to the carry-
over into the milk (Flachowsky et al. 2007; Franke et al. 2009). The most recent study on 
milk-iodine concentration in the United Kingdom (UK) reported an overall value of 427 
µg/L based on samples collected in summer and winter (Stevenson et al. 2018). Based on 
this value, a glass of milk (200 ml) would provide an average of 85 µg iodine, constituting 
around 57% and 34% of the WHO recommended iodine intake for adults (150 µg/day) 
and pregnant women (250 µg/day), respectively (WHO 2007a). 
 
Although fish is a good iodine source, it is not consumed very often in some populations, 
and therefore its contribution to population iodine status is relatively low (Haldimann et 
al. 2005). In many industrialised countries, including the UK, milk and dairy products are 
the main dietary iodine source, contributing to about 25-70% of total daily iodine intake 
(van der Reijden et al. 2017). The results from the latest National Diet and Nutrition 
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Survey (NDNS) indicate that milk and dairy products account for 34% of total iodine 
intake in UK adults aged 19-64 years and 51% of iodine intake in children aged 4-10 
years (Public Health England 2018). Milk and dairy products are also an important dietary 
iodine source in Italy (Mian et al. 2009), Norway (Dahl et al. 2004; Brantsæter et al. 
2013), Iceland (Gunnarsdottir et al. 2013), Denmark (Rasmussen et al. 2002; Rasmussen 
et al. 2014), Switzerland (Walther et al. 2018), Spain (Soriguer et al. 2011) and other 
countries. Although milk is an important source of iodine in the diets of many countries, 
milk-iodine concentration is highly variable, for example with variation according to 
season (i.e., winter milk has a higher iodine concentration than summer milk) 
(Flachowsky et al. 2014), making milk an inconsistent and unreliable source of dietary 
iodine. Additionally, certain population groups (e.g., younger adults, vegans, health-
conscious individuals or individuals with milk allergy or intolerance) are more likely to 
avoid and/or substitute cow’s milk with milk-alternative drinks (Chambers 2018), which, 
unless fortified, have lower iodine content (Bath, Hill, et al. 2017); therefore, this may 
have implications for their iodine status if the iodine intake from other dietary iodine 
sources is not increased. In recent years, there has been an increase in the consumption of 
plant-based milk alternatives; according to Mintel market research, 23% of UK adults 
used plant-based milks in 2019 compared to 19% in 2018 (Mintel 2019). Furthermore, 
the usage of plant-based milks was driven mainly by women (26% vs 19% of men) and 
younger age groups (32% in those aged under 35 vs less than 20% in those aged 45 or 
over) (Mintel 2019). 
 
The main food sources of iodine can vary between countries and even between population 
groups residing in the same country (Rasmussen et al. 2009). To provide information on 
how to achieve adequate iodine intake, it is important to understand the contribution of 
different food sources to population iodine status by investigating the sources of variation 
(e.g., variability in iodine concentration of foods and the differences in consumption 
patterns).  
1.2.4.2 Iodine requirements  
The WHO recommendation for iodine intake for pregnant and lactating women is 250 
µg/day, compared to 150 µg/day for non-pregnant adults (WHO 2007a). The iodine 
requirements for pregnant women are higher than those for the general population, as a 
result of a number of physiological changes that occur during pregnancy: (i) an increase 
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in the demand for thyroid hormones (by 40-50%) for the needs of the mother and the 
developing fetus; (ii) an increased glomerular filtration rate (GFR) that results in an 
increased renal iodide loss; and (iii) supply of iodine from the maternal circulation to the 
fetus in the later stages of pregnancy, after the development of the fetal thyroid (Glinoer 
2004; Delange 2007). Pregnancy-related physiological changes [e.g., high estrogen 
concentration, elevated human chorionic gonadotropin (hCG), modifications in the 
peripheral thyroid-hormone metabolism, increased renal blood flow and GFR]  have a 
stimulatory effect on the thyroid and require thyroidal adaptation from the pre-conception 
steady-state to a pregnancy steady-state, which is maintained until term (Glinoer 2004). 
If iodine intake is restricted during pregnancy, the thyroid may not be able to adapt, 
progressively leading to pathological alterations (e.g., goitrogenesis) (Glinoer 2004).  
 
The increased requirements in pregnancy may be more difficult to meet through diet. 
Furthermore, very low awareness of the importance of iodine during pregnancy and poor 
knowledge of how to achieve adequate iodine intake have been reported in a survey of 
pregnant women and mothers residing in the UK (Combet et al. 2015). Pregnant women 
are therefore an important population group at greater risk of iodine deficiency and they 
need to be provided with more information about how to meet these higher requirements. 
Poor knowledge of iodine nutrition was also reported in a study of women of childbearing 
age (O’Kane et al. 2016) and this is concerning, considering the important role the thyroid 
iodine stores can play in maintaining thyroid-hormone production if iodine intake 
becomes restricted in pregnancy (Glinoer 2004). 
 
1.2.5 Assessment of iodine status  
Currently, there is no validated biomarker suitable for the assessment of iodine status in 
individuals (Pearce and Caldwell 2016). Four methods to assess population iodine status 
are currently available, each with its advantages and disadvantages, including: i) thyroid 
size; ii) serum thyroid-stimulating hormone (TSH); iii) serum thyroglobulin (Tg); and (iv) 
urinary iodine concentration (UIC) (Zimmermann 2008). 
1.2.5.1 Thyroid size  
Thyroid size changes inversely in response to alterations in iodine intake (Rasmussen et 
al. 2002; Zimmermann et al. 2003). Insufficient iodine intake has a stimulatory effect on 
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the thyroid by upregulating its iodide trapping mechanism which over time (i.e., chronic 
iodine deficiency) results in thyroid enlargement (i.e., goitre formation) (Glinoer 2004). 
However, it may take months to years after correction of iodine deficiency for the thyroid 
to return to normal and for that reason, thyroid size is a historical biomarker of population 
iodine nutrition rather than a reflection of its present iodine status (Zimmermann and 
Andersson 2012). Most of this evidence comes from surveys in school-aged children 
before and after the introduction of salt iodisation programmes (Aghini-Lombardi et al. 
1997; Jooste et al. 2000; Zimmermann et al. 2003). For instance, a study in South Africa 
(an endemically goitrous area) showed that goitre rate remained unchanged one year after 
the introduction of mandatory iodisation of salt (25.6% at baseline vs 27.5% one year 
later), despite the increase in the median UIC (Jooste et al. 2000). Moreover, another 
study in Côte d’Ivoire showed that the mean thyroid size in children decreased by 56% 
four years after introduction of iodised salt but the goitre rate remained high, particularly 
in older children (Zimmermann et al. 2003). 
1.2.5.2 Thyroid-stimulating hormone (TSH) 
The secretion of TSH is subject to feedback inhibition by the levels of circulating thyroid 
hormones (Lingvay and Holt 2011). Although in iodine deficiency, serum T4 may be 
slightly low and serum TSH may be elevated (Pearce and Caldwell 2016), TSH usually 
remains within the normal range and it fails to distinguish between iodine-deficient and 
iodine-sufficient populations, making it a relatively insensitive indicator of iodine status 
in adults (WHO 2007a; Zimmermann 2008). TSH, however, is a sensitive biomarker of 
iodine deficiency in newborns (WHO 2007a). As the thyroid of a newborn has a lower 
iodine content than that of an adult, iodine turnover is higher and requires an increased 
TSH stimulation, which is exaggerated in iodine deficiency (Zimmermann 2008). TSH is 
therefore increased in the first few weeks of life in iodine-deficient infants (i.e., transient 
newborn hypothyroidism) and > 3% of newborn TSH values above 5 mIU/L measured in 
whole blood collected three to four days after birth suggests iodine deficiency in the 
population (WHO 2007a). The concentrations of both circulating T3 and T4 are not 
considered as sensitive indicators of iodine status (WHO 2007a; Pearce and Caldwell 
2016). 
1.2.5.3 Thyroglobulin (Tg) 
Tg is a thyroid-specific glycoprotein and is the synthesis site of the thyroid hormones (Ma 
and Skeaff 2014). Small amounts of Tg are normally released into the circulation when 
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iodine intake is sufficient (Zimmermann and Andersson 2012). In iodine-deficient areas, 
Tg is positively correlated with thyroid volume, suggesting that it is an indicator of 
thyroid stimulation (Knudsen et al. 2001). There is increasing evidence that Tg is a 
sensitive marker of iodine status, with studies in schoolchildren (Zimmermann et al. 
2013) and adults (Chong et al. 2015) showing that its concentration increases in iodine 
deficiency and iodine excess. Tg concentration is thought to reflect iodine intake in an 
intermediate period (e.g., in weeks to months) (Zimmermann and Andersson 2012). A 
randomised controlled trial (RCT) showed that Tg decreased in response to a 24-week 
iodine supplementation in adults (Ma et al. 2016). Data on the usefulness of maternal Tg 
concentration for the assessment of iodine status in pregnant populations are limited and 
the findings are inconsistent (Koukkou et al. 2016; Bath, Pop, et al. 2017).  
 
There is an established reference range for Tg measured in dried blood spots (DBS) of 4 
- 40 µg/L in an international cohort of iodine-sufficient school-aged children 
(Zimmermann et al. 2006); based on these and later data, a median Tg concentration < 13 
µg/L and/or < 3% of Tg values < 40 µg/L is proposed to indicate iodine sufficiency in a 
population of school-aged children (Zimmermann et al. 2013). Similar Tg reference 
ranges have been reported in adults (i.e., 3 - 40 µg/L) (Demers and Spencer 2002) and in 
pregnant women (i.e., 0.3 - 43.5 µg/L) (Stinca et al. 2017) but Tg cut-offs to define iodine 
status have not yet been well established in these population groups (Ma and Skeaff 2014; 
Pearce and Caldwell 2016). A recent study proposed a median Tg cut-off ~10 µg/L to be 
used to define iodine sufficiency in a population of pregnant women (Stinca et al. 2017) 
but this needs to be investigated in further studies.  
1.2.5.4 Urinary iodine concentration (UIC) 
UIC (µg/L) is the most commonly-used indicator of iodine status in populations (Pearce 
and Caldwell 2016). In healthy individuals with adequate iodine intake, UIC is considered 
a useful indicator of individual recent iodine intake (i.e., in the last 24-48 hours) since the 
majority of the dietary iodine absorbed is excreted in the urine (> 90%) (Zimmermann 
and Andersson 2012). The amount of iodine excreted in the urine can be measured in a 
casual spot-urine sample (i.e., as spot-UIC in µg/L) or in urine samples collected over a 
24-hour period [i.e., as  24-hour urinary iodine excretion (24-h UIE) in µg/day] (Vejbjerg 
et al. 2009). Although 24-h UIE is considered a better proxy for individual daily iodine 
intake, it is impractical to use in large epidemiological studies and might be subject to 
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selection bias (Vejbjerg et al. 2009; Zimmermann and Andersson 2012). UIC measured 
in spot-urine samples is therefore usually used as the most feasible option and it is the 
method recommended by the WHO (WHO 2007a). To assess population iodine status, 
the WHO recommends that the median UIC from spot-urine samples is compared to 
median-UIC cut-offs that define population iodine status; for a population or group, a 
median UIC <100 µg/L indicates insufficient iodine intake in children and non-pregnant 
adults, while a median UIC <150 µg/L defines iodine deficiency in pregnant populations 
(WHO 2007a). 
1.2.5.5 Population vs individual iodine status  
As a result of day-to-day differences in hydration status (i.e.., urine volume) and iodine 
intake, UIC from spot-urine samples can be misleading when used to estimate iodine 
nutritional status for an individual (Andersen et al. 2008; Vejbjerg et al. 2009; König et 
al. 2011) but is a reliable biomarker of iodine intake for the population as a whole (Pearce 
and Caldwell 2016). Adjustment of UIC by urinary creatinine concentration [i.e., by using 
the urinary iodine-to-creatinine ratio (UI/Creat, µg/g)] can correct for individual 
hydration-status differences and many investigators have shown that, when adjusted, it 
reflects the 24-h UIE and serum iodine concentration better than UIC alone (Rasmussen 
et al. 1999; Knudsen et al. 2000; Andersen et al. 2008; König et al. 2011; Li et al. 2016). 
Although using the ratio of UI/Creat controls for dilution, it might introduce potential 
bias in statistical analyses, since urinary creatinine concentration is also associated with 
age, body mass index (BMI) and ethnicity (Barr et al. 2005) and it can also vary during 
gestation (Baba et al. 2017). Alternative methods of creatinine adjustment have been 
proposed in the literature to help overcome these limitations (Barr et al. 2005; O’Brien et 
al. 2016). For example, using unadjusted UIC (µg/L) as the exposure or outcome variable 
and including creatinine concentration as a separate independent covariate in statistical 
models is a method suggested previously that corrects UIC for dilution by creatinine 
concentration but also ensures that the associations of UIC with other variables are 
independent of creatinine (Barr et al. 2005). Another method used in a few previous 
studies is creating a UIC-corrected-for-creatinine variable that is not correlated with 
creatinine by regressing log-transformed (log) UIC on (log) creatinine and adding the 
residuals of this model to the mean (log) UIC and then transforming this variable back to 
the original scale (Abel, Korevaar, et al. 2018; Murcia et al. 2018). 
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Even though the validity of spot-UIC as a marker of daily iodine intake can be improved, 
one measurement of urinary iodine from a casual spot-urine sample or a 24-hour urine 
collection cannot provide information about individual habitual iodine intake (i.e., over a 
longer period); it has been reported that to estimate individual iodine status with a 20% 
precision, at least 14 repeated spot-UIC samples or ten measured/estimated 24-h UIE are 
required from an individual (König et al. 2011). The collection of many repeat samples 
from each individual is impractical and costly in large population studies and has directed 
attention to other biomarkers that are potentially indicative of longer-term iodine 
nutrition, such as Tg (see Section 1.2.5.3). Validated biomarkers suitable for the 
assessment of iodine status in individuals are still lacking (Pearce and Caldwell 2016). 
1.2.5.6 Assessment of iodine status using UIC in the context of pregnancy 
As discussed previously (Section 1.2.5.4), in healthy non-pregnant iodine-sufficient 
individuals, the iodide metabolism is in an equilibrium (Glinoer 2004) and UIC is a good 
reflection of recent dietary iodine intake (i.e., the last 24-48 hours) (Zimmermann and 
Andersson 2012). Pregnancy, however, may not represent a steady-state of iodine 
metabolism (intake vs excretion) (Glinoer 2004), as discussed in Section 1.2.3.2, and the 
amount of iodine excreted in the urine may not be a good representation of recent dietary 
iodine intake. A number of physiological changes that occur at different gestational time-
points (outlined in Sections 1.2.3.2 and 1.2.4.2) can alter the preconception steady-state 
(Glinoer 2004). For that reason, pregnancy is a special case and these changes can further 
complicate the assessment of iodine status in this population group. 
 
The gestational changes in urinary iodine concentration (measured as UIC or UI/Creat) 
are not clear, as studies have shown mixed results, including an increase, a decrease or 
no change in UIC and/or UI/Creat with advancing pregnancy (Fuse et al. 2013; Bath et 
al. 2015). The current WHO median-UIC thresholds for iodine adequacy in pregnant 
populations refer to the entire duration of gestation (WHO 2007a) and it is unclear 
whether gestation-specific UIC cut-offs are necessary, considering the pregnancy-related 
physiological changes in iodine metabolism. Taking into account these metabolic changes 
and the fact that a single spot-urine iodine measurement provides limited information 
about individual iodine status, as discussed in Section 1.2.5.5, the usefulness of multiple 
urinary iodine measurements to gain a better proxy for iodine status during pregnancy is 
not well researched. For instance, most studies that have investigated the effects of 
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maternal iodine status on child cognition have used a single spot-urine iodine 
measurement as a proxy for iodine status in pregnancy and the benefit of using repeat 
measurements to explore this association has not been investigated. Other biomarkers 
indicative of longer-term iodine nutrition, such as Tg, have also not been widely explored 
in pregnant populations (Section 1.2.5.3).  
 
1.2.6 Effects of iodine deficiency 
1.2.6.1 Iodine-deficiency disorders  
Insufficient iodine intake impairs thyroid-hormone production which can have clinical 
and subclinical health consequences, collectively known as iodine-deficiency disorders 
(IDD) (Martinez and Perez 2012). IDD include hypothyroidism, thyroid enlargement 
(i.e., goitre), mental and growth retardation, cretinism, infant mortality, stillbirths, 
spontaneous abortions and other adverse effects on growth and development 
(Zimmermann et al. 2008; Zimmermann and Boelaert 2015). Globally, iodine deficiency 
is considered the single most important preventable cause of brain damage and mental 
retardation (WHO 2007a). 
1.2.6.2 Epidemiology of iodine deficiency 
Although in the past 15 years a tremendous progress has been made in achieving iodine 
sufficiency in the general population (e.g., the number of countries with insufficient 
iodine intake was 54 in 2003 vs 21 in 2018) (Iodine Global Network 2018), pregnant 
women in many countries still have inadequate iodine intakes (Zimmermann et al. 2015; 
Iodine Global Network 2017). Globally, of the 72 countries with available data on iodine 
status of pregnant women, there are 39 countries (~54%) with inadequate iodine intake 
in the pregnant population (Gizak et al. 2018). In Europe, pregnant women in two thirds 
of the countries with available data on iodine nutrition in pregnancy have inadequate 
iodine status (Zimmermann et al. 2015). 
 
According to the 2019 Global Scorecard for Iodine Nutrition, the UK is classified as 
iodine-sufficient, based on a median UIC of 138 µg/L from data in school-aged children 
and adolescents relating to the years 2013-14 (Iodine Global Network 2019a). However, 
sub-national UIC data from several studies in UK pregnant women indicate that this 
population group is mildly-to-moderately iodine-deficient (Barnett et al. 2002; Pearce et 
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al. 2010; Bath, Steer, et al. 2013; Bath et al. 2014; Bath et al. 2015). A UK survey also 
showed that the median dietary iodine intake estimated from a food-frequency 
questionnaire (FFQ) in pregnancy was below the WHO recommendation (190 µg/day vs 
250 µg/day) (Combet et al. 2015). Furthermore, the most recent NDNS data indicated 
that the median UIC in UK women aged 16-49 years was 102 µg/L and 17% had UIC < 
50 µg/L (Public Health England 2018). Although this value indicates iodine sufficiency 
in the general population (i.e., defined by the WHO as a median UIC 100-199 µg/L), it is 
below the WHO threshold that defines iodine adequacy in pregnancy (i.e., a median UIC 
150-249 µg/L) (WHO 2007a). These statistics are worrying and the current situation in 
the UK and in other countries is of public-health concern as iodine deficiency, if present 
during pregnancy, can have adverse consequences on child neurodevelopment (Bath 
2019; Prentice et al. 2019). 
1.2.6.3 Iodine deficiency in pregnancy  
Although the spectrum of IDD outlined in Section 1.2.6.1 is wide, the most serious 
consequences occur in pregnancy, affecting the developing fetus (Zimmermann et al. 
2008). Severe maternal iodine deficiency can have negative implications on child 
neurodevelopment and result in cretinism which is the most severe manifestation, 
characterised by severely stunted physical growth and mental retardation (Chen and 
Hetzel 2010). Five intervention trials conducted in severely iodine-deficient areas in Papa 
New Guinea, Zaire, Xinjiang province (western China), Peru and Ecuador have 
contributed to the evidence linking severe maternal iodine deficiency to cretinism and 
impaired offspring neurodevelopment (Zimmermann 2009). Severe iodine deficiency 
during pregnancy is also associated with reduced birth weight, increased rate of 
spontaneous abortions and increased infant mortality (Zimmermann 2011). 
 
Nowadays, severe iodine deficiency is relatively rare, largely as a result of salt iodisation 
programmes (Iodine Global Network 2018; Iodine Global Network 2019a), but there is a 
shift towards mild-to-moderate forms of iodine deficiency, particularly in pregnant 
women (Iodine Global Network 2017). There is emerging evidence suggesting that even 
mild-to-moderate iodine deficiency in pregnancy is associated with suboptimal child 
neurodevelopmental outcomes, including executive function (van Mil et al. 2012), IQ 
(Bath, Steer, et al. 2013; Levie et al. 2019), reading ability (Bath, Steer, et al. 2013), 
school performance (Hynes et al. 2013; Hynes et al. 2017), cognitive scores (Murcia et 
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al. 2018) and language skills (Markhus et al. 2018); though not all studies have found 
significant associations (Murcia et al. 2011; Rebagliato et al. 2013; Ghassabian et al. 
2014) and there is a lack of evidence from RCTs in these areas (Zhou et al. 2013; Taylor 
et al. 2014). 
 
The role of iodine in brain development is likely mediated by the action of the thyroid 
hormones which are required for processes involved in brain and neurological 
development (e.g., neurogenesis, neuronal migration, axonal growth, dendritic branching, 
synapse formation and myelination) (Williams 2008). Animal studies have shown an 
association between low thyroid hormone concentration in the mother and lower brain 
weight, white matter, neuronal size and number in the offspring (Redman et al. 2016). In 
humans, brain development begins in the third week post-conception (Stiles and Jernigan 
2010) and thyroid-hormone receptors have been detected in the fetal brain as early as nine 
weeks (Ferreiro et al. 1988), with their concentrations increasing ten-fold by 16 weeks 
(Bernal and Pekonen 1984). However, the fetal thyroid is not functional until around the 
end of the first trimester (Burrow et al. 1994) and this means that the mother is the primary 
source of thyroid hormones for the developing fetus in early pregnancy. This suggests 
that thyroid hormones are important from the very early stages of fetal neurodevelopment 
and optimal maternal iodine intake is required from conception.  Considering the changes 
in iodine metabolism during pregnancy (outlined in Section 1.2.3.2) and the potential 
progressive depletion of the thyroidal iodine stores if iodine intake is restricted in 
pregnancy, adequate iodine intake is important from pre-conception to ensure optimal 
iodine stores in women of childbearing age. 
 
As early pregnancy seems to be the most critical time for adequate iodine supply (de 
Escobar et al. 2004; Zoeller and Rovet 2004), the majority of studies that have 
investigated the association of maternal iodine status with child cognition have focused 
on relatively early maternal exposure to iodine deficiency. However, even after the fetal 
thyroid is fully developed and functional, it still relies on maternal iodine supply to be 
able to synthesise its own hormones (Burrow et al. 1994); this means that optimal iodine 
supply is important throughout pregnancy. As highlighted in Section 1.2.5.6, there is a 
lack of studies that have explored the association of maternal iodine status determined 
from measurements collected at multiple gestational time-points with child cognition.  
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1.2.7 Iodine excess  
The European Food Safety Authority (EFSA) and United States (US) Institute of 
Medicine have set tolerable upper iodine intake levels for adults, including pregnant 
women, at 600 µg/day and 1100 µg/day, respectively (Institute of Medicine US Panel on 
Micronutrients 2001; European Food Safety Authority Scientific Committee on Food 
Scientific Panel on Diabetic Products Nutrition and Allergies 2006). In populations, 
excess iodine intake may be as a consequence of the consumption of over-iodised salt, 
drinking water, certain seaweed species (as discussed in Section 1.2.4.1) or iodine-
containing supplements (Farebrother et al. 2019).  High iodine intakes are well tolerated 
by most healthy euthryoid individuals because the thyroid has several adaptation 
mechanisms to maintain normal thyroid function; these include a reduction of iodide 
transport into the thyroid cells by the NIS and the Wolff-Chaikoff effect (Bürgi 2010). 
The latter is a short-term mechanism that switches on before NIS reacts in response to a 
very high intracellular iodide concentration (i.e., ≥10 -3 molar); this mechanism stops 
thyroid hormone synthesis by blocking the organification of iodide (Bürgi 2010). 
Although most healthy individuals are tolerant to high iodine intakes, disruption of 
thyroid function may occur in susceptible individuals (e.g., those exposed to chronic 
iodine deficiency or patients with autoimmune thyroid disease) (Leung and Braverman 
2014; Farebrother et al. 2019). Goitre, hypothyroidism, hyperthyroidism and/or thyroid 
autoimmunity have been linked to excessive iodine intake (Katagiri et al. 2017; 
Farebrother et al. 2019). 
 
1.2.8 Strategies to combat and prevent iodine deficiency  
1.2.8.1 Salt fortification with iodine  
It has been well recognised that a highly effective strategy to eliminate iodine deficiency 
in populations is through universal salt iodisation; this involves iodisation of salt for both 
human and livestock consumption (WHO 2007a). Worldwide, many countries have 
implemented salt iodisation programmes and 88% of households are currently consuming 
iodised salt; this figure, however, does not include countries for which household survey 
data were not available (UNICEF 2019). This has largely contributed to the decrease in 
the number of iodine-deficient countries in the last two decades (Iodine Global Network 
2016; Iodine Global Network 2018). Salt is considered an appropriate food vehicle for 
iodine fortification as it is widely consumed and consumption is relatively stable during 
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the year, it is inexpensive and consumer acceptability is high as taste/smell are not 
affected (WHO, 2014).  
 
As high sodium intake has been associated with an increased risk of non-communicable 
diseases (e.g., hypertension, heart disease and stroke) (Alam and Johnson 1999; He and 
MacGregor 2002; Morrison and Ness 2011; O’Donnell et al. 2014), there are strategies 
to reduce salt intake in populations; the WHO recommends that adults consume less than 
5 g salt/day (equivalent to 2 g sodium/day) (WHO, 2012). Currently, the WHO, the 
United Nations Children's Fund (UNICEF) and Iodine Global Network recommend that 
the iodine concentration of salt at the point of production should be between 20-40 mg 
iodine/kg salt which should ensure an iodine intake of 150 µg/day (i.e., the WHO 
recommendation for non-pregnant adults), provided that the average salt intake is 10 
g/day (WHO 2007a). Salt-reduction recommendations may therefore affect population 
iodine intake in countries with good coverage of iodised salt and this means that other 
good iodine food sources, such as milk and dairy products may become increasingly 
important as an iodine source (van der Reijden et al. 2017). Furthermore, as in developed 
countries most of the salt (more than 75%) is consumed from processed foods (Brown et 
al. 2009), commitment from the food industry is key for the effective implementation of 
salt iodisation and this is another challenge (Zimmermann 2010; WHO 2014). This 
highlights the importance of iodine-fortified processed foods. For example, in the 
Netherlands, all baked goods are fortified with iodised salt and bread and other bakery 
products are one of the majour contributors to the sufficient iodine intake in this 
population (Verkaik-Kloosterman et al. 2012; Verkaik-Kloosterman et al. 2017).  
1.2.8.2 Iodine supplementation 
Pregnant women have higher iodine requirements than the general population (WHO 
2007a), resulting from the physiological changes that occur in pregnancy (Glinoer 2004; 
Delange 2007). These requirements can be more difficult to meet through diet and 
therefore iodine supplementation may need to be considered. However, the role of iodine 
supplementation in pregnancy is not clear, particularly in areas of mild-to-moderate 
iodine deficiency (Zhou et al. 2013; Taylor et al. 2014). Despite the fact that neither the 
benefits nor the safety of iodine supplementation in mildly-to-moderately iodine-deficient 
women are well researched, health authorities in a number of countries are increasingly 
introducing recommendations for iodine supplementation in pregnancy. For instance, the 
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National Health and Medical Research Council in Australia and New Zealand (The 
National Health and Medical Research Council 2010) and both the European and 
American Thyroid Associations (Lazarus et al. 2014; Alexander et al. 2017) recommend 
supplements containing 150 µg iodine/day for pregnant women or women who are 
planning a pregnancy. By contrast, the WHO and UNICEF jointly recommend 250 µg 
iodine/day for pregnant women only in special cases, depending on the current iodine 
status of the population and the local iodised-salt coverage (WHO and UNICEF 2007). 
The UK has no official recommendations for iodine supplementation (Bath 2019). The 
evidence of iodine supplementation in pregnancy in areas of mild-to-moderate iodine 
deficiency is discussed extensively in Chapter 7. 
 
Although ideally, sufficient iodine intake should be achieved through dietary intake, 
iodine-containing supplements may be considered in individuals who avoid iodine-rich 
foods (e.g., fish, eggs, milk and dairy products), such as vegetarians and vegans (Bath 
2019). Additionally, individuals who are more likely to avoid and/or substitute cow’s 
milk for lower-iodine milk-alternatives (Bath et al., 2017) [e.g., young women of 
childbearing age or individuals with milk-allergy or intolerance (Chambers 2018)] 
without increasing their intake of other good sources of iodine may also be at risk of 
iodine deficiency and may need to consider supplementation (Bath 2019). 
 
1.2.9 Overview of research gaps 
Pregnant women are a known population group at risk of iodine deficiency mainly 
because of the increased iodine requirements in pregnancy. Data on the determinants of 
iodine status in pregnancy are lacking and knowledge of such factors would help to 
identify women likely to have low iodine status and support the design of appropriate 
dietary recommendations. It is known that iodine supplements can be helpful in certain 
circumstances (e.g., vegans) but their role in pregnancy is not clear (e.g., the benefits and 
risks), particularly against a background of mild-to-moderate iodine deficiency.  
 
UIC measured in a single spot-urine sample is a well-established biomarker of iodine 
status in populations and hence the most widely used indicator in public-health 
monitoring and research. It is known that this measure has a limited value for the 
assessment of iodine status in individuals and a validated biomarker for an individual is 
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still lacking. The effect of pregnancy on UIC is also unclear (e.g., the fluctuations with 
gestational age) and the requirement for gestation-specific UIC cut-offs in pregnant 
populations has not been well researched. Multiple spot-UIC measurements have been 
shown to better reflect individual iodine status, however, there is limited evidence as to 
the usefulness of repeated urinary-iodine measurements to provide a better proxy of 
iodine status in pregnancy nor the relationship between this marker and child 
neurodevelopment. The disadvantages of UIC and the need to collect multiple urine 
samples have directed attention to other biomarkers, such as Tg, which has shown 
promising results as a biomarker of iodine status in groups of children and adults but its 
usefulness has not been widely explored in pregnancy.  
 
 
1.3 Thesis outline  
The thesis is organised in a total of eight chapters, including five research chapters that 
were motivated by the research gaps discussed in Section 1.2. To outline the scope of the 
thesis and the research problems covered, this section provides a brief overview of the 
content of each chapter (Chapters 2-8), excluding this introductory chapter (Chapter 1). 
The aims and hypotheses of each study are provided separately in the corresponding 
research chapter (Chapters 3-7). 
 
 Chapter 2 provides information about the data sources used throughout the thesis and 
details about common methods relevant to most chapters, including statistical 
procedures (e.g., multiple imputation), laboratory measurements and dietary 
assessment methods. Information about ethical approval and funding sources is also 
provided as part of this chapter.  
 
 In Chapter 3, the determinants of iodine status in pregnancy were studied, using data 
from three population-based European pregnancy cohorts of differing iodine status. 
Both dietary intake during pregnancy and sociodemographic factors were investigated 
as potential predictors of iodine status. As iodine concentration of foods is highly 
variable and the consumption patterns of iodine-rich foods differ between populations 
(Section 1.2.4.1), the variation in the main dietary contributors to population iodine 
status between the three study settings was explored. The possible explanations of the 
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identified similarities and differences in the main determinants of iodine status in the 
three European populations were discussed. 
 
 In Chapter 4, the gestational changes in urinary iodine concentration (expressed as 
UIC and UI/Creat) were investigated in longitudinal analyses using repeat spot-urine 
iodine measurements from three time-points in pregnancy. In contrast with Chapter 
3, this study used data only from one of the pregnancy cohorts because of the 
availability of three urinary iodine measurements. Median UIC measured in spot-
urine samples is the most common method for the assessment of iodine status in 
populations and the method recommended by the WHO (Section 1.2.5.4). However, 
various physiological changes that occur in pregnancy can complicate the assessment 
of iodine status in this group using this method (e.g., increased renal iodide clearance) 
(Section 1.2.5.6). Furthermore, a single spot-urine iodine measurement provides 
limited information about individual iodine status (Section 1.2.5.5). This study 
therefore investigated whether a single spot-urine iodine measurement is 
representative of iodine availability during the entire pregnancy and whether the 
gestational time-point at urine sampling is an important factor to consider when 
evaluating the iodine status of pregnant populations. 
 
 Considering the disadvantages of using one measurement of urinary iodine from a 
casual spot-urine sample (or a 24-hour urine collection) to provide information about 
individual habitual iodine intake (i.e., iodine status) and the additional problems with 
this measure in pregnancy (discussed in Chapter 4), the usefulness of another 
biomarker, potentially indicative of longer-term iodine nutrition, was investigated in 
Chapter 5. In this study, maternal serum Tg concentration was explored as a functional 
biomarker of iodine status in pregnancy in settings of population iodine sufficiency 
and mild-to-moderate iodine deficiency. Tg has not been widely explored in pregnant 
populations, particularly in different settings of baseline iodine status. Firstly, the 
determinants (dietary and sociodemographic) of Tg were investigated. Secondly, the 
association between maternal urinary iodine (measured as spot-UI/Creat at two 
gestational time-points) and serum Tg was explored cross-sectionally. And thirdly, 
the association between pregnancy iodine status (classified by the two spot-UI/Creat 
measurements) and Tg was studied. 
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 In Chapter 6, the association between maternal pregnancy iodine status (based on 
multiple spot-urine iodine measurements from different gestational time-points) and 
child cognition (assessed as IQ at 8 years) was studied. As discussed previously, a 
single spot-urine iodine measurement provides limited information about iodine 
status in individuals and multiple measurements are needed to get a better estimate of 
individual iodine nutritional status. Most studies that have investigated the association 
of maternal iodine status with child cognition have used a single urinary iodine 
measurement as a proxy for iodine status in pregnancy. Moreover, as early pregnancy 
seems to be a critical period for adequate iodine supply, the majority of studies have 
focused on relatively early pregnancy as an important exposure period. In this study, 
the usefulness of multiple iodine measurements from different time-points in 
pregnancy was explored as a way to provide a better proxy of iodine status during 
pregnancy when assessing the association of maternal iodine status with child 
cognition. 
 
 Although neither the benefits nor the safety of iodine supplementation in pregnancy 
in areas of mild-to-moderate deficiency are well researched, such supplementation is 
increasingly being recommended by health authorities. Chapter 7 includes a 
systematic review of the most up-to-date published data on the effects of iodine 
supplementation in mildly-to-moderately iodine-deficient pregnant women on 
maternal and infant thyroid function and child cognition. This study aimed to 
determine whether the evidence is sufficient to support such recommendation in 
pregnancy in areas of mild-to-moderate iodine deficiency. Based on the critical 
review of existing studies, several suggestions for future studies in this area were also 
provided.  
 
 Chapter 8 is an overall discussion of the research findings presented in the thesis. It 
includes the key findings and their implications, the overall strengths and limitations 
of the thesis, conclusions, as well as several suggestions for future work. 
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Chapter 2                                          
Methods 
 
2.1 Data sources used throughout the thesis 
All data and biological samples that were used throughout this thesis (Chapters 3–6) were 
from three prospective population-based birth cohorts, including the Avon Longitudinal 
Study of Parents and Children (ALSPAC) in the United Kingdom (UK), Generation R in 
the Netherlands and INfancia y Medio Ambiente (INMA) in Spain. These pregnancy 
cohorts were chosen for a collaborative work package that was part of the EUthyroid 
research project (see Section 2.2) and that aimed to investigate maternal iodine status in 
pregnancy and the consequences on cognitive development of the children. The three 
cohorts were specifically selected because of their high data quality and the availability 
of biosamples, as well as because they were representative of settings with differing 
baseline iodine status. Depending on the data that were available from each cohort and 
considering the aims of each study included in this thesis, the research work presented in 
Chapters 3–6 was based on data from all three, two or only one of these cohorts. Summary 
details about each cohort are provided in this section (Table 2.1). 
2.1.1 ALSPAC 
The ALSPAC methodology has been described in detail elsewhere (Boyd et al. 2013; 
Fraser et al. 2013). Briefly, pregnant women who lived in the former Avon area in the 
South-West of England and had an expected delivery date between 1st April 1991 and 31st 
December 1992 were eligible for enrolment. In total, 14,541 pregnant women were 
recruited (71.8% of the total eligible population) and followed up during pregnancy. 
These pregnancies resulted in 13,988 children who survived until they were a year old. 
Many aspects of maternal and child exposures have been assessed over the years using 
questionnaires, health and education records, genetic and biological samples and focused 
clinical assessments.  
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2.1.2 Generation R 
The Generation R study design and cohort profile have been extensively described 
previously (Kooijman et al. 2016). Pregnant women living in Rotterdam, the Netherlands 
who had an expected delivery between April 2002 and January 2006 were eligible for 
inclusion in the study. In total, 9,778 mothers were enrolled (61% response rate based on 
the number of children at birth), of whom 8,879 were recruited when they were pregnant. 
The enrolled women gave live birth to 9,749 children. Extensive assessments were 
performed in the mothers and their children. It should be noted that this cohort was multi-
ethnic, with the largest ethnic groups including the Dutch, Surinamese, Turkish and 
Moroccan groups (Jaddoe et al. 2006). 
 
2.1.3 INMA 
Details about the INMA cohort can be found elsewhere (Guxens et al. 2012). Briefly, the 
INMA project consists of a network of birth-cohorts from seven study areas in Spain, 
including Ribera d’Ebre, Menorca, Granada, Asturias, Valencia, Sabadell and Gipuzkoa. 
Based on the three older cohorts, each with a different aim (i.e., Ribera d’Ebre, Menorca 
and Granada), a common protocol was developed and used for the four new INMA 
cohorts (i.e., Asturias, Valencia, Sabadell and Gipuzkoa). Based on the available data of 
interest, only data from three of the four new cohorts were used as part of this thesis (i.e., 
Valencia, Sabadell and Gipuzkoa). Only women who had a singleton pregnancy and those 
who did not follow an assisted reproduction programme were eligible for recruitment; the 
other inclusion criteria can be found elsewhere (Guxens et al. 2012). In total, 2,150 
pregnant women were recruited at their first pre-natal visit, including 855 from Valencia 
(54% participation rate), 657 from Sabadell (60% participation rate) and 638 from 
Gipuzkoa (68% participation rate). Each cohort had a different period of recruitment: 
Valencia (November 2003 - June 2005), Sabadell (July 2004 - July 2006) and Gipuzkoa 
(April 2006 - January 2008). Assessments of the mothers and their children were carried 
out using questionnaires, interviews, clinical data, biological samples and other data-
collection methods. 
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Table 2. 1  Summary details for each cohort 
 
ALSPAC  Generation R  INMA 
Setting 
Avon, 
United Kingdom 
 
Rotterdam, 
the Netherlands 
 
Valencia, Sabadell 
and Gipuzkoa, 
Spain 
Recruitment years 1991-1992  2002-2006  2003-2008 
Total sample recruited 
during pregnancy 
14,541  8,879  2,150 
Urine sampling for 
iodine measurements 
(time-point) 
spot-urine samples 
collected at random 
times during the 
day; 3 samples 
(at various points in 
pregnancy) 
 
spot-urine samples 
collected at random 
times during the 
day; 2 samples  
(~13 & ~20 weeks) 
 
fasting and non-
fasting spot-urine 
samples; 2 samples 
(~13 and ~34 weeks) 
Urinary iodine 
measurement method 
dynamic reaction 
cell inductively-
coupled plasma 
mass spectrometer 
 
Sandell-Kolthoff 
method 
 
paired-ion reversed-
phase, high-
performance liquid 
chromatography 
with electrochemical 
detection at a silver 
working electrode 
Urinary creatinine 
measurement method 
Jaffe rate method  Jaffe rate method  Jaffe rate method 
Thyroglobulin 
measurements  
(time-point) 
N/A  
1 measurement in 
serum (~13 weeks) 
 
1 measurement in 
serum (~13 weeks) 
Serum thyroglobulin 
measurement method 
N/A  immunoassay  immunoassay 
Dietary assessment 
method (time-point) 
self-administered, 
unquantified 
FFQ (32 weeks) 
 
self-administered, 
semi-quantitative 
FFQ (~13 weeks) 
 
administered by 
trained interviewers, 
semi-quantitative 
FFQ (~13 weeks) 
Abbreviations: FFQ, food-frequency questionnaire; N/A, not available/applicable;  
 
 
2.2 EUthyroid project and other funding 
EUthyroid is a research project that was funded by the European Union’s Horizon 2020 
research and innovation programme (grant agreement No: 634453) and it aimed to 
investigate the iodine intake of the European population (http://euthyroid.eu/). Part of the 
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research included in this thesis was funded by EUthyroid and the data sources used in 
Chapters 3–6 (i.e., the pregnancy cohorts mentioned in Section 2.1) were selected as a 
part of one of the EUthyroid work packages. Although this was a collaborative research 
project, the statistical approach for all the studies included in this thesis that used the 
mentioned data sources (Chapters 3–6) was driven by the author and the author also had 
the primary responsibility for all statistical analyses and the write-up. 
 
This PhD project was also funded by the Waterloo Foundation, the Institute of Food Brain 
and Behaviour and the University of Surrey.  
 
 
2.3 Ethics 
All studies included in this thesis that used individual-participant data (Chapters 3–6) 
were based on secondary analyses of the data that had already been collected as part of 
the pregnancy cohorts; ethical approval was therefore not required for these studies. 
Ethical approval for all cohorts had been obtained prior to recruitment from a number of 
bodies: the ALSPAC Ethics and Law Committee and the Local Research Ethics 
Committees (ALSPAC), the Medical Ethical Committee of the Erasmus Medical Centre 
(Generation R), the Ethical Committee of the Municipal Institute of Medical Investigation 
and the ethical committees of the hospitals involved in the studies (INMA). All 
participating women had provided informed consent. 
 
 
2.4 Laboratory procedures  
All urine and blood measurements used in this thesis (Chapters 3–6) were performed 
externally and the full details about the laboratory procedures from the respective 
laboratories are provided in this section. 
2.4.1 Urinary iodine and creatinine measurements  
Data on urinary iodine and creatinine concentrations were used in Chapters 3–6. In all 
cohorts, urinary iodine and creatinine concentrations were measured in casual spot-urine 
samples collected at various time-points during pregnancy. The urinary iodine and 
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creatinine measurements used included pre-existing measures from each cohort [from 
urine samples that were measured for previous studies (Murcia et al. 2010; Bath, Steer, 
et al. 2013; Ghassabian et al. 2014)] and additional measurements performed for studies 
part of EUthyroid (Section 2.2). For ALSPAC and Generation R, the additional 
measurements were performed for women who had urine samples available for iodine 
measurement, provided that the child had data on intelligence quotient (IQ). In INMA, 
measurements were performed for all women who had additional urine samples, 
regardless of child-IQ data availability. Details about the laboratory measurements in 
each cohort follow and a summary is also provided in Chapter 3. 
 
• ALSPAC 
Full detail about the pre-existing measurements of urinary iodine and creatinine is 
provided elsewhere (Bath, Steer, et al. 2013). The additional urine samples were 
measured in the same laboratory following the same procedure. Briefly, iodine (127I) was 
measured at the Trace Element Unit, Southampton General Hospital (Southampton, UK) 
on a dynamic reaction cell inductively-coupled plasma mass spectrometer (NexION 300D 
Perkin-Elmer, Beaconsfield, UK). The accuracy of the results was verified using the 
certified reference material (CRM) Seronorm urine Levels 1 and 2 (Nycomed, Norway) 
and accuracy was also monitored by measurement of EQUIP samples at regular intervals 
throughout the analysis. Within-run precision gave a relative standard deviation (RSD) 
of 0.8% at 42 µg/L, 2.5% at 84 µg/L, 0.6% at 149 µg/L and 2.0% at 297 µg/L. Between-
run precision was 8.7% RSD at 42 µg/L, 6.5% at 84 µg/L, 7.2% at 149 µg/L and 6.8% at 
297 µg/L. Limit of detection was 1 µg/L. Urinary creatinine was determined by the Jaffe 
rate method using the UniCel DxC Synchron Clinical System Analyser (Beckman 
Coulter, High Wycombe, UK).  
 
• Generation R 
Information about the pre-existing measurements in Generation R has been provided 
previously (Ghassabian et al. 2014). Similarly, the additional measurements of urinary 
iodine were performed at Radboud University Medical Centre (Nijmegen, the 
Netherlands) by the Sandell-Kolthoff method. Iodine calibration was performed using the 
CRM Seronorm urine Levels 1 and 2 (Nycomed, Norway) and four EQUIP samples 
certified for urinary iodine concentration (Centers for Disease Control and Prevention, 
USA). At a level of 216 µg/L the within-assay precision was 5.1% RSD and the between-
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assay precision was 14.3% RSD (n= 30). Limit of detection was 14 µg/L. Urinary 
creatinine was determined by the Jaffe rate method.  
 
• INMA 
The laboratory procedures have been described in detail previously (Espada et al. 2000). 
Briefly, urinary iodine concentration was measured at the Public Health Laboratory 
Standards, Basque Government Department of Health (Basque Country, Spain) 
(Accreditation LE/1108 with ISO 15189 for Clinical Laboratories, National 
Accreditation Entity), using a paired-ion reversed-phase, high-performance liquid 
chromatography with electrochemical detection at a silver working electrode (Waters 
Chromatography, Milford, MA). The accuracy of the results was verified using the CRM 
Seronorm urine Levels 1 and 2 (Nycomed, Norway) and internal quality control samples. 
Within-run precision was 4.5% RSD at 50 μg/L, 3.2% at 100 μg/L and 2.0% at 300 μg/L. 
Between-run precision was 7.9% RSD at 50 μg/L, 3.5% at 100 μg/L and 2.5 % at 300 
μg/L. Limit of detection was 5 μg/L. Urinary creatinine was determined by the Jaffe rate 
method using the Roche Diagnostic Systems Analyser (Basel, Switzerland). 
2.4.2 Creatinine adjustment  
Throughout the thesis, urinary iodine was expressed as both urinary iodine concentration 
(UIC, µg/L) and urinary iodine-to-creatinine ratio (UI/Creat, µg/g). The main analyses in 
each study, however, were based on the UI/Creat. As discussed in Chapter 1 (Section 
1.2.5.5), UIC from a spot-urine sample can be misleading and unreliable, as a result of 
individual hydration-status differences (Rasmussen et al. 1999; Andersen et al. 2008; 
Vejbjerg et al. 2009; König et al. 2011). Adjustment of UIC by urinary creatinine 
concentration reduces its variability due to hydration and many investigators have shown 
that the UI/Creat reflects the 24-hour urinary iodine excretion and serum iodine 
concentration better than UIC alone (Rasmussen et al. 1999; Andersen et al. 2008; König 
et al. 2011; Li et al. 2016); this is  especially the case when it is used in homogenous 
population groups (e.g., the cohorts used in this thesis were all women of childbearing 
age) (Knudsen et al. 2000). UI/Creat has also been used previously in other studies that 
used data from ALSPAC, Generation R and INMA (Bath, Steer, et al. 2013; Ghassabian 
et al. 2014; Murcia et al. 2018).  
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2.4.3 Serum thyroglobulin measurement  
Data on serum thyroglobulin (Tg) concentration were used in Chapter 5. Tg concentration 
was measured in blood samples only in two of the three cohorts (Generation R and 
INMA), therefore the study in Chapter 5 was based on these two cohorts only. In both 
cohorts, the measurements were performed in the same laboratory using the same method; 
full details about the method are provided in Chapter 5. 
 
 
2.5 Dietary assessment methods 
Dietary data were used in Chapters 3–5. In all cohorts, maternal diet had been measured 
with an unquantified or a semi-quantitative food-frequency questionnaire (FFQ or SFFQ). 
Summary details about the (S)FFQs used in each cohort are provided in Chapter 3. The 
processing of the dietary data (e.g., data recoding and harmonisation) are provided in this 
section.  
 
• ALSPAC 
Full details about the assessment of maternal diet using FFQ in ALSPAC are provided 
elsewhere (Emmett et al. 1992; Rogers et al. 1998) and a summary is included in Chapter 
3. As the dietary data were from an unquantified FFQ, food intake in ALSPAC was 
calculated (g/day) by multiplying the frequency of consumption by an average standard 
portion of that food. Foods were then classified into food groups and the amounts of 
individual food items consumed were summed accordingly. To aid comparability 
between cohorts, the creation of food groups in ALSPAC was informed by the food-group 
classification that had already been used in Generation R (Slimani et al. 2002). The 
definitions of the 17 food groups in the three cohorts are shown in Chapter 3 
(Supplemental Table 3.1, Appendix I). Information about the consumption of iodised 
salt was not collected in ALSPAC, however, the influence of iodised salt on iodine status 
of ALSPAC women is likely insignificant, as iodised salt was never common in the UK 
(Phillips 1997) and even nowadays its availability is limited and the iodine concentration 
is low (Bath, Button, et al. 2013). Although intake of drinking water was not assessed in 
ALSPAC, iodine concentration of UK tap water is negligible (<3 µg/L), and thus it was 
unlikely to explain much of the variation in iodine status (Vanderpump et al. 2011).  
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• Generation R 
Summary of the SFFQ that was used in Generation R is provided in Chapter 3. The food 
groups in Generation R had already been formed based on the European Prospective 
Investigation into Cancer and Nutrition (EPIC) SOFT classification (EPIC-SOFT) 
(Slimani et al. 2002; Steenweg-de Graaff et al. 2014). These pre-existing food groups 
were slightly modified to make them comparable with the food groups used in INMA and 
the EPIC-SOFT classification was used as an overall guide. Specific information about 
iodised-salt intake was not collected in this cohort and overall salt intake was included as 
part of the condiments and seasoning food group. Although these data were not available, 
in the Netherlands, most of the iodised salt is consumed as part of bread and other bakery 
products that are fortified with iodised salt, rather than as table salt (Verkaik-Kloosterman 
et al. 2017). Water intake was recorded in Generation R and was included as part of non-
alcoholic beverages food group. 
 
• INMA 
Details about the INMA SFFQ are summarised in Chapter 3. As in Generation R, the food 
groups in INMA had already been formed and several food groups were modified (e.g., 
food groups were merged together or split into two separate food groups) according to 
the EPIC-SOFT classification to harmonise with the food groups used in Generation R. 
Separate information about the consumption of table salt and use of iodine-fortified table 
salt was collected only in this cohort. As in Generation R, water intake in INMA was 
assessed and included as part of the non-alcoholic beverages food group. 
 
 
2.6 Statistical methods  
The statistical methods performed for each study are described separately in the 
respective chapters. For the studies presented in Chapters 3–6, missing data on subject 
characteristics were imputed using the method described in Section 2.6.1.  
2.6.1 Imputation of missing values 
When statistical analyses are based only on the complete cases (i.e., the individuals with 
no missing data) this can result in a substantially smaller sample size and subsequently 
lead to a loss of precision and power, as well as biased results (depending on the reasons 
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for missing data) (Sterne et al. 2009). To overcome these issues, missing values on 
various subject characteristics (e.g., maternal socio-demographics, anthropometrics and 
pregnancy characteristics) that were used in analyses preformed in Chapters 3–6 were 
imputed using multiple imputation procedures. Multiple imputation creates multiple 
plausible imputed data sets, where the missing values are replaced with imputed values 
that are sampled from a predictive distribution based on the observed data. The results 
(from the statistical analyses of interest) from each data set are then combined to give 
overall estimations (Sterne et al. 2009).  
 
Multiple imputation for each study (Chapters 3–6) was performed using the automatic 
method in IBM SPSS Statistics version 25.0 (IBM Corp., Armonk, NY, USA). Multiple 
imputation models were specified for each study using the exposure variables, outcome 
variables and the relevant potential confounders of interest. A total of 20 imputed datasets 
were generated and the analyses were based on the multiply-imputed data set which 
generated the overall estimated results using standard multiple imputation procedures 
(Sterne et al. 2009). Missing dietary data from the FFQs were not imputed because diet 
has wide between-person variability and for that reason, imputation of these data would 
not be sufficiently accurate. 
2.6.2 Multiple imputation details for each study  
Multiple imputation details for each chapter (Chapters 3–6) are provided in this section, 
including the variables that were imputed, the number of missing (imputed) values in total 
and for each variable, and the total number of cases with imputed data. In cases where the 
study was based on more than one cohort, the missing data information is provided 
separately for each cohort.  
2.6.2.1 Chapter 3 
• ALSPAC 
For the women in the analysis (n=2,852), there were 2.6% missing values in total 
(n=1,263) and 19.3% of the cases (n=550) had at least one missing value. Data were 
imputed for 12 out of the 15 variables used in the analysis, including pre-pregnancy body 
mass index (BMI) (n=250), ethnicity (n=96), parity (n=134), smoking status (n=51, 
smoking status variable was made from two imputed smoking variables with n=102 
missing values in total), alcohol consumption (n=101, alcohol consumption variable was 
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made from two imputed variables with n=159 missing values in total), education level 
(n=86), home ownership (n=72), crowding index (n=94), family adversity index (n=30), 
life event score (n=96), marital status (n=47) and living with a partner (n=97). Data were 
not imputed for gestational week at urine sampling, maternal age and child’s sex due to 
no missing values. 
 
• Generation R 
For the women in the analysis (n=2,254), there were 5.5% missing values in total 
(n=1,369) and 31.7% of the cases (n=715) had at least one missing value. Data were 
imputed for nine out of 11 variables, including gestational week at urine sampling (n=1), 
pre-pregnancy BMI (n=12), ethnicity (n=71), smoking status (n=248), alcohol 
consumption (n=254), education level (n=149), net household income (n=479), marital 
status (n=154) and child’s sex (n=1). Data were not imputed for maternal age and parity 
due to no missing values. 
 
• INMA 
For the women in the analysis (n=1,460), there were 1.1% missing values in total (n=154) 
and 5.8% of the cases (n=84) had at least one missing value. Data were imputed for nine 
out of ten variables, including gestational week at urine sampling (n=4), maternal age 
(n=4), ethnicity (n=3), parity (n=2), smoking status (n=44), alcohol consumption (n=56), 
education level (n=5), living with a partner (n=1) and child’s sex (n=35). Data were not 
imputed for pre-pregnancy BMI due to no missing values. 
2.6.2.2 Chapter 4  
For all ALSPAC women in the analysis (n=3,122), there were 2.8% missing values in 
total (n=1,298) and 18.6% of the cases (n=581) had at least one missing value. Data were 
imputed for 12 out of the 15 variables used in the analysis, including pre-pregnancy BMI 
(n=277), ethnicity (n=105), parity (n=143), smoking status (n=55, smoking status 
variable was made from two imputed smoking variables with n=110 missing values in 
total), alcohol consumption (n=106), education level (n=93), home ownership (n=84), 
crowding index (n=111), family adversity index (n=34), life event score (n=103), marital 
status (n=55) and living with a partner (n=77). Data were not imputed for gestational 
week at urine sampling (for all three urinary iodine measurements), maternal age and 
child’s sex due to no missing values. 
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2.6.2.3 Chapter 5  
• Generation R 
For the women in the analysis (n=3,548), there were 7.6% missing values in total 
(n=3,231) and 38.6% of the cases (n=1,370) had at least one missing value. Data were 
imputed for nine out of 12 variables, including maternal age (n=32), pre-pregnancy BMI 
(n=692), ethnicity (n=182), parity (n=32), smoking status (n=432), alcohol consumption 
(n=471), education level (n=296), net household income (n=777) and marital status 
(n=317). Data were not imputed for gestational week at blood sampling, gestational week 
at urine sampling (for both urinary iodine measurements) and child’s sex due to no 
missing values.  
 
• INMA 
For the women in the analysis (n=1,168), there were 2.0% missing values in total (n=261) 
and 10.4% of the cases (n=121) had at least one missing value. Data were imputed for all 
11 variables, including gestational week at urine sampling [total n=17, including 
gestational week at the first urine sampling (n=1) and gestational week at the second urine 
sampling (n=16)], gestational week at blood sampling (n=2), maternal age (n=2), pre-
pregnancy BMI (n=1), ethnicity (n=5), parity (n=4), smoking status (n=77), alcohol 
consumption (n=85), education level (n=6), living with a partner (n=2) and child’s sex 
(n=60). 
 
2.6.2.4 Chapter 6 
For all ALSPAC women in the analysis (n=452), there were 2.2% missing values in total 
(n=191) and 15.9% of the cases (n=72) had at least one missing value. Data were imputed 
for 14 out of the 19 variables, including pre-pregnancy BMI (n=31), ethnicity (n=13), 
parity (n=20), smoking status (n=6, smoking status variable was made from two imputed 
smoking variables with n=12 missing values in total), alcohol consumption (n=14), 
maternal education level (n=14), paternal education level (n=19), home ownership (n=9), 
crowding index (n=10), family adversity index (n=5), life event score (n=15), marital 
status (n=9), living with a partner (n=12) and breastfeeding (n=8). Data were not imputed 
for gestational week at urine sampling (for all three urinary iodine measurements), 
maternal age, child’s sex, birth weight and preterm birth due to no missing values. 
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Chapter 3                                      
Similarities and differences of dietary and other 
determinants of iodine status in pregnant women 
from three European birth cohorts 
 
3.1 Introduction  
Iodine is an essential component of the thyroid hormones which are important for optimal 
fetal and early postnatal neurodevelopment (de Escobar et al. 2004; Glinoer 2007). Mild-
to-moderate maternal iodine deficiency in early pregnancy has been associated with 
suboptimal offspring cognitive outcomes (van Mil et al. 2012; Bath, Steer, et al. 2013; 
Hynes et al. 2013; Hynes et al. 2017; Markhus et al. 2018; Murcia et al. 2018; Levie et 
al. 2019). The early stages of pregnancy mark the beginning of crucial fetal brain 
development processes such as neuron proliferation, migration and differentiation 
(Williams 2008). Though these early processes are thyroid hormone-dependent, the fetal 
thyroid gland is not fully functional until 18-20 weeks (Richard et al. 2012), highlighting 
the importance of thyroid hormone supply from the mother. In this critical early period, 
the mother therefore needs sufficient iodine intake to maintain optimal thyroid function 
(de Escobar et al. 2004). As a result of the increased demand for thyroid hormones and 
other physiological changes associated with pregnancy, pregnant women have a higher 
iodine requirement than the general population, putting them at greater risk of deficiency 
(Glinoer 2004; Delange 2007). 
 
As more than 90% of the dietary iodine absorbed is excreted by the kidneys, urinary 
iodine concentration (UIC) is considered to be a good estimate of recent iodine intake at 
the population level (Zimmermann 2008). In pregnant populations, iodine sufficiency is 
defined by a median UIC in the range of 150-249 µg/L, corresponding to the iodine intake 
of 250 µg/day recommended by the World Health Organisation (WHO) (WHO 2007a). 
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Determining the main food sources of iodine in pregnancy is essential so that pregnant 
women can be given information on how to achieve adequate iodine nutrition. Although 
good food sources of iodine, such as milk, eggs, fish and, in some countries, iodised salt, 
are well-known, the consumption patterns of these foods vary between and within 
populations, as does their iodine content (i.e., as a result of seasonal variation, agricultural 
practices, and differences in iodine content of soil and water) (Haldimann et al. 2005; 
Rasmussen et al. 2009). Consequently, some variation in the importance of different 
iodine food sources to population iodine status is expected between countries, hence 
universal dietary recommendations to increase iodine intake are unlikely to be 
appropriate.  
 
Considering the negative consequences of iodine deficiency in pregnancy and the fact 
that many pregnant women worldwide are still iodine-deficient (Iodine Global Network 
2017), achieving adequate iodine status in the pregnant population is of public-health 
importance. Data are, however, lacking on the determinants of iodine status in pregnancy 
in both deficient and sufficient areas; knowledge of such factors would help to identify 
women likely to have low iodine status. 
  
This study aimed to explore the determinants of iodine status during early pregnancy in 
three European populations of differing iodine status, using data from three population-
based pregnancy cohorts from the United Kingdom (UK), the Netherlands and Spain. The 
objectives of the study were: (i) to establish whether iodine status during early pregnancy 
is associated with maternal socio-demographic, anthropometric, lifestyle factors and 
pregnancy characteristics; (ii) to determine how maternal iodine status is influenced by 
dietary intake during pregnancy; (iii) to identify similarities and differences in the main 
determinants of iodine status between deficient and sufficient pregnant populations. 
 
3.1.1 Hypotheses 
It was hypothesised that milk and dairy products will be positively associated with iodine 
status in at least one of the pregnancy cohorts. Cereals and cereal products (e.g., bread) 
will be positively associated with iodine status in the cohort from the Netherlands. 
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3.2 Methods 
3.2.1 Study population 
Data from three prospective population-based birth cohorts were used: (i) the Avon 
Longitudinal Study of Parents and Children (ALSPAC) in the UK (Boyd et al. 2013; 
Fraser et al. 2013), (ii) Generation R in the Netherlands (Kooijman et al. 2016) and (iii) 
INfancia y Medio Ambiente (INMA) in Spain (Guxens et al. 2012). In ALSPAC, 14,541 
pregnant women living in the former Avon area in the South-West of England with an 
expected delivery date between 1st April 1991 and 31st December 1992 were recruited. In 
Generation R, 9,778 mothers residing in Rotterdam with an expected delivery date from 
April 2002 to January 2006 were enrolled (8,879 of these women were recruited during 
pregnancy). In total, 2,150 pregnant women were recruited as part of the INMA Project 
from three regions in Spain (Valencia, Sabadell and Gipuzkoa), in the period of 
November 2003 to January 2008. The current study was based on secondary analyses of 
the collected data. Ethical approval for all three cohorts had been obtained prior to 
recruitment (full details provided in Chapter 2).  
3.2.2 Selection criteria for the current study 
Women were selected for the current study if they had at least one pre-existing measure 
of urinary iodine and creatinine concentration in pregnancy from previous studies in each 
of the three cohorts (Murcia et al. 2010; Bath, Steer, et al. 2013; Ghassabian et al. 2014) 
or if they had additional urine samples available for iodine measurement, provided that 
the child had a measure of intelligence quotient (IQ) for ALSPAC and Generation R. In 
INMA, iodine was measured in all women with additional urine samples available, 
irrespective of child-IQ data.  
 
Women with a multiple pregnancy, in-vitro fertilisation (IVF), known thyroid disease 
and/or use of thyroid-related medication were excluded (Figure 3.1). The analyses were 
restricted to measures from early pregnancy, as this period is considered as the most 
critical for iodine-dependent brain development (de Escobar et al. 2004; Zoeller and 
Rovet 2004), hence for this study, only samples collected  ≤ 18 weeks’ gestation were 
included.  
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1 Urine samples with UIC > 500 µg/L or UI/Creat > 700 µg/g were excluded only from the ALSPAC cohort, 
as there was a concern about potential contamination of these samples by the use of iodine-containing test-
strips (see ‘Methods’ Section 3.2.4). There was no such concern in Generation R and INMA, therefore the 
exclusion criteria were not applicable to urine samples from these two cohorts. Abbreviations: FFQ, food-
frequency questionnaire; IVF, in-vitro fertilisation; N/A, not applicable; UI/Creat, urinary iodine-to-
creatinine ratio; UIC, urinary iodine concentration 
Enrolled during 
pregnancy 
Total N=25,570 
ALSPAC (n=14,541) 
Generation R (n=8,879) 
INMA (n=2,150) 
Data unavailable:  
Urinary iodine and creatinine concentrations not 
measured Total N=17,761 
ALSPAC (n=11,036)  
Generation R (n=6,467)  
INMA (n=258) 
UI/Creat measured 
Total N=7,809 
ALSPAC (n=3,505) 
Generation R (n=2,412) 
INMA (n=1,892) 
UI/Creat ≤ 18 weeks 
Total N=6,566 
ALSPAC (n=2,852) 
Generation R (n=2,254) 
INMA (n=1,460) 
UI/Creat ≤ 18 weeks  
+ FFQ data 
Total N=5,736 
ALSPAC (n=2,710) 
Generation R (n=1,580) 
INMA (n=1,446) 
Exclusions:  
IVF Total N=12 
(ALSPAC, n=0; Generation R, n=12; INMA, n=0) 
Multiple pregnancy Total N=29 
 (ALSPAC, n=0; Generation R, n=29; INMA, n=0) 
 Thyroid disease and/or thyroid-related medication use 
Total N=140 
(ALSPAC, n=21; Generation R, n=34; INMA, n=85)  
Potentially contaminated samples 1 Total N=362 
(ALSPAC: UIC > 500 µg/L or UI/Creat > 700 µg/g, 
n=363; Generation R, N/A; INMA, N/A) 
UI/Creat available 
Total N=7,269 
ALSPAC (n=3,122) 
Generation R (n=2,340) 
INMA (n=1,807) 
Figure 3. 1  Flow chart of the study population selection 
Exclusions:  
UI/Creat measured > 18 weeks Total N=703 
ALSPAC (n=270)  
Generation R (n=86)  
INMA (n=347) 
Data unavailable:  
FFQ data not available Total N=830 
ALSPAC (n=142)  
Generation R (n=674)  
INMA (n=14) 
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3.2.3 Iodine measurements  
Urinary iodine concentration (UIC, µg/L) was measured in spot-urine samples collected 
at a median (25-75th percentile) gestational age of 11.0 (8.0-15.0) weeks in ALSPAC, 
13.1 (12.1-14.6) weeks in Generation R and 13.0 (12.4-13.9) weeks in INMA. Gestational 
week was established using ultrasound examination (Generation R and INMA) or the date 
of the last menstrual period (ALSPAC). To adjust for variation in intra- and inter-
individual daily hydration status (Rasmussen et al. 1999; Andersen et al. 2008; Vejbjerg 
et al. 2009; König et al. 2011), iodine concentration was corrected by dividing by urinary 
creatinine concentration to give the iodine-to-creatinine ratio (UI/Creat, µg/g). Correcting 
UIC by use of urinary creatinine concentration reduces intra-individual variation (König 
et al. 2011), especially in cohorts of the same sex and age-range [i.e., the cohorts were all 
women of childbearing age (15-44 years)]. The iodine-to-creatinine ratio has previously 
been used in other studies using data from these three cohorts (Bath, Steer, et al. 2013; 
Ghassabian et al. 2014; Murcia et al. 2018).  
 
In each cohort, both the median (25-75th percentile) UIC (µg/L) and UI/Creat (µg/g) were 
reported. The percentage with UI/Creat <150 µg/g was also reported; this cut-off was 
informed by the WHO threshold for iodine adequacy in pregnancy (a median UIC ≥150 
µg/L) (WHO 2007a) and when corrected for creatinine concentration, has been used in 
previous research (Bath, Steer, et al. 2013; Hynes et al. 2017; Murcia et al. 2018).  
3.2.4 Laboratory analyses of urinary iodine and creatinine concentrations 
Details about the laboratory measurements of urinary iodine and creatinine concentrations 
in each cohort were provided in Chapter 2; a brief description follows. 
 
In ALSPAC, UIC was measured on a dynamic reaction cell inductively-coupled plasma 
mass spectrometer at Trace Element Unit, Southampton General Hospital (Southampton, 
UK). In Generation R, UIC was measured by the Sandell-Kolthoff method in Radboud 
University Medical Centre (Nijmegen, the Netherlands). In INMA, UIC was measured 
using a paired-ion reversed-phase, high-performance liquid chromatography with 
electrochemical detection at a silver working electrode at the Public Health Laboratory 
Standards, Basque Government Department of Health (Basque Country, Spain). The 
laboratories were registered with EQUIP and the accuracy of the results was verified 
using certified reference material (CRM) Seronorm urine Levels 1 and 2 (Nycomed, 
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Norway). Details about the within-run and between-run precision have been provided 
elsewhere (Chapter 2). Urinary creatinine concentration was determined by the Jaffe rate 
method in all cohorts.  
 
In ALSPAC, there was concern that some urine samples had been potentially 
contaminated by the use of iodine-containing test-strips (Pearce et al. 2009), and therefore 
samples with UIC >500 µg/L and/or UI/Creat >700 µg/g were excluded (n=412, 11.8%). 
These cut-offs were based on previous information from ALSPAC and from other studies 
of UK pregnant women (Pearce et al. 2010; Bath, Steer, et al. 2013; Bath, Pop, et al. 
2017). Some ALSPAC women had multiple urine samples and in cases where one sample 
was potentially contaminated, the result from the next available uncontaminated sample 
was used (n=50). Although some of the excluded values might be truly high, the majority 
of those are most likely falsely elevated. Considering the fact that very few women in the 
whole ALSPAC cohort and in the sample included in this study used iodine-containing 
supplements, it is not expected that many of the women will have true UIC exceeding 
500 µg/L or UI/Creat >700 µg/g. For example, assuming that 90% of iodine from food is 
excreted in the urine, and an expected daily creatinine excretion of 1.23 g [age- and sex-
specific value for women 25-49 years (Knudsen et al. 2000)], UI/Creat of 700 μg/g would 
be equivalent to an iodine intake of approximately 950 μg [i.e., three portions of cod 
(~690 µg) and eight 200-ml glasses of milk (~240 µg) based on the iodine concentration 
of UK milk in the 1990s (150 µg/kg)] (Lee et al. 1994; Bath and Rayman 2016).  
3.2.5 Dietary assessment  
Maternal diet in all cohorts was assessed using a food-frequency questionnaire (FFQ) 
(Chapter 2, Table 2.1). This was administered in late pregnancy in ALSPAC (at 32 
weeks) and in early pregnancy in Generation R and INMA (at the same time as urine 
sampling). The FFQ was unquantified in ALSPAC, but was semi-quantitative (SFFQ) in 
Generation R and INMA. The FFQ was self-administered in ALSPAC and Generation R, 
but was administered by trained interviewers in INMA. 
 
In ALSPAC, women were asked to indicate how frequently “nowadays” they consumed 
43 food groups and individual foods with five predefined frequency categories, ranging 
from “never or rarely” to “more than once a day”. Portion sizes were not included in the 
questionnaire. The FFQ was not validated but it showed similar mean energy and nutrient 
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intakes to those estimated from a 7-day weighted food record in the Dietary and 
Nutritional Survey of British Adults in 1986-87 (Rogers et al. 1998). More details about 
the design of the FFQ can be found elsewhere (Emmett et al. 1992; Rogers et al. 1998).  
 
In Generation R, SFFQ represented an adapted version of a validated SFFQ in elderly 
subjects (Klipstein-Grobusch et al. 1998) and it was also validated with three 24-hour 
recalls in a sample of Dutch pregnant women in Rotterdam (van den Broek et al. 2015). 
In summary, it contained a list of 293 foods and asked about frequency of consumption 
in the past three months, mostly therefore reflecting the first trimester. Questions about 
portion size, estimated using food photographs or Dutch household measures, methods of 
preparation and additions to foods were also included (Timmermans et al. 2011; van Mil 
et al. 2012). The food list had previously been reduced to 17 main food groups (Steenweg-
de Graaff et al. 2014), based on the European Prospective Investigation into Cancer and 
Nutrition SOFT classification (EPIC-SOFT) (Slimani et al. 2002).  
 
In INMA, SFFQ was based on an expanded adaptation of a 61-item SFFQ (Willett et al. 
1985) that was developed and validated against four 1-week food records (Vioque et al. 
2007; Vioque et al. 2013). Women were asked how often, on average, they had consumed 
a specified standard portion of 100 food items in early pregnancy (since their last 
menstrual period until the time of the interview at ~12 weeks), using nine frequency 
categories, ranging from “never or less than once a month” to “six or more times per day”.  
 
For the current study, in each cohort, food intake (g/day) was calculated by multiplying 
the frequency of consumption by an average standard portion (for the ALSPAC FFQ) or 
a specified portion (for the SFFQ in Generation R and INMA) of that food. Foods were 
then classified into food groups and the amounts of individual food items consumed were 
summed accordingly. To facilitate comparison between cohorts, the classification of food 
groups used in Generation R (Slimani et al. 2002) was used as a template. This required 
the formation of new food groups in ALSPAC, while the pre-existing food groups were 
used in Generation R and INMA, with some minor modifications to make them 
comparable. The definitions of food groups in the individual cohorts are shown in 
Supplemental Table 3.1 (Appendix I). Separate information about the consumption of 
table salt and use of iodine-fortified table salt was collected only in the INMA cohort. 
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More information about the processing of the dietary data from the three cohorts has been 
provided in Chapter 2. 
3.2.6 Iodine-supplement use 
Detailed data on the use of potassium iodide and/or iodine-containing 
multivitamin/mineral supplements during pregnancy were collected only in INMA. For 
this analysis, data on iodine supplements from pre-pregnancy until the end of the first 
trimester, expressed as mean iodine intake from supplements, were used. In the ALSPAC 
sample, only two women took a kelp supplement and one took a potassium-iodide 
supplement; they were excluded from the analysis. Data on the use of iodine-containing 
multivitamin supplements from pre-conception until enrolment (at time of urine sample 
collection) were available only for a sub-set of our Generation R sample (n=381); women 
who took an iodine-containing supplement (n=345) were excluded in sensitivity analyses.  
3.2.7 Maternal and pregnancy characteristics  
Information on pregnancy characteristics, anthropometrics, socio-demographic and 
environmental exposures was collected by means of questionnaires or extracted from 
obstetric medical records. Discrete variables were re-categorised, where possible, to 
facilitate comparisons between cohorts. Exposure factors in these analyses can be 
classified into three groups: (i) maternal factors: maternal age (ALSPAC: at last menstrual 
period; Generation R, INMA: at urine collection); pre-pregnancy body mass index (BMI, 
kg/m2); ethnicity (ALSPAC: White/non-white; Generation R: Dutch/non-Dutch, where 
non-Dutch = Indonesian, Cape Verdian, Moroccan, Dutch Antilles, Surinamese, Turkish, 
other non-Western, Asian, other Western; INMA: Spanish/non-Spanish, where non-
Spanish = Latin American, European or others); parity (zero, one, two or more); smoking 
status (never smoked, smoked initially or until pregnancy was known, continued 
smoking); and alcohol consumption during pregnancy (yes/no); (ii) markers of socio-
economic status: education level (ALSPAC: low = no qualification, certificate of 
secondary education, or vocational; medium = O level or A level; high = a degree; 
Generation R: low = no education or primary; medium = secondary phase 1 and 2; high 
= higher phase 1 and 2; INMA: low = no education, unfinished primary, or primary; 
medium = secondary; high = university degree); monthly net household income 
(Generation R: low <€1200, medium = €1200-2200, high >€2200); home ownership 
(ALSPAC: owned/mortgaged, private/other rented, council rented); crowding index 
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(ALSPAC: ≤1 person per room, +1 person per room); family adversity index [ALSPAC: 
18-item measure of hardships during pregnancy (Bowen et al. 2005), categorised into: no 
adversities, mild (0-2), severe (≥3) (Winsper et al. 2012)]; life event score (ALSPAC: 
exposure to stressful situations during pregnancy); marital status (ALSPAC: never 
married, married, other; Generation R: unmarried or married); and living with father’s 
child/partner (ALSPAC, INMA: yes/no); (iii) child factors: child’s sex (male/female).  
3.2.8 Statistical analyses 
To study the associations of maternal characteristics and diet with iodine status, UI/Creat 
was used as a measure of individual iodine status. UI/Creat was not normally distributed 
but right-skewed. To meet parametric-test assumptions, UI/Creat was transformed using 
the natural logarithm. Outliers were assessed by visual inspection of box-plots. Non-
linearity of the associations of each continuous independent variable with UI/Creat was 
assessed by adding their squared term to the regression models, and also by plotting each 
potential determinant variable against UI/Creat and comparing the fit (R2) of a linear vs 
quadratic function through the data points.  
 
Multiple linear regression models with log-transformed UI/Creat as the dependent 
variable were performed for each cohort using two models: Model 1 included maternal 
and pregnancy factors, markers of socio-economic status and child’s sex as independent 
variables; Model 2 included variables from Model 1 plus dietary intake of food groups.  
 
Analyses of the dietary influences on UI/Creat (Model 2) were also adjusted for estimated 
energy intake (kcal/day). Effect estimates (unstandardised B coefficients) for food groups 
were expressed per 100 g and also per portion (g) (Food Standards Agency 2002). The 
increase in the geometric mean of UI/Creat per 100 g and per portion increase in intake 
and its 95% confidence interval (CI) were calculated by back-transformation 
[exponentiation (EXP)] of the effect estimates and 95% CIs from logarithmic scale. The 
following formulae were used for the back-transformations: Effect estimate per 100 g = 
EXP (intercept + B*100) – EXP (intercept); Lower 95% CI = EXP [intercept + (B*100) 
– (1.96*standard error of estimate (SEE)*100)] – EXP (intercept); Upper 95% CI = EXP 
[intercept + (B*100) + (1.96*SEE*100)] – EXP (intercept). For calculations per portion 
size, the multiplication by 100 in the formulae is replaced with the portion size (g) for 
each food group accordingly. When calculating the effect estimates from Model 2, all 
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categorical covariates were set to their reference group and the continuous covariates 
gestational week, maternal age, BMI and energy intake were centred to their means. Mean 
centering was done so that the effect estimates for the food groups were calculated at 
more realistic values of the covariates (i.e., at their mean values instead of at zero). 
 
Four types of sensitivity analyses were conducted: (i) under-reporting: to account for 
potential under-reporting of energy intake in Model 2, in all cohorts, women with energy 
intakes below the 5th percentile were excluded; (ii) iodine supplements: Model 2 was 
adjusted for iodine-supplement use in INMA (as the only cohort with complete iodine-
supplement data) and iodine-supplement-users were excluded in Generation R (as data 
were available only for a sub-set of the sample); (iii) gestational age: as the median 
gestational week at urine sampling was later in INMA and Generation R than in ALSPAC, 
sensitivity analyses to test the associations with iodine status in the first trimester, using 
samples collected up to 13 weeks were performed; (iv) covariate creatinine-adjustment 
method: since age, BMI and ethnicity are known predictors of urinary creatinine 
concentration (Barr et al. 2005) and urinary creatinine can also vary during gestation 
(Baba et al. 2017), this could result in spurious associations of these variables with the 
ratio of UI/Creat; therefore sensitivity analyses were performed for these variables (BMI, 
age, ethnicity and gestational age) using Model 1 and 2 with the (natural) log-transformed 
UIC (µg/L) unadjusted for creatinine as the dependent variable and creatinine 
concentration added as a separate independent variable to the models. This method has 
been recommended previously (Barr et al. 2005) and ensures that UIC is adjusted for 
dilution by creatinine concentration while the associations of the other variables with UIC 
are independent of urinary creatinine. 
 
All analyses were conducted using multiply-imputed data in order to account for missing 
data on socio-demographic variables. Multiple imputation was performed using the 
automatic method in SPSS. A total of 20 datasets were generated and analysed using 
standard multiple imputation procedures (Sterne et al. 2009). Detailed information about 
the imputed variables has been provided in Chapter 2. Missing FFQ data were not imputed 
(Chapter 2, Section 2.6.1). All statistical analyses were performed with IBM SPSS 
Statistics version 24.0 (IBM Corp., Armonk, NY, USA). Values were considered 
statistically significant at P<0.05. 
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3.3 Results  
3.3.1 Sample characteristics  
After exclusions, the final study population comprised 6,566 pregnant women: 2,852 
from ALSPAC, 2,254 from Generation R and 1,460 from INMA (Figure 3.1). The 
characteristics of the included women by cohort are shown in Table 3.1.  
Table 3. 1  Characteristics of the study population by cohort  
Characteristics 1 
ALSPAC                                     
(n=2,852) 
Generation R          
(n=2,254) 
INMA          
(n=1,460) 
Maternal factors    
Maternal age 2,3 (years), mean (±SD) 28.7 (±4.5) 29.9 (±5.0) 31.4 (±4.1) 
Pre-pregnancy BMI (kg/m2), 
median (25-75th) 3 
22.3 (20.5 - 24.6) 23.5 (21.5 - 26.4) 22.5 (20.8 - 25.0) 
Ethnicity 4, n (%)    
    Reference group 2800 (98.2) 1095 (48.6) 1340 (91.8) 
    Non-white 52 (1.8) N/A N/A 
    Non-Dutch N/A 1159 (51.4) 5 N/A 
    Non-Spanish N/A N/A 120 (8.2) 
Parity 3, n (%)    
    0 1354 (47.5) 1279 (56.7) 806 (55.2) 
    1 965 (33.8) 665 (29.5) 544 (37.3) 
    ≥ 2 533 (18.7) 310 (13.8) 110 (7.5) 
Smoking status, n (%)    
    Never smoked 2169 (76.1) 1671 (74.2) 1020 (69.9) 
    Stopped smoking 333 (11.7) 211 (9.3) 187 (12.8) 
    Continued smoking 350 (12.2) 372 (16.5) 253 (17.3) 
Alcohol consumption, n (%)    
    No 1350 (47.4) 1458 (64.7) 1330 (91.1) 
    Yes 1502 (52.6) 796 (35.3) 130 (8.9) 
Markers of socio-economic status 
Education level, n (%)    
    Low 576 (20.2) 247 (11.0) 337 (23.1) 
    Medium 1780 (62.4) 995 (44.1) 581(39.8) 
    High 496 (17.4) 1012 (44.9) 542 (37.1) 
Net household income (€ per month), n (%) 
    Low < €1200 N/A 492 (21.8) N/A 
    Medium €1200-2200 N/A 597 (26.5) N/A 
    High > €2200 N/A 1165 (51.7) N/A 
Home ownership, n (%)    
    Owned/mortgaged 2425 (85.0) N/A N/A 
    Private/other rented 236 (8.3) N/A N/A 
    Council rented 191 (6.7) N/A N/A 
(continued on next page) 
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Table 3.1  Characteristics of the study population by cohort (continued) 
Characteristics 1 
ALSPAC         
(n=2,852) 
Generation R 
(n=2,254) 
INMA                
(n=1,460) 
Markers of socio-economic status (continued) 
Crowding index, n (%)    
    ≤ 1 person per room 2747 (96.3) N/A N/A 
    + 1 person per room 105 (3.7) N/A N/A 
Family adversity index, n (%)    
    None 0 1395 (48.9) N/A N/A 
    Mild 1-2 1124 (39.4) N/A N/A 
    Severe > 3 333 (11.7) N/A N/A 
Life event score, median (25-75th) 3.0 (2.0 - 5.0) N/A N/A 
Marital status, n (%)    
    Never-married 355 (12.5) 1136 (50.4) N/A 
    Married 2357 (82.6) 1118 (49.6) N/A 
    Other 6 140 (4.9) N/A N/A 
Living with a partner, n (%)    
    Yes 2720 (95.4) N/A 1445 (99.0) 
    No 132 (4.6) N/A 15 (1.0) 
Child factors    
Child’s sex 3, n (%)    
    Male 1405 (49.3) 1147 (50.9) 737 (50.5) 
    Female 1447 (50.7) 1107 (49.1) 723 (49.5) 
1 Data are presented as mean (±SD) for all continuous normally distributed variables, median (25-75th 
percentile) for all continuous non-normally distributed variables and n (%) for the categorical variables. 2 
Maternal age at urine-sample collection, except in ALSPAC (age at last menstrual period). 3 Data were not 
imputed, due to no missing values for maternal age (in ALSPAC and Generation R), pre-pregnancy BMI 
(in INMA), parity (in Generation R) and child's sex (in ALSPAC). The rest of the data are shown after 
multiple imputation of the missing values (see ‘Methods’ Section 3.2.8 and Chapter 2). 4 Categories for 
ethnicity in ALSPAC (Reference group=White), in Generation R (Reference group=Dutch, Non-
Dutch=Indonesian, Cape Verdian, Moroccan, Dutch Antilles, Surinamese, Turkish, other Non-Western, 
Asian and other Western) and in INMA (Reference group=Spanish, Non-Spanish=Latin American and 
European/others). 5 For a detailed breakdown of the numbers in each sub-category of the Non-Dutch ethnic 
group in Generation R, see Table 3.3. 6 ALSPAC (Other=widowed, divorced, or separated). Abbreviations: 
BMI, body mass index; N/A, data not available or not applicable; SD, standard deviation 
 
 
Maternal age varied across cohorts, with women in ALSPAC having a lower mean ± 
standard deviation (SD) age than women in INMA [28.7 (±4.5) vs 31.4 (±4.1) years, 
respectively]. Median BMI was within the healthy range in all cohorts (Table 3.1). The 
majority of mothers defined themselves as White in ALSPAC (98.2%), Spanish in INMA 
(91.8%), while slightly more than half of the women in Generation R said they were non-
Dutch (51.4%). Most women were nulliparous and non-smokers, with similar proportions 
between cohorts. 
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3.3.2 Iodine status in early pregnancy  
The median UI/Creat (25-75th percentile) was 121 (81-193) µg/g in women from the UK 
(ALSPAC) (62.8% <150 µg/g), 151 (96-255) µg/g in women from Spain (INMA) (49.5% 
<150 µg/g) and 210 (140-303) µg/g in women from the Netherlands (Generation R) 
(28.8% <150 µg/g) (Table 3.2). 
 
Table 3.2  Urinary iodine status in early pregnancy (≤ 18 gestational weeks) expressed 
as UIC, UI/Creat and proportion of mothers with UI/Creat below 150 µg/g 
 
ALSPAC 
(n=2,852) 
 Generation R 
(n=2,254) 
 INMA 
(n=1,460) 
Gestational week at urine sampling 1   11.0 (8.0 - 15.0)    13.1 (12.1 - 14.6)   13.0 (12.4 - 13.9) 
Urinary iodine concentration (UIC), µg/L 1      95 (56 - 151)     165 (94 - 277)      130 (76 - 219) 
Iodine-to-creatinine ratio (UI/Creat), µg/g 1    121 (81 - 193)     210 (140 - 303)      151 (96 - 255) 
UI/Creat < 150 µg/g, n (%)  1792 (62.8%)     650 (28.8%)      723 (49.5%) 
1 Data are presented as median (25-75th percentile). Abbreviations: UI/Creat, urinary iodine-to-creatinine 
ratio; UIC, urinary iodine concentration. 
 
3.3.3 Socio-demographic and lifestyle determinants of iodine status 
In multivariable models (adjusted Models 1 and 2), gestational week of urine sample, 
maternal age, and pre-pregnancy BMI were associated with UI/Creat in all three cohorts. 
Gestational week at urine sampling (≤18 weeks) was positively associated with UI/Creat 
in ALSPAC only, where every 1-week difference in gestational week was associated with 
5% higher UI/Creat [exponentiated B (95% CI) = 1.05 (1.05, 1.06)] (Table 3.3). 
However, in sensitivity analyses restricted to samples collected up to 13 weeks, there was 
an association of gestational week with UI/Creat in all three cohorts (ALSPAC: 
exponentiated B=1.03, P<0.001, n=1951; Generation R: exponentiated B=1.03, P=0.049, 
n=1094; INMA: exponentiated B=1.08, P=0.045, n=747) with a larger effect size in 
Generation R and INMA than in the analyses up to 18 weeks. In the sensitivity analyses 
using covariate creatinine-adjustment, the results for the association of gestational week 
up to 18 weeks with UIC did not substantially differ from those with UI/Creat in ALSPAC 
and INMA, while in Generation R the effect size was higher and reached statistical 
significance (Supplemental Table 3.3, Appendix I). 
There was a positive association of maternal age with UI/Creat; a 1-year difference in 
maternal age was associated with 1-2% higher UI/Creat across cohorts (ALSPAC: 
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exponentiated B=1.01, P<0.001; Generation R: exponentiated B=1.02, P<0.001; INMA: 
exponentiated B=1.02, P<0.001). After further adjusting for maternal diet and energy 
intake estimated from the FFQs (Model 2), the effect size of age was attenuated by 16 - 
30% across cohorts, but remained statistically significant (Table 3.3). The positive 
association with age remained in all cohorts, except in Model 2 for ALSPAC, when using 
the covariate creatinine-adjustment method of UIC (Supplemental Table 3.3). 
 
There was a negative association of BMI with UI/Creat; a 1-kg/m2 difference in BMI was 
associated with about 1% lower UI/Creat (ALSPAC: exponentiated B=0.99, P<0.001; 
Generation R: exponentiated B=0.99, P<0.001; INMA: exponentiated B=0.99, 
P=0.005). The association remained statistically significant after adjustment for maternal 
diet and energy intake (Table 3.3, Model 2). However, BMI was not associated with UIC 
(µg/L) with the covariate creatinine-adjustment method in Generation R and INMA but 
remained negatively associated with UIC in ALSPAC, though with a lower effect size 
(Supplemental Table 3.3). 
 
Cohort-specific socio-demographic and lifestyle factors were identified as determinants 
of iodine status. In Generation R, maternal ethnicity and smoking were associated with 
UI/Creat (Table 3.3). Compared to the Dutch women, Moroccan, Turkish and other non-
Western women had 29%, 48% and 17% higher UI/Creat, respectively, whereas 
Surinamese and those from the Dutch Antilles had 11% and 16% lower UI/Creat, 
respectively. Some of these effects were attenuated after accounting for maternal diet in 
Model 2 (Table 3.3). Similarly to UI/Creat, UIC (with covariate creatinine-adjustment) 
also differed by ethnicity; Moroccan, Turkish and other non-Western women still had a 
significantly higher UIC than the Dutch, while the UICs of Surinamese and Dutch 
Antilles women did not significantly differ from those of the Dutch women 
(Supplemental Table 3.3). Generation R women who reported smoking vs those who 
never smoked had 9% lower UI/Creat (exponentiated B=0.91, P=0.035); the association 
remained significant after adjustment for maternal diet (Table 3.3, Model 1 and 2). In 
ALSPAC, having severe family adversity index (exponentiated B=0.90, P=0.016) and 
being married (exponentiated B=1.10, P=0.015) were associated with ~10% lower and 
~10% higher UI/Creat, respectively; the associations remained significant after adjusting 
for maternal diet (Table 3.3). Results for all predictors of UI/Creat included in the 
multivariable models are presented in Supplemental Table 3.2 (Appendix I). 
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Table 3. 3  Determinants of urinary iodine-to-creatinine ratio measured at ≤ 18 gestational weeks that were statistically significant in at least one cohort 
 ALSPAC (n=2,852)  Generation R (n=2,254)  INMA (n=1,460) 
 Adjusted Model 1 
1 Adjusted Model 2 2   Adjusted Model 1 1 Adjusted Model 2 2   Adjusted Model 1 1 Adjusted Model 2 2 
Determinants n B P n B P  n B P n B P  n B P n B P 
Gestational week at urine sampling 2852 0.051 <0.001 2710 0.052 <0.001   2254 0.007 0.300 1580 0.011 0.133   1460 0.004 0.755 1446 -0.009 0.513 
Maternal age 3, years 2852 0.014 <0.001 2710 0.010 0.002   2254 0.018 <0.001 1580 0.015 <0.001   1460 0.020 <0.001 1446 0.014 0.008 
Pre-pregnancy BMI, kg/m2 2852 -0.013 <0.001 2710 -0.012 <0.001   2254 -0.011 <0.001 1580 -0.013 <0.001   1460 -0.013 0.005 1446 -0.010 0.033 
Family adversity index                                         
    None 0 1395 Ref.   1334 Ref.     N/A . . . . .   N/A . . . . . 
    Mild 1-2 1124 -0.007 0.765 1069 -0.003 0.906   N/A . . . . .   N/A . . . . . 
    Severe > 3 333 -0.100 0.016 307 -0.086 0.046   N/A . . . . .   N/A . . . . . 
Marital status                                         
    Never-married 355 Ref.   320 Ref.     1136 Ref.    825 Ref.     N/A . . . . . 
    Married 2357 0.095 0.015 2269 0.119 0.003   1118 0.030 0.285 755 0.044 0.168   N/A . . . . . 
    Other 4 140 0.028 0.666 121 0.051 0.447   N/A . . . . .   N/A . . . . . 
Ethnicity                                          
    Reference group 5 2800 Ref.   2674 Ref.      1095 Ref.   930 Ref.     1340 Ref.   1328 Ref.   
    Non-white 52 -0.018 0.851 36 0.043 0.676   N/A . . . . .   N/A . . . . . 
    Non-Dutch: N/A . . . . .                 N/A . . . . . 
       Indonesian N/A . . . . .   72 -0.047 0.494 58 -0.081 0.286   N/A . . . . . 
       Cape Verdian N/A . . . . .   87 -0.013 0.848 41 0.065 0.502   N/A . . . . . 
       Moroccan N/A . . . . .   165 0.255 <0.001 72 0.182 0.028   N/A . . . . . 
       Dutch Antilles N/A . . . . .   65 -0.174 0.025 37 -0.225 0.031   N/A . . . . . 
       Surinamese N/A . . . . .   196 -0.115 0.017 111 -0.160 0.014   N/A . . . . . 
       Turkish N/A . . . . .   226 0.391 <0.001 103 0.360 <0.001   N/A . . . . . 
       Other, Non-Western N/A . . . . .   107 0.157 0.011 53 0.125 0.137   N/A . . . . . 
       Asian N/A . . . . .   32 0.091 0.383 19 0.028 0.835   N/A . . . . . 
       Other, Western N/A . . . . .   209 0.052 0.228 156 0.062 0.213   N/A . . . . . 
    Non-Spanish N/A . . . . .   N/A . . . . .   120 -0.016 0.810 118 -0.003 0.961 
(continued on next page) 
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Table 3.3  Determinants of urinary iodine-to-creatinine ratio measured at ≤ 18 gestational weeks that were statistically significant in at least one cohort  
(continued) 
 ALSPAC (n=2,852)  Generation R (n=2,254)  INMA (n=1,460) 
 Adjusted Model 1 1 Adjusted Model 2 2  Adjusted Model 1 1 Adjusted Model 2 2  Adjusted Model 1 1 Adjusted Model 2 2 
Determinants n B P n B P  n B P n B P  n B P n B P 
Smoking status                     
    Never smoked 2169 Ref.   2077 Ref.     1671 Ref.   1202 Ref.     1020 Ref.   1011 Ref.   
    Stopped smoking 333 -0.003 0.943 312 -0.010 0.797   211 -0.093 0.035 147 -0.121 0.020   187 -0.060 0.296 186 -0.060 0.287 
    Continued smoking 350 0.018 0.620 321 0.060 0.116   372 -0.008 0.831 231 0.049 0.296   253 -0.001 0.990 249 0.020 0.707 
Effect estimates (B=unstandardised regression coefficient) and P-values from multiple linear regression models performed for each cohort with (natural) log-transformed iodine-to-creatinine 
ratio (UI/Creat) as the dependent variable and maternal characteristics and dietary intakes as independent variables (for full models, see footnotes 1 and 2). Reported B coefficients represent 
the change in the mean (natural) log of UI/Creat per unit increase in the continuous independent variables and for each category compared to the reference for the categorical independent 
variables. 1 Adjusted Model 1 (adjusted for maternal and pregnancy characteristics): ALSPAC Model 1 (R2=0.123, P < 0.0001): gestational week at urine sampling, maternal age (years), pre-
pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, home ownership, crowding index, family adversity index, life event score, marital status and 
child’s sex; Generation R Model 1 (R2=0.086, P < 0.0001): gestational week at urine sampling, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol 
consumption, education level, net household income (€ per month), marital status and child’s sex; and INMA Model 1 (R2=0.021, P < 0.0001): gestational week at urine sampling, maternal 
age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, living with a partner and child’s sex . 2 Adjusted Model 2 (adjusted for 
maternal and pregnancy characteristics + dietary intakes): ALSPAC Model 2 (R2=0.147, P < 0.0001): Model 1 + energy intake (kcal/day) + intake of vegetables (g/day), fruit (g/day), nuts 
and seeds (g/day), potatoes (g/day), legumes (g/day), cereals and cereal products (g/day), cakes, confectionery and added sugar (g/day), added fats (g/day), milk and dairy products (g/day), 
meat and meat products (g/day), eggs (g/day), fish and shellfish (g/day), processed and fried foods (g/day), non-alcoholic beverages (g/day), miscellaneous (g/day); Generation R Model 2 
(R2=0.091, P < 0.0001): Model 1 + energy intake (kcal/day) + intake of vegetables (g/day), fruit (g/day), nuts and seeds (g/day), potatoes (g/day), legumes (g/day), cereals and cereal products 
(g/day), cakes, confectionery and added sugar (g/day), added fats (g/day), milk and dairy products (g/day), meat and meat products (g/day), eggs (g/day), fish and shellfish (g/day), condiments 
and seasoning (g/day), processed and fried foods (g/day), non-alcoholic beverages (g/day), alcoholic beverages (g/day), miscellaneous (g/day); and INMA Model 2 (R2=0.060, P < 0.0001): 
Model 1 + energy intake (kcal/day) + intake of vegetables (g/day), fruit (g/day), nuts and seeds (g/day), potatoes (g/day), legumes (g/day), cereals and cereal products (g/day), cakes, 
confectionery and added sugar (g/day), added fats (g/day), milk and dairy products (g/day), meat and meat products (g/day), eggs (g/day), fish and shellfish (g/day), condiments and seasoning 
(e.g., salt) (g/day), processed and fried foods (g/day), non-alcoholic beverages (g/day), alcoholic beverages (g/day). 3 Maternal age at urine sample collection, except in ALSPAC (age at last 
menstrual period). 4 ALSPAC (Other=widowed, divorced, or separated). 5 Reference group of ethnicity in ALSPAC (Reference group=White), in Generation R (Reference group=Dutch) and 
in INMA (Reference group=Spanish). Abbreviations: BMI, body mass index; N/A, data not available or not applicable; Ref, reference category; UI/Creat, urinary iodine-to-creatinine ratio 
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3.3.4 Dietary determinants of iodine status 
As not all women with urinary iodine measurements before 18 weeks had also completed 
an FFQ, numbers for these analyses were lower in all cohorts (Figure 3.1): ALSPAC 
(n=2,710), Generation R (n=1,580), INMA (n=1,446). The mean daily food-group intakes 
of pregnant women in each cohort are presented in Supplemental Table 3.4 (Appendix 
I). “Milk and dairy products” was the only food group positively associated with UI/Creat 
in all three cohorts: ALSPAC (B (per 100g) = 3.73, P<0.0001); Generation R (B (per 100g) = 
2.34, P=0.001); INMA (B (per 100g) = 6.92, P=0.002) (Supplemental Table 3.5, Appendix 
I). Based on the fully-adjusted models, one-portion increase in consumption of milk and 
dairy products (e.g., a glass of milk, 200 g) (Food Standards Agency 2002) was associated 
with a 5-14 µg/g increase in the geometric mean of UI/Creat (Table 3.4). Intake of “fish 
and shellfish” was positively associated with UI/Creat in pregnant women in Spain 
(INMA) and the UK (ALSPAC), though the effect size per 100 g was more than five 
times larger in INMA women (B=28.04, P=0.029 vs B=5.10, P=0.017). Cohort-specific 
dietary determinants were also identified (Table 3.4). In ALSPAC, consumption of fruit 
(P=0.012) and cakes and confectionery (P=0.028) were positively associated with 
UI/Creat. Intake of cereals and cereal products (P<0.001), eggs (P<0.001), nuts and seeds 
(P=0.001) and added fat (P=0.022) were all positively associated with UI/Creat in 
Generation R. Higher salt intake (including iodised salt) (per 1 g) was associated with 
higher UI/Creat (P=0.003), while increasing meat intake was associated with lower 
UI/Creat (P=0.002) in INMA.  
Excluding women with extremely low energy intakes (< 5th percentile) did not 
considerably change the results, except for small changes in INMA where the association 
between fish intake and UI/Creat was no longer statistically significant (P=0.051) but the 
effect size remained relatively unchanged (data not shown). In INMA, mean daily iodine-
supplement intake was an important determinant of UI/Creat (Standardised B=0.235, 
P<0.0001). Adjusting for iodine-supplement use in INMA attenuated the result for 
maternal age (B=0.012, P=0.018) but did not change the rest of the results substantially 
(data not shown). In Generation R, the exclusion of iodine-supplement users resulted in 
higher effect estimates for some ethnic groups (e.g., Moroccan, Turkish and other 
Western); the associations between intake of non-alcoholic and alcoholic beverages and 
UI/Creat reached statistical significance but the effect sizes remained unchanged; the rest 
of the results remained relatively unchanged (data not shown).
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Table 3. 4  Multivariable associations of food-group intakes estimated from FFQ (per portion size, g) with urinary iodine-to-creatinine ratio measured 
at ≤ 18 gestational weeks that were statistically significant in at least one cohort 
     ALSPAC (n=2,710)  Generation R (n=1,580)  INMA (n=1,446) 
Food group 
Standard 
portion (g) 1 Description 1 B (95% CI) P 2  B (95% CI) P 
3  B (95% CI) P 
4 
Fruit 80 g a portion '5-a-day' 2.22 (0.47, 4.03) 0.012   0.90 (-0.90, 2.75) 0.328   -3.51 (-7.16, 0.20) 0.064 
Nuts and seeds 30 g a handful 5.08 (-0.63, 11.53) 0.083   12.92 (4.83, 21.73) 0.001   18.63 (-10.61, 52.17) 0.223 
Cereals and cereal 
products 
36 g 
a medium slice of 
bread 
0.51 (-0.33, 1.36) 0.238   4.25 (2.23, 6.31) <0.001   0.07 (-5.12, 5.40) 0.978 
Cakes, confectionery 
and added sugar 
50 g a chocolate bar 2.39 (0.25, 4.63) 0.028   2.64 (-1.13, 6.57) 0.172   -9.19 (-22.95, 5.59) 0.217 
Added fats 10 g 
spread on a slice of 
bread 
1.12 (-0.14, 2.41) 0.082   2.70 (0.39, 5.08) 0.022   -4.19 (-11.03, 2.89) 0.243 
Milk and dairy 
products 
200 g a glass of milk 7.77 (5.65, 9.99) <0.001   4.74 (2.01, 7.56) 0.001   14.07 (5.07, 23.45) 0.002 
Meat and meat 
products 
130 g 
a medium portion 
chicken breast 
1.65 (-2.96, 6.78) 0.497   3.75 (-5.35, 13.87) 0.433   -41.48 (-63.44, -16.20) 0.002 
Eggs 50 g an average egg 2.64 (-0.60, 6.12) 0.112   28.10 (12.27, 46.47) <0.001   39.69 (-6.67, 96.68) 0.099 
Fish and shellfish 120 g a medium cod fillet 6.18 (1.07, 11.87) 0.016   2.42 (-19.04, 30.69) 0.845   34.08 (3.28, 69.37) 0.029 
Condiments and 
seasoning (e.g., salt) 5 
5 g 
a level teaspoon 
(WHO) 6 
N/A .   1.34 (-1.50, 4.29) 0.359   214.41 (56.88, 465.35) 0.003 
Effect estimates (B=unstandardised regression coefficient), 95% CIs and P-values from multiple linear regressions performed for each cohort with (natural) log-transformed 
iodine-to-creatinine ratio (UI/Creat) as the dependent variable and food-group intakes as the independent variables, adjusted for covariates (see footnotes 2-4). Reported B 
coefficients represent the actual change in the geometric mean of UI/Creat (µg/g) associated with a portion-size increase in intake of a food group. B coefficients and their 95% 
CIs are calculated by back-transformation from logarithmic scale (see ‘Methods’ Section 3.2.8). When calculating the B coefficients all categorical covariates were set to their 
reference group and the continuous covariates gestational week, maternal age, pre-pregnancy BMI and energy intake were centred to their means. 1 Portion sizes are based on 
Food Standards Agency (2002) Food Portion Sizes (3ed.) London: TSO. 2 P-values from Model 2 in ALSPAC (R2=0.147, P < 0.0001): energy (kcal/day) + gestational week, 
maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking, alcohol consumption, education, home ownership, crowding index, family adversity index, life 
event score, marital status and child’s sex. 3 P-values from Model 2 in Generation R (R2=0.091, P < 0.0001): energy (kcal/day) + gestational week, maternal age (years), pre-
pregnancy BMI (kg/m2), ethnicity, parity, smoking, alcohol consumption, education, net household income (€ per month), marital status and child’s sex. 4 P-values from Model 
2 in INMA (R2=0.060, P < 0.0001): energy (kcal/day) + gestational week, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking, alcohol consumption, 
education, living with a partner and child’s sex. 5 In INMA this food group also included iodised salt. Separate information about the consumption of table salt and use of iodine-
fortified table salt was collected only in the INMA cohort. 6 Maximum daily salt intake, as recommended by WHO (5 g/day salt or 2 g/day Sodium). Abbreviations: BMI, body 
mass index; 95% CI, confidence interval; FFQ, food-frequency questionnaire; N/A, data not available; UI/Creat, urinary iodine-to-creatinine; WHO, World Health Organisation 
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3.4 Discussion 
This study aimed to identify the predictors of iodine status in cohorts of pregnant women 
residing in three countries with differing iodine status. Several dietary (milk and dairy 
products) and maternal factors (maternal age, BMI, gestational week) were associated 
with UI/Creat across all cohorts in adjusted models. Furthermore, important cohort-
specific dietary determinants were identified, such as fish intake in ALSPAC (UK), egg 
and cereal/cereal product intake in Generation R (Netherlands) and fish, (iodised) salt and 
meat intake in INMA (Spain).  
 
The population of pregnant women from the Netherlands (Generation R) was iodine-
sufficient, while the populations from the UK (ALSPAC) and Spain (INMA) were 
mildly-to-moderately iodine-deficient by median UIC. It should be noted that the 
ALSPAC median-UIC value, although from samples that are nearly 25 years old, is 
almost identical to the UK value from the 2017 Global Scorecard for Iodine Nutrition in 
pregnant women i.e., 95 µg/L vs 99 µg/L (Iodine Global Network 2017). The differences 
in iodine status between the countries may be partly explained by differing use of iodised 
salt. The iodised salt penetration rate in households and the food industry (e.g., bread-
making) in the Netherlands has been estimated as 60% and 70%, respectively, while a 
16% penetration rate has been reported in Spanish households (WHO 2007b). By 
contrast, iodisation of salt was never common in the UK (Phillips 1997), and even 
nowadays its availability is very limited (21.5% weighted availability, estimated from a 
shelf survey in supermarket chains that accounted for market share); furthermore, the 
iodine concentration of the major UK brand is low (Bath, Button, et al. 2013). Apart from 
the establishment of the National Milk Scheme in the 1940s in the UK (Phillips 1997), to 
our knowledge, there were no iodine-related education campaigns running in the three 
countries at the time of data collection that could have had an influence on the iodine 
status.  
3.4.1 Socio-demographic and lifestyle determinants of iodine status 
Gestational week of urine samples was positively associated with UI/Creat in ALSPAC 
but not in the other cohorts. This may be because ALSPAC samples were collected at an 
earlier gestational age than in the other cohorts; if the greatest increase in urinary iodine 
excretion is in the first weeks of pregnancy, the effect of gestational age may be attenuated 
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in later samples (i.e., up to 18 weeks as in the current study). Indeed in sensitivity analyses 
restricted to samples collected up to 13 weeks, the effect size was higher in the other two 
cohorts. The positive association between gestational week of urine sample and UI/Creat 
in early pregnancy could be attributed to the progressive increase in glomerular filtration 
rate beginning soon after conception and the subsequent increase in renal iodide loss 
(Glinoer 1997; Cheung and Lafayette 2013); though, data are conflicting as studies have 
reported both an increase and a decrease in UI/Creat with advancing pregnancy (Brander 
et al. 2003; Fuse et al. 2013; Bath et al. 2015; Li et al. 2016). As urinary iodine excretion 
might change during pregnancy as a result of increased renal clearance of iodine, urinary 
iodine measurements from different time-points in pregnancy might not reflect true iodine 
intake (Stilwell et al. 2008). Creatinine clearance has also been shown to vary during 
gestation (Baba et al. 2017), which could have biased the results when using UI/Creat. 
However, gestational week was also positively associated with UIC (µg/L) alone when 
including creatinine separately in the model.  
 
In all three cohorts, BMI was negatively associated with UI/Creat. In a study in non-
pregnant adults (Gerchman et al. 2009), creatinine clearance was positively associated 
with BMI, independent of adiposity, and a positive association with lean thigh-tissue area 
was reported; this suggests that the association of creatinine with BMI might be explained 
by lean body mass. The negative association between BMI and UI/Creat reported in the 
current study may therefore be partly explained by the use of creatinine adjustment and 
may highlight potential issues with the use of this measure of iodine status (Barr et al. 
2005; O’Brien et al. 2016). Indeed in sensitivity analysis, BMI was not associated with 
UIC alone in two of the cohorts when we adjusted for creatinine by including it as a 
covariate in the model instead of using the ratio of UI/Creat.  
 
There was a positive association of maternal age with UI/Creat in all cohorts. Age was 
still significantly associated with UI/Creat after adjustment for dietary intake though the 
effect size was attenuated; it was further reduced when iodine-supplement use in INMA 
was accounted for, suggesting that some of the effect of age could be explained by diet 
and supplement use in older women. Similarly to BMI, age is a known predictor of urinary 
creatinine (Barr et al. 2005). However, in sensitivity analysis when adjusting for 
creatinine separately in the model, unlike BMI, age remained positively associated with 
UIC but with a lower effect size.    
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The iodine status of pregnant women from the Netherlands (Generation R) varied by 
ethnic origin, with higher iodine status in Moroccan, Turkish and other non-Western 
women, and lower iodine status in Surinamese and Dutch Antilles women, even after 
adjusting for socio-demographic factors. Variation in diet may partly explain these 
differences as some of the effect estimates were attenuated when adjusting for dietary 
intake. Alternatively, there may be genetic variability in iodine or creatinine clearance 
(James et al. 1988; Barr et al. 2005). Indeed, when using UIC and adjusting for urinary 
creatinine separately in the model, UIC varied similarly to UI/Creat between the ethnic 
groups though some of  the associations were attenuated and were no longer significant 
(e.g., for Surinamese and Dutch Antilles women). It should be noted that numbers in some 
of these ethnic-group categories were relatively small (n<100). Ethnicity was not 
significantly associated with iodine status in ALSPAC or INMA, but this may reflect the 
small sample sizes of other ethnic groups in these cohorts. Ethnic differences in iodine 
status could help to identify subgroups at high-risk for iodine insufficiency; in countries 
with a large proportion of diverse ethnic groups, culturally-specific approaches to 
improve dietary adequacy may be more suitable than a single solution for the whole 
population. For example, we have created a cookbook of iodine-rich recipes which could 
be adapted for different ethnic groups or different countries (Tattersall et al. 2017).  
3.4.2 Dietary determinants of iodine status 
The only food group that was positively associated with UI/Creat in all three cohorts was 
“milk and dairy products”, demonstrating their significant role as an important dietary 
determinant of iodine status in pregnancy. This finding supported our hypothesis and is 
consistent with the results of other studies in European pregnant women, i.e., in Norway 
(Brantsæter et al. 2009; Brantsæter et al. 2013), Iceland (Gunnarsdottir et al. 2013), Italy 
(Mian et al. 2009), Spain (Torres et al. 2017) and the UK (Bath et al. 2014; Bath et al. 
2015), as well as studies of pregnant women in Australia (Blumenthal et al. 2012).  
 
Based on our model, a portion of “milk and dairy products” equivalent to a glass of milk 
(200 g) was associated with 5 to 14 µg/g increase in UI/Creat across cohorts. The effect 
sizes for milk differed between cohorts; the highest effect size was in Spain (INMA), 
while the lowest was in the Netherlands (Generation R). This is in line with the milk-
iodine concentration in each country [i.e., ~26 µg per 100 g in Spain (Soriguer et al. 
2011),  ~15 µg per 100g in the Netherlands (National Institute for Public Health and the 
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Environment (RIVM) 2016) and 15 µg per 100 g in the UK in 1990/1991 (Lee et al. 
1994)]. The results might be different if repeated now as the iodine concentration in UK 
milk is higher than estimated when ALSPAC women were recruited in 1990/1991, i.e. 
427 vs 150 µg/kg (Lee et al. 1994; Stevenson et al. 2018).  
 
Consumption of eggs and fish were positively associated with UI/Creat, though not 
consistently across the cohorts; the association with egg intake was statistically 
significant only in the Netherlands (Generation R), while intake of fish and shellfish was 
associated with UI/Creat only in Spain (INMA) and the UK (ALSPAC). The effect size 
for eggs was higher than that expected, given their iodine content, but similar to values 
reported previously (Brantsæter et al. 2013). These higher values may reflect the 
consumption of eggs with salt in the Netherlands, which is likely to be iodised. An 
average portion of fish (120 g) was associated with some 6 to 34 µg/g increase in 
UI/Creat, across cohorts. Variation in the effect-size could partly reflect the variability in 
average fish consumption, particularly of white fish, which is a good iodine source (Dahl 
et al. 2004) (e.g., pregnant women in Spain consumed a higher amount of white fish daily 
than did women in the UK). The wide CIs around the estimates probably relate to the 
variability in fish-iodine concentration (Haldimann et al. 2005) [i.e., the proportion of 
oily fish in the food group has a much lower iodine concentration (Dahl et al. 2004)] and 
to the irregular nature of fish consumption which may not be captured by a spot-UI/Creat.  
 
As hypothesised, consumption of cereals and cereal products was a statistically 
significant determinant of UI/Creat only in the Netherlands (Generation R); this 
association is probably driven by consumption of bread which is made with iodised salt 
in the Netherlands (Verkaik-Kloosterman et al. 2012), whereas without iodised salt, bread 
has a low iodine concentration and was not found to be a predictor of iodine status in the 
UK or Spanish cohorts. Intake of iodised table salt was measured only in pregnant women 
from Spain (INMA); 1 g of salt was associated with around 32 µg/g increase in UI/Creat. 
Both of these results suggest that iodised salt consumed either discretionarily (e.g., as 
table salt in Spain), or as part of processed foods (e.g., in bread in the Netherlands) is an 
important dietary determinant of iodine status. The highest UI/Creat was observed in the 
Netherlands (Generation R), followed by Spain (INMA), and the lowest in the UK 
(ALSPAC), suggesting that iodised-salt use might be a key dietary factor with large 
influence on iodine status.  
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Surprisingly, meat intake was negatively associated with UI/Creat in the Spanish cohort 
(INMA), even after controlling for socio-demographic variables. Higher urinary 
creatinine concentrations have been reported in individuals with a high-meat diet, which 
may account for the lower ratio (Lykken et al. 1980; Cross et al. 2011).  
 
Some of the other food-group associations are difficult to explain and may be chance 
findings e.g. the positive association with fruit, and cakes/confectionary in the UK 
(ALSPAC). However, fruit intake was also associated with urinary iodine excretion in 
Norwegian pregnant women (Brantsæter et al. 2009) and the finding might warrant 
further investigation.   
 
Although statistically significant increases in UI/Creat were observed, the effect sizes for 
the food groups were relatively small and the total explained variance in UI/Creat (R2) 
was low. As a result of the physiological changes occurring during gestation (e.g., 
increased renal iodine clearance), pregnancy may not represent a steady state of iodine 
metabolism (intake vs excretion) (Delange 2007). Moreover, the large day-to-day 
variability in iodine intake cannot be captured in a single spot-urine sample and there are 
measurement errors of dietary assessment methods in capturing individual habitual iodine 
intake. In recent years, a number of iodine-specific FFQs have been developed and 
validated (Combet and Lean 2014; Condo et al. 2015; Næss et al. 2019). FFQs and other 
dietary assessment methods may be used to identify the most important sources of dietary 
iodine in the population however, considering the highly variable iodine concentration of 
foods, the lack of compressive and locally-adapted food-composition databases is a 
majour disadvantage of these methods to precisely estimate usual iodine intake (Rohner 
et al. 2014).  
3.4.3 Strengths and limitations 
Strengths of the current study include the large sample size, the inclusion of pregnant 
women from three geographically and culturally different populations. Furthermore, 
associations with the entire range of food groups were explored, rather than focusing on 
a few groups or isolated foods as in previous studies (Mian et al. 2009; Torres et al. 2017).  
 
The current study also has a number of limitations. Firstly, the use of an FFQ for 
measuring diet and the use of spot-urine samples for estimating individual iodine intake 
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have their methodological disadvantages (Andersen et al. 2008; Vejbjerg et al. 2009; 
König et al. 2011; Shim et al. 2014). Although only spot-urine samples were available 
which might not reflect individual iodine intake or status, UI/Creat was used which has 
been shown as a valid alternative to the 24-hour urinary iodine excretion when used in 
homogenous population groups (Knudsen et al. 2000). Although urinary iodine 
concentration was measured in three different laboratories using different assays, each 
laboratory ensured accuracy by use of certified reference materials. Exploring 
associations between data from an FFQ and spot-UI/Creat can also be problematic, as an 
FFQ is designed to measure habitual diet (Willett 2012), whereas a spot-urine sample 
reflects iodine intake in the last 24-48 hours (Zimmermann 2008); this may be reflected 
in the more consistent association between UI/Creat and intake of daily food items (e.g., 
milk) than those infrequently consumed (e.g., fish). However, the large cohort sample 
size would have helped to overcome this limitation to some extent. Secondly, it should 
be noted that in ALSPAC there was a time difference in the administration of the FFQ (at 
32 weeks) and urine-sample collection (≤18 weeks), hence the FFQ might not reflect diet 
during early pregnancy. Although in the other two cohorts the FFQ data and the urine 
samples were collected at the same time, in the FFQ women were asked about their 
dietary intake in the preceding three months (i.e., during the first trimester), while the 
urinary-iodine measurement indicated their very recent intake at around 13 weeks. 
Thirdly, although the classification of foods into food groups was harmonised, there were 
some differences in the foods included in each group which may explain variation in 
effect sizes between cohorts (i.e., in ALSPAC the dairy food group included milk and 
cheese, while in INMA and Generation R, ice cream, yoghurt, cream were also included). 
Fourthly, there were incomplete, or no, data on iodine-supplement use in two of the 
cohorts (Generation R and ALSPAC), which could be an important determinant that we 
were unable to evaluate; however, this is unlikely to be a limitation in ALSPAC as it is 
unlikely that women would have taken an iodine-containing supplement in the early 
1990s [e.g., the overall use of multivitamin and other supplements before 18 weeks in 
ALSPAC was 16.4% and 2.3%, respectively and based on data from the Dietary and 
Nutritional Survey of British Adults in 1986-87, only 17% of non-pregnant women took 
any form of supplements (Rogers et al. 1998)]. Lastly, urinary iodine concentration was 
measured only in women with available child-IQ data in two of the cohorts which might 
have created bias.  
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3.5 Conclusion 
Various maternal characteristics and dietary habits were associated with UI/Creat in 
pregnancy, some of which were population-specific. For that reason, universal 
interventions and dietary recommendations to improve the iodine intake of pregnant 
women might not be appropriate; a country-specific approach needs to be adopted. 
Between countries, but also within countries with a large proportion of different ethnic 
groups, culturally-specific recommendations are probably necessary. Achieving and 
maintaining iodine sufficiency in populations requires monitoring the dietary 
determinants of iodine status so that appropriate action can be taken, where necessary. 
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Chapter 4                                             
Gestational changes in iodine status of pregnant 
women 
 
4.1 Introduction  
Iodine status in populations is usually assessed by the median urinary iodine 
concentration (UIC) measured in spot-urine samples – a method recommended by the 
World Health Organisation (WHO) (WHO 2007a). The WHO recommends that the 
median UIC is compared to median-UIC cut-offs that define population iodine status; 
median UIC <150 µg/L is used to define iodine deficiency in pregnant populations (WHO 
2007a). In healthy non-pregnant individuals with adequate iodine intake, the iodide 
metabolism is in equilibrium (Glinoer 2004) and UIC is a good reflection of recent dietary 
iodine intake (i.e., the last 24-48 hours), with approximately 90% excreted in the urine 
(Zimmermann and Andersson 2012). Pregnancy, however, may not represent a steady-
state of iodine metabolism (intake vs excretion) (Glinoer 2004) and the amount of iodine 
excreted in the urine may not be a good representation of recent dietary iodine intake. A 
number of physiological changes that occur at different points during gestation can alter 
the preconception steady-state (Glinoer 2004), including increased renal iodide clearance, 
increased synthesis of thyroid hormones and increased transfer of iodide and thyroid 
hormones from the mother to the fetus (Delange 2007). Pregnancy is, thus, a special case 
and these changes can complicate the assessment of iodine status in this population group. 
 
Current WHO median-UIC thresholds for iodine adequacy in pregnant populations refer 
to the entire duration of gestation (WHO 2007a); it is unclear whether gestation-specific 
UIC cut-offs are necessary, considering the physiological changes that occur during 
pregnancy. There is conflicting evidence regarding the dynamics of urinary iodine 
excretion across pregnancy [measured as UIC or urinary iodine-to-creatinine ratio 
(UI/Creat)], with studies reporting an increase, a decrease or no change with advancing 
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gestation (Fuse et al. 2013; Bath et al. 2015). In previous cross-sectional analyses 
(Chapter 3), gestational age up to 18 weeks was positively associated with UI/Creat after 
adjusting for maternal diet, suggesting that the amount of iodine excreted in urine might 
change over the course of pregnancy and the time-point at urine sampling might be an 
important factor in evaluating the iodine status of pregnant populations. 
 
The aim of this study, therefore, was to assess the changes in urinary iodine concentration 
longitudinally in pregnancy using repeated measurements from spot-urine samples 
collected at three time-points during pregnancy. 
4.1.1 Hypothesis 
It was hypothesised that urinary iodine concentration (expressed as UI/Creat) would 
increase with advancing pregnancy. 
 
 
4.2 Methods 
4.2.1 Study population  
This study used data and urine samples from pregnant women recruited as part of the 
Avon Longitudinal Study of Parents and Children (ALSPAC), a population-based 
prospective birth cohort (Boyd et al. 2013; Fraser et al. 2013). Briefly, 14,541 pregnant 
women from the Bristol area in the South-West of England with delivery expected 
between April 1991 and December 1992 were recruited during pregnancy and followed 
up. Ethical approval for the ALSPAC cohort had been obtained prior to the recruitment 
(see Chapter 2). The current study was based on secondary analyses of the collected 
ALSPAC data hence ethical approval was not required. 
4.2.2 Selection criteria for the current study 
This study was focused on ALSPAC women who provided multiple urine samples during 
pregnancy and had their urinary iodine and creatinine concentrations previously measured 
(details provided in Chapters 2 and 3). Women who had thyroid disease (e.g., hypo- or 
hyperthyroidism), used thyroid-related/iodine-containing medication [including kelp or 
potassium iodide (KI) supplements], or had a multiple pregnancy were excluded from the 
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analyses (Figure 4.1). Women with potentially contaminated urine samples were also 
excluded (for more details, see Section 4.2.3).  
4.2.3 Urinary iodine and creatinine measurements  
Women included in these analyses had up to three measurements of urinary iodine and 
creatinine concentrations from spot-urine samples collected during pregnancy (Figure 
4.1). After all exclusions were applied, only one woman had provided a fourth urine 
sample; this was not included in further analyses. In the total ALSPAC sample, the 
median gestational week at the three urine-sample collections was 12, 17 and 34 weeks, 
respectively. Gestational week was established using the date of the last menstrual period. 
The full details of the laboratory measurements of urinary iodine and creatinine 
concentrations have been provided in a previous chapter (Chapter 2). As explained in 
detail elsewhere (Chapter 2, Chapter 3, Chapter 5), to account for the variability in UIC 
that is due to individual hydration status, UIC was adjusted for urinary creatinine 
concentration by using UI/Creat. 
 
There was a concern that some urine samples were contaminated as a result of the use of 
iodine-containing test-strips (Pearce et al. 2009). For that reason, urine samples collected 
at each time-point in pregnancy that had measured values for UIC >500 µg/L and/or 
UI/Creat >700 µg/g were classified as problem urines [n=413 (11.8%) samples at the first 
urine-sample collection; n=122 (19.7%) samples at the second urine-sample collection; 
n=91 (27.3%) samples at the third urine-sample collection] and were excluded from 
further analyses (in total 413 women had samples that were probably contaminated). As 
previously, these UIC and UI/Creat cut-offs were based on previous work in the ALSPAC 
cohort and other studies of UK pregnant women (Chapter 3). For women who had 
multiple urinary iodine and creatinine measurements (i.e., from more than one time-point 
in pregnancy), if a sample was potentially contaminated and excluded, the results from 
the next available uncontaminated urine sample (and the gestational week at urine 
sampling) were used (i.e., samples were moved forward). A total of 50 contaminated 
samples were replaced with later samples for 50 women; in total 363 (10.4%) women 
were excluded from the analyses (Figure 4.1). 
 
61 
 
1 Urine samples with UIC > 500 µg/L or UI/Creat > 700 µg/g were excluded, as there was a concern that 
these samples could have been potentially contaminated by the use of iodine-containing test-strips. A 
number of the excluded potentially contaminated samples were replaced with a later uncontaminated 
sample, if available; this is, therefore, the final number of excluded contaminated samples after a few were 
replaced (for more details see ‘Methods’ Section 4.2.3). Abbreviations: ALSPAC, the Avon Longitudinal 
Study of Parents and Children; KI, potassium iodide; UIC, urinary iodine concentration; UI/Creat, urinary 
iodine-to-creatinine ratio 
 
Data unavailable:  
Urinary iodine and creatinine 
concentrations not measured 
N=11,036 
Enrolled during pregnancy 
in ALSPAC (Phase I) 
N=14,541 
 
Urinary iodine and 
creatinine measured 
N=3,505 
 
At least one urinary iodine 
and creatinine measurement 
available  
N=3,122 
Exclusions: 
Total N=383 
Multiple pregnancy, N=0 
Thyroid disease, N=17 
(16 hypothyroidism and 1 
hyperthyroidism) 
Thyroid-related/iodine-containing 
medication (including kelp and KI 
supplements), N=20 
Potentially contaminated samples 
(UIC > 500 µg/L or UI/Creat > 700 µg/g), 
N=3631 
Two urinary iodine and 
creatinine measurements 
available  
N=486 
Three urinary iodine and 
creatinine measurements 
available   
N=203 
Figure 4. 1  Flow chart of the study population selection from the ALSPAC cohort 
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4.2.4 Dietary assessment  
As milk-intake was a significant dietary predictor of UI/Creat in our previous cross-
sectional analyses in ALSPAC (Dineva et al. 2019) and in another study in UK pregnant 
women (Bath et al. 2015), the effect of habitual milk intake on the changes in maternal 
UI/Creat over the course of pregnancy was explored in the current study. Maternal diet 
in ALSPAC was assessed with an unquantified food-frequency questionnaire (FFQ), self-
administered at 32 weeks. More detailed information about the design of the FFQ and the 
food-intake calculations have been provided previously (Chapters 2 and 3).  For the 
current study, the estimated milk intake was used as a continuous variable (g/day), and 
also to form milk-intake groups based on portion size (≤1 glass/day vs >1 glass/day) 
(Food Standards Agency 2002).  
4.2.5 Statistical analyses 
This study aimed to investigate the agreement between repeated urinary iodine 
measurements during pregnancy and explore the gestational changes in UIC and 
UI/Creat. None of the three measurements of UIC, urinary creatinine concentration and 
UI/Creat during pregnancy were normally distributed (they were right-skewed), therefore 
medians (25-75th percentiles) were reported. In the group of women who had provided 
multiple spot-urine samples (at two or three time-points in pregnancy), the correlations 
between the repeated measurements of UIC, urinary creatinine and UI/Creat (roughly 
from the first, second and third trimesters) were examined using Spearman’s rank 
correlation (rs).  
 
The association of gestational week with UIC, urinary creatinine concentration and 
UI/Creat was explored cross-sectionally (at each measurement time-point) and 
longitudinally (across all three measurement time-points).  
 
Cross-sectionally, the association of gestational week with maternal UIC, urinary 
creatinine and UI/Creat was explored separately at each measurement time-point in 
pregnancy using univariable and multiple linear regression models. These models were 
performed in all women who had at least one measurement and also in those who had all 
three measurements during pregnancy (most of these women had one measurement in 
each trimester). To comply with the assumption of normality of the residuals in regression 
analysis, UIC and UI/Creat were transformed using the natural logarithm. As a number 
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of creatinine values were > 0 and < 1 (resulting in negative values when transformed with 
the natural logarithm), a constant of 1 was added to all creatinine values prior to natural 
log-transformation. The residuals of each model were assessed for normality by visual 
inspection of histograms. Box-plots were visually inspected to assess outliers. Non-
linearity of the association between gestational week and UIC, urinary creatinine and 
UI/Creat at each time-point was evaluated by including non-linear higher-order 
polynomial trends in the regression models (i.e., quadratic and cubic terms for gestational 
week), by visually inspecting the scatterplots of gestational week against the iodine and 
creatinine measures and comparing the fit (R2) of a linear vs quadratic vs cubic function 
through the data points. The multiple regression models were adjusted for maternal age 
(years), pre-pregnancy body mass index (BMI, kg/m2), daily milk intake (g/day), family 
adversity index and marital status. These covariates were selected based on our previous 
analyses of the determinants of iodine status in ALSPAC (Chapter 3) and were also 
informed by a previous UK study investigating the gestational changes in urinary iodine 
concentration  (Bath et al. 2015).  
 
To investigate, longitudinally, the trajectory of UIC, urinary creatinine and UI/Creat 
during pregnancy, only women who had three repeated measurements (predominantly 
one in each trimester) were included. To examine the mean gestational changes across 
trimesters, repeated-measures analyses of variance (ANOVA) were used with (natural) 
log-transformed UIC or urinary creatinine or UI/Creat from the three trimesters as the 
repeated dependent variable and with trimester at urine sampling as the within-subject 
factor. The assumption of sphericity was assessed using the Mauchly’s test of sphericity. 
If sphericity was violated (P<0.05), the results were reported after the Greenhouse-
Geisser correction. If a within-subject main effect of trimester was observed, post-hoc 
tests of the differences in means between trimesters were also performed and the P-values 
were adjusted for multiple comparisons with the Bonferroni correction. Geometric mean 
ratios [and their 95% confidence intervals (CIs)] of UIC, urinary creatinine and UI/Creat 
between trimesters were calculated by exponentiation of the respective logarithmic-scale 
mean differences between trimesters (and their 95% CIs). To investigate the effect of the 
interactions between covariates (e.g., maternal age, pre-pregnancy BMI and daily milk 
intake) and the within-subject factor (i.e., trimester) on UIC, urinary creatinine and 
UI/Creat, repeated-measures analyses of covariance (ANCOVA) were performed. As 
recommended (Schneider et al. 2015), all covariates used in the ANCOVA were centred 
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to the mean by subtracting the mean from each value. To investigate whether the changes 
in UIC and UI/Creat over the trimesters were different depending on maternal habitual 
milk intake (estimated from the FFQ), a mixed-design ANOVA with one between-subject 
factor with two levels (milk intake groups ≤1 glass/day vs >1 glass/day) and one within-
subject factor with three levels (trimester) was used. As only five women did not consume 
any milk, it was not possible to split women into groups of non-consumers vs consumers 
of milk.  
 
As repeated-measures ANOVA assumes a common trend over time for all individuals in 
the sample, the necessity of modelling trends for individuals within the sample was 
assessed by calculating the interclass correlation coefficient (ICC) (Shek and Ma 2011). 
ICC measures the proportion of the total variability in the dependent variable (i.e., UIC, 
urinary creatinine and UI/Creat) that is explained by between-individual differences 
(Shek and Ma 2011). It can vary from 0 to 1 and the closer to 1, the smaller is the within-
individual variability (i.e., indicating stability of the outcome variable over time) and the 
larger the between-individual variability. Low ICC suggests that the between-individual 
variability is relatively small and the trends over time are similar across the sample of 
individuals, thus accounting for individual trajectories over time may not be necessary 
(Curran et al. 2010; Shek and Ma 2011). It has been reported that an ICC of 0.25 or higher 
indicates that a more complex model (e.g., individual growth curves) is required (Shek 
and Ma 2011).  
 
Prior to statistical analyses, missing values on maternal characteristics (excluding FFQ 
data) were imputed for all women included in the analyses using multiple imputation. 
Full details about this procedure and the imputed variables have been provided elsewhere 
(Chapter 2). Multiple imputation and all statistical analyses were performed with IBM 
SPSS Statistics version 25.0 (IBM Corp., Armonk, NY, USA). Statistical significance 
was set at P<0.05. 
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4.3 Results 
4.3.1 Sample characteristics 
After all exclusions, a total of 3,122 women provided at least one uncontaminated urine 
sample during pregnancy, of whom 486 and 203 provided two and three urine samples, 
respectively (Figure 4.1). The characteristics of the included women who provided at least 
two urine samples and of those who provided all three samples are presented in Table 
4.1. Briefly, the mean [± standard deviation (SD)] age of all women was 28.6 (±4.5) years 
and the median pre-pregnancy BMI was within the healthy range. The vast majority of 
women defined themselves as White and were non-smokers (Table 4.1). 
4.3.2 Iodine status from repeated measurements 
The median UIC and UI/Creat at each measurement time-point in the sample of women 
with repeated measures (i.e., those who provided at least two urine samples in pregnancy) 
were: 98 µg/L and 104 µg/g at median (25-75th percentile) 9 (6 - 11) weeks (n=486); 102 
µg/L and 172 µg/g at 17 (16 - 19) weeks (n=486); and 135 µg/L and 161 µg/g at 34 (33 - 
35) weeks (n=203). According to the WHO population median-UIC cut-offs for iodine 
adequacy in pregnancy (WHO 2007a; Zimmermann 2007), this group of pregnant women 
was classified as mildly-to-moderately iodine-deficient at all three time-points in 
pregnancy. The median (25-75th percentile) UIC and UI/Creat during pregnancy in the 
group of women who provided all three urine samples (predominantly one in each 
trimester) (n=203) are presented in Figure 4.2 (A-C); the distribution of values at each 
time-point are shown in Figure 4.3 (A-C). As with the larger group, this smaller group 
of women was also classified as iodine-deficient in all three trimesters by median UIC.  
 
Table 4. 1  Characteristics of the study population from the ALSPAC cohort 
 ALSPAC cohort 
Characteristics 1 Women with at least 
two urine samples 
(n=486) 
 
Women with all three 
urine samples 
(n=203) 
Maternal factors    
Maternal age 2,3 (years), mean (±SD) 28.7 (±4.5)  28.5 (±4.4) 
Pre-pregnancy BMI (kg/m2), median (25-75th) 22.6 (20.5 - 24.9)  22.4 (20.4 - 24.7) 
Ethnicity, n (%)    
    White 475 (97.7%)  197 (97.0%) 
    Non-white 11 (2.3%)  6 (3.0%) 
(continued on next page) 
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Table 4.1 Characteristics of the study population from the ALSPAC cohort (continued) 
 ALSPAC cohort 
Characteristics 1 Women with at least 
two urine samples 
(n=486) 
 
Women with all three 
urine samples 
(n=203) 
Maternal factors (continued) 
Parity, n (%)    
    0 239 (49.2%)  120 (59.1%) 
    1 166 (34.1%)  55 (27.1%) 
    ≥ 2 81 (16.7%)  28 (13.8%) 
Smoking status, n (%)    
    Never smoked 386 (79.4%)  169 (83.2%) 
    Stopped smoking 46 (9.5%)  18 (8.9%) 
    Continued smoking 54 (11.1%)  16 (7.9%) 
Alcohol consumption, n (%)    
    No 256 (52.7%)  107 (52.9%) 
    Yes 230 (47.3%)  96 (47.1%) 
Markers of socio-economic status 
Education level, n (%)    
    Low 86 (17.7%)  36 (17.7%) 
    Medium 319 (65.6%)  131 (64.6%) 
    High 81 (16.7%)  36 (17.7%) 
Home ownership, n (%)    
    Owned/mortgaged 439 (90.3%)  187 (92.1%) 
    Private/other rented 33 (6.8%)  12 (5.9%) 
    Council rented 14 (2.9%)  4 (2.0%) 
Crowding index, n (%)    
    ≤1 person per room 475 (97.7%)  199 (98.0%) 
    +1 person per room 11 (2.3%)  4 (2.0%) 
Family adversity index, n (%)    
    None (0) 264 (54.3%)  117 (57.6%) 
    Mild (1-2) 171 (35.2%)  67 (33.0%) 
    Severe (≥3) 51 (10.5%)  19 (9.4%) 
Life event score, median (25-75th) 3.0 (2.0 - 5.0)  3.0 (2.0 - 5.0) 
Marital status, n (%)    
    Married 409 (84.2%)  170 (83.7%) 
    Never-married 56 (11.5%)  27 (13.3%) 
    Other 4 21 (4.3%)  6 (3.0%) 
Living with a partner, n (%)    
    Yes 466 (95.9%)  195 (96.1%) 
    No 20 (4.1%)  8 (3.9%) 
Child factors    
Child’s sex 3, n (%)    
    Male 248 (51.0%)  103 (50.7%) 
    Female 238 (49.0%)  100 (49.3%) 
1 Data are presented as mean (±SD) for all continuous normally distributed variables, median (25-75th percentile) for 
all continuous non-normally distributed variables and n (%) for the categorical variables. 2 Maternal age at last 
menstrual period. 3 For women with at least two urine samples (n=486) data were not imputed for maternal age and 
child’s sex due to no missing values; the rest of the data are shown after multiple imputation of the missing values (see 
‘Methods’ Section 4.2.5). 4 Other=widowed, divorced, or separated. Abbreviations: ALSPAC, Avon Longitudinal 
Study of Parents and Children; BMI, body mass index; SD, standard deviation 
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Figure 4. 2  Changes in maternal UIC, Creatinine and UI/Creat during pregnancy in 
women with three repeated measurements 
The boxes and whiskers represent the median and 25-75th percentile, respectively, for maternal UIC (A), 
Creatinine (B) and UI/Creat (C) in each trimester. Median (25-75th percentile) gestational week at urine 
sampling in each trimester is 9.0 (7.0 - 11.0) weeks in the first trimester, 17.0 (16.0 - 18.0) weeks in the 
second trimester and 34.0 (33.0 - 35.0) weeks in the third trimester. Results are based on 203 women who 
provided three consecutive urine samples during pregnancy (one in each trimester). Abbreviations: 
UI/Creat, iodine-to-creatinine ratio; UIC, urinary iodine concentration 
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Figure 4. 3  Scatter plots of maternal UIC (A), Creatinine (B) and UI/Creat (C) at the 
three urine-sampling time-points during pregnancy in women with three repeated 
measurements  
Individual symbols represent the values for the individual women at the three consecutive urine-sampling 
time-points during pregnancy at median (min – max) 9.0 (3.0 – 13.0) weeks (measurement 1 ◇), 17.0 (11.0 
– 27.0) weeks (measurement 2 ) and 34.0 (26.0 – 40.0) weeks (measurement 3 ), respectively. 
Abbreviations: UI/Creat, iodine-to-creatinine ratio; UIC, urinary iodine concentration 
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The iodine status of the whole group of ALSPAC women (i.e., those who provided at 
least one urine sample in pregnancy) are provided in Supplemental Table 4.1 (Appendix 
I). 
 
In the sample of women with repeated measures, there were significant but only weak 
correlations between the repeated UIC, creatinine and UI/Creat measurements during 
pregnancy (Table 4.2). In women who provided a urine sample in each trimester, 
UI/Creat measured in the first trimester (median 9 weeks) was only weakly correlated 
with the UI/Creat measured in the second trimester (median 17 weeks) (rs=0.22, P=0.002, 
n=203) and it was not correlated with the measures from the third trimester (median 34 
weeks) (rs=0.02, P=0.796, n=203). UI/Creat measures from the second and third 
trimesters were not significantly correlated (rs=0.12, P=0.097, n=203). 
 
 
Table 4. 2  Correlations between repeated measurements of maternal UIC, Creatinine and 
UI/Creat during pregnancy 
UIC  First UIC  Second UIC  Third UIC 
First UIC  N/A  0.15**  0.08 
Second UIC  -  N/A  0.13 
Third UIC   -  -  N/A 
       
Creatinine  First Creatinine  Second Creatinine  Third Creatinine 
First Creatinine   N/A  0.08  0.18* 
Second Creatinine  -  N/A  0.10 
Third Creatinine  -  -  N/A 
       
UI/Creat  First UI/Creat  Second UI/Creat  Third UI/Creat 
First UI/Creat  N/A  0.20***  0.02 
Second UI/Creat  -  N/A  0.12 
Third UI/Creat  -  -  N/A 
Correlation values are Spearman’s rank correlation coefficients (rs). N=486 for correlations with all second 
measurements and N=203 for correlations with all third measurements. * P<0.05; ** P=0.001; *** P<0.001; 
Abbreviations: N/A, not applicable; UI/Creat, iodine-to-creatinine ratio; UIC, urinary iodine concentration 
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4.3.3 Gestational changes in UIC, Creatinine and UI/Creat 
4.3.3.1 Association of gestational week with UIC, Creatinine and UI/Creat (cross-
sectional analyses) 
In women who provided all three urine samples during pregnancy (predominantly one in 
each trimester), gestational week was positively associated with maternal UIC and 
UI/Creat within the first trimester only [minimum (min) – maximum (max): 3-13 weeks] 
(Table 4.3). For every 1-week increase, UIC increased by 4% [exponentiated B (95% CI) 
= 1.04 (1.00, 1.08)] and UI/Creat increased by 6% [exponentiated B (95%) = 1.06 (1.02, 
1.09)]. There was no statistically significant association between gestational week and 
urinary creatinine concentration in any of the three trimesters (Table 4.3). 
 
In all women who provided at least one urine sample during pregnancy, gestational week 
was non-linearly associated with UIC, urinary creatinine and UI/Creat at the first 
measurement time-point (min – max: 1-42 weeks), exhibiting a quadratic trend over time 
(Supplemental Table 4.2, Appendix I). At the second measurement time-point (min – 
max: 9-42 weeks), there was a linear positive association of gestational week with UIC, 
which increased by 2% per 1-week increase [exponentiated B (95% CI) = 1.02 (1.01, 
1.03)], while UI/Creat rate of change was not constant over time, as the association of 
gestational week with UI/Creat exhibited a cubic trend over time (Supplemental Table 
4.2). At the third-measurement time-point (min – max: 26-40 weeks), gestational week 
was not associated with UIC or urinary creatinine or UI/Creat (Supplemental Table 4.2). 
4.3.3.2 Changes in UIC, Creatinine and UI/Creat across trimesters (longitudinal 
analyses) 
In women who provided urine samples roughly in each trimester during pregnancy 
(n=203), UIC, urinary creatinine concentration and UI/Creat changed significantly with 
advancing gestation (P<0.001) (Table 4.4). Maternal UIC and UI/Creat increased 
significantly across trimesters, while urinary creatinine concentration decreased [Figure 
4.2 (A-C)]. In comparison to their concentrations in the first trimester, by the third 
trimester, UIC and UI/Creat had increased on average by 30% and 62%, respectively 
(Table 4.4). By contrast, maternal creatinine concentration decreased by 10% on average 
in the third trimester, compared to its first-trimester concentration (Table 4.4). Over the 
course of the three trimesters, the largest average rate of increase in UIC was between the 
second and the third trimesters, while the steepest average increase in UI/Creat occurred 
between the first and second trimesters.  
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Table 4. 3  Association of gestational week with maternal UIC, Creatinine and UI/Creat in each trimester for women who provided three repeated 
urine samples during pregnancy 
  First trimester (n=203)  Second trimester (n=203)  Third trimester (n=203) 
  B (95% CI) P  B (95% CI) P  B (95% CI) P 
UIC, µg/L          
Model 1 1          
Gestational week (linear)  0.042 (0.004, 0.080)  0.032  0.022 (-0.017, 0.061) 0.274  -0.008 (-0.057, 0.040) 0.734 
Creatinine, g/L          
Model 1 1          
Gestational week (linear)  -0.008 (-0.023, 0.006) 0.242  0.000 (-0.013, 0.013) 0.980  -0.002 (-0.017, 0.012) 0.757 
UI/Creat, µg/g          
Model 1 1          
Gestational week (linear)   0.054 (0.022, 0.086) 0.001  0.019 (-0.011, 0.050) 0.216  -0.002 (-0.038, 0.034) 0.921 
1 Effect estimates (B=unstandardised regression coefficients), their 95% CI and P-values are from multiple linear regression models performed for each time-point at urine 
sampling (i.e., in each trimester) with (natural) log-transformed UIC or Creatinine or UI/Creat as the dependent variable and gestational week at each urine sampling as the 
independent variable. Models were adjusted for maternal age (years), pre-pregnancy BMI (kg/m2), milk intake (g/day), family adversity index and marital status. Reported B 
coefficients represent the change in the mean (natural) log of UIC (µg/L), Creatinine (g/L) and UI/Creat (µg/g) per one week increase in gestational age at urine sampling. 
Abbreviations: BMI, body mass index; 95% CI, confidence interval; UI/Creat, iodine-to-creatinine ratio; UIC, urinary iodine concentration 
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Table 4. 4  Repeated-measures ANOVA exploring the effect of advancing pregnancy on maternal UIC, Creatinine and UI/Creat 
 Geometric mean ratio (95% CI) 1  P 2  F (df, error df)  Partial  η2  Overall P 3 
UIC, µg/L     11.313 (2, 404)  0.053  <0.001 
    Trimester 1 UIC 1.00 (Ref.)         
    Trimester 2 UIC 0.93 (0.78, 1.11)   1.000       
    Trimester 3 UIC 1.30 (1.10, 1.54)  0.001       
          
    Trimester 2 UIC 1.00 (Ref.)         
    Trimester 3 UIC 1.40 (1.16, 1.68)  <0.001       
Creatinine, g/L 4     28.017 (1.9, 391)  0.122  <0.001 
    Trimester 1 Creatinine 1.00 (Ref.)         
    Trimester 2 Creatinine 0.83 (0.78, 0.89)  <0.001       
    Trimester 3 Creatinine 0.90 (0.85, 0.95)  <0.001       
          
    Trimester 2 Creatinine 1.00 (Ref.)         
    Trimester 3 Creatinine 1.08 (1.02, 1.14)  0.005       
UI/Creat, µg/g     42.475 (2, 404)  0.174  <0.001 
    Trimester 1 UI/Creat 1.00 (Ref.)         
    Trimester 2 UI/Creat 1.50 (1.32, 1.71)  <0.001       
    Trimester 3 UI/Creat 1.62 (1.41, 1.87)   <0.001       
          
    Trimester 2 UI/Creat 1.00 (Ref.)         
    Trimester 3 UI/Creat 1.08 (0.94, 1.24)  0.490       
1 Geometric mean ratios represent the ratios of the geometric mean of UIC, Creatinine or UI/Creat in each trimester and their respective geometric mean in the reference 
trimester. Geometric mean ratios and their 95% CIs were calculated by exponentiation of the logarithmic-scale mean differences (in UIC, Creatinine and UI/Creat) between 
trimesters and their 95% CIs from repeated-measures analysis of variance (ANOVA) with (natural) log-transformed UIC or Creatinine or UI/Creat from the three trimesters as 
the repeated dependent variable and trimester at urine sampling as the within-subject factor. 2 P-values are from post-hoc tests of the differences in means between trimesters 
and are adjusted for multiple comparisons with the Bonferroni correction. 3 P-values for the overall mean change in UIC, Creatinine and UI/Creat during pregnancy from 
repeated-measures ANOVA with (natural) log-transformed UIC or Creatinine or UI/Creat from the three trimesters as the repeated dependent variable and trimester at urine 
sampling as the within-subject factor. 4 Results for Creatinine are from repeated-measures ANOVA with a Greenhouse-Geisser correction. Abbreviations: ANOVA, analyses 
of variance; 95% CI, confidence interval; df, degrees of freedom; Ref., reference; UI/Creat, iodine-to-creatinine ratio; UIC, urinary iodine concentration 
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The mean change in UIC and UI/Creat over the three trimesters was similar between the 
two groups of women with different habitual milk intake (≤ 1 glass/day vs >1 glass/day) 
(UIC P-interaction=0.981; UI/Creat P-interaction=0.774). There were no significant 
interactions between maternal age and trimester (at the 5% or 10% level), between pre-
pregnancy BMI and trimester (at the 5% level) or between milk intake and trimester (at 
the 5% or 10% level) in relation to UIC, urinary creatinine or UI/Creat (data not shown). 
 
Based on the ICC calculations, 5% (ICC=0.05) and 8% (ICC=0.08) of the total variability 
in UIC and UI/Creat, respectively, were explained by between-individual differences. 
Between-individual differences accounted for 8% (ICC=0.08) of the total variability in 
urinary creatinine concentration.  
 
 
4.4 Discussion 
The aim of this study was to assess the changes in urinary concentration (expressed as 
UIC and UI/Creat) during pregnancy using three repeated spot-urine iodine 
measurements. As hypothesised, in this cohort of pregnant women, urinary iodine 
concentration increased over the course of gestation; in comparison to their 
concentrations in the first trimester, by the third trimester, UIC and UI/Creat increased on 
average by 30% and 62%, respectively. The repeated measurements of urinary iodine 
(expressed as UIC and UI/Creat) from three different time-points in pregnancy were only 
weakly correlated. 
 
The longitudinal analyses with repeated measures during pregnancy in this study 
confirmed the findings of an association between gestational week and maternal UI/Creat 
from the previous cross-sectional analyses in ALSPAC (Chapter 3). The current study 
was focused on a smaller sample of pregnant women with repeated measures and for this 
group, UI/Creat increased across trimesters. A positive association between gestational 
week and UI/Creat was also found cross-sectionally, such that within the first trimester, 
for every 1-week increase, UI/Creat increased by 6%. This effect-size was similar to that 
of our previous study that included a larger sample of women with UI/Creat measured up 
to 18 weeks (Chapter 3).  
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There are a few possible reasons for the changes in UI/Creat with advancing pregnancy. 
A number of physiological events occur at different time-points during pregnancy, such 
as an increase in renal blood flow and glomerular filtration rate (GFR) beginning in the 
first weeks of gestation and an increased transfer of iodine from the maternal circulation 
to the fetus that occurs later in gestation (Glinoer 2004). Renal plasma flow increases up 
to 80% and GFR increases by approximately 50% during pregnancy (Cheung and 
Lafayette 2013). A marked change in GFR was previously observed 5-7 weeks after the 
last menstrual period (Davison and Dunlop, 1980). Renal iodide clearance is mainly 
dependent on GFR, as there is no evidence of tubular secretion or active transport, and 
reabsorption of iodide is mainly passive (Soldin 2002). The overall increase in UI/Creat 
from the first trimester (median 9 weeks) to the second trimester (median 17 weeks) in 
this study may therefore be as a result of this increase in GFR that leads to an increased 
renal iodide clearance. The fetal thyroid becomes functional towards the end of the first 
trimester (Burrow et al. 1994) and its ability to accumulate iodine is evident by 12 weeks 
when its iodine concentrating capacity starts to increase progressively,  reaching a peak 
at around 24 weeks (Richard et al. 2012). The lack of further change in UI/Creat between 
the second and third trimester might be as a result of increasing transfer of maternal 
circulating iodide to the fetus with less being lost in the urine. The role of the placenta in 
iodide metabolism during pregnancy is not yet well understood (Burns et al. 2011). If 
iodide is increasingly transferred/stored in the placenta a decrease in urinary iodine 
excretion (measured as UI/Creat) would be expected in later pregnancy.   
 
Alternatively, the overall increase in UI/Creat from the first to the third trimester could 
be explained by an increase in the dietary intake of iodine-rich foods (e.g., milk and dairy 
products) with advancing gestation. Though, data on maternal diet from multiple time-
points in pregnancy were not available to evaluate this effect in ALSPAC, the single 
measurement of diet from the FFQ was used to explore whether habitual milk intake 
modified the change in urinary iodine across trimesters. Milk iodine concentration in the 
UK is higher in winter than in summer (Stevenson et al. 2018) and as milk and dairy 
products are the main source of iodine in the UK diet (Public Health England 2018), this 
seasonal change in milk iodine concentration could result in a seasonal change in iodine 
status (Vanderpump et al. 2011). As pregnancy spans seasons, the effect of advancing 
gestation on UI/Creat could therefore be explained by the change in iodine content of 
milk with season (increasing from summer to winter) (Bath et al. 2015). In a previous UK 
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study, the effect of season on the gestational changes in UI/Creat (steeper increase in 
winter vs summer) was most pronounced in high-milk consumers (>280 ml/day) (Bath et 
al. 2015). In the current study, the increase in UI/Creat was equivalent in women who 
consumed less than a glass of milk and in those who consumed more than a glass daily. 
This suggests that the increase in UI/Creat with advancing pregnancy observed in this 
cohort of pregnant women is unlikely explained by season (i.e., through its effect on milk 
iodine concentration). The difference in the trajectory of UI/Creat across trimesters 
between non-consumers and consumers of milk could not be explored, as in this sample 
of pregnant women, only five women did not consume any milk. In addition, as women 
who used any type of iodine-containing medication, including potassium iodide or kelp 
supplements, were excluded from the study, changes during pregnancy are unlikely to be 
attributable to iodine-supplement use. 
 
It is also important to note that the proportion of women with potentially-contaminated 
urine samples was greatest at the last urine-sampling time-point in pregnancy (see 
‘Methods’ Section 4.2.3). Although women were excluded on the basis of previously-
used cut-offs for UIC and UI/Creat, the effect of residual contamination of those late 
samples cannot be excluded. However, similar results that showed an increase in UI/Creat 
with advancing gestation were also found in a previous study of UK pregnant women 
where there was no risk of iodine contamination by the use of dip-sticks (Bath et al. 2015). 
 
Although significant, the changes in UI/Creat with advancing gestation observed in this 
study were relatively small and the results may not be applicable to other pregnant 
populations. Similar trends of increasing UI/Creat during pregnancy were found in some 
previous studies (Fuse et al. 2011; Fuse et al. 2013; Moreno-Reyes et al. 2013; Bath et 
al. 2015; Li et al. 2016) but not in others (Smyth et al. 1997; Brander et al. 2003). Studies 
that used UIC (instead of UI/Creat) similarly reported mixed results with regard to the 
effect of advancing gestation: UIC increased (Aguayo et al. 2013; Caldwell et al. 2013; 
Moreno-Reyes et al. 2013); decreased (Brander et al. 2003; Ainy et al. 2007; Stilwell et 
al. 2008; Tahirović et al. 2009; Li et al. 2016); or remained unchanged (Koukkou et al. 
2002; Vila et al. 2008; Alvarez-Pedrerol et al. 2010; Luton et al. 2011; Fuse et al. 2013).  
 
As discussed above, there are two potential explanations for the observed changes in 
UI/Creat during pregnancy. Firstly, if the increase in UI/Creat with advancing gestation, 
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as reported in this study, is the result of physiology, urine samples collected at different 
time-points in pregnancy might not truly reflect dietary iodine availability. Time-point at 
urine sampling might, therefore, be an important factor to consider when assessing the 
iodine status of pregnant populations, as suggested in some previous studies (Stilwell et 
al. 2008; Bath et al. 2015). If our results are replicated in future studies, particularly if 
they have larger numbers of repeat urine samples together with dietary assessments to 
account for underlying dietary changes, trimester-specific cut-offs may well be necessary 
to classify the iodine status of pregnant populations. Secondly, if the changes in UI/Creat 
are related to dietary change, the results of this study highlight the fact that a single urinary 
iodine measurement at one time-point in pregnancy is not representative of iodine status 
at other points in pregnancy. The repeated urinary-iodine measures in the three trimesters 
were only weakly correlated. The small ICCs also suggested poor reproducibly of the 
repeated measures from the same individual (i.e., large within-individual variability). As 
a result of the large within-individual, day-to-day differences in urinary-iodine 
concentration that result from variation in daily iodine intake and hydration (i.e., urine 
volume) (Andersen et al. 2008; Vejbjerg et al. 2009; König et al. 2011), poor agreement 
between repeated spot-urine iodine measurements is to be expected. Although the use of 
UI/Creat can account for the variation in hydration status and is a better reflection of daily 
iodine intake than UIC alone, especially when used in homogenous population groups 
(i.e., of the same sex and age-range) (Rasmussen et al. 1999; Knudsen et al. 2000; 
Andersen et al. 2008; König et al. 2011; Li et al. 2016), at least ten measurements of 24-
hour urinary iodine excretion are required to estimate iodine status in an individual (König 
et al. 2011). The limited ability of a single measurement of urinary iodine (from spot- or 
24-hour urine samples) to provide information about individual habitual iodine intake, 
has directed attention to other biomarkers reflective of longer-term iodine intake and also 
indicative of thyroid function, such as the thyroid-specific glycoprotein, thyroglobulin 
(Tg) (Pearce and Caldwell 2016). The usefulness of Tg as a biomarker of iodine status 
has been widely explored in schoolchildren (Zimmermann et al. 2013) and adults (Chong 
et al. 2015; Ma et al. 2016) but not as much in pregnant populations (Bath, Pop, et al. 
2017). The usefulness of Tg as a biomarker of iodine status in pregnancy was investigated 
and discussed in detail in Chapter 5. 
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4.4.1 Strengths and limitations 
A strength of this study was the use of repeated iodine measures in the same women to 
assess the changes during pregnancy. A repeated-measures design is much more powerful 
(as opposed to a cross-sectional design), as each individual serves as their own control 
when observing the changes over time (Singh et al. 2013).  
 
There are a number of limitations to consider: 
1. Firstly, although most women who had three urinary iodine measurements had 
provided a urine sample in each trimester, the number of weeks between the repeated 
samples was not consistent between women (i.e., in some women the repeated 
samples were closer together, while in others they were further apart).  
 
2. Secondly, women who had all three urinary iodine measurements were a selected 
group that constituted only a small proportion of the total sample of women who had 
at least one urinary-iodine measurement during pregnancy (6.5%); thus, this smaller 
group may not be representative of the general pregnant population. A comparison 
between ALSPAC women with a single iodine measurement and those with multiple 
measurements is provided in Chapter 6 (Supplemental Table 6.1, Appendix I) and 
the potential selection bias is discussed. 
 
3. Thirdly, the sample of women in this study was classified as mildly-to-moderately 
iodine-deficient and the conclusions may well not be the same in a setting with 
different iodine status. As discussed previously, the results of the gestational changes 
in urinary iodine concentration from previous studies are conflicting and this might 
be partly explained by differences in iodine status and thyroid iodine stores. For 
instance, in a setting with even lower iodine status, a decline in urinary iodine 
concentration during pregnancy might be expected, resulting from an adaptation to 
up-regulate iodide trapping in the thyroid and to minimise the renal iodide losses 
(Glinoer 2004). 
 
4. Fourthly, to explore the change in iodine concentrations over time, repeated-measures 
ANOVA was used, which required the use of a categorical, within-subject factor (i.e., 
trimester), instead of the actual gestational week at urine sampling; thus, the analyses 
only provide information about the average change across trimesters but not within-
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trimesters (i.e., across gestational weeks). However, individual regression models for 
each trimester were also performed cross-sectionally, where gestational week was 
used as the predictor variable, thus providing more information about the change in 
UI/Creat over time within each trimester. These two approaches showed that there 
was an overall increase in UI/Creat from the first to the third trimester and the largest 
average rate of increase was within the first trimester. 
 
5. Fifthly, using repeated-measures ANOVA, as opposed to more advanced statistical 
techniques (e.g., mixed modelling), might have resulted in a loss of information, as 
repeated-measures ANOVA investigates individual trends over time as an aggregate 
(i.e., assuming a common trend of change for all individuals in the sample) rather than 
on an individual level (e.g., individuals within the sample might have different 
trajectories over time) (Shek and Ma 2011). According to the ICC results, however, 
only 5-8% of the total variability in the urinary iodine and creatinine measurements 
was explained by inter-individual differences, suggesting that the parameters of the 
trajectory of change over time were similar across the whole sample of individuals 
and a more complex model accounting for the between-individual differences was 
probably not necessary (Curran et al. 2010; Shek and Ma 2011).  
 
6. Sixthly, no measure of season at urine-sample collection was available. As explained 
previously, iodine status can be affected by season (Vanderpump et al. 2011) because 
of the seasonal changes in milk iodine concentration (i.e., higher iodine content of 
winter milk) (Stevenson et al. 2018). As pregnancy spans seasons, the gestational 
changes in UI/Creat could be explained partly by change in season (Bath et al. 2015). 
However, ALSPAC women were recruited all year around (i.e., from April 1991 to 
December 1992) and season is unlikely to explain the changes in UI/Creat during 
pregnancy. Additionally, as the effect of season is expected to be more pronounced 
in women who consume more milk (Bath et al. 2015), whether habitual milk intake 
modified the change in UI/Creat across trimesters was explored and there was no 
differential effect by milk intake (i.e., the increase in UI/Creat was equivalent in 
women who consumed less than a glass of milk and in those who consumed more 
than a glass daily). 
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7. Finally, the data on milk intake were collected only at the end of pregnancy (at 32 
weeks) and information about milk consumption in the earlier stages of pregnancy 
was not available, thus, the effect of maternal dietary changes on the UI/Creat 
trajectory across pregnancy could not be evaluated.  
 
 
4.5 Conclusion 
The results of this study suggest that the amount of iodine excreted in urine changes over 
the course of pregnancy. In a setting of mild-to-moderate iodine deficiency, both UIC and 
UI/Creat increased from the first to the third trimester. The results from this study confirm 
that a single urinary iodine measurement does not capture iodine availability during all 
stages of pregnancy. To provide more information about iodine status across pregnancy, 
other more stable biomarkers, indicative of longer-term iodine nutrition, such as Tg, 
might be helpful to use in conjunction with spot-UIC or UI/Creat; however, these need to 
be explored further. Additionally, as repeat measures within each trimester were not 
available for the women in this study, perhaps future studies could collect repeat urine 
samples within each trimester to provide a better estimate of usual iodine intake. Whether 
the gestational changes in iodine availability across the stages of pregnancy have an effect 
on offspring neurodevelopmental outcomes is also not clear and is an important topic for 
future work. 
 
 
80 
 
Chapter 5                                       
Thyroglobulin as a biomarker of iodine status in 
pregnant women  
 
5.1 Introduction  
Currently, the recommended and most widely-used method for assessment of iodine 
status in populations is the median urinary iodine concentration (UIC, µg/L) (WHO 
2007a; Pearce and Caldwell 2016). As more than 90% of the dietary iodine absorbed is 
excreted in the urine, UIC reflects individual recent iodine intake (i.e., in the last 24-48 
hours) but provides limited information about individual iodine status and thyroid 
function (Zimmermann and Andersson 2012). UIC is usually measured in a single spot-
urine sample and as a result of day-to-day differences in hydration status (i.e., urine 
volume) and iodine intake, it can be misleading when used to estimate iodine nutritional 
status for an individual (Andersen et al. 2008; Vejbjerg et al. 2009; König et al. 2011). 
Adjustment of UIC by urinary creatinine concentration [i.e., by using the urinary iodine-
to-creatinine ratio (UI/Creat, µg/g)] can correct for individual hydration-status 
differences and many investigators have shown that, when adjusted, it reflects the 24-
hour urinary iodine excretion (24-h UIE) (i.e., a proxy for individual daily iodine intake) 
and serum iodine concentration better than UIC alone (Rasmussen et al. 1999; Knudsen 
et al. 2000; Andersen et al. 2008; König et al. 2011; Li et al. 2016). Even though the 
validity of spot-UIC as a marker of daily iodine intake can be improved, one measurement 
of urinary iodine from a casual spot-urine sample or 24-hour urine collection cannot 
provide information about individual habitual iodine intake (i.e., over a longer period); it 
has been shown that to estimate individual iodine status with a 20% precision, at least 14 
repeated spot-UIC samples or ten measured/estimated 24-h UIE are required from an 
individual (König et al. 2011). This, however, is impractical and costly in large 
population studies. Biomarkers that provide information about usual iodine intake and are 
also indicative of thyroid function would therefore be useful and would potentially add 
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value to the assessment of iodine status in populations, alongside the commonly-used 
spot-UIC. 
 
Thyroglobulin (Tg) is a thyroid-specific glycoprotein and is the synthesis site of thyroid 
hormones (Ma and Skeaff 2014). Small amounts of Tg are normally released into the 
circulation when iodine intake is sufficient (Zimmermann and Andersson 2012). In 
iodine-deficient areas, Tg is positively correlated with thyroid volume, suggesting that it 
is an indicator of thyroid stimulation (Knudsen et al. 2001). There is increasing evidence 
that Tg is a sensitive marker of iodine status in children and adults, showing that its 
concentration increases in iodine deficiency and excess. For instance, in a cross-sectional 
study of schoolchildren from 12 countries, Tg concentration followed a U-shaped curve, 
with the lowest Tg (~13 ng/ml) when median UIC was 100-299 µg/L (adequate and more-
than-adequate iodine intakes) (Zimmermann et al. 2013). In a cohort study in three 
regions in China, the 5-year change (increase) in Tg was higher in the regions with mild 
iodine deficiency and excess than in the region with more-than-adequate intake (Chong 
et al. 2015), though the difference was small. Tg concentration is thought to reflect iodine 
intake over a longer period (e.g., in weeks to months) (Zimmermann and Andersson 
2012). A randomised controlled trial (RCT) in mildly iodine-deficient adults showed that 
Tg decreased by 27% in response to a 24-week iodine supplementation (i.e., median 20 
ng/ml at baseline vs 13 ng/ml at 24 weeks) while it remained unchanged in the placebo 
group (i.e., 16 vs 15 ng/ml) (Ma et al. 2016). The usefulness of Tg as a biomarker of 
iodine status in pregnant populations has not been as widely explored in different settings 
of baseline iodine status. Since pregnant women can be particularly vulnerable to iodine 
deficiency (Glinoer 2004), monitoring the iodine status of this population group is crucial. 
 
This study, therefore, aimed to explore the usefulness of maternal serum Tg concentration 
as a functional biomarker of iodine status in pregnancy in settings of population iodine 
sufficiency (median UIC ≥150 µg/L) and mild-to-moderate iodine deficiency (median 
UIC 50-149 µg/L). The objectives of the study were: (i) to investigate whether various 
maternal characteristics, including maternal diet and iodine-supplement use, are 
determinants of Tg concentration; (ii) to explore cross-sectionally the association between 
urinary iodine concentration (measured as spot-UI/Creat) and Tg during pregnancy; and 
(iii) to investigate the association between iodine status (classified by two repeated spot-
UI/Creat measurements during pregnancy) and Tg. 
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5.1.1 Hypothesis 
It was hypothesised that iodine status (as measured by UI/Creat) would be negatively 
associated with serum Tg. 
 
 
5.2 Methods 
5.2.1 Study population  
This study used samples and data from pregnant women recruited as part of two 
prospective population-based birth cohorts: Generation R in the Netherlands (Kooijman 
et al. 2016) and INfancia y Medio Ambiente (INMA) in Spain (Guxens et al. 2012). In 
Generation R, 9,778 mothers residing in Rotterdam with an expected delivery date 
between April 2002 and January 2006 were enrolled, of whom 8,879 were recruited 
during pregnancy. In INMA, a total of 2,150 women were recruited during pregnancy 
from three regions of Spain (Valencia, Sabadell and Gipuzkoa), in the period November 
2003 to January 2008. Ethical approval for both cohorts had been obtained prior to 
recruitment (see Chapter 2). 
5.2.2 Selection criteria for the current study 
For these analyses, only pregnant women who had their serum Tg concentration measured 
were selected. Women with multiple pregnancies, in-vitro fertilisation (IVF), known 
thyroid disease and/or use of thyroid-related medication were excluded (Figure 5.1). 
Since the presence of thyroglobulin antibodies (Tg-Ab) can interfere with the 
measurement of Tg (i.e., Tg-Ab positive subjects can have underestimated or 
overestimated Tg depending on the assay used) (Ma and Skeaff 2014), women with Tg-
Ab titres above 40 IU/ml (manufacturer’s cut-off) were considered as Tg-Ab positive and 
were excluded.  
 
Women in this study had up to two urinary iodine and creatinine measurements during 
pregnancy. To investigate cross-sectionally the association between each urinary iodine 
measurement (expressed as UI/Creat measured in a single spot-urine sample) and Tg, the 
analyses were restricted to women who had at least one urinary iodine and creatinine 
measurement (i.e., from at least one time-point in pregnancy) (Figure 5.1). To explore the 
association between pregnancy iodine status, as classified by both spot-UI/Creat 
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measurements, and Tg, the analyses were further restricted to women who had two 
urinary iodine and creatinine measurements (i.e., from two time-points in pregnancy). 
 
1 In INMA, all values under the limit of detection (LOD=0.2 ng/ml) were replaced with one half of LOD 
(0.1 ng/ml). In Generation R, the samples with values < LOD had been diluted three or six times prior to 
measurement due to insufficient sample volume, hence they were excluded from the analyses without 
replacing with half LOD (for full details see ‘Methods’ Section 5.2.3). Abbreviations: IVF, in-vitro 
fertilisation; LOD, limit of detection; Tg-Ab, thyroglobulin antibody; UI/Creat, urinary iodine-to-creatinine 
ratio 
Figure 5. 2: Flow chart of the study population selection 
Data unavailable:  
Thyroglobulin concentration not measured 
Total N=5,944 
Generation R (n=5,071)  
INMA (n=873) 
Enrolled during pregnancy  
Total N=11,029 
Generation R (n=8,879) 
INMA (n=2,150) 
 
Thyroglobulin measured 
Total N=5,085 
Generation R (n=3,808) 
INMA (n=1,277) 
 
Thyroglobulin available 
Total N=4,716 
Generation R (n=3,548) 
INMA (n=1,168) 
Exclusions: 
Total N=369 
Multiple pregnancy Total N=34 
(Generation R, n=34; INMA, n=0) 
IVF Total N=16 
(Generation R, n=16; INMA, n=0) 
Thyroid disease and/or use of thyroid-
related medication Total N=123 
(Generation R, n=57; INMA, n=66) 
Tg-Ab positivity (Tg-Ab > 40 IU/ml)  
Total N=200  
(Generation R, n=151; INMA, n=49) 
Values < LOD (LOD=0.2 ng/ml)  
Total N=39 
(Generation R, n=39; INMA, n=231)  
Thyroglobulin + 1st / 2nd UI/Creat  
Total N=2,071/1,649 
Generation R (n=1,071/649) 
INMA (n=1,000/1,000) 
Thyroglobulin + both UI/Creat  
Total N=1,542 
Generation R (n=648) 
INMA (n=894) 
Figure 5. 1  Flow chart of the study population selection 
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5.2.3 Serum thyroglobulin measurements 
Blood samples in both cohorts were collected after recruitment in early pregnancy [at a 
median (25-75th percentile) gestational week 13.2 (12.2 - 14.9) in Generation R and 13.4 
(12.7 - 14.3) in INMA]. Serum Tg and Tg-Ab concentrations were measured using an 
immunoassay (IMMULITE, Siemens Healthcare Diagnostics, UK) at the Swiss Federal 
Institute of Technology in Zurich, Switzerland. Both assays were calibrated using 
standards provided by the manufacturer (IMMULITE, Siemens Healthcare Diagnostics, 
UK). The coefficients of variation (CVs) for Tg were 9.3% at 1.9 ng/ml (n=35), 7.1% at 
9.6 ng/ml (n=35) and 7.6% at 58.8 ng/ml (n=35). The CVs for Tg-Ab were 8.1% at 38.5 
IU/ml (n=32) and 9.2% at 538.0 IU/ml (n=32). According to the manufacturer’s cut-offs, 
Tg concentration >55 ng/ml was considered elevated and Tg-Ab concentration >40 IU/ml 
was considered as positive.  
 
A small number of the measured Tg values were under the assay limit of detection (LOD) 
(i.e., <0.2 ng/ml) [1.0% (n=39) in Generation R and 1.8% (n=23) in INMA]. In 
Generation R, due to insufficient sample volume, the samples that measured values below 
LOD had been diluted three (n=34) or six times (n=5) prior to measurement to reach the 
required volume for laboratory analysis, hence it was uncertain whether the values would 
be below the LOD had they not been diluted. For that reason, these samples were excluded 
from further statistical analyses. In INMA, there was no issue with dilution and the values 
that were below the LOD were replaced with one half of LOD (i.e., 0.1 ng/ml) – a 
common method for handling below-detection values (Croghan and Egeghy 2003). 
Although alternative computational methods with smaller overall bias and error rates are 
available, simple substitution techniques have been shown to produce little bias and very 
similar error rates when the percentage of substituted values is low (i.e., 5-10%) (Croghan 
and Egeghy 2003). In INMA, the percentage of undetectable Tg values was <2% and 
after the study exclusion criteria were applied (Figure 5.1), less than 0.3 % (n=3) of all 
Tg values were substituted with half LOD for use in the analyses. 
5.2.4 Urinary iodine measurements 
Spot-urine samples for the measurement of urinary iodine and creatinine concentrations 
were collected at two time-points during pregnancy in each cohort. The first urine sample 
was collected at the same time as the blood sample for serum Tg measurement; i.e., at a 
median (25-75th percentile) gestational week 13.1 (12.1-14.6) in Generation R and 13.4 
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(12.7-14.3) in INMA. The second urine sample was collected later in pregnancy at a 
median (25-75th percentile) 20.5 (19.9-21.1) weeks in Generation R and 33.9 (32.6-34.9) 
weeks in INMA. Gestational week in both cohorts was established using ultrasound 
examination. The details of the laboratory measurement of urinary iodine and creatinine 
concentrations are provided elsewhere (see Chapter 2). As explained previously, to 
reduce the variability of UIC resulting from individual hydration-status differences, UIC 
was corrected by urinary creatinine and the UI/Creat was used in preference to UIC 
(Knudsen et al. 2000; König et al. 2011). 
5.2.5 Dietary assessment and iodine-supplement use  
Maternal diet during pregnancy was assessed using a semi-quantitative food-frequency 
questionnaire (SFFQ) administered in early pregnancy (at the time when the blood sample 
and the first urine sample were collected). Full details about the design of each SFFQ and 
the food intake calculations are provided in Chapters 2 and 3. For the current study, 
comparable food groups to those in Chapter 3 were formed (Chapter 3, Supplemental 
Table 3.1, Appendix I). The data on food-group intake were used to explore the 
association with maternal serum Tg concentration. Some food-group intakes (e.g., milk 
and dairy, fish and shellfish, cereal and cereal products, eggs and salt) have been shown 
to be associated with UI/Creat in these two cohorts (Dineva et al. 2019). 
 
Self-reported data on use of iodine-containing supplements from pre-conception until 
enrolment in early pregnancy (approximately until the end of the first trimester) were 
available for all INMA women included in this study but only for a sub-set of Generation 
R women. RCTs have shown that iodine supplementation of mildly-to-moderately iodine-
deficient pregnant women resulted in a reduction in maternal serum Tg by 18-37% over 
the course of pregnancy, while an increase in Tg by 13-60% from initial values was 
observed in the women not supplemented with iodine (Pedersen et al. 1993; Nøhr et al. 
2000; Brucker-Davis et al. 2013; Censi et al. 2019). Cross-sectional studies have reported 
lower Tg in women who used iodine supplements than in those who did not (mean 
difference ranged from 5.3 to 11.1 ng/ml) (Nøhr and Laurberg 2000; Katko et al. 2017; 
Manousou et al. 2019). The data on iodine-supplement use in the current study were 
therefore used to investigate whether the findings of previous studies in a mildly-to-
moderately iodine-deficient population were valid (i.e., in INMA) and to explore the 
association with Tg in an iodine-sufficient population (i.e., in Generation R).  
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5.2.6 Statistical analyses 
UIC, UI/Creat and Tg concentrations were not normally distributed but right-skewed, 
therefore medians (25-75th percentiles) were reported as descriptive measures of central 
tendency (spread) and non-parametric tests were used for simple comparisons. Women 
were dichotomised on the basis of having elevated Tg concentration, defined as Tg >40 
ng/ml [based on previous studies in adults and schoolchildren (Ma and Skeaff 2014)] and 
Tg >55 ng/ml [the assay manufacturer’s cut-off (see ‘Methods’ Section 5.2.3)]. 
 
5.2.6.1 Maternal characteristics, diet and iodine-supplement use as determinants of 
serum Tg  
Maternal characteristics (e.g., gestational week, anthropometrics, parity, socio-
demographic and socio-economic factors, and lifestyle), maternal diet and iodine-
supplement use were first studied as potential determinants of Tg concentration in 
pregnancy. Data on maternal characteristics in both cohorts were recoded and harmonised 
as before (see Chapter 3). The differences in the median Tg concentration according to 
various maternal characteristics were explored using a Mann-Whitney U test (for 
variables with two categories) and a Kruskal-Wallis test (for variables with more than 
two categories). Multivariable regression models were also performed in each cohort with 
maternal characteristics and child’s sex as independent variables and Tg as the dependent 
variable. To meet the parametric-test assumptions of linear regression, in these analyses, 
Tg was transformed using the natural logarithm and the residuals of the models were 
visually assessed for normality. Outliers were assessed by visual inspection of box-plots. 
Non-linearity of the associations of each continuous independent variable with Tg was 
examined by adding their squared term to the regression models, and also by plotting each 
potential determinant variable against Tg and comparing the fit (R2) of a linear vs 
quadratic function through the data points. 
 
To investigate the influence of maternal diet on Tg, all food-group intakes estimated from 
the SFFQ were used as continuous predictors of Tg concentration (log-transformed) in 
univariable and multiple linear regression models. The multivariable models included all 
food groups and were adjusted for estimated daily energy intake (kcal/day), the maternal 
characteristics mentioned previously and child’s sex. Selected foods that are known good 
sources of dietary iodine and that were part of the food groups associated with UI/Creat 
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in our previous study (e.g., milk, fish, eggs, salt and bread; see Chapter 3) were further 
explored as predictors of Tg by grouping women in categories of food consumption. The 
differences in median Tg between the categories of food consumption were investigated 
using Mann-Whitney U tests and Kruskal-Wallis tests, as appropriate. The Chi-square 
tests were also used to compare the proportion of women with elevated Tg (Tg >40 ng/ml 
and Tg >55 ng/ml) across the categories of food consumption. The analyses with food 
consumption categories were also adjusted for the same covariates as above, using 
multiple linear [for the mean (log) Tg] and logistic [for the odds ratio (OR) of elevated 
Tg >40 ng/ml and Tg >55 ng/ml] regression models. 
 
The differences in Tg concentration and in the percentage of women with elevated Tg 
were examined between iodine-supplement users and non-users using a Mann-Whitney 
U test and a Chi-square test, respectively. The association between mean daily iodine 
intake from supplements and Tg was explored using Spearman’s rank correlation (rs) in 
INMA only (iodine content of supplements was not available in Generation R). The 
association of the iodine-supplement variables (dichotomous and continuous) with (log) 
Tg was also explored in multiple linear regression models adjusted for gestational week 
at blood extraction, maternal age, pre-pregnancy body mass index (BMI, kg/m2), 
ethnicity, parity, smoking status, alcohol consumption and education level. The 
regression model was also adjusted for thyroid peroxidase antibody (TPO-Ab) status in 
Generation R only (TPO-Ab were not measured in INMA). 
 
5.2.6.2 Association of single spot-UI/Creat with Tg 
The associations of UI/Creat measured in each of the two spot-urine samples and Tg were 
explored. Cross-sectionally, the correlation of the first (from early pregnancy) and the 
second (from later pregnancy) UI/Creat with Tg were investigated using Spearman’s rank 
correlation (rs). The continuous association between each UI/Creat measurement and Tg 
(log-transformed) was also explored using multiple linear regression models adjusted for 
confounders. The selection of confounders that were included in all UI/Creat vs Tg 
models in this study was informed by a previous study investigating the association 
between the two (Bath, Pop, et al. 2017), as well as by our own results on the determinants 
of Tg identified in this study (i.e., those that were statistically significantly associated 
with Tg in at least one of the cohorts were included) and the determinants of UI/Creat 
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identified in our previous work (Dineva et al. 2019), described in full detail in Chapter 3. 
The variables included in the models for each cohort were gestational week at blood 
extraction, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking 
status, alcohol consumption and level of education (TPO-Ab status was additionally 
included in Generation R). 
 
Women were split into categories based on each of their UI/Creat measures. In total, three 
UI/Creat groupings were created using the following cut-offs: i) <150 µg/g (i.e., 
insufficient intake) vs ≥150 µg/g (i.e., sufficient intake) [threshold was informed by WHO 
criteria for UIC that define adequacy in pregnant populations (WHO 2007a) and when 
corrected for creatinine has been used in other studies (Bath, Steer, et al. 2013; Bath, Pop, 
et al. 2017)]; ii) <100 µg/g, 100-149 µg/g, 150-249 µg/g (i.e., adequate intake; reference 
group), ≥250 µg/g [cut-offs were based on a methodology used in previous studies 
(Moreno-Reyes et al. 2013; Bath, Pop, et al. 2017)]; and iii) <50 µg/g (i.e., severe 
deficiency), 50-149 µg/g (i.e., mild-to-moderate deficiency), 150-499 µg/g (i.e., adequate 
and more-than-adequate intake; reference group), ≥500 µg/g (i.e., excessive intake) 
[thresholds were informed by WHO criteria (WHO 2007a) and a previous study 
(Zimmermann 2007) to explore the effects of iodine intake indicative of severe deficiency 
and excess]. Median Tg concentration was then compared according to the categories of 
each of the UI/Creat groupings, using either a Mann-Whitney U test or a Kruskal-Wallis 
test. The associations of UI/Creat groupings with Tg were also adjusted for the previously 
used covariates in multiple regression models. 
 
Median UIC, UI/Creat and proportion of women with UI/Creat <150 µg/g (i.e., 
insufficient iodine intake) were also compared between women with ‘normal’ vs those 
with elevated Tg (defined as Tg >40 ng/ml or >55 ng/ml), using a Mann-Whitney U test 
and a Chi-square test, respectively.  
 
5.2.6.3 Association of UI/Creat from repeated samples with Tg 
To explore the association of pregnancy iodine status with Tg, women were broadly 
classified into three iodine-status groups based on two repeat spot-UI/Creat 
measurements collected during pregnancy: (i) women with both spot-UI/Creat 
measurements <150 μg/g (i.e., insufficient); (ii) women with one spot-UI/Creat 
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measurement <150 μg/g (i.e., borderline insufficient); and (iii) women with both spot-
UI/Creat measurements ≥150 μg/g (i.e., sufficient). The difference in Tg concentration 
between the three iodine status groups was investigated using a Kruskal-Wallis test and 
also by a multiple regression model adjusted for the covariates mentioned previously.  
 
Sensitivity analyses in the group of women classified as borderline insufficient were 
performed, where the association of the mean of the first and second UI/Creat 
measurements with Tg was explored continuously using Spearman’s rank correlation (rs). 
Women were dichotomised into groups based on their mean UI/Creat (i.e., <150 µg/g vs 
≥150 µg/g) and the difference in Tg was examined with a Mann-Whitney U test. The 
association of the mean UI/Creat (continuous and dichotomised) with Tg was adjusted 
for confounders in multiple regression models. 
 
As done previously, missing values on maternal characteristics were imputed for women 
included in these analyses using multiple imputation. Full details about the method and 
the imputed variables are provided in Chapter 2. Missing FFQ data were not imputed due 
to wide inter-person variability. All statistical analyses and the multiple imputation of 
missing values were conducted using IBM SPSS Statistics version 25.0 (IBM Corp., 
Armonk, NY, USA). Statistical significance was set at P<0.05. 
 
 
5.3 Results 
5.3.1 Sample characteristics 
After all exclusions, a total of 4,716 pregnant women were included in the analyses: 3,548 
from Generation R and 1,168 from INMA (Figure 5.1). The characteristics of the study 
population by cohort are described in Table 5.1. The median Tg concentration during 
early pregnancy (at median 13 weeks) was 11.1 ng/ml in Generation R (3.6% >40 ng/ml) 
and 11.5 ng/ml in INMA (4.5% >40 ng/ml) (Table 5.2). The group of women from 
Generation R (the Netherlands) was classified as iodine-sufficient at both time-points 
during pregnancy (median UIC ≥150 µg/L at approximately 13 and 21 weeks), while the 
group from INMA (Spain) was mildly-to-moderately iodine-deficient (median UIC <150 
µg/L at approximately 13 and 34 weeks) (Table 5.2). 
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Table 5. 1  Characteristics of the study population by cohort 
Characteristics 1 
Generation R          
(n=3,548) 
 INMA                
(n=1,168) 
Maternal factors    
Maternal age 2 (years), mean (±SD) 29.7 (±5.0)  31.5 (±4.1)  
Pre-pregnancy BMI (kg/m2), median (25-75th) 22.8 (20.7 - 25.7)  22.4 (20.7 - 24.8) 
TPO-Ab status, n (%)    
    Negative  3060 (95.9%)  N/A 
    Positive 130 (4.1%)  N/A 
Ethnicity 3, n (%)    
    Reference group 1865 (52.5%)  1070 (91.6%) 
    Non-Dutch 1683 (47.5%)  N/A 
    Non-Spanish N/A  98 (8.4%) 
Parity, n (%)    
    0 2033 (57.3%)  639 (54.7%) 
    1 1040 (29.3%)  446 (38.2%) 
    ≥ 2 475 (13.4%)  83 (7.1%) 
Smoking status, n (%)    
    Never smoked 2524 (71.1%)  836 (71.6%) 
    Stopped smoking 337 (9.5%)  160 (13.7%) 
    Continued smoking 687 (19.4%)  172 (14.7%) 
Alcohol consumption, n (%)    
    No 1650 (46.5%)  1059 (90.7%) 
    Yes 1898 (53.5%)  109 (9.3%) 
Markers of socio-economic status    
Education level, n (%)    
    Low 386 (10.9%)  248 (21.2%) 
    Medium 1612 (45.4%)  464 (39.7%) 
    High 1550 (43.7%)  456 (39.1%) 
Net household income (€ per month), n (%)    
    Low < €1200 780 (22.0%)  N/A 
    Medium €1200-2000 713 (20.1%)  N/A 
    High > €2000 2055 (57.9%)  N/A 
Marital status, n (%)    
    Married 1703 (48.0%)  N/A 
    Never-married 1845 (52.0%)  N/A 
Living with a partner, n (%)    
    Yes N/A  1157 (99.1%) 
    No N/A  11 (0.9%) 
Child factors 
   
Child’s sex 4, n (%)    
    Male 1807 (50.9%)  587 (50.3%) 
    Female 1741 (49.1%)  581 (49.7%) 
1 Data are presented as mean (±SD) for all continuous normally distributed variables, median (25-75th 
percentile) for all continuous non-normally distributed variables and n (%) for the categorical variables. 2 
Maternal age at blood extraction. 3 Categories of ethnicity in Generation R (Reference group=Dutch, Non-
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Dutch=Indonesian, Cape Verdian, Moroccan, Dutch Antilles, Surinamese, Turkish, other Non-Western, 
Asian, and other Western) and in INMA (Reference group=Spanish, Non-Spanish=Latin-American and 
European/others); for a detailed breakdown of the numbers in each sub-category of the Non-Dutch and 
Non-Spanish ethnic groups, see Table 5.3. 4 Data were not imputed for child’s sex in Generation R due to 
no missing values; the rest of the data are shown after multiple imputation of the missing values (see 
‘Methods’). Abbreviations: BMI, body mass index; N/A, data not available or not applicable; SD, standard 
deviation; TPO-Ab, thyroid peroxidase antibody 
 
 
Table 5. 2  Descriptives of serum thyroglobulin and urinary iodine concentrations in Tg-
Ab negative pregnant women 
 
n 
Generation R 
(n=3,548) 
 n 
INMA 
(n=1,168) 
Thyroglobulin measurement 3548   1168  
Gestational week at blood extraction  13.2 (12.2 - 14.9)   13.4 (12.7 - 14.3) 
Thyroglobulin (Tg), ng/ml  11.1 (7.0 - 17.1)   11.5 (6.9 - 18.8) 
Elevated Tg (> 40 ng/ml) 1, n (%)  127 (3.6%)   52 (4.5%) 
Elevated Tg (> 55 ng/ml) 2, n (%)  58 (1.6%)   24 (2.1%) 
First urinary iodine measurement 1071   1000  
Gestational week at first urine sampling  13.1 (12.1 - 14.6)   13.4 (12.7 - 14.3) 
First UIC, µg/L  166 (97 - 285)   131 (76 - 222) 
First UI/Creat, µg/g  209 (138 - 307)   147 (93 - 246) 
First UI/Creat < 150 µg/g, n (%)  311 (29.0%)   513 (51.3%) 
Second urinary iodine measurement 649   1000  
Gestational week at second urine sampling  20.5 (19.9 - 21.1)   33.9 (32.6 - 34.9) 
Second UIC, µg/L  155 (90 - 261)   134 (83 - 226) 
Second UI/Creat, µg/g  223 (153 - 317)   167 (107 - 293) 
Second UI/Creat < 150 µg/g, n (%)  152 (23.4%)   431 (43.1%) 
Data are presented as median (25-75th percentile) for all continuous variables and n (%) for the categorical 
variables. 1 Cut-off value for elevated Tg based on previous studies in adults and school-aged children (see 
‘Methods’ Section 5.2.6). 2 Cut-off value considered elevated from the laboratory where the Tg 
measurements were performed (see ‘Methods’ Section 5.2.3). Abbreviations: Tg, thyroglobulin; Tg-Ab, 
thyroglobulin antibody; UI/Creat, urinary iodine-to-creatinine ratio; UIC, urinary iodine concentration 
 
 
5.3.2 Maternal characteristics, diet and iodine-supplement use as determinants of 
serum Tg  
5.3.2.1 Maternal characteristics  
In both cohorts, women who reported smoking during pregnancy vs those who never 
smoked had a higher median Tg concentration (P<0.001) (Table 5.3).  
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Table 5. 3  Median (25-75th percentile) thyroglobulin concentration (ng/ml) according to 
subject characteristics 
  
Generation R 
(n=3,548) 
  
 
INMA 
(n=1,168) 
 
 n Median (25-75th) P 1  n Median (25-75th) P 1 
Maternal factors        
TPO-Ab status   0.179     
    Negative  3060 11.2 (7.1 - 17.0)   N/A   
    Positive 130 9.4 (4.8 - 20.5)   N/A   
Ethnicity   <0.001    0.917 
    Reference group 2 1865 11.4 (7.2 - 17.3)   1070 11.5 (6.9 - 19.0)  
    Non-Dutch:        
       Indonesian 95 10.8 (7.1 - 16.0)   N/A   
       Cape Verdian 155 13.6 (7.8 - 18.8)   N/A   
       Moroccan 198 10.1 (6.2 - 14.8)   N/A   
       Dutch Antilles 114 17.1 (10.6 - 27.9)   N/A   
       Surinamese 316 12.1 (7.3 - 18.7)   N/A   
       Turkish 300 8.7 (6.0 - 12.9)   N/A   
       Other, Non-Western 143 10.5 (6.7 - 15.7)   N/A   
       Asian 51 10.1 (7.2 - 15.9)   N/A   
       Other, Western 311 10.5 (6.5 - 16.6)   N/A   
    Non-Spanish:        
       Latin-American N/A    67 10.9 (7.7 - 17.0)  
       European/others N/A    31 12.3 (5.9 - 19.8)  
Parity   0.002    0.122 
    0 2033 11.4 (7.3 - 17.6)   639 11.0 (6.9 - 18.4)  
    1 1040 10.9 (6.9 - 16.3)   446 11.6 (6.9 - 18.7)  
    ≥ 2 475 10.5 (6.3 - 16.2)   83 13.9 (7.5 - 24.8)  
Smoking status   <0.001    <0.001 
    Never smoked 2524 10.7 (6.7 - 16.2)   836 10.7 (6.3 - 17.4)  
    Stopped smoking 337 11.0 (7.3 - 17.8)   160 12.5 (8.0 - 20.9)  
    Continued smoking 687 13.0 (8.4 - 19.2)   172 15.8 (9.4 - 26.9)  
Alcohol consumption   <0.001    0.002 
    No 1650 10.5 (6.7 - 16.3)   1059 11.3 (6.7 - 18.4)  
    Yes 1898 11.5 (7.3 - 17.6)   109 14.8 (8.9 - 23.1)  
Markers of socio-economic status 
Education level   0.694    <0.001 
    Low 386 10.9 (6.8 - 16.6)   248 12.9 (8.5 - 23.3)  
    Medium 1612 11.2 (7.0 - 17.4)   464 11.4 (6.9 - 18.5)  
    High 1550 11.1 (7.0 - 17.0)   456 10.8 (6.1 - 17.0)  
(continued on next page) 
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Table 5. 3  Median (25-75th percentile) thyroglobulin concentration (ng/ml) according 
to subject characteristics (continued) 
 
 
Generation R 
(n=3,548) 
 
 
 
INMA 
(n=1,168) 
 
 n Median (25-75th) P 1  n Median (25-75th) P 1 
Markers of socio-economic status (continued) 
Net household income  
(€ per month) 
  
0.799 
    
    Low < €1200 780 11.1 (7.0 - 17.1)   N/A   
    Medium €1200-2200 713 11.1 (7.0 - 17.0)   N/A   
    High > €2200 2055 11.1 (7.0 - 17.2)   N/A   
Marital status   <0.001     
    Married 1703 10.8 (6.7 - 16.2)   N/A   
    Never-married 1845 11.4 (7.2 - 18.0)   N/A   
Living with a partner       0.013 
    Yes N/A    1157 11.4 (6.9 - 18.7)  
    No N/A    11 20.2 (12.9 - 33.7)  
Child factors        
Child’s sex   0.923    0.581 
    Male 1807 11.1 (7.0 - 17.3)   587 11.5 (6.8 - 18.6)  
    Female 1741 11.1 (7.1 - 16.7)   581 11.5 (7.1 - 19.6)  
1 P-values from a Mann-Whitney U test (for two-categorical variables) or a Kruskal-Wallis test (for 
variables with more than two categories). 2 Reference group of ethnicity in Generation R (Reference 
group=Dutch) and in INMA (Reference group=Spanish). Abbreviations: N/A, data not available or not 
applicable; TPO-Ab, thyroid peroxidase antibody 
 
Smoking during pregnancy was still consistently positively associated with Tg in analysis 
adjusted for other maternal characteristics (P<0.001) (Table 5.4). In INMA, even women 
who smoked only in the beginning of pregnancy and then stopped had a significantly 
higher Tg concentration than women who never smoked (B=0.197, P=0.034). Smoking 
remained positively associated with Tg after further adjustment for maternal diet and 
iodine-supplement use (data not shown). Alcohol consumption was also associated with 
higher median Tg in both cohorts (Table 5.3), however, in adjusted analysis, this 
association remained statistically significant only in INMA (B=0.205, P=0.049) (Table 
5.4). Maternal ethnicity was associated with Tg concentration only in Generation R (the 
Netherlands), where compared to the Dutch women, Turkish women had a lower Tg, and 
Cape Verdian women and those from the Dutch Antilles had a higher Tg (Table 5.4). 
After accounting for maternal diet, the results for ethnicity remained largely unchanged, 
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except that the Tg of Cape Verdian women was no longer significantly higher (data not 
shown). Similarly, adjusting for overall supplement-use and iodine-containing 
supplement-use (in a smaller sample for which data were available) did not considerably 
change the results for ethnicity (data not shown). In adjusted analysis, increasing parity 
was negatively associated with Tg only in Generation R. In INMA, more educated women 
had lower Tg than those with lower education level (Table 5.4). Gestational week (at 
blood sampling), maternal age, pre-pregnancy BMI, maternal TPO-Ab status (in 
Generation R only), household income, marital status/living with a partner and child’s 
sex were not associated with serum Tg in adjusted analysis (Table 5.4). 
 
Table 5. 4  Determinants of thyroglobulin concentration in pregnancy from adjusted 
analyses 
  
Generation R 
(n=3,190) 
 
 
 
INMA 
(n=1,168) 
 
 n B (95% CI) P 1  n B (95% CI) P 2 
Maternal factors         
Gestational week at 
blood extraction 
3190 -0.013 (-0.026, 0.001) 0.064  1168 0.021 (-0.011, 0.054) 0.203 
Maternal age, years 3190 0.006 (-0.000, 0.013) 0.058  1168 -0.013 (-0.029, 0.002) 0.084 
Pre-pregnancy BMI, 
kg/m2 
3190 0.001 (-0.006, 0.008) 0.823  1168 -0.002 (-0.017, 0.012) 0.735 
TPO-Ab status        
    Negative  3060 Ref.   N/A   
    Positive 130 -0.127 (-0.258, 0.005) 0.059  N/A   
Ethnicity        
    Reference group 3 1690 Ref.   1070 Ref.  
    Non-Dutch:        
       Indonesian 85 -0.078 (-0.243, 0.087) 0.355  N/A   
       Cape Verdian 136 0.164 (0.020, 0.307) 0.026  N/A   
       Moroccan 175 -0.040 (-0.179, 0.100) 0.578  N/A   
       Dutch Antilles 104 0.404 (0.241, 0.567) <0.001  N/A   
       Surinamese 279 0.099 (-0.007, 0.206) 0.067  N/A   
       Turkish 271 -0.307 (-0.425, -0.188) <0.001  N/A   
       Other, Non-Western 127 -0.062 (-0.206, 0.083) 0.403  N/A   
       Asian 45 -0.019 (-0.212, 0.249) 0.875  N/A   
       Other, Western 278 -0.036 (-0.133, 0.060) 0.457  N/A   
    Non-Spanish:        
       Latin-American N/A    67 -0.036 (-0.276, 0.204) 0.770 
       European/others N/A    31 -0.065 (-0.409, 0.279) 0.711 
(continued on next page) 
95 
 
Table 5. 4  Determinants of thyroglobulin concentration in pregnancy from adjusted 
analyses (continued) 
 
 
Generation R 
(n=3,190) 
 
 
 
INMA 
(n=1,168) 
 
 n B (95% CI) P 1  n B (95% CI) P 2 
Maternal factors (continued) 
Parity        
    0 1833 Ref.   639 Ref.  
    1 920 -0.082 (-0.144, -0.020) 0.009  446 0.065 (-0.060, 0.189) 0.307 
    ≥ 2 437 -0.123 (-0.212, -0.035) 0.007  83 0.169 (-0.065, 0.403) 0.157 
Smoking status        
    Never smoked 2275 Ref.   836 Ref.  
    Stopped smoking 295 0.024 (-0.071, 0.119) 0.620  160 0.197 (0.015, 0.380) 0.034 
    Continued smoking 620 0.248 (0.174, 0.323) <0.001  172 0.385 (0.210, 0.560) <0.001 
Alcohol consumption        
    No 1476 Ref.   1059 Ref.  
    Yes 1714 0.026 (-0.040, 0.091) 0.442  109 0.205 (0.001, 0.410) 0.049 
Markers of socio-economic status 
Education level        
    Low 343 Ref.   248 Ref.  
    Medium 1443 -0.012 (-0.113, 0.089) 0.815  464 -0.234 (-0.384, -0.083) 0.002 
    High 1404 -0.019 (-0.131, 0.094) 0.746  456 -0.228 (-0.385, -0.017) 0.004 
Net household income  
(€ per month) 
       
    Low < €1200 689 Ref.   N/A   
    Medium €1200-2200 636 0.027 (-0.077, 0.132) 0.606  N/A   
    High > €2200 1865 -0.001 (-0.106, 0.104) 0.987  N/A   
Marital status        
    Married 1539 Ref.    N/A   
    Never-married 1651 -0.041 (-0.102, 0.021) 0.194  N/A   
Living with a partner        
    Yes N/A    1157 Ref.  
    No N/A    11 0.361 (-0.213, 0.935) 0.217 
Child factors 
 
      
Child’s sex        
    Male 1625 Ref.   587 Ref.  
    Female 1565 -0.001 (-0.053, 0.051) 0.971  581 -0.003 (-0.119, 0.112) 0.958 
Effect estimates (B=unstandardised regression coefficients), their 95% CIs and P-values are from multiple 
linear regression models performed for each cohort with (natural) log-transformed thyroglobulin (Tg) as 
the dependent variable and maternal characteristics as independent variables (for full models, see footnotes 
1 and 2). Reported B coefficients represent the change in the mean (natural) log of Tg per unit increase in 
the continuous independent variables and for each category compared to the reference for the categorical 
independent variables. 1 Generation R Model (R2=0.038, P < 0.0001): gestational week at blood extraction, 
maternal age (years), pre-pregnancy BMI (kg/m2), TPO-Ab status, ethnicity, parity, smoking status, alcohol 
consumption, education level, net household income (€ per month), marital status and child’s sex. 2 INMA 
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Model (R2=0.043, P < 0.0001): gestational week at blood extraction, maternal age (years), pre-pregnancy 
BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, living with a partner 
and child’s sex. 3 Reference group of ethnicity in Generation R (Reference group=Dutch) and in INMA 
(Reference group=Spanish). Abbreviations: BMI, body mass index; 95% CI, confidence interval; N/A, 
data not available or not applicable; Ref., reference category; Tg, thyroglobulin; TPO-Ab, thyroid 
peroxidase antibody 
 
5.3.2.2 Maternal diet  
In total, 2,768 women from Generation R and 1,155 women from INMA who had a Tg 
measurement had also completed an SFFQ during pregnancy. In INMA, there were no 
statistically significant continuous associations between intake of any food-group and Tg 
in models adjusted for energy intake and maternal characteristics (data not shown). In 
Generation R, consumption of milk and dairy products was associated with lower Tg 
concentration (B (per 100 g) = -0.20, P=0.030), while vegetable intake was associated with 
higher Tg (B (per 100 g) =0.58, P=0.037).  
 
When women were categorised by their consumption of known good food-sources of 
iodine (e.g., milk, fish, eggs, salt in INMA and bread in Generation R), in both cohorts, 
women who reported some milk consumption (e.g., up to a glass of milk or more) had a 
lower median Tg concentration than those who reported no milk consumption; this 
difference, however was more subtle in women from Generation R and was statistically 
significant only in women from INMA (Table 5.5). In INMA, even when adjusting for 
maternal characteristics (e.g., pre-pregnancy BMI, socio-demographic and economic 
factors) and energy intake, compared to women who consumed no milk, those who had 
up to a glass of milk or more than one glass per day had a significantly lower Tg (B (≤1 
glass) = -0.328, P=0.001; B (>1 glass) = -0.269, P=0.010). In adjusted analyses in Generation 
R, though in the same direction, milk consumption was not statistically significantly 
associated with Tg (B (≤1 glass) = -0.042, P=0.534; B (>1 glass) = -0.115, P=0.102). The 
proportion of women with elevated Tg (>55 ng/ml) was statistically significantly larger 
in no-milk consumers vs those who drank at least some milk daily (i.e., regardless of the 
amount) in Generation R (4.1% vs 1.5%, P=0.028) and in INMA (6.3% vs 1.5%, P=0.004) 
(for a breakdown per glass, see Supplemental Table 5.1, Appendix I). Similar patterns 
were observed when using a cut-off of Tg >40 ng/ml but the differences did not reach 
statistical significance in INMA and were only significant in Generation R (Supplemental 
Table 5.1, Appendix I). In adjusted logistic regressions, the odds of elevated Tg were 
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significantly lower in milk-consumers vs milk non-consumers in Generation R (only 
when elevated Tg >55 ng/ml) and INMA (when elevated Tg >40 and >55 ng/ml) (data 
not shown). 
 
There were no statistically significant differences in Tg among the categories of fish 
(Table 5.5) or egg consumption (data not shown) in either of the cohorts. Bread 
consumption in women from Generation R was also not associated with Tg in unadjusted 
(Table 5.5 and Supplemental Table 5.1) or adjusted analyses (data not shown). In INMA, 
women who consumed some (iodised) salt had a lower Tg concertation than non-users 
(Table 5.5) and there was a lower proportion of women with elevated Tg in this group 
than in the group of non-users (Supplemental Table 5.1), though these differences were 
not statistically significant in unadjusted or adjusted analyses (data not shown). 
 
Table 5. 5  Median (25-75th percentile) thyroglobulin concentration (ng/ml) according to 
maternal food-group intake and iodine-containing supplement-use 
  
Generation R 
(n=2,768) 
 
 
 
INMA 
(n=1,155) 
 
 n Median (25-75th) P 1  n Median (25-75th) P 1 
Milk intake    0.113    0.004 
    None 148 11.9 (7.3 - 18.0)   111 14.1 (7.6 - 21.9)  
    ≤ 1 glass (≤ 200 g/day) 1506 11.2 (7.2 - 17.4)   615 10.8 (6.2 - 18.0)  
    > 1 glass (> 200 g/day) 1114 10.8 (6.8 - 16.6)   429 11.6 (7.9 - 19.0)  
Fish and shellfish intake    0.093    0.430 
    None 555 10.4 (6.9 - 16.3)   N/A   
    Some 2213 11.2 (7.1 - 17.3)   N/A   
    < 60 g/day N/A    480 11.7 (6.9 - 18.9)  
    60-120 g/day N/A    561 11.4 (7.0 - 18.9)  
    > 120 g/day N/A    114 10.8 (6.1 - 18.4)  
Bread intake   0.101     
    Below median (≤  98 g/day) 1378 11.2 (7.1 - 17.9)   N/A   
    Above median (> 98 g/day) 1377 10.9 (7.0 - 16.3)   N/A   
Salt intake        0.186 
    None (0 g/day) N/A    374 12.0 (6.8 - 21.1)  
    Some (> 0 g/day) N/A    781 11.3 (6.9 - 18.1)  
Iodine-containing supplement-use    0.476    0.005 
    No 72 12.4 (8.1 - 15.2)   631 12.1 (7.3 - 20.1)  
    Yes 521 11.2 (7.6 - 16.2)   537 10.8 (6.4 - 17.3)  
1 P-values from a Mann-Whitney U test (for two-categorical variables) or a Kruskal-Wallis test (for 
variables with more than two categories). 
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5.3.2.3 Maternal iodine-supplement use 
Data on iodine-containing supplement-use was available for all 1,168 women in INMA 
but only for a sub-set of 593 women in Generation R. In total, 521 women in Generation 
R (88%) and 537 (46%) women in INMA used iodine-containing supplements pre-
conception and in the first three months of pregnancy. Women who used iodine-
containing supplements had a lower median Tg by about 1 ng/ml than women who were 
non-users, though this difference was statistically significant only in INMA (Table 5.5). 
The proportion of women with Tg concentration >40 ng/ml was statistically significantly 
smaller in iodine-supplement users than in non-users in INMA (2.8% vs 5.9%, P=0.017), 
while there was no difference in Generation R (Supplemental Table 5.1). In adjusted 
analyses in both cohorts, there was no statistically significant association of iodine-
containing supplement-use with Tg (Generation R: B=0.023, P=0.825; INMA: B= -0.045, 
P=0.442). Although there was a weak negative correlation between the mean daily iodine 
intake from supplements and Tg in INMA (rs= -0.089, P=0.002, n=1,168), this association 
did not remain statistically significant in adjusted analysis (B= -0.001, P=0.144). Mean 
iodine intake from supplements was not available in Generation R (see ‘Methods’). 
5.3.3 Association of single spot-UI/Creat with Tg 
There was a weak negative correlation between UI/Creat and Tg in Generation R (first 
UI/Creat rs= -0.057, P=0.064, n=1071; second
 UI/Creat rs= -0.115, P=0.003, n=649) and 
in INMA (first UI/Creat rs= -0.150, P<0.001, n=1000; second
 UI/Creat rs= -0.138, 
P<0.001, n=1000). In analysis adjusted for confounders, the first UI/Creat (from early 
pregnancy) was not associated with Tg but the second UI/Creat (from later pregnancy) 
was still negatively associated with Tg in both cohorts (Table 5.6). 
 
When exploring the association of early-pregnancy UI/Creat (i.e., measured in urines 
collected at the same time as the blood samples for the Tg measurements) with Tg, 
compared to pregnant women in the group with UI/Creat ≥150 µg/g (i.e., sufficient iodine 
intake), those with UI/Creat <150 µg/g (i.e., insufficient iodine intake) had a significantly 
higher median Tg concentration both in Generation R (12.0 vs 10.4 ng/ml, P=0.010) and 
in INMA (12.8 vs 10.4 ng/ml, P<0.001) (Table 5.7). In adjusted analyses, having 
UI/Creat <150 µg/g vs ≥150 µg/g was still associated with statistically significantly 
higher Tg in both cohorts (Table 5.6). Compared to women with UI/Creat between 150-
249 µg/g (i.e., adequate iodine intake), pregnant women with UI/Creat <100 µg/g had 
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significantly higher Tg in both cohorts (Table 5.6). Serum Tg of women with UI/Creat in 
the range 100-149 µg/g was also higher than in women with adequate iodine intake, 
though not statistically significantly so (Table 5.6). In INMA, the group of women with 
iodine intake indicative of mild-to-moderate deficiency (i.e., UI/Creat 50-149 µg/g) had 
significantly higher Tg than the group with adequate and more-than-adequate intake (i.e., 
UI/Creat 150-499 µg/g). There was a trend for an even higher Tg in the group of women 
with iodine intake indicative of severe deficiency (i.e., UI/Creat <50 µg/g) (Table 5.7). 
There were no signs of an increase in Tg in the groups of women with more-than-adequate 
(i.e., UI/Creat ≥250 µg/g) or excessive (i.e., UI/Creat ≥500 µg/g) iodine intake (Table 
5.7). When women were grouped in the same way but based on their second UI/Creat 
measurement (measured in urines collected later in pregnancy than the blood sampling 
for Tg measurement), there were no statistically significant differences in Tg between 
most of the UI/Creat groups in adjusted analysis (Table 5.6), though there was a trend for 
a decreasing median Tg with increasing UI/Creat (Table 5.7). 
 
Table 5. 6  Associations of first and second UI/Creat measurement (continuous and as 
UI/Creat groups) and UI/Creat status groups (based on both UI/Creat measurements) with 
thyroglobulin concentration from adjusted analyses 
  
Generation R 
(n=1,040) 
 
 
 
INMA 
(n=1,000) 
 
 n B (95% CI) P 1  n B (95% CI) P 2 
First UI/Creat measurement 
UI/Creat, µg/g 1040 -0.000 (-0.000, 0.000) 0.688  1000 -0.000 (-0.001, 0.000) 0.109 
Grouping 1        
    < 150 µg/g 299 0.111 (0.000, 0.221) 0.050  513 0.157 (0.037, 0.276) 0.010 
    ≥ 150 µg/g  741 Ref.   487 Ref.  
Grouping 2        
    < 100 µg/g 106 0.202 (0.023, 0.382) 0.027  284 0.206 (0.043, 0.370) 0.013 
    100 - 149 µg/g 193 0.082 (-0.061, 0.225) 0.262  229 0.104 (-0.067, 0.275) 0.232 
    150 - 249 µg/g 328 Ref.   245 Ref.  
    ≥ 250 µg/g  413 0.022 (-0.096, 0.139) 0.718  242 0.005 (-0.163, 0.174) 0.949 
Grouping 3        
    < 50 µg/g  
299 3   0.110 (-0.002, 0.222)  0.053 
 53 0.229 (-0.046, 0.504) 0.102 
    50 - 149 µg/g   460 0.140 (0.014, 0.265) 0.029 
    150 - 499 µg/g 677 Ref.   436 Ref.  
    ≥ 500 µg/g  64 -0.009 (-0.218, 0.200) 0.934  51 -0.078 (-0.353, 0.196) 0.576 
(continued on next page) 
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Table 5. 6  Associations of first and second UI/Creat measurement (continuous and as  
UI/Creat groups) and UI/Creat status groups (based on both UI/Creat measurements) with 
thyroglobulin concentration from adjusted analyses (continued) 
 
  
Generation R 
(n=1,040) 
 
 
 
INMA 
(n=1,000) 
 
 n B (95% CI) P 1  n B (95% CI) P 2 
Second UI/Creat measurement 
UI/Creat, µg/g 637 -0.001 (-0.001, -0.000) 0.006  1000 -0.000 (-0.000, -0.000) 0.041 
Grouping 1        
    < 150 µg/g 147 0.001 (-0.157, 0.158) 0.991  431 0.067 (-0.054, 0.187) 0.277 
    ≥ 150 µg/g  490 Ref.   569 Ref.  
Grouping 2        
    < 100 µg/g 45 0.082 (-0.186, 0.350) 0.547  226 0.042 (-0.127, 0.210) 0.627 
    100 - 149 µg/g 102 -0.129 (-0.326, 0.069) 0.202  205 0.033 (-0.139, 0.205) 0.709 
    150 - 249 µg/g 221 Ref.   260 Ref.  
    ≥ 250 µg/g  269 -0.124 (-0.277, 0.028) 0.111  309 -0.057 (-0.214, 0.100) 0.479 
Grouping 3        
    < 50 µg/g  
147 3  -0.022 (-0.179, 0.136) 0.789 
 35 -0.128 (-0.446, 0.189) 0.437 
    50 - 149 µg/g   396 0.081 (-0.045, 0.208) 0.207 
    150 - 499 µg/g 452 Ref.   489 Ref.  
    ≥ 500 µg/g  38 -0.383 (-0.673, -0.093) 0.010  80 -0.016 (-0.242, 0.209) 0.885 
UI/Creat status      
 
  
    Insufficient  59 0.241 (0.006, 0.477) 0.045  248 0.188 (0.026, 0.350) 0.023 
    Borderline                      
    insufficient 
209 0.032 (-0.113, 0.176) 0.667  335 0.086 (-0.062, 0.233) 0.255 
    Sufficient 368 Ref.   311 Ref.  
Effect estimates (B=unstandardised regression coefficients), their 95% CIs and P-values are from multiple 
linear regression models performed for each cohort with (natural) log-transformed thyroglobulin (Tg) as 
the dependent variable and UI/Creat continuous or UI/Creat groups/status as independent variables. Models 
were adjusted for maternal characteristics (for full models, see footnotes 1 and 2). Reported B coefficients 
represent the change in the mean (natural) log of Tg (ng/ml) per unit increase in UI/Creat (µg/g) and for 
each UI/Creat group compared to the reference (‘iodine sufficient’) group. 1 Generation R models were 
adjusted for: gestational week at blood extraction, maternal age (years), pre-pregnancy BMI (kg/m2), TPO-
Ab status, ethnicity, parity, smoking status, alcohol consumption and education level. 2 INMA models were 
adjusted for: gestational week at blood extraction, maternal age (years), pre-pregnancy BMI (kg/m2), 
ethnicity, parity, smoking status, alcohol consumption and education level. 3 In Generation R, the UI/Creat 
sub-groups < 50 and 50 - 149 µg/g were combined into < 150 µg/g group for both UI/Creat measurements 
due to small numbers in the < 50 µg/g group (i.e., n=7 for 1st UI/Creat and n=2 for 2nd UI/Creat). 
Abbreviations: BMI, body mass index; 95% CI, confidence interval; Ref., reference category; Tg, 
thyroglobulin; TPO-Ab, thyroid peroxidase antibody; UI/Creat, urinary iodine-to-creatinine ratio 
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Table 5. 7  Median (25-75th percentile) thyroglobulin concentration (ng/ml) according to 
first and second UI/Creat measurement groups (based on each UI/Creat measurement) 
and iodine status groups (based on both UI/Creat measurements) 
  
Generation R 
(n=1,071) 
 
 
 
INMA 
(n=1,000) 
 
 n Median (25-75th) P 1  n Median (25-75th) P 1 
First UI/Creat measurement 
Grouping 1   0.010    <0.001 
    < 150 µg/g 311 12.0 (7.4 - 17.9)   513 12.8 (7.8 - 21.7)  
    ≥ 150 µg/g  760 10.4 (6.5 - 16.4)   487 10.4 (6.2 - 16.1)  
Grouping 2   0.028    <0.001 
    < 100 µg/g 113 13.2 (7.7 - 19.9)   284 13.9 (8.3 - 21.7)  
    100 - 149 µg/g 198 11.6 (7.2 - 16.6)   229 11.9 (6.9 - 21.2)  
    150 - 249 µg/g 340 10.2 (6.5 - 16.1)   245 10.6 (6.1 - 17.4)  
    ≥ 250 µg/g  420 10.6 (6.5 - 16.7)   242 10.1 (6.4 - 15.4)  
Grouping 3   0.031    <0.001 
    < 50 µg/g 
311  2     12.0 (7.4 - 17.9)  
 53 14.4 (7.9 - 22.7)  
    50 - 149 µg/g  460 12.6 (7.8 - 21.3)  
    150 - 499 µg/g 695 10.4 (6.5 - 16.6)   436 10.5 (6.1 - 16.5)  
    ≥ 500 µg/g  65 10.0 (6.5 - 15.9)   51 9.6 (6.7 - 14.7)  
Second UI/Creat measurement 
Grouping 1   0.433    0.001 
    < 150 µg/g 152 11.6 (6.7 - 17.6)   431 12.8 (7.7 - 20.7)  
    ≥ 150 µg/g  497 10.8 (6.6 - 16.5)   569 10.9 (6.6 - 16.9)  
Grouping 2   0.175    0.002 
    < 100 µg/g 48 12.5 (7.8 - 17.3)   226 13.3 (7.9 - 22.0)  
    100 - 149 µg/g 104 10.6 (6.4 - 17.7)   205 12.2 (6.9 - 19.7)  
    150 - 249 µg/g 223 10.9 (6.9 - 17.2)   260 11.7 (7.2 - 17.3)  
    ≥ 250 µg/g  274 10.2 (6.4 - 15.3)   309 10.3 (6.2 - 16.5)  
Grouping 3   0.001    0.006 
    < 50 µg/g 
152  2     11.6 (6.7 - 17.6)  
 35 11.8 (4.9 - 20.9)  
    50 - 149 µg/g  396 12.9 (7.7 - 20.7)  
    150 - 499 µg/g 458 11.1 (6.7 - 17.0)   489 11.0 (6.7 - 16.8)  
    ≥ 500 µg/g  39 8.2 (4.0 - 10.9)   80 10.5 (6.1 - 17.9)  
UI/Creat status    0.052    <0.001 
    Insufficient  61 12.6 (7.4 - 20.0)   248 14.5 (8.3 - 22.6)  
    Borderline insufficient 214 11.5 (6.7 - 17.3)   335 11.8 (7.1 - 18.5)  
    Sufficient  373 10.2 (6.5 - 15.9)   311 10.1 (6.1 - 15.6)  
1 P-values from a Mann-Whitney U test (for two-categorical variables) or a Kruskal-Wallis test (for 
variables with more than two categories). 2 In Generation R, the UI/Creat sub-groups < 50 and 50 - 149 
µg/g were combined into < 150 µg/g group for both UI/Creat measurements due to small numbers in the < 
50 µg/g group (i.e., n=7 for 1st UI/Creat and n=2 for 2nd UI/Creat). Abbreviations: UI/Creat, urinary iodine-
to-creatinine ratio 
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In INMA, women with elevated Tg (>40 ng/ml or >55 ng/ml) had a significantly lower 
early-pregnancy UIC and UI/Creat than women with Tg in the normal range (Table 5.8). 
Similar patterns were observed in Generation R women but the differences were not 
statistically significant. There was also a significantly higher proportion of INMA women 
with UI/Creat <150 µg/g (i.e., insufficient iodine intake) in the group with elevated Tg 
(based on both definitions) than in the group with normal Tg (when Tg >40 ng/ml: 70.5% 
vs 50.4%, P=0.014; when Tg >55 ng/ml: 78.9% vs 50.8%, P=0.028). In Generation R, 
the proportions of women with UI/Creat <150 µg/g were only slightly higher in the group 
with elevated Tg and were statistically non-significant (Table 5.8). Though similar patters 
were observed for the later-pregnancy UI/Creat measurements, the differences were 
relatively subtle and mostly statistically non-significant (Table 5.8). 
5.3.4 Association of UI/Creat from repeated samples with Tg 
When classifying pregnant women into iodine-status groups based on repeated UI/Creat 
measures from two time-points in pregnancy, the lowest Tg was observed in the group of 
women broadly classified as iodine-sufficient (i.e., having two UI/Creat measures ≥150 
µg/g) in both cohorts (Table 5.7). There was a trend for an increased Tg in the groups of 
women classified as iodine-insufficient/borderline-iodine-insufficient compared to 
women in the iodine-sufficient group. In adjusted analysis in both cohorts, however, only 
women who were broadly classified as iodine-insufficient (i.e., having two UI/Creat 
measures <150 µg/g) had statistically significantly higher Tg than women in the iodine-
sufficient group (Table 5.6).  
In sensitivity analyses in the borderline iodine-insufficient group, there was a weak 
negative correlation between the mean UI/Creat and Tg in both cohorts; it reached 
statistical significance only in INMA (rs= -0.131, P=0.016, n=335) and not in Generation 
R (rs= -0.101, P=0.139, n=214). After adjusting the analyses for confounders, the mean 
UI/Creat was still negatively associated with Tg in INMA but again not in Generation R 
(Generation R: B= 0.000, P=0.971; INMA: B= -0.001, P=0.028). When dichotomising 
women based on their mean UI/Creat into groups of <150 µg/g vs ≥150 µg/g, women 
with a mean UI/Creat <150 µg/g had a higher median (25-75th percentile) Tg 
concentration than those with a mean UI/Creat ≥150 µg/g in both cohorts [Generation R: 
13.1 (6.2-20.0) ng/ml vs 11.3 (6.9-16.6) ng/ml, P=0.325; INMA: 12.7 (8.4-21.3) ng/ml vs 
11.2 (6.9-18.2) ng/ml, P=0.148]; however these differences were not statistically 
significant in either univariable, or multivariable analyses (data not shown).
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Table 5. 8  Descriptives of both UIC and UI/Creat measurements in women with normal vs elevated serum Tg (>40 ng/ml 1or >55 ng/ml 2) 
 
Generation R (n=1,071)  INMA  (n=1,000) 
  Normal Tg  Elevated Tg    Normal Tg  Elevated Tg  
Cut-off > 40 ng/ml 1 n Tg ≤ 40 ng/ml n Tg > 40 ng/ml P 3  n Tg ≤ 40 ng/ml n Tg > 40 ng/ml P 3 
First urinary iodine measurement            
First UIC, µg/L 1029 167 (98 - 286) 42 161 (97 - 256) 0.562  956 134 (77 - 225) 44 95 (63 - 138) 0.004  
First UI/Creat, µg/g 1029 210 (139 - 309) 42 174 (127 - 282) 0.082  956 148 (95 - 249) 44 105 (70 - 159) 0.005  
First UI/Creat < 150 µg/g, n (%) 1029 297 (28.9%) 42 14 (33.3%) 0.651  956 482 (50.4%) 44 31 (70.5%) 0.014  
Second urinary iodine measurement 
Second UIC, µg/L 622 156 (91 - 262) 27 148 (86 - 225) 0.506  958 134 (82 - 231) 42 124 (90 - 170) 0.618 
Second UI/Creat, µg/g 622 227 (156 - 319) 27 177 (137 - 238) 0.038  958 168 (106 - 296) 42 140 (109 - 269) 0.286 
Second UI/Creat < 150 µg/g, n (%) 622 144 (23.2%) 27 8 (29.6%) 0.585  958 407 (42.5%) 42 24 (57.1%) 0.086  
Cut-off > 55 ng/ml 2 n Tg ≤ 55 ng/ml n Tg > 55 ng/ml P 
3  n Tg ≤ 55 ng/ml n Tg > 55 ng/ml P 3 
First urinary iodine measurement            
First UIC, µg/L 1058 167 (97 - 285) 13 141 (98 - 292) 0.624  981 132 (76 - 223) 19 97 (55 - 135) 0.027 
First UI/Creat, µg/g 1058 209 (139 - 307) 13 188 (112 - 302) 0.374  981 148 (95 - 247) 19 102 (66 - 142) 0.012 
First UI/Creat < 150 µg/g, n (%) 1058 306 (28.9%) 13 5 (38.5%) 0.539  4 981 498 (50.8%) 19 15 (78.9%) 0.028 
Second urinary iodine measurement 
Second UIC, µg/L 639 155 (90 - 261) 10 147 (82 - 262) 0.822  982 134 (83 - 228) 18 117 (87 - 141) 0.299 
Second UI/Creat, µg/g 639 224 (153 - 317) 10 194 (138 - 260) 0.361  982 167 (106 - 294) 18 149 (100 - 219) 0.200 
Second UI/Creat < 150 µg/g, n (%) 639 149 (23.3%) 10 3 (30%) 0.706    4 982 421 (42.9%) 18 10 (55.6%) 0.403 
Data are presented as median (25-75th percentile) for all continuous variables and n (%) for the categorical variables. 1 Cut-off value for elevated Tg based on previous studies 
in adults and school-aged children (see ‘Methods’ Section 5.2.6). 2 Cut-off value considered elevated from the laboratory where the Tg measurements were performed (see 
‘Methods’ Section 5.2.3). 3 P-values from a Mann-Whitney U test or a Chi-square test (after Continuity Correction for comparisons in 2x2 tables). 4 Fisher's Exact Test P-value 
was reported due to some cells with expected count < 5. Abbreviations: Tg, thyroglobulin; UI/Creat, urinary iodine-to-creatinine ratio; UIC, urinary iodine concentration
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5.4 Discussion  
This study aimed to identify the determinants of serum Tg and explore its usefulness as a 
potential biomarker of iodine status in pregnant women using multiple urinary-iodine 
measurements. Several factors were related to serum Tg concentration in pregnancy, 
including maternal iodine intake (as measured by UI/Creat), smoking, ethnicity, iodine-
supplement use and maternal milk intake. In agreement with the hypothesis, urinary 
iodine concentration (expressed as UI/Creat) was negatively associated with Tg in these 
two pregnancy cohorts from regions of sufficient and insufficient iodine intakes.  
5.4.1 Maternal characteristics, diet and iodine-supplement use as determinants of 
serum Tg 
5.4.1.1 Smoking 
Smoking is a factor known to interfere with the function of the thyroid gland (Kapoor and 
Jones 2005). As in several other studies in pregnant women (Brucker-Davis et al. 2012; 
Andersen et al. 2013; Katko et al. 2017), significantly higher serum Tg concentration was 
found in smoking mothers in both pregnancy cohorts included in this study. Thiocyanate, 
an end-product of tobacco smoke detoxification, can interfere with iodine transport in the 
thyroid by competitively inhibiting the sodium-iodide symporter (NIS), thereby 
decreasing iodide uptake by thyrocytes (Dohán et al. 2003; Tonacchera et al. 2004). 
Despite that inhibition, the increased thyroid activity from the autoregulatory mechanisms 
that maintain iodide uptake for thyroid hormone synthesis results in an increase in thyroid 
volume and serum Tg; thus Tg is a non-specific marker of the activity or stimulation state 
of the thyroid (Knudsen et al. 2002; Glinoer 2004). The effect of smoking on serum Tg 
seemed stronger in INMA than in Generation R, perhaps because iodide transport by the 
NIS is affected more by competitive inhibition when iodine intake is lower (Knudsen et 
al. 2002; Andersen et al. 2013). 
5.4.1.2 Ethnicity  
In Generation R (the Netherlands), compared to Dutch women, Turkish women had a 
significantly lower Tg, while women from the Dutch Antilles had a significantly higher 
Tg. These ethnic differences could be at least partly explained by differences in iodine 
intake. In our previous study in this cohort, we also showed ethnic differences in UI/Creat; 
compared to Dutch women, Turkish women had significantly higher UI/Creat, while 
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women from the Dutch Antilles had significantly lower UI/Creat (Dineva et al. 2019) 
(see Chapter 3).  Ethnicity was not associated with Tg in INMA, though the INMA cohort 
was not as multi-ethnic, the proportion of non-Spanish ethnic groups being very small. 
5.4.1.3 Iodine-supplement use 
Only in INMA, pregnant women who used iodine-containing supplements pre-pregnancy 
and in the first trimester had statistically significantly lower serum Tg, with a smaller 
proportion of this group having elevated Tg (>40 ng/ml) than the group of non-users. In 
adjusted analysis, however, iodine-supplement use was not a significant predictor of 
maternal Tg concentration in either cohort. Women in Generation R were overall iodine-
sufficient so iodine-supplementation would not have been expected to prevent an increase 
in Tg that might be related to iodine deficiency. It should also be noted that the data on 
iodine-supplement use were collected only for a limited number of women in the 
Generation R cohort and the number of women who did not use supplements (i.e., the 
reference group) was very small relatively to those who reported iodine-supplement use. 
By contrast, INMA women were mildly-to-moderately iodine-deficient thus, iodine 
supplementation might have alleviated the increase in Tg associated with thyroidal 
adaptation to low iodine intakes (i.e., enhanced thyroidal stimulation) (Glinoer 2004); 
though the difference in Tg between women who reported iodine-supplement use and 
those who were non-users was small (about 1 ng/ml) and probably clinically insignificant. 
Several RCTs in mildly-to-moderately iodine-deficient pregnant women have shown that 
iodine supplementation resulted in a reduction in maternal serum Tg by 18-37% over the 
course of pregnancy (Pedersen et al. 1993; Nøhr et al. 2000; Brucker-Davis et al. 2013; 
Censi et al. 2019) and cross-sectional studies have reported a difference between iodine-
supplement users and non-users ranging from 5.3 to 11.1 ng/ml (Nøhr and Laurberg 2000; 
Katko et al. 2017; Manousou et al. 2019) (see Chapter 7). In the current study, although 
there was a significant negative correlation between the mean daily iodine intake from 
supplements and Tg in INMA women, it was only weak and the association was not 
significant in adjusted analyses, possibly suggesting that the dose of iodine used by most 
women might have been insufficient to have an effect on Tg [e.g., total mean daily iodine 
intake from supplements was <40 µg/day and only 8% (n=88) had an iodine supplement 
intake ≥150 µg/day]. An intervention study in mildly-to-moderately iodine-deficient 
pregnant women showed that Tg decreased by 36% over the course of pregnancy in the 
106 
 
group taking the higher dose of iodine supplement (200 µg/day), while it increased by 
25% in the group with the lower dose (50 µg/day) (Antonangeli et al. 2002). 
5.4.1.4 Milk consumption  
Maternal consumption of milk was associated with lower Tg in both pregnancy 
populations. In our previous study, milk and dairy-product intake was a significant 
predictor of maternal UI/Creat in both of these cohorts (Dineva et al. 2019).  Although in 
our previous study (Chapter 3), the intake of cereal products (e.g., bread) and fish were 
predictors of UI/Creat in Generation R and INMA, respectively, these food groups were 
not associated with Tg in the current study. The lack of an association between bread 
consumption and Tg in Generation R could be because most women consumed bread 
regularly, contributing to their iodine intake, and the differences in the amount of bread 
consumed daily between the categories of bread intake studied were not sufficiently large 
to observe differences in Tg. Similarly, in INMA, all women consumed fish and the 
differences in Tg between no fish consumption and some consumption could not be 
evaluated and only small differences were observed between the categories of fish intake. 
5.4.2 Assessment of iodine status in pregnancy using serum Tg 
As hypothesised, UI/Creat was negatively associated with serum Tg concentration. In 
early pregnancy, the group of women with UI/Creat <150 µg/g had higher Tg than the 
group with UI/Creat ≥150 µg/g in both pregnancy cohorts. Serum Tg was even more 
elevated in the group of women with UI/Creat <100 µg/g and there was a trend for even 
higher Tg in the group of INMA women with UI/Creat <50 µg/g. The increased serum 
Tg in the groups with suboptimal iodine nutrition is likely as a result of an increased 
thyroidal activity. The thyroid adapts in order to keep up with the increased demand for 
thyroid hormone during pregnancy, even though the iodine supply is insufficient, thereby 
leading to an increased amount of Tg that is being released in the circulation (Glinoer 
2004). These results, therefore, suggest that Tg might be a good indicator of iodine 
nutrition in groups of pregnant women. 
 
Although Generation R women were iodine-sufficient and INMA women were mildly-
to-moderately iodine-deficient, the overall median Tg and the percentage of women with 
elevated Tg were only slightly higher in INMA women. Most previous studies in iodine-
deficient pregnant populations have reported a median Tg ≥13 ng/ml (Moreno-Reyes et 
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al. 2013; Ma and Skeaff 2014; Bath, Pop, et al. 2017; Katko et al. 2017). In the current 
study, the overall median Tg in both cohorts was around 11 ng/ml and it reached ≥13 
ng/ml only in the sub-groups with UI/Creat <100 µg/g. As Tg was measured in the first 
trimester, it could be that women in INMA could draw on their iodine stores to 
compensate for their low iodine intake. With advancing pregnancy, however, if iodine 
intake remains suboptimal, the stores will get progressively depleted resulting in a 
progressive rise in serum Tg concertation (Glinoer 2004). Indeed, a previous study in 
mildly-to-moderately iodine-deficient pregnant women has shown that Tg increased over 
the course of gestation in the group of women with UI/Creat <150 µg/g but remained 
unchanged in the group with UI/Creat ≥150 µg/g (Bath, Pop, et al. 2017). This being the 
case, the differences in Tg between the two cohorts in this study might have been more 
apparent if Tg had been measured in later pregnancy. 
 
In both cohorts, the median Tg of pregnant women in the groups with sufficient iodine 
intake (i.e., UI/Creat ≥150 µg/g) was around 10 ng/ml. Pregnant women with sufficient 
iodine status (classified from two repeated UI/Creat measures during pregnancy) also had 
a median Tg ~10 ng/ml. These results are in agreement with a relatively recent study that 
measured Tg from a dried-blood spot in pregnant women across 11 countries and 
suggested that a median Tg ~10 ng/ml can be used to indicate iodine sufficiency in a 
pregnant population (Stinca et al. 2017). 
 
Previous studies in schoolchildren and pregnant women have shown a U-shaped 
association between UIC and Tg, where increased Tg concertation was observed in the 
groups with low and excessive iodine intakes (Zimmermann et al. 2013; Shi et al. 2015). 
Similar results were also reported in a more recent study with data from 11 countries with 
varying iodine status, where Tg was higher in pregnant women residing in countries with 
severe iodine deficiency and more-than-adequate iodine intake than in those with 
sufficient intake (Stinca et al. 2017). In the current study, however, Tg was not increased 
in the groups with more-than-adequate or excessive iodine intakes (i.e., UI/Creat ≥250 
and ≥500 µg/g, respectively). Additionally, there was no significant non-linear 
association between UI/Creat and Tg. However, it should be noted that the number of 
women in the groups with excessive iodine intake in both cohorts was probably too small 
to detect these effects.  
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On an individual level, only a weak negative correlation was found between UI/Creat and 
Tg, which was statistically significant only in INMA women. This finding is in agreement 
with other studies that have investigated the relationship of UI/Creat and UIC with serum 
Tg during pregnancy (Moreno-Reyes et al. 2013; Koukkou et al. 2016; Katko et al. 2017; 
Stinca et al. 2017). Unlike urinary iodine which reflects recent iodine intake (i.e., in the 
last 24-48 hours) and is not directly indicative of thyroid function, Tg concentration 
provides information about longer-term iodine intake (i.e., in weeks to months) 
(Zimmermann and Andersson 2012) and is a non-specific marker of thyroid activity 
(Glinoer 1997). A strong association between the two would not be expected on an 
individual level, as iodine concentration in a casual spot-urine sample is an imprecise 
estimate of habitual iodine intake in an individual (König et al. 2011). In this study, the 
measurement of Tg in the first trimester could be a reflection of iodine intake during very 
early pregnancy and even pre-pregnancy. The observed weak negative association 
between Tg in the first trimester and first-trimester UI/Creat (reflecting the last 24-48 
hours) might be because the high Tg concentration in early pregnancy is to some extent 
related to low maternal pre-pregnancy iodine stores. The low iodine stores (reflected by 
high Tg) might result in an increased iodide uptake by the thyroid and subsequently, a 
decrease in urinary iodine loss (reflected in low UI/Creat).  
 
The negative correlation between UI/Creat in early pregnancy and Tg in women from 
Generation R was weak and not statistically significant. In agreement with those results, 
a previous study with data from multiple countries found no statistically significant 
correlation between UIC and Tg in countries with sufficient or more-than-adequate iodine 
intake though a significant negative correlation was found in iodine-deficient countries 
(Stinca et al. 2017). Similar findings were reported in studies in iodine-sufficient pregnant 
women from China and Brazil (Zhang et al. 2017; Mioto et al. 2018). The difference in 
Tg between the UI/Creat groups (<150 vs ≥150 µg/g) seemed more subtle in Generation 
R than in INMA. In Generation R, the median UI/Creat and the proportion of women with 
UI/Creat <150 µg/g were not significantly different between the groups with elevated Tg 
(Tg >40 and >55 ng/ml) and normal Tg and the median UI/Creat was indicative of 
sufficient iodine intake (i.e., UI/Creat ≥150 µg/g) in both Tg groups (normal and 
elevated). Conversely, in INMA, UI/Creat was nearly 150 µg/g in the group of women 
with normal Tg and ~100 µg/g in the groups with elevated Tg. The more subtle 
associations between Tg and UI/Creat in Generation R could be because most Generation 
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R women had UI/Creat ≥150 µg/g (i.e., ~70%) thus, this cohort had limited variation in 
iodine intake. Possibly within populations that are overall iodine-sufficient, even if iodine 
intake becomes low during pregnancy (e.g., low UI/Creat at the time of urine-sampling), 
women might have good iodine stores (as they live in an iodine-sufficient country) to 
keep up with the increased thyroid-hormone production during pregnancy without 
stressing the thyroid, thereby preventing the increase in serum Tg. 
 
In adjusted analyses, the second UI/Creat measurement from urine samples collected later 
in pregnancy (i.e., after the blood samples for Tg measurement) was mostly not 
significantly associated with Tg when women were split into UI/Creat groups, though it 
was continuously associated with Tg and the same trends for decreasing Tg with 
increasing UI/Creat were observed across groups. This was expected, as UI/Creat was 
from later pregnancy and Tg was from early pregnancy. The later-pregnancy UI/Creat in 
combination with the early-pregnancy UI/Creat appeared to provide a more accurate 
evaluation of the iodine status of women during pregnancy – women broadly classified 
as having sufficient pregnancy iodine status (early- and late-pregnancy UI/Creat ≥150 
µg/g) had the lowest Tg. 
 
Although in these analyses there was an association of spot-UI/Creat and UI/Creat status 
with serum Tg during pregnancy, it should be noted that Tg is a good but non-specific 
marker of iodine nutrition and is also dependent on thyroid activity (Laurberg et al. 2007). 
The effect of pregnancy on thyroid activity should be considered when using Tg as a 
biomarker of iodine nutrition in pregnant women as physiological changes occur that are 
unrelated to iodine status and can influence Tg [e.g., an increased thyroid secretory 
activity and a peak in human chorionic gonadotropin (hCG) at the end of the first 
trimester] (Laurberg et al. 2007; Koukkou et al. 2016).  
 
Overall, the results from the current study demonstrated that Tg seems a good marker of 
iodine status in groups of pregnant women (i.e., at group/population level), with higher 
Tg concentration in the groups of women with low iodine intakes. Median Tg 
concentration around 10 ng/ml seems indicative of sufficient iodine intake (defined by 
UI/Creat ≥150 µg/g) in a group of pregnant women, confirming the findings by Stinca et 
al. 2017. Tg concentration might be a more sensitive biomarker of iodine status in 
pregnant populations if measured later in pregnancy (e.g., in the third trimester) for two 
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reasons: i) the ability of Tg to distinguish between an iodine-sufficient and mildly-to-
moderately iodine-deficient pregnant population might be dependent on the maternal 
thyroid iodine stores; if iodine intake remains low in pregnancy, the stores will get 
progressively depleted resulting in a progressive rise in serum Tg in the later stages of 
pregnancy and a more apparent difference between an iodine-sufficient and a mildly-to-
moderately iodine-deficient group of pregnant women; ii) Tg is a non-specific marker of 
thyroid stimulation and thus, its concentration might be influenced by pregnancy-related 
changes other than iodine intake, such as the increase in thyroid secretory activity and the 
peak in hCG at the end of the first trimester.  
 
Although Tg seems a useful biomarker of iodine nutrition in groups, the use of Tg for an 
individual is unclear. As Tg concentration seems to reflect changes in iodine intake in the 
preceding weeks to months, Tg should be validated using multiple urinary-iodine 
measurements collected prior to the Tg measurement, or a measurement of long-term 
iodine intake estimated from an FFQ. An RCT in mildly iodine-deficient adults showed 
that 24 weeks of iodine supplementation were required to observe a fall in Tg from 20 
ng/ml at baseline to 13 ng/ml (the proposed cut-off for children) (Ma et al. 2016). These 
findings were supported by an RCT in mildly-to-moderately iodine-deficient pregnant 
women, where compared to its first-trimester values, by the third trimester, Tg decreased 
by 27% in response to iodine supplementation, while it increased by 17% in the placebo 
group (Censi et al. 2019). The changes in Tg during pregnancy might be dependent on 
the baseline iodine status and the amount of iodine stored in the thyroid. For instance, in 
a previous study of pregnant women, Tg increased from 17 ng/ml at 12 weeks to 20 ng/ml 
at 35 weeks in the group of women with UI/Creat <150 µg/g but remained unchanged in 
the group with UI/Creat ≥150 µg/g (~16 ng/ml) (Bath, Pop, et al. 2017). Tg also did not 
differ by trimester in iodine-sufficient euthyroid pregnant women (Stinca et al. 2017).  
5.4.3 Strengths and limitations  
This study used data from a large number of pregnant women residing in areas of iodine 
sufficiency and mild-to-moderate iodine deficiency thus provides the ability to explore 
the relationship between urinary iodine concentration and Tg in two different settings of 
baseline iodine status. Data on a number of maternal socio-demographic and socio-
economic characteristics were available and were accounted for in these analyses, 
minimising their potential confounding effect on the association between iodine and Tg. 
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The simultaneous measurement of Tg-Abs enabled the exclusion of Tg-Ab positive 
women thus limiting their known interference with the interpretation of Tg measurements 
(Ma and Skeaff 2014).   
 
This study has several limitations. Only a single measurement of Tg from early pregnancy 
was available therefore the potential change in Tg over the course of pregnancy and the 
association of UI/Creat with Tg in late pregnancy could not be evaluated. Another 
limitation was the use of single spot-urine samples for the measurement of urinary iodine 
at each time-point in pregnancy. This limitation was somewhat accounted for by 
expressing the iodine concentration per unit creatinine, using the UI/Creat instead of UIC 
alone, which, as discussed, has lower variability and better reflects the 24-h UIE and 
serum iodine concentration (Rasmussen et al. 1999; Knudsen et al. 2000; Andersen et al. 
2008; König et al. 2011; Li et al. 2016). The use of repeated urinary iodine measurements 
(from early and late pregnancy) may have also improved the classification of pregnant 
women into pregnancy iodine-status groups. Information on iodine-supplement use was 
available only for a sub-set of Generation R women and there were no data on supplement 
dose hence the effect of iodine-containing supplements on Tg could not be fully evaluated 
in this cohort. This study included data from the Generation R and INMA cohorts only; 
although the full thyroid-function profile of the ALSPAC cohort has been analysed 
previously (Nelson et al. 2018), it did not include a measurement of Tg.   
 
 
5.5 Conclusion  
The results of this study suggest that Tg can be a useful marker of suboptimal iodine 
nutrition in subgroups of pregnant women residing in areas of overall iodine sufficiency 
and mild-to-moderate iodine deficiency. However, the ability of Tg to distinguish 
between overall iodine-sufficient and mildly iodine-deficient populations is not clear and 
might be confounded by maternal pre-pregnancy thyroidal iodine stores and by the time-
point in pregnancy at which Tg is measured. The findings suggest that Tg can be used as 
a complementary functional indicator of iodine status, alongside biomarkers of recent 
iodine intake such as urinary iodine concentration, to monitor the iodine nutritional status 
in populations. Validated biomarkers of individual iodine status are still lacking and 
require future work in the field.  
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Chapter 6                                      
Association of maternal iodine status from repeated 
urinary iodine measurements during pregnancy with 
child verbal, non-verbal and total IQ 
 
6.1 Introduction  
Optimal iodine nutrition during pregnancy is important because iodine is an essential part 
of the thyroid hormones which are required for processes involved in brain and 
neurological development (e.g., neurogenesis, neuronal migration and differentiation) 
(Williams 2008). Brain development begins around two weeks after conception (Bell et 
al. 2016) and thyroid-hormone receptors have been detected in the fetal brain as early as 
nine weeks (Ferreiro et al. 1988), with their concentrations increasing ten-fold by 16 
weeks (Bernal and Pekonen 1984). This suggests that thyroid hormones are important 
from the very early stages of fetal neurodevelopment and adequate iodine intake is 
required from conception. As the fetal thyroid is not functional until around the end of 
the first trimester (Burrow et al. 1994), the mother is the primary source of thyroid 
hormones for the fetus in early pregnancy (i.e., in the first trimester). As early pregnancy 
seems to be the most critical time for adequate iodine supply (de Escobar et al. 2004; 
Zoeller and Rovet 2004), the majority of studies that have investigated the association of 
maternal iodine status with child cognition have focused on relatively early time-windows 
of exposure and have predominantly used a single spot-urine iodine measurement to 
assess maternal iodine status [expressed as urinary iodine concentration (UIC) or iodine-
to-creatinine ratio (UI/Creat)] (van Mil et al. 2012; Bath, Steer, et al. 2013; Ghassabian 
et al. 2014; Markhus et al. 2018; Murcia et al. 2018; Levie et al. 2019). 
 
Although early pregnancy is a critical time for optimal iodine nutrition, the fetus is still 
reliant on maternal supply of iodine in the later stages of pregnancy to synthesise its own 
hormones after the fetal thyroid is fully functional (Burrow et al. 1994); this suggests that 
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optimal iodine availability during the entire pregnancy is important. Depending on the 
developmental timing of thyroid-hormone deficiency, thyroid-hormone deficits may have 
an effect on specific neuropsychological functions (Zoeller and Rovet 2004); therefore, 
an exposure to iodine deficiency during different time-points in pregnancy may well have 
an effect on different aspect of fetal brain development. 
 
The measurement of urinary iodine concentration in a casual spot-urine sample provides 
a good estimate of recent iodine intake (Zimmermann and Andersson 2012) but the 
problems with using a single spot-urine sample to assess habitual iodine intake (i.e., over 
longer period) or iodine nutritional status in individuals have been discussed widely in 
the literature (Andersen et al. 2008; Vejbjerg et al. 2009; König et al. 2011). The 
assessment of iodine status from urine samples can be even more complex during 
pregnancy, as the amount of iodine excreted in the urine might change with advancing 
gestation, as shown in Chapter 4 and in a number of other studies (Fuse et al. 2011; Fuse 
et al. 2013; Moreno-Reyes et al. 2013; Bath et al. 2015; Li et al. 2016), suggesting that 
the measurement of urinary iodine at one time-point in pregnancy does not capture iodine 
availability during all stages of pregnancy.  
 
Previous analyses using data from the Avon Longitudinal Study of Parents and Children 
(ALSPAC) used a single urinary-iodine measurement as a proxy for maternal iodine 
status and the analyses were restricted to the first 13 weeks (Bath, Steer, et al. 2013). 
There is limited evidence of the usefulness of repeated urinary-iodine measurements from 
different time-points in pregnancy in gaining a better proxy measure of iodine availability 
across gestation; it is also unclear whether such measures that also provide information 
about iodine status from the later stages of pregnancy (i.e., beyond the first trimester) 
would be related to child cognition. Only a few studies have used multiple measurements 
of iodine status in pregnancy to relate to child cognition (Hynes et al. 2013; Hynes et al. 
2017) and therefore the aim of this study was to explore the association of maternal 
pregnancy iodine status (i.e., based on multiple urinary-iodine measurements from 
different gestational time-points, including measures ≥13 weeks) with child cognition, 
assessed as intelligence quotient (IQ) scores at 8 years.  
 
Because iodine deficiency at different gestational time-points may have an effect on 
different cognitive outcomes, alongside the measure of total (full-scale) IQ [regarded as 
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the best measure of general intelligence that is correlated with brain size and cortical 
thickness (Colom et al. 2010)], measures of verbal and non-verbal IQ were also used as 
outcomes in this study. Verbal IQ is a measure of an individual’s language-based abilities 
(e.g., reasoning, ability to express and perceive ideas in words) and changes in verbal IQ 
have been positively correlated with changes in grey matter density and volume in an area 
in the left motor cortex that is activated by speech (Ramsden et al. 2011). By contrast, 
non-verbal IQ is a measure of an individual’s visual and motor skills (e.g., ability to 
integrate visual stimuli, hand movements); changes in non-verbal IQ were positively 
correlated with changes in grey matter density in the anterior cerebellum (an area 
associated with hand movements) (Ramsden et al. 2011). Verbal IQ is a better predictor 
of school achievement than non-verbal IQ (Nicholson and Alcorn 1993; DeThorne and 
Schaefer 2004).   
 
6.1.1 Hypothesis 
Low maternal iodine status based on multiple urinary-iodine measurements collected 
across pregnancy (including measures beyond the first trimester) would be associated 
with lower child-IQ scores. 
 
 
6.2 Methods 
6.2.1 Study population  
This study used data from pregnant women recruited as part of the Avon Longitudinal 
Study of Parents and Children (ALSPAC). ALSPAC is a prospective population-based 
birth cohort from the Bristol area in the South-West of England that recruited 14,541 
pregnant women with an expected date of delivery between April 1, 1991 and December 
31, 1992 (Boyd et al. 2013; Fraser et al. 2013). The ALSPAC cohort had ethical approval 
prior to recruitment (see Chapter 2) and the current study was based on secondary 
analyses of the ALSPAC data.  
6.2.2 Selection criteria for the current study  
A subsample of ALSPAC women who had multiple (at least two) measurements of 
urinary iodine and creatinine concentrations during pregnancy and whose children had 
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available data on IQ at 8 years were included in this study (Figure 6.1). Women with 
multiple pregnancy, those who had thyroid disease (including hypo- or hyperthyroidism), 
or those who used thyroid-related/iodine-containing medication (including kelp or iodine-
containing supplements) were excluded. 
6.2.3 Urinary iodine and creatinine measurements  
Urinary iodine and creatinine concentrations were measured in spot-urine samples 
collected at various time-points in pregnancy. The women included in this study had up 
to three urinary iodine and creatinine measurements available (Figure 6.1). Only one 
woman had a fourth measurement but this fourth sample was not included in further 
analyses. The three spot-urine samples were collected at a median of 9, 17 and 34 
gestational weeks, respectively. Gestational week was established using the date of the 
last menstrual period. The full laboratory information about the measurement of urinary 
iodine and creatinine concentrations is provided elsewhere (Chapter 2). In line with the 
work presented in previous chapters (Chapter 3, Chapter 4 and Chapter 5), the variability 
in UIC resulting from individual hydration-status differences was accounted for by 
adjusting UIC for the urinary creatinine concentration (i.e., using the UI/Creat in 
preference to UIC alone).  
 
As previously explained in detail (Chapter 4), a number of urine samples that measured 
UIC >500 µg/L and/or UI/Creat >700 µg/g were excluded as potentially contaminated by 
the use of iodine-containing test-strips. Where possible, these excluded samples were 
replaced with measurements from a later uncontaminated urine sample in women who 
had multiple measurements.  
6.2.4 Child neurodevelopment  
For this study, child verbal, non-verbal (performance) and total (full-scale) IQ at age 8 
years [median (25-75th percentile) 8.6 (8.5 - 8.7) years] were used as outcomes. In 
ALSPAC, child IQ was assessed in the research clinic using the abbreviated Wechsler 
Intelligence Scale for Children 3rd edition (WISC-III) (Wechsler et al. 1992; Boyd et al. 
2013). The IQ measures were used as continuous outcomes (i.e., the full range of scores) 
and also as suboptimum outcomes (i.e., defined as scores in the bottom quartile or < 85 
points) (see Section 6.2.5).  
116 
 
1 Urine samples with UIC > 500 µg/L or UI/Creat > 700 µg/g were excluded, as there was a concern that 
these samples could have been potentially contaminated by the use of iodine-containing test-strips. A 
number of the excluded potentially contaminated samples were replaced with a later uncontaminated 
sample, if available; this is, therefore, the final number of excluded contaminated samples after a few were 
replaced (for more details see ‘Methods’ Section 6.2.3 and Chapters 3 and 4). Abbreviations: ALSPAC, 
the Avon Longitudinal Study of Parents and Children; IQ, intelligence quotient; KI, potassium iodide; UIC, 
urinary iodine concentration; UI/Creat, urinary iodine-to-creatinine ratio 
 
At least one urinary iodine and 
creatinine measurement 
available + Child IQ 
N=3,080 
Data unavailable:  
Urinary iodine and creatinine concentrations 
not measured 
N=11,036 
 
Enrolled during pregnancy in 
ALSPAC (Phase I) 
N=14,541 
 
Urinary iodine and creatinine 
measured 
N=3,505 
 
At least one urinary iodine and 
creatinine measurement  
available 
N=3,122 
Exclusions: 
Total N=383 
Multiple pregnancy, N=0 
Thyroid disease, N=17 
(16 hypothyroidism and 1 hyperthyroidism) 
Thyroid-related/iodine-containing 
medication (including kelp and KI 
supplements), N=20 
Potentially contaminated samples 
(UIC > 500 µg/L or UI/Creat > 700 µg/g), 
N=3631 
  
Multiple (2/3) urinary iodine 
and creatinine measurements 
available + Child IQ 
N=452 
Three urinary iodine and 
creatinine measurements 
available + Child IQ  
N=178 
 
Data on child IQ at 8 years  
not available: 
N=42 
 
Figure 6. 1  Flow chart of the study population selection from the ALSPAC cohort 
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The suboptimum scores are useful to identify the number of individuals at the low-end of 
IQ, where the effect of iodine deficiency might be more apparent and clinically relevant. 
However, using the continuous scores provides greater power to detect an effect. A 3-
point and a 4-point difference from the mean IQ of the group would be significant at the 
5% (i.e., at P<0.05) and 1% (i.e., at P<0.01) level, respectively (Nicholson and Alcorn 
1993). 
6.2.5 Statistical analyses 
All measures of child IQ approximated normal distribution and means [± standard 
deviation (SD)] were used to describe the central tendency and spread of these measures 
in the study sample. None of the three measurements of maternal UI/Creat during 
pregnancy were normally distributed (right-skewed), therefore medians (25-75th 
percentile) were reported as the descriptives. As previously (Chapter 4), the correlations 
between the repeated UI/Creat measurements were also explored for the women with 
multiple measures included in this study (i.e., those who also had child IQ data available) 
using Spearman’s rank correlations (rs). 
 
The analyses were performed for the whole sample (i.e., women who had at least two 
measurements) and also separately for a subsample of these women who had all three 
measurements. After all exclusion criteria were applied (Figure 6.1), the differences in 
characteristics between ALSPAC women (with available child IQ data) who had a single 
iodine measurement only and those who had multiple measurements during pregnancy 
were explored using independent samples t-tests (for continuous normally distributed 
variables), Mann-Whitney U tests (for continuous non-normally distributed variables) 
and Chi-square tests (for categorical variables). 
 
The association of the repeated urinary iodine measurements (expressed as UI/Creat) with 
child verbal, non-verbal and total IQ scores at 8 years was investigated. To utilise the 
information from the repeated spot-UI/Creat measurements during pregnancy, two 
exposure variables were created and used as a proxy for iodine availability/status during 
pregnancy. Firstly, the mean of the repeated spot-UI/Creat measurements was calculated 
in the total sample of women with multiple (two or three) measurements (i.e., it 
represented the mean of two or the mean of three spot-UI/Creat measures) and also in the 
subsample of women who had all three measurements (i.e., it represented the mean of 
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three spot-UI/Creat measures). Similarly, the mean gestational week at urine-sample 
collection was also calculated. Secondly, similarly to the methodology used in Chapter 5, 
women were broadly classified into three iodine status groups based on the repeated spot-
UI/Creat measurements: (i) women with all (two or three) spot-UI/Creat measurements 
<150 μg/g (i.e., insufficient); (ii) women with at least one spot-UI/Creat measurement 
<150 μg/g (i.e., borderline insufficient); and (iii) women with all (two or three) spot-
UI/Creat measurements ≥150 μg/g [i.e., sufficient (reference group)]. This iodine status 
classification was applied to the total sample of women with multiple (two or three) 
measurements (i.e., iodine status was based on two or three spot-UI/Creat measures) and 
also separately for the subsample with three measurements (i.e., iodine status was based 
on three spot-UI/Creat measures). 
 
The continuous association of the mean UI/Creat with the full range of child verbal, non-
verbal and total IQ scores was explored using univariable and multiple linear regression 
models. To comply with the assumption of normality of linear regression analyses, the 
residuals of these models were visually assessed for normality. Potential outliers were 
assessed using box-plots. The non-linearity of the association of the mean UI/Creat with 
the IQ scores was investigated by the addition of non-linear terms to the regression 
models (including quadratic and cubic terms) and also by assessing the fit (R2) of a linear 
vs non-linear (quadratic or cubic) trends through the data points, using a scatterplot of 
mean UI/Creat against each of the IQ scores. The multiple regression models were 
adjusted for potential confounders; these were selected on the basis of previous studies 
investigating the effect of maternal iodine status on child neurodevelopmental outcomes 
in ALSPAC and other pregnancy cohorts (Bath, Steer, et al. 2013; Levie et al. 2019), and 
also informed by the determinants of iodine status in ALSPAC that were identified in 
Chapter 3 (Dineva et al. 2019). Ten potential confounders were used in all models, 
including mean gestational week at urine sampling, maternal age (years), pre-pregnancy 
body mass index (BMI) (kg/m2), ethnicity, parity, smoking status, maternal education 
level, family adversity index, marital status and child's sex.  
 
In addition to the iodine status classification (insufficient, borderline insufficient and 
sufficient) as explained above, the mean UI/Creat was used to dichotomise women into 
two groups [<150 µg/g (i.e., insufficient intake) vs ≥150 µg/g (i.e., sufficient intake; 
reference group)]. This cut-off was informed by WHO criteria that define iodine adequacy 
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in pregnant populations (a median UIC ≥150 µg/L) (WHO 2007a) and has been used with 
UI/Creat in previous studies (Bath, Steer, et al. 2013; Hynes et al. 2017; Murcia et al. 
2018; Levie et al. 2019). The associations of the dichotomised mean UI/Creat and the 
iodine status classification of repeated UI/Creat with the full range of IQ scores were also 
investigated in univariable and multiple regression models adjusted for the previously 
mentioned potential confounders.  
 
To investigate the associations of the dichotomised mean UI/Creat and the classification 
of repeated UI/Creat during pregnancy with the risk of suboptimum child IQ scores, 
logistic regression models were used, with women who had mean UI/Creat ≥150 µg/g 
and those who had ‘sufficient’ UI/Creat status [i.e., women with all (two or three) spot-
UI/Creat measurements ≥150 μg/g] as the reference groups, respectively. Suboptimum 
scores on all IQ measures were defined in two ways: (i) as scores in the bottom quartile 
(i.e., in the lowest 25% of scores), informed by (Bath, Steer, et al. 2013) and (ii) as scores 
less than 85 IQ points, informed by (Levie et al. 2019). All logistic regression models 
were adjusted for the confounders mentioned previously. 
 
Missing values for the confounders and other maternal characteristics mentioned were 
imputed for women in the analyses using multiple imputation. Details about the 
imputation method and the imputed variables are provided in Chapter 2. All statistical 
analyses, including the multiple imputation, were performed using IBM SPSS Statistics 
version 25.0 (IBM Corp., Armonk, NY, USA). Statistical significance was considered 
when P<0.05. 
 
 
6.3 Results 
6.3.1 Sample characteristics  
After all exclusions, this study included a total of 452 women who had multiple (at least 
two) urinary iodine measurements during pregnancy, of whom 178 had three 
measurements (Figure 6.1). The characteristics of the study sample with multiple 
measurements and the subsample with three measurements are presented in Table 6.1.  
 
120 
 
Table 6. 1  Characteristics of the study population from the ALSPAC cohort with 
repeated urinary iodine measurements and data on child IQ 
 ALSPAC cohort 
Characteristics 1 Women with at least two  
iodine measurements  
(n=452) 
 
Women with three  
iodine measurements 
(n=178) 
Maternal factors    
Maternal age 2,3 (years), mean (±SD) 28.9 (±4.4)  28.9 (±4.3) 
Pre-pregnancy BMI (kg/m2), median (25-75th) 22.6 (20.6 - 24.8)  22.4 (20.4 - 24.5) 
Ethnicity, n (%)    
    White 443 (98.0%)  176 (98.9%) 
    Non-white 9 (2.0%)  2 (1.1%) 
Parity, n (%)    
    0 223 (49.3%)  106 (59.5%) 
    1 154 (34.1%)  48 (27.0%) 
    ≥ 2 75 (16.6%)  24 (13.5%) 
Smoking status, n (%)    
    Never smoked 363 (80.3%)  152 (85.4%) 
    Stopped smoking 39 (8.6%)  14 (7.9%) 
    Continued smoking 50 (11.1%)  12 (6.7%) 
Alcohol consumption, n (%)    
    No 240 (53.1%)  95 (53.4%) 
    Yes 212 (46.9%)  83 (46.6%) 
Markers of socio-economic status    
Maternal education level, n (%)    
    Low 78 (17.3%)  30 (16.8%) 
    Medium 294 (65.0%)  113 (63.5%) 
    High 80 (17.7%)  35 (19.7%) 
Paternal education level, n (%)    
    Low 104 (23.0%)  36 (20.2%) 
    Medium 236 (52.2%)  90 (50.6%) 
    High 112 (24.8%)  52 (29.2%) 
Home ownership, n (%)    
    Owned/mortgaged 411 (90.9%)  167 (93.8%) 
    Private/other rented 28 (6.2%)  8 (4.5%) 
    Council rented 13 (2.9%)  3 (1.7%) 
Crowding index, n (%)    
    ≤1 person per room 444 (98.2%)  176 (98.9%) 
    +1 person per room 8 (1.8%)  2 (1.1%) 
Family adversity index, n (%)    
    None (0) 248 (54.9%)  104 (58.4%) 
    Mild (1-2) 160 (35.4%)  59 (33.2%) 
    Severe (≥3) 44 (9.7%)  15 (8.4%) 
Life event score, median (25-75th) 3.0 (2.0 - 5.0)  3.0 (2.0 - 5.0) 
(continued on next page) 
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Table 6.1  Characteristics of the study population from the ALSPAC cohort with 
repeated urinary iodine measurements and data on child IQ (continued) 
 ALSPAC cohort 
Characteristics 1 Women with at least two  
iodine measurements  
(n=452) 
 
Women with three  
iodine measurements 
(n=178) 
Markers of socio-economic status (continued) 
Marital status, n (%)    
    Married 381 (84.3%)  151 (84.8%) 
    Never-married 50 (11.1%)  21 (11.8%) 
    Other 4 21 (4.6%)  6 (3.4%) 
Living with a partner, n (%)    
    Yes 434 (96.0%)  172 (96.6%) 
    No 18 (4.0%)  6 (3.4%) 
Child factors    
Child’s sex 3, n (%)    
    Male 229 (50.7%)  91 (51.1%) 
    Female 223 (49.3%)  87 (48.9%) 
Birth weight 3, n (%)    
    <2500 g 16 (3.5%)  4 (2.2%) 
    ≥2500 g 436 (96.5%)  174 (97.8%) 
Preterm birth 3, n (%)    
    Yes (<37 weeks) 16 (3.5%)  4 (2.2%) 
    No (≥37 weeks) 436 (96.5%)  174 (97.8%) 
Breastfeeding, n (%)    
    Yes 382 (84.5%)  154 (86.5%) 
    No 70 (15.5%)  24 (13.5%) 
1 Data are presented as mean (±SD) for all continuous normally distributed variables, median (25-75th 
percentile) for all continuous non-normally distributed variables and n (%) for the categorical variables. 2 
Maternal age at last menstrual period. 3 For women with at least two urinary iodine measurements (n=452) 
data were not imputed for maternal age, child’s sex, birth weight and preterm birth due to no missing values; 
the rest of the data are shown after multiple imputation of the missing values (see ‘Methods’ Section 6.2.5). 
4 Other=widowed, divorced, or separated. Abbreviations: ALSPAC, Avon Longitudinal Study of Parents 
and Children; BMI, body mass index; IQ, intelligence quotient; SD, standard deviation 
 
Compared to the group of ALSPAC women with a single iodine measurement only 
(n=2,628), in the group of women with multiple iodine measurements, who were included 
in this study (n=452), there were significantly higher proportions of women who were 
non-smokers (P=0.047) and who did not consume alcohol during pregnancy (P=0.005) 
(Supplemental Table 6.1, Appendix I). Furthermore, higher proportions of women in 
these analyses lived in owned or mortgaged housing (P<0.001) and had no family 
adversities (i.e., hardships during pregnancy) (P=0.020) than in the group of women with 
a single measurement. 
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6.3.2 Iodine status from repeated measurements  
In the total sample of women in this study, the median UI/Creat at the three measurement 
time-points in pregnancy was 104 µg/g (UIC: 98 µg/L) at median 9 weeks, 170 µg/g 
(UIC: 97 µg/L) at median 17 weeks and 171 µg/g (UIC: 133 µg/L) at median 34 weeks 
(Table 6.2). The median (25-75th percentile) of the distribution of mean UI/Creat values 
(i.e., the means of the repeated measures for each woman with multiple measurements) 
was 154 µg/g (110 - 216) [UIC: 115 µg/L (78 - 161)] in the total sample of women 
(n=452) and 152 µg/g (113 - 198) [UIC: 120 µg/L (83 - 156)] in the subsample with three 
measures (n=172). Based on the classification of women into pregnancy iodine status 
groups using the repeated UI/Creat measures (see ‘Methods’ Section 6.2.5), 72 (15.9%), 
259 (57.3%) and 121 (26.8%) women were broadly classified as iodine sufficient, 
borderline insufficient and insufficient, respectively.  
 
As previously shown in a slightly bigger sample of ALSPAC women with multiple iodine 
measurements (Chapter 4: Table 4.2), the repeated UI/Creat measurements in women 
included in this study (i.e., those who also had child IQ data) were only weakly correlated 
(1st vs 2nd UI/Creat: rs=0.18, P<0.001, n=452; 1
st vs 3rd UI/Creat: rs= -0.01, P=0.875, 
n=178; 2nd vs 3rd UI/Creat: rs=0.10, P=0.172, n=178).  
 
6.3.3 Verbal IQ  
The mean UI/Creat during pregnancy was not associated with the full range of child 
verbal IQ scores (Table 6.3). Maternal mean UI/Creat <150 µg/g was also not statistically 
significantly associated with child verbal IQ in the total sample with multiple 
measurements [-1.3 points, 95% Confidence Interval (CI): -4.2 to 1.6, P=0.377] or in the 
subsample with three measurements (-3.3 points, 95% CI: -8.1 to 1.5, P=0.174) (Table 
6.3). In all women with multiple measurements, maternal mean UI/Creat was not 
associated with the risk of suboptimum verbal IQ scores in children, when suboptimum 
scores were defined as scores in the bottom quartile (Table 6.4) or below 85 points 
(Supplemental Table 6.2, Appendix I). Maternal iodine status classification was also 
not associated with the full range of child verbal IQ (Table 6.3) or with the risk of 
suboptimum scores (Table 6.4; Supplemental Table 6.2, Appendix I). 
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Table 6. 2  Descriptives of child IQ measures and maternal urinary iodine concentration 
for pregnant women with at least two and those with three urinary iodine measurements 
available 
 n 
Women with at 
least two iodine 
measurements  
(n=452) 
 
n 
Women with  
three iodine  
measurements  
(n=178) 
Child IQ measurements 1 452   178  
Child age at IQ assessment, years 2  8.6 (8.5 - 8.7)   8.6 (8.5 - 8.7)  
Verbal IQ 3  109.8 (±16.5)   111.8 (±16.4) 
Non-verbal (performance) IQ 3  99.6 (±17.5)   101.5 (±18.3) 
Total IQ 3  105.8 (±16.7)   107.9 (±17.2) 
Verbal IQ < 85 points 4, n (%)  31 (6.9%)   9 (5.1%) 
Non-verbal IQ < 85 points 4, n (%)  82 (18.1%)   30 (16.9%) 
Total IQ < 85 points 4, n (%)  46 (10.2%)   17 (9.6%) 
First urinary iodine measurement 452   178  
Gestational week at first urine sampling 2  9.0 (6.0 - 11.0)   9.0 (6.0 - 11.0) 
First UIC, µg/L 2  98 (62 - 150)   91 (59 - 150) 
First UI/Creat, µg/g 2  104 (73 - 152)   96 (69 - 146) 
First UI/Creat < 150 µg/g, n (%)  334 (73.9%)   134 (75.3%) 
Second urinary iodine measurement 452   178  
Gestational week at second urine sampling 2  17.0 (16.0 - 19.0)   17.0 (16.0 -18.0) 
Second UIC, µg/L 2  97 (54 - 159)   90 (53 - 141) 
Second UI/Creat, µg/g 2  170 (102 - 261)   153 (94 - 223) 
Second UI/Creat < 150 µg/g, n (%)  197 (43.6%)   87 (48.9%) 
Third urinary iodine measurement 178     
Gestational week at third urine sampling 2  34.0 (33.0 - 35.0) 
Third UIC, µg/L 2  133 (78 - 209) 
Third UI/Creat, µg/g 2  171 (110 - 250) 
Third UI/Creat < 150 µg/g, n (%)  77 (43.3%) 
1 Child IQ was assessed using the abbreviated Wechsler Intelligence Scale for Children 3rd edition (WISC-
III) (Wechsler et al. 1992); range of possible scores: 40-160 points. 2 Data are presented as median (25-75th 
percentile). 3 Data are presented as mean (±SD). 4 Cut-off value to define suboptimum verbal, non-verbal 
and total IQ was based on previous studies (see ‘Methods’ Section 6.2.5). Abbreviations: IQ, intelligence 
quotient; SD, standard deviation; UI/Creat, urinary iodine-to-creatinine ratio; UIC, urinary iodine 
concentration; WISC-III, Wechsler Intelligence Scale for Children 3rd edition 
 
 
6.3.4 Non-verbal IQ 
The mean UI/Creat during pregnancy was not associated with the full range of child non-
verbal IQ scores (Table 6.3). Compared to women with mean UI/Creat ≥150 µg/g, women 
with mean UI/Creat <150 µg/g had children with lower non-verbal IQ scores, although 
this association was not statistically significant in the total sample with multiple 
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measurements (-2.5 points, 95% CI: -5.7 to 0.6, P=0.115] or in the subsample with three 
measurements (-4.0 points, 95% CI: -9.3 to 1.2, P=0.133) (Table 6.3). There was, 
however, a significantly increased risk of suboptimum non-verbal IQ scores in children 
born to women with mean UI/Creat <150 µg/g, compared to those born to women with 
mean UI/Creat ≥150 µg/g [Odds ratio (OR) 1.7, 95% CI: 1.1 to 2.7, P=0.031] (Table 6.4). 
The effect was similar when suboptimum IQ scores were defined using 85 points as a cut-
off value (Supplemental Table 6.2). When classifying women into pregnancy iodine-
status groups based on the repeated UI/Creat measures, child non-verbal IQ was lower in 
the groups of women broadly classified as iodine insufficient (i.e., had all UI/Creat 
measures <150 µg/g) and borderline iodine insufficient (i.e., had at least one UI/Creat 
measure <150 µg/g) than in the group classified as iodine sufficient (i.e., had all UI/Creat 
measures ≥150 µg/g); however, this association was statistically significant only in the 
subsample whose status was classified based on three repeated measures (Table 6.3). 
Children born to women classified as iodine insufficient or borderline insufficient during 
pregnancy also had an increased risk of suboptimum non-verbal IQ scores, compared to 
children born to women classified as iodine sufficient throughout the whole pregnancy 
[OR (insufficient) 2.6, 95% CI: 1.1 to 6.4, P=0.034; OR (borderline insufficient) 2.6, 95% 
CI: 1.1 to 5.9, P=0.026] (Table 6.4). When IQ < 85 points was used to define suboptimum 
scores, the increased risk of suboptimum non-verbal IQ remained statistically significant 
only in the iodine insufficient group (Supplemental Table 6.2). 
 
6.3.5 Total IQ 
Although child total IQ scores tended to be lower in the group of women with mean 
UI/Creat <150 µg/g than in the group with mean UI/Creat ≥150 µg/g, mean UI/Creat was 
not significantly associated with the full range (Table 6.3) or with the risk of suboptimum 
total IQ scores in children (Table 6.4). However, children whose mothers were broadly 
classified as borderline iodine insufficient (i.e., had at least one UI/Creat measure during 
pregnancy <150 µg/g) had an increased risk of suboptimum total IQ, compared to children 
whose mothers were classified as iodine sufficient during pregnancy [i.e., had all 
(two/three) UI/Creat measures ≥150 µg/g] (OR 2.5, 95% CI 1.2 to 5.5, P=0.020) (Table 
6.4). 
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Table 6. 3  Association of maternal mean UI/Creat and UI/Creat status (based on two or three UI/Creat measurements) with child verbal, non-
verbal and total IQ at 8 years from adjusted analyses for women with multiple urinary iodine measurements during pregnancy 
   Verbal IQ 
 
 Non-verbal IQ   Total IQ 
  n B (95% CI) P 
 
 B (95% CI) P   B (95% CI) P 
Women with at least two iodine measurements (n=452) 
Mean UI/Creat, µg/g  452 -0.01 (-0.02, 0.01) 0.460   -0.00 (-0.02, 0.02) 0.965   -0.00 (-0.02, 0.01) 0.665 
Mean UI/Creat groups             
    < 150 µg/g  211 -1.30 (-4.18, 1.58) 0.377   -2.54 (-5.70, 0.62) 0.115   -2.11 (-5.03, 0.80) 0.155 
    ≥ 150 µg/g   241 Ref.    Ref.    Ref.  
UI/Creat status             
    Insufficient   121 -0.33 (-4.96, 4.30) 0.887   -4.26 (-9.33, 0.81) 0.099   -2.54 (-7.22, 2.15) 0.289 
    Borderline insufficient  259 -0.72 (-4.84, 3.40) 0.731   -4.52 (-9.04, 0.00) 0.050   -2.84 (-7.01, 1.34) 0.183 
    Sufficient  72 Ref.    Ref.    Ref.  
Women with three iodine measurements (n=178) 
Mean UI/Creat, µg/g  178 0.01 (-0.02, 0.04) 0.566   0.00 (-0.03, 0.04) 0.887   0.01 (-0.03, 0.04) 0.704 
Mean UI/Creat groups             
    < 150 µg/g  82 -3.30 (-8.06, 1.46) 0.174   -4.02 (-9.26, 1.23) 0.133   -3.91 (-8.76, 0.95) 0.115 
    ≥ 150 µg/g   96 Ref.    Ref.    Ref.  
UI/Creat status             
    Insufficient   32 -2.21 (-11.93, 7.50) 0.655   -11.26 (-21.80, -0.71) 0.036   -7.09 (-16.94, 2.76) 0.158 
    Borderline insufficient  127 -3.29 (-11.59, 5.00) 0.437   -11.35 (-20.35, -2.35) 0.013   -7.95 (-16.36, 0.46) 0.064 
    Sufficient  19 Ref.    Ref.    Ref.  
Effect estimates (B=unstandardised regression coefficients), their 95% CIs and P-values are from multiple linear regression models performed for each outcome (i.e., the child 
IQ measures) and in each sample of women (those with at least two and those with three iodine measurements) with child verbal or non-verbal or total IQ as the dependent 
variable and mean UI/Creat continuous/groups or UI/Creat status as the independent variable. Models were adjusted for mean gestational week at urine sampling, maternal age 
(years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, education level, family adversity index, marital status and child's sex. Reported B coefficients represent 
the change in child mean verbal, non-verbal or total IQ (IQ points) per unit increase in mean UI/Creat (µg/g) and for each mean UI/Creat group or UI/Creat status group 
compared to the reference (‘iodine sufficient’) group. Abbreviations: BMI, body mass index; 95% CI, confidence interval; IQ, intelligence quotient; Ref., reference group; 
UI/Creat, urinary iodine-to-creatinine ratio 
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Table 6. 4  Risk of suboptimum verbal, non-verbal and total IQ in children at 8 years (score in the bottom quartile) according to maternal mean 
UI/Creat (<150 µg/g vs ≥ 150 µg/g) and UI/Creat status (based on two or three UI/Creat measurements), adjusted for potential confounders 
   Suboptimum Verbal IQ 
 
 Suboptimum Non-verbal IQ   Suboptimum Total IQ 
  n OR (95% CI) P 
 
 OR (95% CI) P   OR (95% CI) P 
Women with at least two iodine measurements (n=452) 
Mean UI/Creat groups             
    < 150 µg/g  211 1.00 (0.62, 1.60) 0.989   1.69 (1.05, 2.71) 0.031   1.36 (0.85, 2.16) 0.196 
    ≥ 150 µg/g   241 Ref.    Ref.    Ref.  
UI/Creat status             
    Insufficient   121 0.97 (0.44, 2.12) 0.936   2.63 (1.08, 6.40) 0.034   1.81 (0.77, 4.26) 0.174 
    Borderline insufficient  259 1.17 (0.59, 2.34) 0.657   2.58 (1.12, 5.92) 0.026   2.52 (1.16, 5.46) 0.020 
    Sufficient  72 Ref.    Ref.    Ref.  
Women with three iodine measurements (n=178) 
Mean UI/Creat groups             
    < 150 µg/g  82 1.33 (0.61, 2.88) 0.474   1.47 (0.66, 3.28) 0.341   1.49 (0.66, 3.34) 0.336 
    ≥ 150 µg/g   96 Ref.    Ref.    Ref.  
UI/Creat status 1   N/A    N/A    N/A  
Effect estimates (OR=odds ratios), their 95% CIs and P-values are from multiple logistic regression models performed for each outcome (i.e., the child IQ measures) and in 
each sample of women (those with at least two and those with three iodine measurements) with child verbal or non-verbal or total IQ [categorised into scores in the bottom 
quartile (suboptimum) or ≥ bottom quartile] as the dependent variable and mean UI/Creat groups or UI/Creat status as the independent variable. Models were adjusted for mean 
gestational week at urine sampling, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, education level, family adversity index, marital status 
and child's sex. Reported OR are for child verbal, non-verbal or total IQ in the bottom quartile (i.e., suboptimum) when maternal mean UI/Creat <150 µg/g [vs mean UI/Creat 
≥150 µg/g (reference group)] or maternal UI/Creat status = ’insufficient’ or ‘borderline insufficient’ [vs UI/Creat status = ‘sufficient’ (reference group)]. 1 For women with three 
iodine measurements (n=178), the models using UI/Creat status were not performed due to no/small number of women with children with suboptimum IQ scores (in the bottom 
quartile) in the reference ‘iodine sufficient’ group (i.e., n=2 for verbal IQ, n=1 for non-verbal IQ and n=0 for total IQ). Abbreviations: BMI, body mass index; 95% CI, 
confidence interval; IQ, intelligence quotient; N/A, data not available or not applicable; OR, odds ratio; Ref., reference group; UI/Creat, urinary iodine-to-creatinine ratio 
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6.4 Discussion 
This study aimed to investigate the association of iodine status based on multiple urinary-
iodine measurements collected during pregnancy with child IQ scores. The results partly 
supported the hypothesis that low maternal pregnancy iodine status was associated with 
lower child IQ scores. After adjustment for confounders, consistently low maternal 
UI/Creat during pregnancy was associated with lower non-verbal IQ scores and an 
increased risk of suboptimum scores in children at 8 years. Evidence of lower child total 
IQ scores was also observed in the groups of women with lower UI/Creat during 
pregnancy but the associations were mostly not statistically significant.  
 
Pregnancy UI/Creat was not associated with child verbal IQ. This is in contrast to the 
results from a previous study using data from ALSPAC (Bath, Steer, et al. 2013) and to 
our previous results from an individual-participant data meta-analysis in three pregnancy 
cohorts (ALSPAC, INMA and Generation R) (Levie et al. 2019) where there were 
associations of maternal iodine status with child verbal IQ but not non-verbal IQ. 
Furthermore, other studies in mildly iodine-deficient and iodine-sufficient populations 
have reported an association of low maternal iodine status with lower spelling scores 
during childhood (Hynes et al. 2013) and adolescence (Hynes et al. 2017) and impaired 
executive functioning (van Mil et al. 2012). This evidence, therefore, suggests that the 
effects of iodine deficiency might be more specific to verbal and reading skills and less 
evident for non-verbal skills. However, the previous studies that did not find an 
association with child non-verbal IQ were mainly focused on early pregnancy as an 
important time-window of susceptibility to potential negative effects and also used a 
single spot-urine iodine measurement as the exposure. It could be that the cognitive 
functions that are related to verbal IQ are more susceptible to iodine deficits early in 
pregnancy, while those related to non-verbal IQ may be more vulnerable to iodine 
deficiency present also in the later stages of pregnancy. 
 
Literature suggest that even mild thyroid hormone deficits may have an effect on specific 
neuropsychological functions depending on the timing of deficiency (Zoeller and Rovet 
2004). The assessment of the consequences of maternal iodine deficiency on fetal brain 
development therefore may also require knowledge of the developmental timing of the 
deficiency and the specific thyroid-hormone dependent events that could be affected (i.e., 
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events that could also be affected by maternal iodine deficiency). For instance, thyroid 
hormone deficiency in early pregnancy is associated with deficits in offspring visual 
attention, visual processing and gross motor skills, while deficiency that occurs later in 
pregnancy is further linked to problems with visual and visuospatial skills, slower 
response speed and fine motor deficits (Zoeller and Rovet 2004).  
 
Non-verbal (performance) IQ from the WISC-III scale that was used in ALSPAC is 
composed of five subtests, including picture completion, coding, picture arrangement, 
block design and object assembly (Wechsler et al. 1992). These tasks rely on cognitive 
skills, such as processing speed (i.e., response speed in solving non-verbal problems), 
visual-spatial skills and visual-motor coordination (Beres et al. 2000). A study using data 
from structural brain scans showed that non-verbal (performance) IQ (measured with 
Wechsler’s intelligence scales) was associated with grey matter density in the anterior 
cerebellum – a brain structure associated with motor movements of the hand (i.e., fine 
motor skills) (Ramsden et al. 2011). The skills required to complete the non-verbal IQ 
tasks therefore seem similar to the skills that might be negatively affected by thyroid 
hormone deficiency occurring in late pregnancy (e.g., visuospatial and fine motor skills; 
response speed) but also in early pregnancy (e.g., visual processing and attention) (Zoeller 
and Rovet 2004).  
 
A previous study in the Spanish pregnancy cohort INMA found a negative association 
between low maternal UI/Creat and lower perceptual-performance and fine motor 
function in the offspring at 4-5 years (Murcia et al. 2018). In a Norwegian study, maternal 
iodine intake below the Estimated Average Requirement during pregnancy (<160 µg/day) 
was associated with reduced fine motor skills in children at 3 years (Abel, Caspersen, et 
al. 2017). A few intervention studies in mildly-to-moderately iodine-deficient 
populations have shown some benefit of iodine supplementation during pregnancy on 
child motor development (Berbel et al. 2009; Velasco et al. 2009), however, the three 
most recent randomised controlled trials (RCTs) in areas of mild-to-moderate iodine 
deficiency have not shown any benefit of maternal iodine supplementation on child motor 
(and mental) development (Brucker-Davis et al. 2015; Zhou et al. 2015; Gowachirapant 
et al. 2017). In contrast to the intervention studies, two cohort studies have reported some 
negative effects of maternal iodine-supplement use on child psychomotor development at 
1 year (Murcia et al. 2011; Rebagliato et al. 2013) but these results were not confirmed 
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when children were 4-5 years (Murcia et al. 2018). Global cognitive tests administered 
in infancy (i.e., particularly before 2 years) have low predictive capacity for childhood 
intelligence and behaviour (Peyre et al. 2017; Gould et al. 2019). Although cognitive tests 
may be more valid if administered when children are older, there are also more 
confounding factors that need to be considered (e.g., social, environmental and 
nutritional) (Slater 1995; Bryan et al. 2004). 
 
The specific cognitive processes that might be vulnerable to maternal iodine deficiency 
are not well understood. It has been previously proposed that tasks related to infant visual 
information processing (e.g., visual attention) might be more sensitive to the effects of 
iodine deficiency on child neurodevelopment and also to iodine supplementation in future 
RCTs (Bell et al. 2016). Tasks related to non-verbal intelligence are not dependent on 
language abilities that may be acquired later in childhood (e.g., in the family environment 
or through education), and therefore, could be less dependent on social factors (DeThorne 
and Schaefer 2004). A very recent synopsis of longitudinal studies that have investigated 
the effects of maternal mild-to-moderate iodine deficiency on offspring 
neurodevelopment concluded that mild-to-moderate gestational iodine deficiency was 
associated with a disorder characterised by difficulties in neural transmitting speed that 
are usually related to difficulties in working memory capacity and attention and response 
inhibition; this disorder seemed to be captured by verbal rather than non-verbal IQ 
measures (Hay et al. 2019). 
 
This study adds to the existing evidence that low maternal iodine status based on multiple 
urinary-iodine measurements during pregnancy is associated with poorer child cognitive 
development even in a setting of mild-to-moderate deficiency. On a continuous scale, the 
differences in IQ observed in this study were only small and probably clinically non-
significant. As previously noted, most differences in child IQ that were linked to mild-to-
moderate maternal iodine deficiency in previous studies were subtle (around 6-7 points) 
and although these children had lower IQ scores, they were typically within the average 
IQ range (Hay et al. 2019). Although the effects of mild-to-moderate iodine deficiency 
on IQ seem only subtle, this milder suboptimal neurodevelopment can have important 
cognitive and psycho-social consequences for the offspring. A disorder associated with 
mild-to-moderate gestational iodine deficiency was recently identified by Hay et al. 
(2019) as Gestational Iodine Deficiency Processing Disorder (GIDPD), which is 
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associated with some degree of information processing difficulties that can influence 
learning and psycho-social development (Hay et al. 2019). GIDPD is suggested to have 
wider implication than the subtle reduction in IQ points observed in studies, including 
specific learning disorders and potentially Autistic Spectrum Disorder (Hay et al. 2019). 
This might have implications on an individual level [e.g., neurodevelopmental deficits in 
early childhood may result in poorer school performance and limited career opportunities 
later in life (Hynes et al. 2013; Piccolo et al. 2016; Hynes et al. 2017) as well as negative 
effects on individual’s psycho-social wellbeing (Hay et al. 2019)] and also on a 
population level [e.g., a slight decrease in population’s average IQ was linked to a lower 
economic growth (Jones and Schneider 2006)]. 
 
The results of the current study also highlight the importance of optimal habitual iodine 
intake during the entire pregnancy. The potential effects of the patterns of change in 
iodine status across the stages of pregnancy on offspring neurodevelopment have not been 
well researched. For instance, it is unclear whether low maternal iodine intake in early 
pregnancy can be compensated for in later pregnancy or what happens if optimal iodine 
status in early pregnancy is followed by low iodine intakes in the remaining stages of 
pregnancy. 
6.4.1 Strengths and limitations 
The measurement of urinary iodine at one time-point in pregnancy does not capture iodine 
nutrition during the entire pregnancy (Chapter 4), therefore, one of the strengths of this 
study was the use of repeated urinary iodine measurements from different time-points in 
pregnancy to assess maternal iodine status. To our knowledge, only a few previous studies 
in pregnant women investigating the association between maternal iodine status and child 
neurodevelopmental outcomes have used multiple urinary iodine measurements to assess 
pregnancy iodine status; in those studies, however, multiple measures were used only in 
approximately half of the total included sample (Hynes et al. 2013; Hynes et al. 2017); 
total sample size in these studies was 228 and 266 women, respectively. 
 
There are several limitations to consider. Firstly, a relatively small sample of women with 
multiple urinary iodine measurements was included in this study. This could have resulted 
in a lack of power to detect effects in the analyses. For instance, a retrospective power 
calculation showed that to detect a difference in IQ of 3 points with 95% power (i.e., at 
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P<0.05), requires nearly triple the sample size used in this study (~1300 individuals). 
Secondly, these women were a selected group and represented a very small proportion of 
both the total ALSPAC cohort (3.1%) and of the women who had at least one urinary 
iodine measurement and child IQ data available (14.7%) (Figure 6.1). Indeed, when 
women included this study (i.e., those with multiple iodine measures and child IQ data) 
were compared with women with a single iodine measure (and child IQ data), some 
differences in sociodemographic characteristics were observed (e.g., women in this study 
were less likely to smoke, consume alcohol and have family adversities). This potential 
selection bias suggests that our results in this group of women may not be applicable to a 
larger population. Thirdly, urinary iodine concentration had been measured (for previous 
studies) predominantly in the ALSPAC women who also had data on child IQ which 
might have also created bias (see Chapters 2 and 3). Fourthly, although the analyses were 
adjusted for various potential confounding factors, the confounding effects of factors that 
were not included in the models (e.g., factors that were not considered or not available in 
the dataset) cannot be excluded, considering the observational design of this study. 
Finally, as extensively discussed in previous chapters (Chapter 3, Chapter 4 and Chapter 
5), the problems with using single spot-urine samples for the assessment of iodine status 
in individuals are recognised in the literature (Andersen et al. 2008; Vejbjerg et al. 2009; 
König et al. 2011). This limitation was partly accounted for by using UI/Creat in 
preference to UIC [i.e., UIC was corrected for the variability in urine volume (Rasmussen 
et al. 1999; Knudsen et al. 2000; Andersen et al. 2008; König et al. 2011; Li et al. 2016)] 
and also by using multiple spot-urine iodine measurements to provide a better estimate of 
individual habitual iodine intake (i.e., iodine status) during pregnancy. 
 
 
6.5 Conclusion  
The results of this study add to the evidence that optimal maternal iodine intake during 
pregnancy is important for child neurodevelopment and also suggest that iodine status 
beyond early pregnancy might be potentially associated with different cognitive outcomes 
to those related to deficiency in early pregnancy. Due to the observational design and the 
small sample size of this study, the results should be interpreted with caution and 
replicated in future studies with a larger number of women with repeated urinary iodine 
measurements from different gestational time-points. The evidence on the effects of 
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maternal mild-to-moderate iodine deficiency on child neurodevelopment is inconclusive 
and, as shown in our systematic review of the literature (Chapter 7), there is a lack of 
good-quality evidence from RCTs with child cognitive outcomes. It is also unclear 
whether different patterns of change in iodine nutritional status over the course of 
pregnancy can have a differential effect on child cognitive outcomes. 
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Chapter 7                                        
Systematic review of the effects of iodine supplements 
on thyroid function and child neurodevelopment in 
mildly-to-moderately iodine-deficient pregnant women 
 
7.1 Introduction 
Although tremendous progress has been made in achieving iodine sufficiency in the 
general population of many countries (Iodine Global Network 2016; Iodine Global 
Network 2017), some population sub-groups, such as pregnant women, still have 
inadequate iodine intake and are at high risk of deficiency (Zimmermann et al. 2015; 
Iodine Global Network 2017). As a result of the physiological changes that occur during 
pregnancy (Glinoer 2004; Delange 2007), pregnant women have higher iodine 
requirements than the general population (WHO 2007a) that can be more difficult to meet 
through diet, and therefore supplementation may need to be considered. This is of public-
health concern as iodine deficiency in pregnancy can have adverse consequences on child 
neurodevelopment (Bath 2019) but the role of iodine supplements in pregnancy is not 
clear. 
 
As a component of thyroid hormones, iodine is required for brain development in 
pregnancy and early life (de Escobar et al. 2004; Glinoer 2007). Severe iodine deficiency 
is known to have a negative effect on thyroid function (Zimmermann and Boelaert 2015); 
when it occurs during pregnancy, it has negative implications for child neurodevelopment 
and may result in cretinism (Zimmermann 2009). Nowadays, severe iodine deficiency is 
relatively rare, largely as a result of salt-iodisation programmes (Iodine Global Network 
2016), but mild-to-moderate iodine deficiency is prevalent, particularly in pregnant 
women (Iodine Global Network 2017). Although maternal mild-to-moderate iodine 
deficiency is an emerging public-health problem, its effects on maternal and infant 
thyroid function and child cognition are less well understood than those of severe 
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deficiency. Observational studies are suggestive of a deleterious effect of maternal mild-
to-moderate iodine deficiency on child neurodevelopmental outcomes, including 
executive function (van Mil et al. 2012), intelligence quotient (IQ) scores (Bath, Steer, et 
al. 2013), reading ability (Bath, Steer, et al. 2013), school performance (Hynes et al. 
2013; Hynes et al. 2017), cognitive scores (Murcia et al. 2018) and language skills 
(Markhus et al. 2018); though not all studies have found significant associations (Murcia 
et al. 2011; Rebagliato et al. 2013; Ghassabian et al. 2014). These mixed findings could 
be because of differences in the method of defining maternal iodine deficiency (e.g., using 
urinary iodine concentration vs urinary iodine-to-creatinine ratio), the tools for cognitive 
assessment, child age at cognitive testing, the underlying population iodine status and the 
sample size. 
 
The benefits and safety of iodine supplementation in pregnancy in areas of mild-to-
moderate iodine deficiency remain unclear. Two previous systematic reviews found 
inconsistent results on the effects of iodine supplementation of mildly-to-moderately 
iodine-deficient mothers on maternal and infant thyroid function and few studies have 
reported on the effects on child neurodevelopment (Zhou et al. 2013; Taylor et al. 2014). 
Despite the insufficient evidence available and the inconsistent findings from previous 
studies, health authorities in a number of countries are increasingly introducing 
recommendations for iodine supplementation in pregnancy.  
 
In an attempt to assess whether the state of the current evidence is sufficient to support 
such recommendations in areas of mild-to-moderate iodine deficiency, the aim of this 
study was to review critically and systematically the most up-to-date evidence on the 
effects of maternal iodine supplementation on maternal and infant thyroid function and 
child cognition. The current review focuses on summarising several aspects of study 
design that might explain the inconsistent findings and may need to be considered in 
future studies: (i) the importance of maternal baseline iodine status and thyroid iodine 
stores; (ii) the type, dose and timing of iodine supplementation; and (iii) the type of child 
cognitive assessment and the age of the child at cognitive testing. 
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7.2 Methods 
The reporting of this systematic review follows the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al. 2009). The 
review is registered with PROSPERO (registration number: CRD42018100277) and the 
study protocol is available online (https://www.crd.york.ac.uk/prospero). 
7.2.1 Eligibility criteria 
The four main inclusion criteria were: (i) the exposure of interest i.e., any type, dose and 
regimen of iodine supplementation during pregnancy; (ii) the population of interest i.e., 
pregnant women with mild-to-moderate iodine deficiency [defined as a median urinary 
iodine concentration (UIC) in the range of 50-149 µg/L (Zimmermann 2007) at baseline 
in the total population or only in those who did not use iodine supplements and/or iodised 
salt]; (iii) the outcomes of interest, including maternal and infant/child thyroid function 
[e.g., measurements of thyroid-stimulating hormone (TSH), thyroxine (T4), thyroglobulin 
(Tg) concentration, thyroid volume, thyroid peroxidase antibody titre (TPO-Ab), 
thyroglobulin antibodies (Tg-Ab), prevalence of hypothyroxinaemia, hypothyroidism, or 
hyperthyroidism and any other relevant thyroid effects] and child neurodevelopment 
(e.g., measures of motor and mental development, IQ scores, language, communication 
and behaviour-related outcomes); and iv) the study design i.e., observational studies, non-
randomised and/or uncontrolled intervention studies and randomised controlled trials 
(RCTs); all types of study designs were included to maximise the available information.  
 
As the focus of this review was on mild-to-moderate iodine deficiency, studies in iodine-
sufficient (UIC ≥ 150 μg/L) (WHO 2007a) or severely iodine-deficient populations (UIC 
< 50 μg/L; areas of endemic goitre) (Zimmermann 2007) were excluded. Studies that 
addressed supplementation in infants were also excluded, as the interest was on exposure 
before birth. Additionally, studies in languages other than English, unpublished or non-
peer reviewed articles (e.g., meeting abstracts or letters), case-reports, narrative 
reviews/comment articles and other systematic reviews or meta-analyses were excluded. 
These eligibility criteria were incorporated to give an abstract checklist (Supplemental 
Methods 1, Appendix II) that was used during abstract screening. 
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7.2.2 Search methods  
For the identification of relevant articles, PubMed database 
(http://www.ncbi.nlm.nih.gov/pubmed/) was searched in June 2018 (latest search date 4th 
June 2018) using a combination of search terms (Supplemental Methods 2, Appendix 
II). The search was restricted to human studies, studies in English language and no date 
restriction was applied. Additional articles were identified by consulting experts in the 
field and from the reference lists of relevant publications identified during screening.  
7.2.3 Study selection process 
Titles and abstracts of all articles that resulted from the search were independently 
screened by two reviewers (MD and HF) using the pre-specified abstract checklist with 
the study eligibility criteria (Supplemental Methods 1). Following the initial abstract 
screening, the full texts of the records whose abstracts were identified by both or either 
of the reviewers as potentially eligible for inclusion were retrieved and carefully reviewed 
for eligibility. In cases of disagreement between the two reviewers at any stage of the 
study selection process, it was resolved through discussion with the rest of the review 
team. All studies that were eligible after full-text review were included in the data 
extraction stage and the rest were excluded (with documented reasons). 
7.2.4 Data extraction 
Relevant data from the included studies were independently extracted by two reviewers 
(MD and HF) using a predefined and piloted data-extraction form. All extracted data were 
managed and stored in Microsoft Excel. As at the screening stage, any discrepancies 
regarding the extracted data were resolved through discussion with the review team. The 
following types of data were extracted from each included study: reference details (e.g., 
author(s) and year of publication), study details (e.g., study design and country), 
participant details (e.g., sample size and baseline iodine status), intervention details for 
intervention studies (e.g., type and dosage of supplementation, start and duration of 
intervention, information about placebo/control treatment), supplement-use details for 
observational studies (e.g., study groups and comparisons, iodine dose and vehicle, start 
and/or duration of reported supplement use) and outcome details (e.g., results on all pre-
specified maternal and infant/child thyroid function outcomes, time-point at measurement 
and results on any child neurodevelopment outcomes, including the type of cognitive 
assessment, assessor and child age at testing). In addition to the extracted data on maternal 
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thyroid function, where possible, the change in maternal thyroid-function parameters 
during pregnancy was calculated (as % increase or decrease), using the first and the last 
reported values. In a few cases, where only one measurement was available during 
gestation but a measurement was repeated at term or post-partum, the corresponding term 
or post-partum values were used for the calculations. Quantitative synthesis (i.e., a meta-
analysis) of the included studies was not performed because of the differences in study 
design (e.g., different treatments, including iodine dose and vehicle, different timing of 
supplement initiation, duration of treatment and control groups etc.).  
7.2.5 Risk-of-bias judgment and quality assessment  
The risk of bias of all included RCTs and non-randomised and/or uncontrolled 
intervention studies was assessed using the Cochrane Risk-of-Bias Tool (Higgins and 
Green 2011; Higgins et al. 2011). Risk of bias was judged as low, high or unclear for 
individual elements from six domains of bias (selection, performance, detection, attrition, 
reporting and other sources of bias). The quality of the included cohort- and cross-
sectional studies was judged using the Newcastle-Ottawa scale (Wells et al. [n.d.]) by 
awarding stars for three broad study perspectives [i.e.,  selection of study groups 
(maximum 4 stars), comparability of the groups (maximum 2 stars) and ascertainment of 
the outcomes (maximum 3 stars)]; an adapted version of this scale was used for the cross-
sectional studies. The overall quality of these studies was graded as ‘good’ (3 or 4 stars 
in selection domain, and 1 or 2 stars in comparability domain, and 2 or 3 stars in outcome 
domain), ‘fair’ (2 stars in selection domain, and 1 or 2 stars in comparability domain, and 
2 or 3 stars in outcome domain), or ‘poor’ (0 or 1 star in selection domain, or 0 stars in 
comparability domain, or 0 or 1 stars in outcome domain).  
 
 
7.3 Results  
7.3.1 Study selection 
The study selection process and the number of studies at each review stage are illustrated 
in a PRISMA flow diagram (Figure 7.1). The initial electronic database search yielded a 
total of 307 records. Eight other potentially relevant articles were identified after 
consulting experts in the field or from the reference lists of articles identified by the 
search. After screening all abstracts, 274 records failed to meet the inclusion criteria and 
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were excluded. Following full-text review of the remaining 41 records, a total of 31 
publications were included in this review – 23 from the search and eight from other 
sources/reference lists (Figure 7.1). The excluded potentially eligible full-text articles and 
the reasons for their exclusion are provided in Supplemental Table 7.1 (Appendix I). 
 
1 Details of the excluded studies and the reasons for exclusion are provided in Supplemental Table 7.1 
(Appendix I). Abbreviations: UIC, urinary iodine concentration  
Figure 7. 1  PRISMA flow diagram of the search results and study selection process 
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eligibility  
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Studies included in qualitative 
synthesis  
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Full-text articles excluded, with 
reasons1 Total (n=10) 
• Not addressing outcomes  
(n=4) 
• Severe iodine deficiency 
(median UIC < 50 µg/L or area 
of endemic goitre) (n=4) 
• Iodine sufficiency  
(median UIC ≥ 150 µg/L) (n=2) 
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7.3.2 Characteristics of included studies 
The 31 studies included were published between 1981 and 2017; 18 were observational 
(eight prospective cohort studies and ten cross-sectional studies) and 13 were 
interventions (nine RCTs and four non-randomised and/or uncontrolled interventions). 
Only four studies addressed all three outcomes (maternal and infant/child thyroid function 
and child neurodevelopment) (Velasco et al. 2009; Santiago et al. 2013; Brucker-Davis 
et al. 2015; Gowachirapant et al. 2017). A summary of the studies by outcome, including 
maternal thyroid function, infant/child thyroid function and child neurodevelopment are 
provided in Table 7.1, Table 7.2 and Table 7.3, respectively. 
 
Studies were mostly based in Europe, including Spain (Berbel et al. 2009; Velasco et al. 
2009; Marco et al. 2010; Rebagliato et al. 2010; Murcia et al. 2011; Rebagliato et al. 
2013; Santiago et al. 2013; Menéndez Torre et al. 2014; Murcia et al. 2018), Italy 
(Romano et al. 1991; Antonangeli et al. 2002; Moleti et al. 2008; Moleti et al. 2011; 
Moleti et al. 2016), Denmark (Pedersen et al. 1993; Nøhr and Laurberg 2000; Nøhr et al. 
2000), France (Brucker-Davis et al. 2013; Brucker-Davis et al. 2015), Germany 
(Liesenkötter et al. 1996; Klett et al. 1999), Norway (Abel, Caspersen, et al. 2017; Abel, 
Ystrom, et al. 2017), Poland (Gietka-Czernel et al. 2010; Zygmunt et al. 2015), Latvia 
(Konrade et al. 2015) and Hungary (Katko et al. 2017). Four studies were conducted 
outside of Europe [Russia (Fadeyev et al. 2003), Chile (Silva and Silva 1981), Australia 
(Zhou et al. 2015), India and Thailand (Gowachirapant et al. 2017)]. The sample size of 
pregnant women ranged from 60 to 77,164 in the observational studies and from 35 to 
832 in the interventions. The forms of iodine supplementation were iodised salt (three 
studies) (Romano et al. 1991; Moleti et al. 2008; Moleti et al. 2016), drops of potassium-
iodide (KI) solution (two studies) (Silva and Silva 1981; Pedersen et al. 1993), KI tablets 
(eight studies) (Liesenkötter et al. 1996; Klett et al. 1999; Antonangeli et al. 2002; Berbel 
et al. 2009; Velasco et al. 2009; Santiago et al. 2013; Zhou et al. 2015; Gowachirapant 
et al. 2017) and iodine-containing multivitamin/mineral tablets (12 studies) (Nøhr and 
Laurberg 2000; Nøhr et al. 2000; Gietka-Czernel et al. 2010; Moleti et al. 2011; Murcia 
et al. 2011; Brucker-Davis et al. 2013; Brucker-Davis et al. 2015; Konrade et al. 2015; 
Zygmunt et al. 2015; Abel, Caspersen, et al. 2017; Abel, Ystrom, et al. 2017; Katko et 
al. 2017). The exact iodine vehicle was unclear in five studies – it was either a KI or an 
iodine-containing multivitamin/mineral tablet (Fadeyev et al. 2003; Marco et al. 2010; 
Rebagliato et al. 2010; Rebagliato et al. 2013; Murcia et al. 2018); in one study no 
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information about the vehicle was provided (Menéndez Torre et al. 2014). In intervention 
studies, the dose of iodine ranged from 50 (Antonangeli et al. 2002) to 300 µg/day (Silva 
and Silva 1981; Velasco et al. 2009; Santiago et al. 2013), mainly as KI tablets. In 
observational studies, the iodine dose in the supplement-user groups ranged from ≤100 to 
≥200 µg/day, mainly in the form of multivitamin/mineral tablets. The exact dose of iodine 
supplement was not reported or was unclear in four studies (Marco et al. 2010; Menéndez 
Torre et al. 2014; Zygmunt et al. 2015; Moleti et al. 2016). A few observational studies 
specifically investigated the effect of initiation of iodine-supplement in the pre-
conception period as iodised salt (Moleti et al. 2008; Moleti et al. 2011; Moleti et al. 
2016) or iodine-containing multivitamin/mineral supplement (Katko et al. 2017).  
 
7.3.3 Risk of bias and quality of included studies 
As a result of incomplete reporting, the risk of bias in many of the included RCTs and 
other intervention studies was unclear in several domains, particularly allocation-
concealment and selective-reporting (Figure 7.2). Adequate random allocation sequence 
was used to generate the study groups in only four RCTs (Brucker-Davis et al. 2013; 
Brucker-Davis et al. 2015; Zhou et al. 2015; Gowachirapant et al. 2017) and in one 
intervention study (Santiago et al. 2013), all conducted after 2012. Only two trials were 
double-blinded and placebo-controlled (Nøhr et al. 2000; Gowachirapant et al. 2017); 
another trial was started as a double-blinded and placebo-controlled but was aborted early 
due to withdrawal of funding support, at which time it was unblinded (Zhou et al. 2015). 
Most trials and intervention studies had effective blinding of outcome assessors for 
subjective outcomes (e.g., child neurodevelopment) or the outcomes were objective (e.g., 
laboratory measurements). More risk-of-bias assessment details, including the summary 
of the support for the risk-of-bias judgements of all included RCTs and intervention 
studies are provided in Supplemental Table 7.2 (Appendix I). The quality of all 
included cohort studies was rated as ‘good’, while cross-sectional studies were mostly of 
‘poor’ or ‘fair’ quality (Supplemental Table 7.3, Appendix I).  
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Study 
(first author, year) 
Risk of bias 
RCTs (n=9) 
 
Silva, 1981 
       
Romano, 1991 
       
Pedersen, 1993 
       
Liesenkötter, 1996 
       
Nøhr, 2000 
       
Brucker-Davis, 2013 
       
Brucker-Davis, 2015 
       
Zhou, 2015 
       
Gowachirapant, 2017 
       
Other intervention studies (n=4) 
Antonangeli, 2002  
       
Berbel, 2009 
 
n/a 
     
Velasco, 2009 
 
n/a 
     
Santiago, 2013 
       
 
 
 
 
 
 
 
Figure 7.2 Risk-of-bias assessment summary of included randomised controlled trials 
(RCTs) and other intervention studies using the Cochrane Risk of Bias Tool 
Abbreviations:  N/A, not applicable (for non-randomised studies); RCT, randomised controlled trial 
Risk of bias 
 
 
 + 
 
- 
 ? 
Low 
Unclear 
High 
142 
 
7.3.4 Maternal thyroid function  
In total, 24 studies reported on the effects of iodine supplementation in pregnancy on 
maternal thyroid function (12 interventions and 12 observational; Table 7.1). 
7.3.4.1 Thyroid-stimulating hormone (TSH) 
The results from various studies for the effect of iodine (as iodised salt or as supplement 
tablets) on maternal TSH were very inconsistent. In all eight RCTs that assessed maternal 
thyroid function, there was no significant difference in TSH between the iodine and 
control groups at various time-points during, or at the end of, the intervention (Silva and 
Silva 1981; Romano et al. 1991; Pedersen et al. 1993; Liesenkötter et al. 1996; Nøhr et 
al. 2000; Brucker-Davis et al. 2013; Brucker-Davis et al. 2015; Gowachirapant et al. 
2017). Additionally, five of those trials also found no significant difference between 
groups in the change of TSH over time (Romano et al. 1991; Liesenkötter et al. 1996; 
Brucker-Davis et al. 2013; Brucker-Davis et al. 2015; Gowachirapant et al. 2017). 
However, three trials (median UIC: 51-54 µg/L) found a differential effect of iodine 
supplementation on the trajectory of TSH over the course of pregnancy – two studies in 
Denmark (Pedersen et al. 1993; Nøhr et al. 2000) reported no change in TSH in the iodine 
group and a significant increase of 21-25 % from initial values in the controls, while one 
study in Chile showed that TSH decreased by 46% in the iodine group and there was no 
change in the controls (Silva and Silva 1981). Three out of four non-RCT interventions 
also found no significant difference in TSH at different doses (Antonangeli et al. 2002; 
Santiago et al. 2013) or timing of initiation (Berbel et al. 2009) of KI supplement.  
 
Three prospective cohort studies in Italy found significantly lower TSH in pregnant 
women who used iodised salt for at least two years prior to conception and continued into 
pregnancy than in those who started using it upon becoming pregnant (Moleti et al. 2008), 
or in those who did not use iodised salt during pregnancy (Moleti et al. 2016), or in those 
who started taking iodine-containing multivitamin/mineral supplements in early 
pregnancy (Moleti et al. 2011). Only the last of these studies looked at the effect of iodine 
as supplement tablets; in that study, women who took 150 µg iodine/day from 
multivitamin/mineral tablets from around nine gestational weeks had a significantly 
higher TSH and a higher proportion of these women had elevated TSH during pregnancy 
than women who used iodised salt long-term (26% vs 15%) (Moleti et al. 2011). 
However, when supplement-users were compared to the group who did not use iodised 
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salt or supplements, there was no difference in the proportion with elevated TSH (26% vs 
29%); a higher TSH was observed only in late pregnancy. Results from cross-sectional 
studies comparing maternal TSH between iodine-supplement users vs non-users during 
pregnancy were mixed – four studies found no significant difference (Fadeyev et al. 2003; 
Marco et al. 2010; Menéndez Torre et al. 2014; Zygmunt et al. 2015), two studies found 
higher (Rebagliato et al. 2010; Katko et al. 2017) and one found lower TSH (Nøhr and 
Laurberg 2000) in pregnant women who used iodine supplements.  
7.3.4.2 Free thyroxine (FT4) 
Five RCTs found no significant difference in FT4 (Pedersen et al. 1993; Nøhr et al. 2000; 
Brucker-Davis et al. 2013; Brucker-Davis et al. 2015) or total T4 (Liesenkötter et al. 
1996) during, or at the end of, the intervention between the iodine-supplemented group 
and the controls, while two studies found a slightly higher FT4 (Gowachirapant et al. 
2017) and higher total T4 (Silva and Silva 1981) in the iodine group. Six out of seven 
RCTs that investigated maternal FT4 (or total T4 in one study) found that it decreased by 
5-24% in the iodine groups and by 17-40% in the control groups during pregnancy and 
there was no differential effect of iodine supplementation on the gestational changes in 
FT4 (Pedersen et al. 1993; Liesenkötter et al. 1996; Nøhr et al. 2000; Brucker-Davis et 
al. 2013; Brucker-Davis et al. 2015; Gowachirapant et al. 2017). Additionally, other 
intervention studies found no significant difference in FT4 between different doses of 
iodine supplements (Antonangeli et al. 2002; Santiago et al. 2013), or significantly higher 
FT4 when supplementation was started during pregnancy vs at term (13 vs 10 pmol/L) 
(Berbel et al. 2009), or  significantly lower FT4 in the iodine group (Velasco et al. 2009). 
  
Two prospective cohort studies found significantly higher FT4 during pregnancy in 
women who used iodised salt for at least two years prior to conception and continued 
using it in pregnancy than in women who started using iodised salt when pregnant (Moleti 
et al. 2008), or in those who did not use iodised salt (Moleti et al. 2016). Another study 
by the same group also found that women who started taking 150 µg iodine/day as 
multivitamin/mineral tablets from nine gestational weeks had a significantly lower FT4 
during pregnancy than women who used iodised salt from pre-conception; FT4 in 
supplement-users, however, was no different to that in women who used neither 
supplements nor iodised salt (Moleti et al. 2011). As with TSH, the results for maternal 
FT4 from cross-sectional studies comparing pregnant women who used iodine 
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supplements vs those who did not were inconsistent – four studies found no significant 
difference (Marco et al. 2010; Menéndez Torre et al. 2014; Zygmunt et al. 2015; Katko 
et al. 2017), one study found slightly lower (Rebagliato et al. 2010) and one found higher 
FT4 (8.4 vs 7.9 pmol/L) (Nøhr and Laurberg 2000) in iodine-supplement users.  
7.3.4.3 Thyroglobulin (Tg) 
Four out of six RCTs reported significantly lower serum Tg in women who were 
administered iodine during pregnancy than in the controls (Pedersen et al. 1993; Brucker-
Davis et al. 2013; Brucker-Davis et al. 2015; Gowachirapant et al. 2017), while two trials 
found no significant difference between groups (Liesenkötter et al. 1996; Nøhr et al. 
2000). Three trials showed that Tg decreased by 18-37% over the course of pregnancy in 
the supplemented women while Tg increased by 13-60% in the group who were not 
supplemented with iodine (Pedersen et al. 1993; Nøhr et al. 2000; Brucker-Davis et al. 
2013). One intervention study showed that Tg decreased by 26% in the group taking 
iodine but the change was not significant (Velasco et al. 2009). There was no difference 
in Tg or its change over time according to different doses of iodine supplement (300 vs 
200 µg/day) in one study (Santiago et al. 2013), while another showed that Tg decreased 
by 36% in response to a higher dose (200 µg iodine/day) but it increased by 25% with a 
lower dose (50 µg iodine/day) (Antonangeli et al. 2002).  
 
One cohort study found significantly lower serum Tg in pregnant women who used 
iodised salt for at least two years before pregnancy than in women who started using it 
upon becoming pregnant (10 vs 24 µg/L) (Moleti et al. 2008). Two cross-sectional studies 
found significantly lower Tg in women who used iodine supplements than in those who 
did not (mean difference 5-11 µg/L) (Nøhr and Laurberg 2000; Katko et al. 2017), with 
one reporting lower Tg only in women who started taking iodine supplements pre-
pregnancy [9.1 µg/L (pre-pregnancy) vs 14.5 µg/L (pregnancy start)] (Katko et al. 2017).  
7.3.4.4 Thyroid volume  
Four out of five RCTs  found no significant difference in thyroid volume between the 
iodine and the control groups during, or at the end of, the intervention (Romano et al. 
1991; Liesenkötter et al. 1996; Brucker-Davis et al. 2013; Gowachirapant et al. 2017). 
However, in two trials, iodine supplementation prevented or diminished the increase in 
thyroid volume with advancing pregnancy – thyroid volume did not change over gestation 
in the iodine group but it increased significantly by 16% in the controls in one trial 
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(Romano et al. 1991), while in another trial  thyroid volume increased in both groups but 
the increase was greater in the controls [31% (controls) vs 16% (iodine)] (Pedersen et al. 
1993). No significant difference in thyroid volume was reported in two intervention 
studies that used different doses of iodine (Antonangeli et al. 2002; Santiago et al. 2013), 
however one of the studies showed a decrease in post-partum thyroid volume only in the 
group taking the higher dose (200 µg/day vs 50 µg/day) (Antonangeli et al. 2002).  
 
A cross-sectional study found significantly lower thyroid volume in mothers who used 
iodine supplements than those who did not (12.9 vs 16.8 ml) (Fadeyev et al. 2003), while 
two studies found no significant difference between those groups (Klett et al. 1999; 
Zygmunt et al. 2015). 
7.3.4.5 Other relevant outcomes  
None of the RCTs found a significant difference between the iodine group and controls 
in the frequency of TPO-Ab positivity or TPO-Ab titres (Liesenkötter et al. 1996; Nøhr 
et al. 2000; Gowachirapant et al. 2017), or the percentage with detectable Tg-Ab (Nøhr 
et al. 2000). Furthermore, one trial found no significant difference in the proportion of 
women that developed post-partum thyroid disease (PPTD) [59% (iodine) vs 46% 
(controls)], or its type and severity between the group supplemented with iodine and the 
controls (Nøhr et al. 2000). A later intervention study also reported no enhancement of 
the occurrence of PPTD in the mothers in relation to iodine supplementation (Antonangeli 
et al. 2002). None of the six cross-sectional studies that investigated the effect of iodine-
supplement use vs no use on markers of thyroid autoimmunity found a significant 
difference in the frequency of Tg-Ab (Nøhr and Laurberg 2000; Marco et al. 2010) or 
TPO-Ab positivity (Fadeyev et al. 2003; Marco et al. 2010; Menéndez Torre et al. 2014; 
Konrade et al. 2015), or their titres (Zygmunt et al. 2015). An observational cohort study 
found that long-term use of iodised salt (i.e., started from pre-pregnancy) significantly 
reduced the risk of maternal thyroid failure (defined as overt hypothyroidism or isolated 
hypothyroxinaemia) by nearly 83% compared to short-term use (i.e., started during 
pregnancy) (Moleti et al. 2008).   
 
Two RCTs did not find a difference in the frequency of adverse events (e.g., abortions, 
neonatal deaths) or any side effects (e.g., nausea, diarrhoea, sweating, palpitations) 
between the iodine and the placebo groups (Zhou et al. 2015; Gowachirapant et al. 2017). 
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Table 7. 1  Summary of findings from 24 studies for the effect of iodine supplements during pregnancy on maternal thyroid function 
Study design Maternal thyroid outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status1 
Iodine exposure: 
dose2, study group (start 
of supplement) (n) 
Iodine 
vehicle/s 
TSH FT4 Serum Tg Thyroid volume Other 
RCTs (n=8) 
Silva, 1981, 
Chile 
54 µg/L A: 300 µg/d, iodine (9-32 
wks.) (n=36) 
B: no iodine (n=10) 
KI solution 
at 785 
µg/ml (10 
drops) 
A: ↓46% 
B: ↓13% (NS) 
(wks. 9-32 vs 15-40) 
Decreased in iodine grp; no 
change in no-iodine grp; no 
difference between grps at 
delivery 
Total T4 was assessed: 
A: ↑44% 
B: ↓1% (NS) 
(wks. 9-32 vs 15-40) 
Increased in iodine grp; no 
change in no-iodine grp; higher 
in iodine grp at delivery 
N/A N/A N/A 
Romano, 1991, 
Italy 
31 µg/24h A: 120-180 µg/d, IS (≤13 
wks.) (n=17) 
B: no IS (n=18) 
IS at 20 mg 
iodide per 
kg 
No change in either grp (1st - 
3rd trim); no difference 
between grps at any time-
point between 1st and 3rd trim 
N/A N/A A: ↑ 4% (NS) 
B: ↑16% 
(1st - 3rd trim) 
Increased in B vs 
no change in A; 
no difference at 
3rd trim between 
A vs B (10.2 vs 
11.7 ml, NS)3 
N/A 
Pedersen, 1993, 
Denmark 
51 µg/L A: 200 µg/d, iodine (17-18 
wks.) (n=28) 
B: no iodine (n=26) 
KI solution 
(10 drops) 
A: ↑5% (NS)4 
B: ↑21% 
(wks. 17 vs 37) 
Increased in B vs no change 
in A; no difference between 
grps at any time-point 
A: ↓13% 4 
B: ↓20% 4 
(wks. 17 vs 37) 
Decreased in both grps with no 
difference in variation over time 
or at any time-point between 
grps 
A: ↓18% 4 
B: ↑60% 4 
(wks.17 vs 37) 
Decreased in A; 
increased in B; 
lower in A at all 
time-points 
A: ↑16% 
B: ↑31% 
(wks. 17 vs 37) 
Increased in both 
grps with higher 
increase in no-
iodine grp 
N/A 
Liesenkötter, 
1996, Germany  
64 µg/L A: 230 µg/d, iodine (11.2 
wks.) (n=38) 
B: no iodine (n=70) 
KI tablet 
(300 µg) 
A: ↓32% (NS) 
B: ↑29% (NS) 
(wks. 10-12 vs PP) 
No difference between grps 
at end of intervention PP 
Total T4 was assessed: 
A: ↓22% (NS) 
B: ↓40% (NS) 
(wks. 10-12 vs PP) 
No difference between grps at 
end of intervention PP 
A:↓50% (NS) 
B:↓19% (NS) 
(wks. 10-12 vs 
PP) 
No difference 
between grp PP 
A: ↑27% (NS) 
B: ↑19% (NS) 
(wks. 10-12 vs 
PP) 
No difference 
between grps PP 
No change in 
frequency of 
TPO-Ab 
positivity in 
either grp 
         
(continued on next page) 
147 
 
Table 7. 1  Summary of findings from 24 studies for the effect of iodine supplements during pregnancy on maternal thyroid function (continued) 
Study design Maternal thyroid outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status1 
Iodine exposure: 
dose2, study group (start 
of supplement) (n) 
Iodine 
vehicle/s 
TSH FT4 Serum Tg Thyroid volume Other 
RCTs (continued) 
Nøhr, 2000, 
Denmark5 
51 µg/L A: 150 µg/d, MV + iodine 
(P+PP) (11 wks.) (n=22) 
B: 150 µg/d, MV + iodine 
(P) (11 wks.) (n=20) 
C: MV - iodine (n=24) 
MV tablet 
(+ 50 µg 
Se) 
A&B: ↑4 % (NS) 
C: ↑25%  
(wks. 11 vs 35) 
Increased in the no-iodine 
grp only; difference in the 
change over time between 
grps; no difference between 
grps at 35 wks. 
A: ↓5%  
B: ↓16%  
C: ↓20%  
(wks. 11 vs 35) 
Decreased in all grps; no 
difference in change over time 
or at 35wks.  between grps 
A: ↓37%  
B: ↑5% (NS) 
C: ↑13% 
(wks. 11 vs 35) 
Decreased in 
MV+iodine & 
increased in  
MV-iodine; no 
difference 
between grps at 
35 wks. 
N/A No difference 
PPTD between 
grps (59 vs 60 vs 
46 %, NS); no 
difference in 
TPO-Ab titres 
between grps; no 
difference in % 
with Tg-Ab 
between grps at 
35 wks. 
Brucker-Davis, 
2013, France 
103 µg/L A: 150 µg/d, MV + iodine 
(<12 wks.) (n=32) 
B: MV - iodine (n=54) 
MV tablet  A: ↓6% (NS) 
B: ↑16% (NS) 
(wks. 12 vs 33) 
No change in both grps; no 
difference between grps at 
any time-point 
A: ↓18%  
B: ↓21% 
(wks. 12 vs 33) 
Decreased in both grps 
similarly; no difference between 
grps at any time-point 
A: ↓29%  
B: ↑28% (NS) 
(wks. 12 vs 22) 
Decreased only in 
iodine grp at 2nd 
trim only; lower 
in iodine grp in 
2nd trim 
A: ↓3% (NS) 
B: ↑8% (NS) 
(wks. 12 vs 33) 
No change in 
both grps; no 
difference 
between grps at 
any time-point 
N/A 
Brucker-Davis, 
2015, France 
117 µg/L A: 150 µg/d, MV + iodine 
(<10 wks.) (n=19) 
B: MV - iodine (n=25) 
MV tablet  A: ↓3% (NS) 
B: ↑14% (NS) 
(wks. 12 vs 33) 
No difference between grps 
at any time-point 
A: ↓18%  
B: ↓17% 
(wks. 12 vs 33) 
No difference between grps at 
any time-point 
A: ↓17% 
B: ↑61% 
(wks. 12 vs 33) 
Lower in  
iodine grp 
(2nd & 3rd trim) 
N/A N/A 
Gowachirapant 
2017, Thailand  
& India 
131 µg/L A: 200 µg/d, iodine (10.8 
wks.) (n=412) 
B: placebo (n=420) 
KI tablet  A: ↑18% 
B: ↑25% 
(wks. 10-11 vs 30-33) 
No difference between grps 
during pregnancy 
A: ↓24% 
B: ↓22% 
(wks. 10-11 vs 30-33) 
Marginally higher in iodine grp 
during pregnancy  
A: ↑5% 
B: ↑7% 
(wks. 10-11 vs 
30-33) 
Lower in iodine 
grp during 
pregnancy 
A: ↑7% 
B: ↓1% 
(wks. 10-11 vs 
30-33) 
No difference 
between grps in 
pregnancy 
No difference in 
TPO-Ab titres or 
% with raised 
TPO-Ab (>35 
IU/ml) during 
pregnancy  
         
(continued on next page) 
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Table 7. 1  Summary of findings from 24 studies for the effect of iodine supplements during pregnancy on maternal thyroid function (continued) 
Study design Maternal thyroid outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status1 
Iodine exposure: 
dose2, study group (start 
of supplement) (n) 
Iodine 
vehicle/s 
TSH FT4 Serum Tg Thyroid volume Other 
Intervention studies (n=4) 
Antonangeli, 
2002, Italy 
74 µg/L A: 200 µg/d, iodine (10-16 
wks.) (n=32) 
B: 50 µg/d, iodine (10-16 
wks.) (n=35) 
KI tablet 
(262/131 
µg) 
A: ↑9% (NS)6 
B: ↑9% (NS)6 
(wks. 10-16 vs 29-33) 
No change in either grp; no 
difference between grps at 
any time-point 
A: ↓13% 6 
B: ↓13% 6 
(wks. 10-16 vs 29-33) 
Decreased in both grps 
similarly; no difference between 
grps at any time point 
A:↓36% (NS)6 
B: ↑25% (NS)6 
(wks. 10-16 vs 
29-33); NS 
change in either 
grp; no diff. 
between grps at 
any time-point 
A: ↑3% (NS) 
B: ↑10% (NS) 
(wks. 10-16 vs 
29-33); Small 
increase in B; no 
diff.  between 
grps at any time-
point in 
pregnancy; 
decreased PP in 
A 
No difference in 
the occurrence of 
PPTD; no side 
effects  
Berbel, 2009, 
Spain7 
75 µg/L8 A: 153 µg/d, iodine (4-6 
wks) (n=92) 
B: 153 µg/d, iodine (12-14 
wks) (n=102) 
C: 153 µg/d, iodine (term) 
(n=151) 
KI tablet 
(200 µg) 
No difference between grps 
at term A vs B vs C (2.10 vs 
2.28 vs 2.13 mU/L, NS) 
Higher in grps A & B (when 
iodine was started in pregnancy) 
vs C (at term) (13.3 vs 13.1 vs 
9.9 pmol/L); no difference for A 
vs B 
N/A N/A N/A 
Velasco, 2009, 
Spain 
69 µg/L9 A: 300 µg/d, iodine (≤13 
wks.) (n=133) 
B: no iodine (n=61) 
KI tablet 
(300 µg) 
A: ↑8% (NS) 
B: N/A 
(1s - 3rd trim) 
No change in iodine grp; 
lower in iodine grp in 3rd 
trim (1.99 vs 2.47 mU/L) 
A: ↓26% 
B: N/A 
(1s - 3rd trim) 
Decreased in iodine grp; lower 
in iodine grp in 3rd trim (7.77 vs 
8.98 pmol/L) 
A: ↓27% (NS) 
B: N/A 
(1s - 3rd trim) 
Decreased in 
iodine grp but NS 
N/A N/A 
Santiago, 2013, 
Spain10 
109 µg/L A: 300 µg/d, iodine (<10 
wks.) (n=38) 
B: 200 µg/d, iodine (<10 
wks.) (n=55) 
C: n/a, IS (<10 wks.) 
(n=38) 
KI tablet 
(300/200 
µg) & IS 
A: ↑43% (NS) 
B: ↑20% (NS) 
C: ↑30% (NS) 
(wks. <10 vs 36) 
No difference in the change 
over time or at any time-
point between grps 
A: ↓25% 
B: ↓27% 
C: ↓28% 
(wks. <10 vs 36) 
No difference in change over 
time or at any time-point 
between grps 
A:↑7% (NS) 
B:↓2% (NS) 
C:↑0% (NS) 
(wks. <10 vs 36) 
No change in all 
grps; no diff 
between grps  
A: ↑7% 
B: ↑28% 
C: ↑3% 
(wks. <10 vs 36) 
No difference in 
change over time 
or any time-point  
N/A 
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Table 7. 1  Summary of findings from 24 studies for the effect of iodine supplements during pregnancy on maternal thyroid function (continued) 
Study design Maternal thyroid outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status1 
Iodine exposure: 
dose2, study group (start 
of supplement) (n) 
Iodine 
vehicle/s 
TSH FT4 Serum Tg Thyroid volume Other 
Prospective cohort studies (n=3)    
Moleti, 2008, 
Italy 
63 µg/L A: 190 µg/d, long-term IS-
user (min 24 months pre-
conception) (n=62); 
B: 105 µg/d, short-term IS-
user (pregnant) (n=38) 
IS at 30 
ppm KIO3 
A:↑ 28%(1st - 3rd trim) 
B:↑ 37% 
Lower in long-term IS-users 
at all time-points 
A: ↓ 19% (1st - 3rd trim) 
B: ↓ 19%  
Decreased in both grps; higher 
in long-term IS-users at all time-
points 
Lower in long-
term IS-users: 
(10.2 vs 24.1 
µg/L) 
 
N/A 82.5% RR 
reduction of 
thyroid failure in 
long vs short-
term IS-users 
Moleti, 2011, 
Italy 
52 µg/L A: 150 µg/d, iodine-user 
(+IS) (9 wks. median) 
(n=168) 
B: n/a, long-term IS-user 
(min 24 months pre-
conception) (n=105) 
C: non-user (n=160) 
MV tablet 
& IS 
A: ↑ 3% (NS) 
B: ↑ 12% (NS) 
C: ↑ 7%  (NS) 
(wks. 6-9 vs 33-term) 
Higher in iodine-users vs 
long-term IS-users at all 
time-points and vs non-users 
in late pregnancy; higher % 
with elevated TSH in A vs B 
and no difference vs C 
A: ↓ 21%  
B: ↓ 21% 
C: ↓ 21% 
(wks. 6-9 vs 33-term) 
Decreased in all grps; lower in 
iodine-users vs long-term IS-
users & no difference vs non-
users; higher % with low FT4 in 
non-users vs iodine-users and 
long-term IS-users 
N/A N/A N/A 
Moleti, 2016, 
Italy 
48 µg/L A: n/a, IS-user (min 24 
months pre-conception) 
(n=15) 
B: no IS-user (n=15) 
C: n/a, IS-user (+LT4) 
(n=15) 
D: n/a, no IS-user (+LT4) 
(pre-conception) (n=15) 
IS & LT4 A: ↑ 57% 
B: ↑ 77% 
C: ↓ 34% (NS) 
D: ↓ 54% 
(wks. ≤12 vs 31-term) 
Lower in IS-users vs no IS-
users from 13-18 wks. 
onwards 
A: ↓ 23%  
B: ↓ 17% 
C: ↓ 13%  
D: ↓ 7% 
(wks. ≤12 vs 31-term) 
Higher in IS-users vs no IS-
users at all time-points; no 
difference between C & D 
N/A 
 
N/A N/A 
Cross-sectional studies (n=9) 
Klett, 1999, 
Germany  
48 µg/L8 A: 135 µg/d, iodine-user 
(n=32) 
B: non-user (n=57) 
KI tablet 
(175 µg) 
N/A N/A N/A No difference 
between A vs B 
at delivery (16.7 
vs 19.5 ml, NS) 
N/A 
Nøhr, 2000, 
Denmark 
35 µg/L8 A: 150 µg/d, iodine-user 
(n=49) 
B: non-user (n=95) 
MV tablet Lower in iodine-users at 
term (2.06 vs 2.23 mU/L) 
Higher in iodine-users at term 
(8.4 vs 7.9 pmol/L) 
Lower A at term 
(14.7 vs 25.8 
µg/L) 
N/A No difference in 
frequency of Tg-
Ab positivity 
(continued on next page) 
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Table 7. 1  Summary of findings from 24 studies for the effect of iodine supplements during pregnancy on maternal thyroid function (continued) 
Study design  Maternal thyroid outcomes    
First author, 
year (ref.), 
country 
Baseline 
iodine 
status1 
Iodine exposure: 
dose2, study group (start 
of supplement) (n) 
Iodine 
vehicle/s 
TSH FT4 Serum Tg Thyroid volume Other 
Cross-sectional studies (continued) 
Fadeyev, 2003, 
Russia 
48-87 
µg/L11 
A: 150-200 µg/d, iodine-
user (n=90) 
B: non-user (n=125) 
KI or MV 
tablet 
No difference between A vs 
B in any trimester (3rd trim: 
0.93 vs. 1.26 mU/L, NS) 
N/A N/A Lower A in 3rd 
trim (12.9 vs. 
16.8 ml) 
No difference in 
TPO-Ab +ve  
Marco, 2010, 
Spain 
164 µg/L A: n/a, iodine-user (n=381) 
B: n/a, IS-user (n=75) 
C: non-user (n=69) 
KI or MV 
tablet & IS 
No difference between A vs 
B vs C at 26 wks. (1.73 vs 
1.67 vs 2.51 mU/L, NS); no 
difference in % with TSH > 
4 mU/L 
No difference between A vs B 
vs C at 26 wks. (11.6 vs 11.6 vs 
11.6 pmol/L, NS); no difference 
in % with FT4 < 5.1 pmol/L 
N/A N/A No difference in 
Tg-Ab and TPO-
Ab +ve and % 
with hypoT4 
Rebagliato, 
2010, Spain 
137 µg/L A: ≥200 µg/d, iodine-user 
(3 mo pre-conception up to 
< 24 wks.) (n=601) 
B: 100-199 µg/d, iodine-
user (3 mo pre-conception 
up to < 24 wks.) (n=298) 
C: <100 µg/d, iodine-
user/non-user (3 mo pre-
conception up to < 24 
wks.) (n=945) 
KI or MV 
tablet 
Higher % with TSH > 3 
mU/L in ≥200 µg/d iodine-
users (7.5 vs 6.7 vs 4.9 %); 
being in ≥200 µg/d iodine-
user grp vs <100 µg/d 
associated with higher TSH 
and increased risk of TSH > 
3 mU/L  (OR=2.5) 
Lower in A (≥200 µg/d iodine-
users) vs B & C (10.1 vs 10.9 vs 
10.7 pmol/L) 
N/A N/A N/A 
Menéndez-
Torre, 2014, 
Spain  
197 µg/L A: n/a, iodine-user (n=88) 
B: non-user (n=85) 
N/A No difference between A vs 
B (2.30 vs 1.94 mU/L, NS); 
higher % with TSH > 2.5 
mU/L (42.5 vs 26.5 %) 
No difference between A vs B 
(15.2 vs 14.9 pmol/L, NS) 
N/A N/A No diff in % 
TPO-Ab positive 
(9.4 vs 9.1 %, 
NS) 
Konrade, 2015, 
Latvia 
69 µg/L 
(81 µg/g) 
A: ≥150 µg/d, iodine-user 
(n=48) 
B: 100-149 µg/d, iodine-
user (n=70) 
C: <100 µg/d, iodine-
user/non-user (n=570) 
MV tablet N/A Only baseline levels in total 
sample were reported 
N/A N/A No diff in % 
with TPO-Ab > 
60 U/ml between 
grps (12.8 vs 8.9 
vs 13.7 %) and 
no diff in odds of 
elevated TPO-
Ab in A vs C 
         
(continued on next page) 
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Table 7. 1  Summary of findings from 24 studies for the effect of iodine supplements during pregnancy on maternal thyroid function (continued) 
Study design  Maternal thyroid outcomes    
First author, 
year (ref.), 
country 
Baseline 
iodine 
status1 
Iodine exposure: 
dose2, study group (start 
of supplement) (n) 
Iodine 
vehicle/s 
TSH FT4 Serum Tg Thyroid volume Other 
Cross-sectional studies (continued) 
Zygmunt, 2015, 
Poland 
80 µg/L A: n/a, iodine-user (n=52) 
B: non-user (n=63) 
MV tablets No difference between A vs 
B (1.76 vs 1.76 mU/L, NS) 
No difference in A vs B (13.0 vs 
13.3 pmol/L, NS) 
N/A No difference 
between A vs B 
(12.2 vs 11.8 ml, 
NS) 
No difference in 
TPO-Ab 
between A vs B 
(27.9 vs 30.6 
IU/ml, NS) or 
Tg-Ab (20.4 vs 
40.2 IU/ml, NS) 
Katko, 2017, 
Hungary 
162 µg/L A: ≥150 µg/d, iodine-user 
(min 4wks. preconception) 
(n=27) 
B: ≥150 µg/d, iodine-user 
(pregnancy ≤16 wks.) 
(n=51) 
C: non-user (n=74) 
MV tablets Higher in iodine-user (P) vs 
non-user (1.97 vs 1.62 
mU/L); no difference in 
iodine-user (pre-P) vs non-
user (1.72 vs 1.62 mU/L, 
NS) 
No difference between A vs B 
vs C (13.9 vs 13.2 vs 13.3 
pmol/L, NS) 
Lower in A vs C 
(9.1 vs 14.6 
µg/L); no 
difference 
between B vs. C 
(14.5 vs 14.6 
µg/L, NS)  
N/A N/A 
1 Baseline iodine status was expressed as median urinary iodine concentration (UIC, µg/L), median urinary iodine-to-creatinine ratio (UI/Creat, µg/g) or median urinary iodine excretion (UIE, 
µg/24h) of the total sample. If baseline iodine status values were not available for the total sample, values for the control group/group who did not use iodine-containing supplements and/or 
iodised salt were used. 2 In some cases where the authors only provided the KI dose used but not the actual iodine content of the tablets, the dose was converted to µg of iodide to facilitate 
comparisons between studies. 3 Thyroid volume values were estimated from a bar-chart in the original paper in Romano, 1991. 4 Values for these parameters were estimated from graphs in 
the original paper in Pedersen, 1993. 5 Women in this study were a selected group positive for TPO-Ab in Nøhr, 2002. 6 The calculated % values are based on values for these parameters 
estimated from graphs in the original paper in Antonangeli, 2002. 7 Women in this study were a very selected group (i.e., A=euthryoid vs B&C=hypothyroxinaemic in 1st trim or at term, 
respectively) in Berbel, 2009. 8 Median UIC values at baseline were not reported and values measured at delivery/term were used for these studies - Berbel, 2009; Klett, 1999; Nøhr & 
Laurberg, 2002. 9 Baseline iodine status value was based on a sub-group of women from the area who had miscarriage and were not included in this study in Velasco, 2009.  10 Women in this 
study were also split by IS-use for at least 1 year before pregnancy; IS-users had significantly lower thyroid volume in 3rd trim vs no IS-users (no differences in TSH, FT4 or Tg were observed), 
regardless of iodine-supplement use and group allocation in Santiago, 2013. 11 Baseline iodine status value was based on the median UIC in parts of the study area, as the median of exact 
sample was not reported in this study in Fadeyev, 2003. Abbreviations: Diff., difference; FT4, free thyroxine; Grp/s, group/s; IS, iodised salt; KI, potassium iodide; LT4, levothyroxine; mo., 
months; MV, multivitamin supplement; N/A, data not available/reported; NS, not statistically significant; OR, odds ratio; P, pregnancy; PP, post-partum; PPTD, post-partum thyroid disease; 
Pre-P, pre-pregnancy; RCTs, randomised controlled trials; Ref., reference; RR, relative risk; Se, selenium; T4, thyroxine; Tg, thyroglobulin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid 
peroxidase antibody; Trim, trimester; TSH, thyroid-stimulating hormone; Wks., weeks 
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7.3.5 Infant/child thyroid function  
Infant/child thyroid function was an outcome in 12 studies in total (eight interventions 
and four observational; Table 7.2). 
7.3.5.1 Thyroid-stimulating hormone (TSH) 
The majority of studies showed no effect of maternal iodine supplementation on neonatal 
TSH. None of the five RCTs that reported infant TSH showed any significant difference 
between the iodine and the control groups in cord-blood (Silva and Silva 1981; Pedersen 
et al. 1993; Brucker-Davis et al. 2015) or newborn TSH (Zhou et al. 2015; Gowachirapant 
et al. 2017). One out of two non-RCT intervention studies also showed no significant 
effect of different doses of maternal iodine supplementation on TSH in cord-blood 
(Santiago et al. 2013). Only two studies – one cross-sectional (Nøhr and Laurberg 2000) 
and one inadequately controlled intervention study (Velasco et al. 2009) – showed 
significantly  higher TSH in cord-blood in the iodine-supplemented women (7.9 vs 3.8 
mU/L; 9 vs 7.1 mU/L). Three out of four cross-sectional studies comparing iodine-
supplement users with  non-users found no significant difference in neonatal TSH 
between groups (Klett et al. 1999; Gietka-Czernel et al. 2010; Marco et al. 2010). 
7.3.5.2 Free thyroxine (FT4) 
Four out of five RCTs that assessed neonatal/child FT4 or total T4 showed no significant 
difference between the iodine and control groups (Pedersen et al. 1993; Brucker-Davis et 
al. 2015; Zhou et al. 2015; Gowachirapant et al. 2017). One of the RCTs showed 
significantly higher cord-blood total T4 in the iodine group than in the controls (145 vs 
120 nmol/L) (Silva and Silva 1981). Only one cross-sectional study reported on neonatal 
FT4 and showed significantly higher cord-blood concentration in mothers who used 
iodine than in non-users (12.5 vs 11.7 pmol/L) (Nøhr and Laurberg 2000). 
7.3.5.3 Thyroglobulin (Tg) 
One RCT reported significantly lower cord-blood Tg in the intervention vs control group 
(38 vs 67 µg/L) (Pedersen et al. 1993), while two reported no significant difference 
between groups (Brucker-Davis et al. 2015; Zhou et al. 2015). Only one cross-sectional 
study reported on neonatal serum Tg and found lower cord-blood concentration in iodine-
users than in non-users (34 vs 57 µg/L) (Nøhr and Laurberg 2000). 
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Table 7. 2  Summary of findings from 12 studies for the effect of iodine supplements during pregnancy on neonatal/child thyroid function 
Study design Neonatal/child thyroid outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status 1 
Iodine exposure: 
dose 2, study group (start of 
supplement) (n) 
Iodine 
vehicle/s 
TSH FT4 Serum Tg 
Thyroid 
volume 
Other 
RCTs (n=6)         
Silva, 1981, 
Chile 
54 µg/L A: 300 µg/d, iodine (9-32 wks.) 
(n=36) 
B: no iodine (n=10) 
KI solution 
at 785 
µg/ml (10 
drops) 
No difference between grps 
A vs B in cord-blood (5.7 vs 
8.3 mU/L, NS) 
Higher total T4 in iodine 
group (145.4 vs 119.7 
nmol/L) 
N/A N/A N/A 
Pedersen, 1993, 
Denmark 
51 µg/L A: 200 µg/d, iodine (17-18 wks.) 
(n=28) 
B: no iodine (n=26) 
KI solution 
(10 drops) 
No difference between grps 
A vs B in cord-blood (6.8 vs 
7.8 mU/L, NS) 
No difference between 
grps A vs B (13.6 vs 13.6 
pmol/L, NS) 
Lower in iodine 
group (38 vs 67 
µg/L) 
N/A N/A 
Liesenkötter, 
1996, Germany  
64 µg/L A: 230 µg/d, iodine (11.2 wks.) 
(n=38) 
B: no iodine (n=70) 
KI tablet 
(300 µg) 
Measured in new-born but 
not reported 
N/A N/A Lower in iodine 
group (0.7 vs 
1.5 ml) 
No difference in 
frequency of TPO-
Ab placental 
transfer between 
grps 
Brucker-Davis, 
2015, France 
117 µg/L A: 150 µg/d, MV + iodine (<10 
wks.) (n=19) 
B: MV - iodine (n=25) 
MV tablet  No difference between grps 
A vs B in cord-blood (8.0 vs 
6.2 mU/L, NS) 
No difference between 
grps A vs B (13.4 vs 12.8 
pmol/L, NS) 
No difference 
between grps A 
vs B (66.8 vs 
96.1 µg/L, NS) 
N/A N/A 
Zhou, 2015, 
Australia 
137 µg/L A: 150 µg/d, iodine (15.2 wks.) 
(n=29)3 
B: placebo (n=30)3 
KI tablet  No difference between grps 
A vs B in cord- blood (8.2 
vs 6.6 mU/L, NS) or in 
new-born (2.1 vs. 2.2 mU/L, 
NS) 
No difference between 
grps A vs B (14.4 vs 13.8 
pmol/L, NS) 
No difference 
between grps A 
vs B (73 vs 64 
µg/L, NS) 
N/A N/A 
Gowachirapant, 
2017, Thailand & 
India 
131 µg/L A: 200 µg/d, iodine (10.8 wks.) 
(n=412)4 
B: placebo (n=420)4 
KI tablet  No difference between grps 
at birth, 1 year, 2 or 5 years  
No difference between 
grps in total T4 at birth, 1 
year, 2 or 5 years; FT4 
measured in newborns 
and at 2 years but not 
reported 
N/A Measured at 2 
years but not 
reported 
N/A 
Intervention studies (n=2) 
Velasco, 2009, 
Spain 
69 µg/L5 A: 300 µg/d, iodine (≤13 wks.) 
(n=133) 
B: no iodine (n=61) 
KI tablet 
(300 µg) 
Higher in iodine group in 
cord-blood (7.93 vs 3.77 
mU/L) 
N/A N/A N/A N/A 
(continued on next page) 
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Table 7. 2  Summary of findings from 12 studies for the effect of iodine supplements during pregnancy on neonatal/child thyroid function (continued) 
Study design Neonatal/child thyroid outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status 1 
Iodine exposure: 
dose 2, study group (start of 
supplement) (n) 
Iodine 
vehicle/s 
TSH FT4 Serum Tg 
Thyroid 
volume 
Others 
Intervention studies (continued) 
Santiago, 2013, 
Spain  
109 µg/L A: 300 µg/d, iodine (<10 wks.) 
(n=38) 
B: 200 µg/d, iodine (<10 wks.) 
(n=55) 
C: n/a, IS (<10 wks.) (n=38) 
KI tablet 
(300/200 
µg) & IS 
No difference between grps 
A vs B vs C in cord-blood 
(3.22 vs 2.49 vs 2.98 mU/L, 
NS) 
N/A N/A No difference 
between grps A 
vs B vs C (0.42 
vs 0.42 vs 0.49 
ml, NS) 
N/A 
Cross-sectional studies (n=4) 
Klett, 1999, 
Germany  
48 µg/L6 A: 135 µg/d, iodine-user (n=32) 
B: non-user (n=57) 
KI tablet 
(175 µg) 
No difference between grps 
(exact values not reported 
by group) 
N/A N/A Lower in iodine 
group (1.0 vs 
1.2 ml) 
N/A 
Nøhr, 2000, 
Denmark 
35 µg/L6 A: 150 µg/d, iodine-user (n=49) 
B: non-user (n=95) 
MV tablet Higher in iodine group in 
cord-blood (9.00 vs 7.07 
mU/L) 
Higher in iodine group 
(12.5 vs 11.7 pmol/L) 
Lower in iodine 
group (34.3 vs 
56.7 µg/L) 
N/A No difference in 
frequency of Tg-Ab 
positivity between 
grps 
Gietka-Czernel, 
2010, Poland 
113 µg/L A: 150 µg/d, iodine-user (n=35) 
B: non-user (n=65)7 
MV tablet No difference between grps 
A vs B in new-born (1.57 vs 
1.33 mU/L, NS)8 
N/A N/A N/A N/A 
Marco, 2010, 
Spain 
164 µg/L A: n/a, iodine-user (n=381) 
B: n/a, IS-user (n=75) 
C: non-user (n=69) 
KI or MV 
tablet & IS 
No difference between grps 
(exact values not reported 
by group) 
N/A N/A N/A N/A 
1 Baseline iodine status was expressed as median urinary iodine concentration (UIC, µg/L), median urinary iodine-to-creatinine ratio (UI/Creat, µg/g) or median urinary iodine excretion (UIE, 
µg/24h) of the total sample. If baseline iodine status values were not available for the total sample, values for the control group/group who did not use iodine-containing supplements and/or 
iodised salt were used. 2 In some cases where the authors only provided the KI dose used but not the actual iodine content of the tablets, the dose was converted to µg of iodide to facilitate 
comparisons between studies. 3 Numbers for the cord-blood tests were smaller 19 and 22 for group A and B, respectively in Zhou, 2015. 4 Numbers for child blood tests were smaller (e.g., at 
5 years there were 159 in each group) in Gowachirapant, 2017. 5 Baseline iodine status value was based on a sub-group of women from the area who had miscarriage and were not included 
in this study in Velasco, 2009. 6 Median UIC values at baseline were not reported and values measured at delivery were used for these studies - Klett, 1999; Nøhr & Laurberg, 2002. 7 Some 
of the women in group B (n=35) also took MV tablets (without iodine) in Gietka-Czernel, 2010. 8 TSH measurements were performed for a total of 68 newborns, numbers per group were not 
reported in Gietka-Czernel, 2010. Abbreviations: FT4, free thyroxine; Grp/s, group/s; IS, iodised salt; KI, potassium iodide; MV, multivitamin supplement; N/A, data not available/reported; 
NS, not statistically significant; RCTs, randomised controlled trials; Ref., reference; T4, thyroxine; Tg, thyroglobulin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody; 
TSH, thyroid stimulating hormone; Wks., weeks 
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7.3.5.4 Thyroid volume  
The only RCT that reported on infant thyroid volume found that it was significantly lower 
in the infants born to the iodine-supplemented mothers than in those to the controls (0.7 
vs 1.5 ml) (Liesenkötter et al. 1996). One uncontrolled intervention study found no 
significant difference in infant thyroid volume between two groups of mothers taking 
different doses of iodine and a group using only iodised salt (Santiago et al. 2013). One 
cross-sectional study found significantly lower thyroid volume in infants of mothers who 
were iodine-supplement users than in those of non-users (1.0 vs 1.2 ml) (Klett et al. 1999). 
7.3.5.5 Other relevant outcomes  
An RCT found no significant increase in the frequency of TPO-Ab placental transfer or 
induction of autoimmunity when mothers were supplemented with iodine (Liesenkötter 
et al. 1996). Additionally, a cross-sectional study found no significant difference in the 
frequency of cord-blood Tg-Ab positivity between iodine-users and non-users (Nøhr and 
Laurberg 2000). 
 
7.3.6 Child neurodevelopment  
The effects of maternal iodine supplementation on child neurodevelopment were 
addressed in 12 studies (six interventions and six observational; Table 7.3).  
7.3.6.1 Motor development 
Three RCTs (median UIC range: 117-137 µg/L) studied the effect of iodine 
supplementation in pregnancy on child neurodevelopment (Brucker-Davis et al. 2015; 
Zhou et al. 2015; Gowachirapant et al. 2017) but only one was adequately-powered 
(Gowachirapant et al. 2017). None of the three trials found either a beneficial or harmful 
effect of maternal iodine supplementation at doses of 150 or 200 µg/day as KI or iodine-
containing multivitamin/mineral tablet on child motor development between ages 1 to 2 
years. Three non-randomised and/or inadequately controlled intervention studies (median 
UIC range: 69-109 µg/L) also investigates the effect of iodine supplementation on child 
neurodevelopment (Berbel et al. 2009; Velasco et al. 2009; Santiago et al. 2013). Two of 
these interventions found significantly higher psychomotor development scores (Velasco 
et al. 2009), gross motor and fine motor coordination quotients (Berbel et al. 2009) at 1.5 
years in children of women supplemented with 200 or 300 µg iodine/day from KI tablets. 
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Two prospective observational studies based on data from four sub-cohorts of the multi-
centre Spanish pregnancy cohort INMA reported significantly lower psychomotor 
development scores (around 5 points) at 1 year in the children of women who used iodine 
supplements in doses ≥150 µg/day vs 0-99 µg/day (taken as iodine-containing 
multivitamin/mineral or KI tablet) (Murcia et al. 2011; Rebagliato et al. 2013). This 
inverse association was also observed when the estimates from all four sub-cohorts were 
pooled (Rebagliato et al. 2013), however the overall estimate was driven by only two of 
the sub-cohorts (i.e., Valencia and Asturias) that initially showed a significant negative 
effect. In a later study by the same group, these negative effects on motor development 
were not confirmed at age 4-5 years in any of the sub-cohorts, or when the estimates were 
pooled (Murcia et al. 2018). A large Norwegian cohort study (MoBa) found no 
association in adjusted analyses of iodine-supplement use in doses >200 or 1-200 µg/day 
vs no use, with either fine or gross motor development at 3 years, as well as with the odds 
of not walking unaided at 17 months (Abel, Caspersen, et al. 2017).  
 
7.3.6.2 Mental development 
All three RCTs that assessed neurodevelopmental outcomes found no statistically 
significant difference between children born to mothers who were given iodine during 
pregnancy and those of the control group in terms of cognitive development and language 
at age 1 to 2 years (Brucker-Davis et al. 2015; Zhou et al. 2015; Gowachirapant et al. 
2017). Verbal IQ, performance IQ, full-scale IQ, processing speed, global executive 
function and auditory performance at 5.4 years were also not significantly different 
between children of supplemented mothers and those of the controls (Gowachirapant et 
al. 2017). In the non-RCT intervention studies,  there was no significant difference 
between groups in child mental development (Velasco et al. 2009; Santiago et al. 2013), 
language quotient (Berbel et al. 2009), or total development (Berbel et al. 2009; Santiago 
et al. 2013). 
 
None of the Spanish INMA studies showed a significant association of maternal iodine-
supplement use with child mental development at 1 year (Murcia et al. 2011; Rebagliato 
et al. 2013) or cognitive function at 4-5 years (Murcia et al. 2018). Additionally, there 
was no association of iodine-supplement use (mainly from multivitamin/mineral tablets) 
with language or communication delay in the Norwegian MoBa cohort (Abel, Caspersen, 
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et al. 2017). By contrast, a cohort study in Italian pregnant women reported significantly 
higher full-scale (by 13 points), verbal (by 14 points) and performance IQ (by 10 points) 
at ages from 6-12 years in children of  women who used iodised salt for at least two years 
pre-conception vs those of women who did not use iodised salt (Moleti et al. 2016).  
 
7.3.6.3 Behavioural development  
None of the three RCTs reported either a beneficial or a negative effect of iodine 
supplementation on child behaviour, including adaptive behaviours at 1.5 years (Zhou et 
al. 2015), social-emotional behaviours at 1.5 (Zhou et al. 2015) and 2 years (Brucker-
Davis et al. 2015) and total difficulties at 5.4 years (Gowachirapant et al. 2017). By 
contrast, non-RCT intervention studies reported a better socialisation quotient (Berbel et 
al. 2009) and a more favourable behaviour (Velasco et al. 2009) in children of iodine-
supplemented mothers than in those of mothers who were not supplemented during 
pregnancy.  
 
Behavioural outcomes were reported only in two of the observational studies, both using 
data from the Norwegian cohort MoBa, where iodine was used mainly in the form of 
multivitamin/mineral tablets (Abel, Caspersen, et al. 2017; Abel, Ystrom, et al. 2017). In 
these studies, children born to women with low habitual dietary iodine intake (<160 
µg/day) and who took a supplement containing up to 200 µg iodine/day, were more likely 
to have internalising (but not externalising) behavioural problems (Abel, Caspersen, et al. 
2017), had an increased risk of attention-deficit hyperactivity disorder (ADHD) diagnosis 
and a significantly higher ADHD symptom score at 8 years than those of non-supplement 
users (Abel, Ystrom, et al. 2017). 
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Table 7. 3  Summary of findings from 12 studies for the effect of iodine supplements during pregnancy on child neurodevelopment 
Study design Cognitive assessment Child neurodevelopment outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status 1 
Iodine exposure: 
dose 2, study group 
(start of supp) (n) 
Iodine 
vehicle/s 
Cognitive test (scales) 
Child age 
(years) at 
assessment 
Assessor  
RCTs (n=3)        
Brucker-Davis, 
2015, France 
117 µg/L A: 150 µg/d, MV + 
iodine (<10 wks.) (n=19) 
B: MV - iodine (n=25) 
MV tablet  Bayley Scales of 
Infant and Toddler 
Development – 3rd ed.  
2 years Blinded 
investigator & 
parent-reported  
No differences in composite scores or percentile ranks between grps for 
any of the outcomes: 
Cognitive development: 110 vs 110, NS; Language: 104.5 vs 100, NS; 
Motor development: 110 vs 110, NS; Social-emotional behaviours 
score: 100 vs 90, NS 
Zhou, 2015, 
Australia 
137 µg/L A: 150 µg/d, iodine 
(15.2 wks.) (n=29) 
B: placebo (n=30) 
KI tablet  Bayley Scales of 
Infant and Toddler 
Development – 3rd ed.  
1.5 years Parent-reported  No differences continuously or as % with delayed score (score < 85/70) 
between grps for any of the outcomes: 
Cognitive development: 99.4 vs 101.7, NS; Language: 97.2 vs 97.9, 
NS; Motor development: 93.9 vs 92.4, NS; Social-emotional 
behaviour: 105.8 vs 105.4, NS; Adaptive behaviours score: 105.2 vs 
103.5, NS 
Gowachirapant 
2017, Thailand  
& India 
131 µg/L A: 200 µg/d, iodine 
(10.8 wks.) (n=412)3 
B: placebo (n=420)3 
KI tablet  WPPSI - 3rd ed. 
BRIEF-P (executive 
function);    SDQ 
(behaviour); Acoustic 
testing; NBAS 
(newborn 
development); BSID – 
3rd ed. 
5.4 years  
(WPPSI, 
BRIEF-P, 
SDQ, 
Acoustic) 
 
6 wks. 
(NBAS)  
 
1 & 2 years 
(BSID) 
Clinical 
psychologist  
administered to 
the child 
(WPPSI, NBAS, 
& BSID) and to 
the mother of 
each child 
(BRIEF-P & 
SDQ) 
No differences continuously or as % with delayed score (score < 85) 
between grps for verbal, performance, full-scale IQ, processing speed 
and global executive function:  
Verbal IQ: 89.5 vs 90.2, NS; Performance IQ: 97.5 vs 99.1, NS; 
Processing speed: 113.4 vs 115.0, NS; Full-scale IQ: 94.9 vs 96.1, NS; 
Global execute function: 90.6 vs 91.5, NS; Total difficulties: 9.3 vs 
9.1, NS; Auditory performance: left (15.0 vs 13.3, NS) or right ear 
(13.3 vs 13.3, NS); New-born neurodevelopment: No difference 
overall; Infant cognitive development: No difference; Infant language: 
lower expressive language at 1 year in A vs B (14.8 vs 15.2); Infant 
motor development: No difference  
Intervention studies (n=3) 
Berbel, 2009, 
Spain4 
75 µg/L5 A: 153 µg/d, iodine (4-6 
wks.) (n=92)6 
B: 153 µg/d, iodine (12-
14 wks.) (n=102)6 
C: 153 µg/d, iodine 
(term) (n=151)6 
KI tablet 
(200 µg) 
Brunet-Lézine scale, 
revised 1997 (gross & 
fine motor 
coordination, language 
skills, socialisation) 
1.5 years Two blinded 
specialists  
Total development quotient: Higher in A vs B & C (101.8 vs 92.2 vs 
87.5); no difference between B vs C (NS); % with delayed performance 
(< 85) observed only in B & C (25% & 36.8%); Gross motor 
coordination quotient: Higher in A vs B & C (108 vs 91 vs 92)7; no 
difference between B vs C (NS) 
Fine motor coordination quotient: Higher in A vs B & C (110 vs 95 vs 
90)7; no difference between B vs C (NS); Language quotient: No 
difference between grps A vs B vs C (96 vs 92 vs 90)7; Socialisation 
quotient: Higher in A vs C only (102 vs 87)7; no diff. between A or C vs 
B (95, NS)7 
       (continued on next page) 
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Table 7. 3  Summary of findings from 12 studies for the effect of iodine supplements during pregnancy on child neurodevelopment (continued) 
Study design Cognitive assessment Child neurodevelopment outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status 1 
Iodine exposure: 
dose 2, study group 
(start of supp) (n) 
Iodine 
vehicle/s 
Cognitive test (scales) 
Child age 
(years) at 
assessment 
Assessor  
Intervention studies (continued) 
Velasco, 2009, 
Spain 
69 µg/L8 A: 300 µg/d, iodine (≤13 
wks.) (n=133) 
B: no iodine (n=61) 
KI tablet 
(300 µg) 
Bayley Scales of 
Infant Development 
(mental, motor and 
behaviour scales) 
0 - 1.5 years 
(mean per 
group A vs 
B: 5.5 vs 
12.4 
months) 
Independent 
researcher blind 
to the design 
sequence of the 
study 
Mental development: No difference between grps A vs B ( 109.2 vs 
108.9, NS); Psychomotor development: Higher in A vs B (108.7 vs 
102.7); highest values seen only in breast-fed children; Behaviour 
rating: Higher odds of a more similar or a higher mode than the mode 
for the age group in A vs B for reaction to persons (OR=6.93), reaction 
to the mother (OR=2.68), cooperation (OR=22.45), activity (OR=9.67), 
arousal (OR=5.87), and producing sounds (OR=10.24) 
Santiago, 2013, 
Spain 
109 µg/L A: 300 µg/d, iodine (<10 
wks.) (n=38)9 
B: 200 µg/d, iodine (<10 
wks.) (n=55)9 
C: n/a, IS (<10 wks.) 
(n=38)9 
KI tablet 
(300/ 
200 µg) 
& IS 
Bayley Scales of 
Infant Development  
(mental and motor 
scales) 
1 year 
(mean 12.8 
months) 
Independent 
investigator 
blind to the type 
of study design 
Mental development: No difference between grps A vs B vs C (104.5 
vs 101.3 vs 105.6, NS); Psychomotor development: No difference 
between grps A vs B vs C (98.6 vs 94.2 vs 100.9, NS); Total 
development: No difference between grps A vs B vs C (203.5 vs 195.5 
vs 206.9, NS) 
No difference in any of the outcomes when split by long-term IS-use (for 
at least 1 year pre-pregnancy) 
Prospective cohort studies (n=6) 
Murcia, 2011, 
Spain  
132 
µg/L10 
A: ≥150 µg/d, iodine-
user (≤13 or >13 wks.) 
(n=222) 
B: 100-149 µg/d, iodine-
user (≤13 or >13 wks.) 
(n=298) 
C: <100 µg/d, iodine-
user/non-user (≤13 or 
>13 wks.) (n=169) 
MV 
tablet 
Bayley Scales of 
Infant Development  
1 year 
(mean 12.3 
months) 
Trained 
psychologist  
Mental development: No difference between grps A vs B vs C (99.6 vs 
99.8 vs 100.7, NS); no association in adjusted analyses A vs C (+0.7 
points, NS); no difference in odds of MDI < 85 A vs C (OR=1.1, NS); 
Psychomotor development: Lower in A and B vs C (97.1 vs 100.6 vs 
102.6); negative association in adjusted analyses A vs C (-5.2 points); 
higher odds of PDI < 85 in A vs C (OR=1.8) with stronger association in 
girls vs boys (OR=4.0 vs 1.1) 
Rebagliato, 
2013, Spain  
125 µg/L A: ≥150 µg/d, iodine-
user (≤13 or >13 wks.) 
(n=598) 
B: 100-149 µg/d, iodine-
user (≤13 or >13 wks.) 
(n=228) 
C: <100 µg/d, iodine-
user/non-user (≤13 or 
>13 wks.) (n=675) 
KI or 
MV 
tablet 
Bayley Scales of 
Infant Development 
(mental & motor 
scales) 
1 year 
(mean 16 
months) 
Trained 
psychologist  
Mental development: No difference between grps A vs B vs C in all 
sub-cohorts (Asturias: 96.8 vs 97.9 vs 98.6, NS; Gipuzkoa: 98.3 vs 101.3 
vs 106.7, NS; Sabadell: 99.3 vs. 103.7 vs 98.3, NS); no association in 
adjusted pooled analyses A vs C (-1.8 points, NS); no difference in risk 
of MDI < 85 in adjusted pooled analyses in A vs C (OR=1.7, NS); 
Psychomotor development: No difference between grps A vs B vs C in 
Gipuzkoa and Sabadell (Gipuzkoa: 98.9 vs 98.9 vs 99.4, NS; Sabadell: 
101.4 vs 97.4 vs 99.4, NS); lower in A vs B & C in Asturias (Asturias: 
93.3 vs 100.5 vs 98.2); no association in adjusted pooled analyses A vs C 
(-0.9 points, NS); no difference in risk of PDI < 85 in adjusted pooled 
analyses in A vs C (OR=1.5, NS) 
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Table 7. 3  Summary of findings from 12 studies for the effect of iodine supplements during pregnancy on child neurodevelopment (continued) 
Study design Cognitive assessment Child neurodevelopment outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status 1 
Iodine exposure: 
dose 2, study group 
(start of supp) (n) 
Iodine 
vehicle/s 
Cognitive test (scales) 
Child age 
(years) at 
assessment 
Assessor  
Prospective cohort studies (continued) 
Moleti, 2016, 
Italy 
48 µg/L A: n/a, IS-user (min 24 
months pre-conception) 
(n=15) 
B: no IS-user (n=15) 
C: n/a, IS-user (+LT4) 
(n=15) 
D: n/a, no IS-user 
(+LT4) (pre-conception) 
(n=15) 
IS & 
LT4 
Wechsler Intelligence 
Scale for Children - 3rd 
ed. (full-scale, verbal 
and performance IQ) 
6-12 years 
(mean 9.4-
9.8 years) 
Trained 
psychologist 
(blind) 
Full-scale IQ: Higher in IS-users (A&C) vs non-users (B&D): A vs B 
(93.1 vs 81.7) & C vs D (96.1 vs 81.3); higher by 13 points in IS-users 
(A+C) vs non-users (B+D), regardless of LT4 treatment (94.5 vs 81.5); 
3-fold higher % with defective cognitive function in no IS vs IS-users 
(76.9 vs 23.1 %, OR=7.7); Verbal IQ: Higher in IS-users (A&C) vs 
non-users (B&D): A vs B (90.1 vs 80.3) & C vs D (97.2 vs 79.6); higher 
by 14 points in IS-users (A+C) vs non-users (B+D), regardless of LT4 
treatment (93.5 vs 79.6); Performance IQ: Higher in IS-users (A&C) vs 
non-users (B&D): A vs B (98.2 vs 87.3) & C vs D (97.4 vs 87.5); higher 
by 10 points in IS-users (A+C) vs non-users (B+D), regardless of LT4 
treatment (97.4 vs 87.4) 
Murcia, 2017, 
Spain 
123 µg/L A: ≥150 µg/d, iodine-
user (≤13 or >13 wks.) 
(n=610) 
B: 100-149 µg/d, iodine-
user (≤13 or >13 wks.) 
(n=457) 
C: <100 µg/d, iodine-
user/non-user (≤13 or 
>13 wks.) (n=719) 
KI or 
MV 
tablet 
McCarthy Scales of 
Children's Abilities                     
(cognitive and motor 
scales) 
4-5 years 
(mean 4.8 
years) 
Trained 
psychologist  
Cognitive function: No association with total scale or the subscales in 
adjusted pooled analyses A vs C (+0.3 points, NS) (mean scores per 
group not reported); no association of timing or dose of supplement; 
Motor function: No association with total scale or the subscales in 
adjusted pooled analyses A vs C (+1.2 points, NS) (mean scores per 
group not reported); no association of timing or dose of supplement; 
Abel, 2017, 
Norway 
122 
µg/24h11 
A: >200 µg/d, iodine-
user (0-26 wks. pre-
conception up to 22 
wks.) (n=1159) 
B: 1-200 µg/d, iodine-
user (0-26 wks. pre-
conception up to 22 
wks.) (n=14091) 
C: non-user (n=33047) 
MV 
tablet 
mainly 
Language delay scale 
by Dale et al., 2003; 
Ages and Stages 
Questionnaire 
(comm.& motor 
skills); Motor 
milestone (walking 
unaided); 
Child behaviour 
checklist  
3 years Mother-reported In women with habitual iodine intake ≥160 µg/d – NS associations with 
all outcomes; results for women with habitual intake <160 µg/d reported: 
Language delay: No association A & B vs C (OR=1.02 & 1.06, NS); 
Communication delay z score: No association A & B vs C (Beta=0.04 
& 0.00, NS); Internalising behaviour problems: Higher odds in B vs C 
(OR=1.14) & no difference for A vs C (OR=1.01, NS); Externalising 
behaviour problems: No association A & B vs C (OR=1.21 & 1.07, 
NS); Not walking at 17 months: No association in adjusted analyses A 
& B vs C (OR=1.15 & 1.05, NS); Fine motor delay z score: No 
association A & B vs C (Beta=0.00 & 0.00, NS); Gross motor delay z 
score: No association A & B vs C (Beta=0.02 & 0.0, NS) 
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Table 7. 3  Summary of findings from 12 studies for the effect of iodine supplements during pregnancy on child neurodevelopment (continued) 
Study design Cognitive assessment Child neurodevelopment outcomes 
First author, 
year (ref.), 
country 
Baseline 
iodine 
status 1 
Iodine exposure: 
dose 2, study group 
(start of supp) (n) 
Iodine 
vehicle/s 
Cognitive test (scales) 
Child age 
(years) at 
assessment 
Assessor  
Prospective cohort studies (continued) 
Abel, 2017, 
Norway 
61 µg/L12 A: >200 µg/d, (0-26 
wks. pre-conception up 
to 22 wks.) (n=1864) 
B: 1-200 µg/d (0-26 
wks. pre-conception up 
to 22 wks.) (n=21940) 
C: non-user (n=53360) 
MV 
tablet 
manly  
ADHD diagnosis; 
ADHD Rating Scale 
(ADHD symptom 
score) 
8 years  Patient registry 
(diagnosis) & 
mother-reported 
(symptoms) 
ADHD diagnosis: no difference in risk between A & B vs C; increased 
risk in B vs C only when supplement started 0-12 wks. in women with 
low habitual iodine intake <160 µg/d (HR=1.29);  
ADHD symptom score: higher in B vs C in some adjusted analyses 
(Beta=0.05) and in fully-adjusted analyses only when supplement start 0-
12 wks. (Beta=0.06) in women with iodine intake <160 µg/d 
1 Baseline iodine status was expressed as median urinary iodine concentration (UIC, µg/L), median urinary iodine-to-creatinine ratio (UI/Creat, µg/g) or median urinary iodine excretion (UIE, 
µg/24h) of the total sample. If baseline iodine status values were not available for the total sample, values for the control group/group who did not use iodine-containing supplements and/or 
iodised salt were used. 2 In some cases where the authors only provided the KI dose used but not the actual iodine content of the tablets, the dose was converted to µg of iodide to facilitate 
comparisons between studies. 3 Number of children with cognitive tests were smaller (e.g., for WPPSI A=159 vs B=154 and for BRIEF-P A=159 vs B=156) in Gowachirapant, 2017. 4 Women 
in this study were a very selected group (i.e., A=euthryoid vs B&C=hypothyroxinaemic in 1st trimester or at term, respectively) in Berbel, 2009.  5 Median UIC values at baseline were not 
reported and values measured at delivery/term were used for this study in Berbel, 2009. 6 Number of children with cognitive tests were smaller (e.g., A=13 vs B=12 vs C=19) in Berbel, 2009. 
7 Values were estimated from bar-charts from the original manuscript in Berbel, 2009. 8 Baseline iodine status value was based on a sub-group of women from the area who had miscarriage 
and were not included in this study in Velasco, 2009. 9 Number of children with cognitive tests were smaller (e.g., A=30 vs B=47 vs C=25) in Santiago, 2013. 10 Baseline iodine status value 
was extracted from Rebagliato, 2010, as the median UIC of the exact sample was not reported in this study in Murcia, 2011. 11 Baseline iodine status value for this study was based on 24-
hour UIE and iodine intake estimated from a food frequency questionnaire in Abel, 2017. 12 Baseline iodine status was measured only in a sub-set of 1950 women for this study and the 
presented total value is based only on women who did not use iodine-containing supplements in Abel, 2017. Abbreviations: ADHD, attention-deficit hyperactivity disorder; BRIEF-P, 
Behaviour Rating Inventory of Executive Function – Preschool Version; BSID, Bayley Scales of Infant Development; Ed., edition; Grp/s, group/s; HR, hazard ratio; IQ, intelligence quotient; 
IS, iodised salt; KI, potassium iodide; LT4, levothyroxine; MDI, Mental Development Index; MV, multivitamin supplement; N/A, data not available/reported; NBAS, Neonatal Behavioural 
Assessment Scale; NS, not statistically significant; OR, odds ratio; PDI, Psychomotor Development Index; RCTs, randomised controlled trials; Ref., reference; SDQ, Strengths and Difficulties 
Questionnaire; Supp, supplement; Wks., weeks; WPPSI, Wechsler Preschool and Primary Scale of Intelligence 
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7.4 Discussion 
7.4.1 Summary of evidence 
This systematic review has critically assessed the available evidence on the effects of 
iodine supplementation in mildly-to-moderately iodine-deficient pregnant women on 
maternal and infant thyroid function and child neurodevelopment. There was a lack of 
RCT evidence and many observational studies were classified as of poor quality, 
particularly the cross-sectional studies, where the study groups were not comparable and 
confounding factors were mostly not controlled for. In most studies, maternal iodine 
supplementation had no effect on maternal TSH and FT4, however, there was some 
evidence of a reduction in maternal serum Tg. While cross-sectional differences in 
maternal thyroid volume were generally not found, there was some evidence of a 
preventative or diminishing effect of iodine supplementation on the increase in thyroid 
volume with advancing gestation. Iodine supplements did not have an effect on markers 
of maternal thyroid autoimmunity (e.g., Tg-Ab and TPO-Ab) or the occurrence, severity 
and type of maternal PPTD. Most studies showed no effect of maternal iodine 
supplementation on infant thyroid function (TSH and FT4) or markers of thyroid 
autoimmunity in cord blood, though some studies showed a reduction in infant thyroid 
volume and cord-blood Tg.  
 
Overall there was a lack of data on child cognitive outcomes with only one adequately-
powered RCT (Gowachirapant et al. 2017); that RCT showed no effect on child motor or 
mental development, or behaviour. The other two RCTs were underpowered because one 
failed to achieve the required sample size after it was aborted early due to withdrawal of 
funding support (Zhou et al. 2015), while the other trial was set out as a pilot and included 
only around 50% of the original cohort of 86 mother-child pairs (Brucker-Davis et al. 
2015). Overall, results from cohort studies and non-RCT interventions showed no effect 
of maternal iodine supplements on mental development (Berbel et al. 2009; Velasco et 
al. 2009; Murcia et al. 2011; Rebagliato et al. 2013; Santiago et al. 2013; Abel, 
Caspersen, et al. 2017; Murcia et al. 2018), but there were inconsistent effects, both 
harmful (Murcia et al. 2011; Rebagliato et al. 2013) and beneficial (Berbel et al. 2009; 
Velasco et al. 2009), respectively, on motor development. The effects on  child behaviour 
were mixed; non-RCT interventions showed positive effects on externalising-type 
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behaviour (Berbel et al. 2009; Velasco et al. 2009), while cohort studies reported negative 
associations with internalising behaviour (Abel, Caspersen, et al. 2017) and ADHD 
symptoms/diagnosis (Abel, Ystrom, et al. 2017) in those with low iodine intake (though 
after adjustment for multiple testing and using matched controls, these effects were 
attenuated).  
 
Two observational studies, published after the literature search for this review, also 
showed no beneficial effects of iodine-supplement use in pregnancy on cognition and 
language skills in infancy and toddlerhood (Markhus et al. 2018), and child language and 
learning abilities at 8 years (Abel, Brandlistuen, et al. 2018). 
 
7.4.2 Explanation of results 
7.4.2.1 Pre-pregnancy/baseline iodine status and the importance of iodine stores 
The lack of effects of maternal iodine supplementation on child cognitive development 
might be explained by the ability of mildly-to-moderately iodine-deficient mothers to 
maintain normal thyroid hormone levels despite the increased demands during pregnancy. 
The thyroid might be able to adapt to maternal mild-to-moderate iodine deficiency by 
maintaining the euthryoid status of the mother; this could explain the lack of effect on 
thyroid function in most studies. This adaptation to low iodine intake, however, is 
achieved through enhanced thyroidal stimulation (Glinoer 2004), which may put a strain 
on the maternal thyroid, resulting in an elevation of serum thyroglobulin and 
progressively, goitrogenesis. Indeed in most studies, iodine supplementation resulted in 
a reduction in serum thyroglobulin (i.e., it might have alleviated the stress on the thyroid) 
but there was mostly no effect on maternal thyroid volume, possibly because this marker 
responds only slowly to changes in iodine intake (Zimmermann 2008). 
 
The ability of the thyroid to adapt when iodine intake is insufficient is possibly dependent 
on the maternal intrathyroidal iodine stores accumulated  pre-pregnancy  (Glinoer 2004). 
Because the early stages of pregnancy are a critical time for adequate iodine supply (Levie 
et al. 2019), supplementation upon confirmation of pregnancy might be too late. Indeed, 
a series of cohort studies (Moleti et al. 2008; Moleti et al. 2011; Moleti et al. 2016) in an 
Italian area of mild-to-moderate iodine deficiency has shown that mothers who used 
iodised salt for at least two years before they became pregnant, thus likely securing their 
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iodine stores, had lower TSH and higher FT4 during pregnancy than those who did not 
use iodised salt, or those who started using it only when they became pregnant. 
Furthermore, there was a beneficial effect on the IQ scores of children whose mothers 
used iodised salt long before conception, though the sample size in this study was very 
small (Moleti et al. 2016). 
 
The pre-pregnancy iodine status might have also played a role in the three RCTs with 
child neurodevelopment outcomes. All three trials were conducted in an area with 
baseline iodine status indicative of mild deficiency; the median UIC in all trials was above 
100 µg/L (range: 117-137 µg/L) (Brucker-Davis et al. 2015; Zhou et al. 2015; 
Gowachirapant et al. 2017). In the only adequately-powered RCT, both countries from 
which pregnant women were recruited had universal salt iodisation programmes enabling 
women to store iodine that they could draw on when pregnant; this might have affected 
the null outcome in this study (Gowachirapant et al., 2017). It has been proposed 
previously that iodine deficiency in pregnancy becomes significant when intake falls 
below 100 µg/day (Glinoer 2004).  
 
An abrupt increase in iodine intake during pregnancy might also have negative effects, 
especially in those with low iodine intake prior to pregnancy. Women who started taking 
iodine supplements (Moleti et al. 2011) or iodised salt (Moleti et al. 2008) upon becoming 
pregnant had higher TSH and lower FT4 than women who had been using iodised salt 
pre-pregnancy. Similar results were also found in a study that was published after the 
search for this review, where introduction of iodine-containing supplements at 13 weeks 
was associated with lower FT4, while longer term use was not (Abel, Korevaar, et al. 
2018). Some negative effects were also seen on behaviour, including an increased risk of 
ADHD diagnosis and a higher ADHD symptom score when the supplement was started 
during pregnancy only in women with habitually low iodine intake (below 160 µg/day) 
(Abel, Ystrom, et al. 2017). Iodine supplement use vs no use during pregnancy was also 
associated with higher odds of internalising behaviour problems in children of women 
with daily iodine intake <160 µg but not in those with intake ≥160 µg (Abel, Caspersen, 
et al. 2017). 
 
Differences in maternal baseline iodine status might also partly explain the inconsistent 
results on maternal and infant thyroid function. For instance, iodine supplementation 
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lowered cord-blood Tg, only in the studies with a baseline median UIC < 100 µg/L (range: 
35-51 µg/L) (Pedersen et al. 1993; Nøhr and Laurberg 2000) but not in the studies with a 
median UIC >100 µg/L (range: 117-137 µg/L) (Brucker-Davis et al. 2015; Zhou et al. 
2015). Similarly, maternal iodine supplementation resulted in a lower infant thyroid 
volume in two studies with a median UIC < 100 µg/L (range: 48-64 µg/L) (Liesenkötter 
et al. 1996; Klett et al. 1999) but not in one study with a median UIC of 109 µg/L 
(Santiago et al. 2013). In observational studies where the baseline UIC was > 100 µg/L 
(range: 130-138 µg/L) (Rebagliato et al. 2010; Menéndez Torre et al. 2014; Katko et al. 
2017), mothers who used iodine supplements had higher TSH and/or a higher proportion 
with elevated TSH. The RCTs with baseline UIC >100 µg/L found mostly no difference 
in maternal TSH or FT4 between the iodine and control groups (Brucker-Davis et al. 2013; 
Brucker-Davis et al. 2015; Gowachirapant et al. 2017). By contrast, in several RCTs with 
median UIC < 100 µg/L (range: 51-54 µg/L) (Silva and Silva 1981; Pedersen et al. 1993; 
Nøhr et al. 2000), iodine supplementation prevented or reduced the increase in TSH over 
the course of pregnancy. 
 
7.4.2.2 Type, dose and timing of supplementation  
In a total of 12 studies, iodine was part of a multivitamin/mineral supplement (this was 
the most studied from of iodine supplementation), making it hard to isolate its effect from 
other components or their interaction. Only three RCTs In the observational studies that 
have shown negative effects of iodine supplementation on infant psychomotor 
development (Murcia et al. 2011; Rebagliato et al. 2013) and behaviour (Abel, Caspersen, 
et al. 2017; Abel, Ystrom, et al. 2017), iodine was supplied mostly as 
multivitamin/mineral tablets. None of the studies that looked only at specific KI 
supplements have reported negative effects on child neurodevelopment. Regardless of 
supplement type, in observational studies looking at supplement use, it is important to 
consider the behaviours associated with supplement taking that could bias the results in 
either direction (e.g., worried/health-seeking behaviour of the mother). Indeed, the 
negative effects of maternal iodine-supplement use on child ADHD symptoms and 
diagnosis were attenuated when the control group in the analyses was restricted to 
mothers who used supplements without iodine (matched controls) (Abel, Ystrom, et al. 
2017). 
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Most studies did not address the potential effects of co-deficiencies (e.g., other nutrients 
that may have an effect on thyroid function and/or cognition). Three RCTs compared the 
effect of iodine-containing multivitamin/mineral tablets to multivitamin/mineral tablets 
without iodine to account for the effect of other nutrients (Nøhr et al. 2000; Brucker-
Davis et al. 2013; Brucker-Davis et al. 2015); in one of these studies the 
multivitamin/mineral tablets also contained 50 µg selenium (also important for normal 
thyroid function) (Nøhr et al. 2000). 
 
Some observational studies have shown a negative effect of iodine supplement in doses 
≥150 µg/day on motor development (Murcia et al. 2011; Rebagliato et al. 2013) and ≥200 
µg/day on behaviour (Abel, Caspersen, et al. 2017; Abel, Ystrom, et al. 2017). In those 
studies, however, iodine was mainly from multivitamin/mineral tablets. In RCTs, a dose 
of 200 µg/day as KI was not associated with any negative effects. In a number of studies, 
it was unclear whether the iodine dose was expressed as µg KI or µg of iodide (from KI); 
as only 76% of KI is iodide (Iodine Global Network 2019b), the dose must be clearly 
specified in future studies.  
 
An intervention study administering iodine supplementation at different times during 
pregnancy found that supplementation at 4-6 weeks was more effective in improving 
infant neurodevelopment than supplementation at 12-14 weeks or later (Berbel et al. 
2009). In that study, however, women in the group with the earliest administration of 
supplement were euthyroid at baseline, while the other two groups with later 
administration were hypothyroxinaemic, thus the effect of timing of iodine 
supplementation cannot be distinguished from that of maternal baseline FT4 
concentrations (Berbel et al. 2009). Two RCTs (Brucker-Davis et al. 2015; 
Gowachirapant et al. 2017) and one non-RCT intervention study (Santiago et al. 2013) 
that administered iodine in the first trimester (around 10 weeks) showed no effect on child 
development, while one non-RCT intervention study (Velasco et al. 2009) reported a 
beneficial effect. Although all these studies administered iodine early in pregnancy, they 
showed mixed results which might be explained by pre-pregnancy iodine status or by a 
lag period before any benefits of iodine supplementation are seen (Glinoer 2004). 
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7.4.2.3 Child cognitive assessment  
To assess adequately the consequences of iodine deficiency, it is crucial to know the 
specific developmental events that occur at the time of exposure to deficiency and that 
are thyroid-hormone dependent (i.e., could be affected by maternal iodine deficiency) 
(Zoeller and Rovet 2004). None of the studies that investigated iodine supplementation 
during pregnancy found an effect on child mental development. This could be either 
because there is indeed no effect or because the outcomes measured were insufficiently 
specific. In most studies, child neurodevelopment was measured using global 
developmental assessments, such as the Bayley Scales of Infant Development (BSID). 
Global cognitive tests administered in infancy (i.e., particularly before 2 years) have low 
predictive capacity for childhood intelligence and behaviour (Peyre et al. 2017; Gould et 
al. 2019). In INMA, the negative effects of maternal iodine supplementation on child 
motor development (measured with BSID) at 1 year (Murcia et al. 2011; Rebagliato et 
al. 2013) were not confirmed when children were older (4-5 years) (Murcia et al. 2018). 
Although cognitive tests may be more valid when administered at an older age, there are 
also more confounding factors that need to be considered (e.g., social, environmental and 
nutritional) (Slater 1995; Bryan et al. 2004). Knowledge of the development of specific 
brain systems that are vulnerable to iodine deficiency might enable more iodine-sensitive 
cognitive tasks  to be designed, such as outcomes related to infant visual information 
processing (e.g., attention, habituation, recognition memory) (Bell et al. 2016). 
 
7.4.3 Safety of iodine supplementation  
Based on the current evidence, iodine supplementation is not expected to trigger maternal 
or infant autoimmunity in areas of mild-to-moderate iodine deficiency, as there was no 
evidence of a detrimental effect on markers of thyroid autoimmunity in the mother or in 
cord-blood. One study showed that iodine supplementation was safe in TPO-Ab positive 
women and was not associated with the incidence, severity or duration of PPTD (Nøhr et 
al. 2000). 
 
Some studies reported an elevated TSH in newborns of iodine-supplemented mothers 
(Nøhr and Laurberg 2000; Velasco et al. 2009), which may be due to an inhibitory effect 
of iodine on the fetal thyroid gland and not of clinical significance (Nøhr and Laurberg 
2000) or as a result of a neonatal adaptation mechanism to ensure adequate FT4 (Velasco 
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et al. 2009). Elevated TSH was also reported in the mothers who took iodine supplements 
but this was only evident in a few studies where the baseline iodine status was relatively 
high (Rebagliato et al. 2010; Menéndez Torre et al. 2014; Katko et al. 2017). Some 
observational studies have also shown negative effects on child psychomotor 
development (Murcia et al. 2011; Rebagliato et al. 2013) and behaviour (Abel, Caspersen, 
et al. 2017; Abel, Ystrom, et al. 2017). However, 200 µg iodine/day as KI in an RCT 
(Gowachirapant et al. 2017) did not result in any negative effects and therefore seems 
safe; though as a considerable proportion of women were probably iodine-sufficient at 
baseline, further evidence of safety of iodine supplementation is needed in areas of 
moderate deficiency. 
 
7.4.4 Current recommendations in light of the evidence  
There are inconsistencies between different authorities in the recommendations for iodine 
supplementation during pregnancy. Both the European and the American Thyroid 
Associations recommend iodine supplementation with 150 µg/day for all women who are 
currently pregnant or planning a pregnancy (Lazarus et al. 2014; Alexander et al. 2017). 
By contrast, the World Health Organisation (WHO) and the United Nations Children's 
Fund (UNICEF) jointly recommend 250 µg iodine/day for pregnant women only in areas 
with low iodised-salt coverage (WHO and UNICEF 2007). There are also disparities on 
a national level; for instance, the United Kingdom (UK) has no specific recommendations 
for iodine supplementation in pregnancy (Bath 2019), while Australia and New Zealand 
have a mandatory iodine fortification programme and the local Medical Research Council 
recommends 150 µg iodine/day for all pregnant women or those considering becoming 
pregnant (The National Health and Medical Research Council 2010).  
 
Most of the evidence reviewed comes from relatively poor-quality studies, thus current 
recommendations for iodine supplementation in areas of mild-to-moderate deficiency are 
based on weak evidence. As the role of iodine supplementation in pregnancy is still 
unclear, pregnant women should ensure they consume enough iodine and if necessary, 
slowly increase their iodine intake and avoid abrupt changes. Health professionals should 
also be aware of the importance of iodine and consider iodine intake when discussing the 
foods to avoid during pregnancy (e.g., fish). As it is becoming increasingly clear that the 
role of pre-pregnancy iodine status is important, women of childbearing age who are 
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considering a pregnancy should ensure their usual iodine intake is sufficient and be 
mindful of their food choices (e.g., those who use unfortified plant-based milk should 
think about increasing their intake of other good sources of iodine and/or opting for 
fortified plant-based milks). The food industry also has an important role in ensuring 
sufficient iodine intake in the population (e.g., by fortifying plant-based milks with iodine 
and using iodised salt in place of non-iodised salt in their products). 
 
Most iodine-supplementation RCTs investigated the effects on thyroid volume and 
function but not child neurodevelopment. With only one adequately-powered RCTs with 
child-development outcomes (Gowachirapant et al. 2017), there is a lack of good-quality 
evidence on the effects of iodine supplementation on child neurodevelopment. 
Furthermore, there is no evidence on the effects of iodine supplementation on child 
neurodevelopment in moderate iodine deficiency (i.e., UIC < 100 µg/L). Considering the 
possible explanation of the mixed findings from previous studies discussed above 
(Section 7.4.2), a future RCT should be conducted in an area of moderate iodine 
deficiency (i.e., median UIC < 100 µg/L) and recruit women in early pregnancy (i.e., no 
later than the first trimester). Children should be followed up to at least three years to be 
able to use child cognitive tests with better predictive capacity of later development (i.e., 
IQ scores). To detect a meaningful difference in child IQ of at least three points with 95 
% power, a sample size of 651 per group would be required. Considering the importance 
of maternal pre-pregnancy iodine stores, a measure of maternal iodine intake/status pre-
pregnancy would be useful (e.g., dietary questionnaires or thyroglobulin measurements). 
Although more good-quality evidence is needed, iodine supplementation trials may be 
seen as unethical in areas of mild-to-moderate iodine deficiency due to widespread 
recommendation of iodine supplements; conducting such trials becomes less feasible as 
countries increasingly introduce these recommendations.  
 
7.4.5 Strengths and limitations 
This systematic review provides an updated synthesis of all the evidence that is currently 
available. It includes new observational evidence and three new RCTs that were not 
included in a previous review in mild-to-moderate iodine deficiency (Taylor et al. 2014). 
Previous systematic reviews were limited to RCTs (Zhou et al. 2013; Harding et al. 2017), 
while other intervention and observational studies were included in this review, in an 
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attempt to provide a more comprehensive summary of the evidence. Although cross-
sectional studies were of relatively low quality, they can be useful in identifying common 
trends.  
 
There are some limitations that need to be considered. Only one electronic database (i.e., 
PubMed) was searched, so additional relevant studies might have been missed. The search 
was restricted to English language, perhaps missing some relevant studies published in 
languages other than English. To identify studies in areas of mild-to-moderate iodine 
deficiency, non-validated cut-offs were used (UIC of 50-149 µg/L) (Zimmermann 2007), 
and thus studies labelled as being conducted in such areas but with baseline median UIC 
outside this pre-defined range (i.e., below 50 µg/L) might have been omitted.  
 
In terms of comparability between the included studies, along with the different cognitive 
assessment tools used, it is also important to note that different assays with different limits 
of detection were used for the measurement of maternal and infant thyroid markers across 
the different studies. Although all included studies used the same equation to calculate 
thyroid volume, two different correction factors were used (i.e., 0.524 or 0.479); thyroid-
volume calculations based on these two factors have been shown to perform differently 
when compared to thyroid-volume measurements using computed tomography (CT) 
scans (Shabana et al. 2006). 
 
 
7.5 Conclusion 
There is insufficient, good-quality evidence to support current recommendations for 
iodine supplementation during pregnancy in areas of mild-to-moderate iodine deficiency. 
There is a need for more studies in such areas, particularly for well-designed clinical trials 
with child cognitive outcomes in areas of moderate deficiency (i.e., median UIC < 100 
µg/L). Considering the potential importance of maternal thyroidal iodine stores, future 
trials investigating the effects of iodine supplementation should include measures of pre-
pregnancy iodine status, for example, a dietary questionnaire and/or measures of 
thyroglobulin allowing for analysis of the interaction between iodine supplementation 
and pre-pregnancy status. The potential for conducting iodine supplementation trials in 
the future is likely to be limited by ethical and feasibility considerations. 
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Chapter 8                                             
Thesis findings and future work  
 
8.1 Thesis key findings and their implications 
The research work presented in this thesis contributes to the further understanding of 
several aspects of iodine nutrition in pregnancy and the findings have implications for 
public-health policy and future research. 
 
8.1.1 Achieving adequate iodine nutrition in pregnancy  
Because of the higher iodine requirements in pregnancy (WHO 2007a), achieving 
adequate iodine nutrition in this population group can be challenging. In Chapter 3, milk 
and dairy products were found to be an important common dietary determinant of iodine 
status in three pregnant populations, i.e., populations from the United Kingdom (UK), the 
Netherlands and Spain. Country-specific dietary determinants were also found which 
highlighted the variability between countries in the main contributors to population iodine 
status. Although some foods are good iodine sources, if they are not widely consumed, 
they will have only minimal contribution to population iodine status. These findings 
suggest that knowledge of the dietary determinants of population iodine status and 
monitoring of changes in the consumption patterns of iodine-rich foods are important as 
this information might help to identify potential shifts in population iodine status. This 
might be particularly important in populations such as that of the UK without a formal 
universal salt-iodisation policy, as individual food choice is the main determinant of 
iodine intake and this might have implications for certain population groups. For instance, 
over the last 40 years, there has been a decline in milk consumption in the UK, as 
demonstrated by data on milk purchase (Department for Environment Food & Rural 
Affairs 2017). Although consumption of cow’s milk is much higher that of other milks, 
in recent years there has been a rise in the consumption of plant-based cow’s milk-
alternative drinks (e.g., soya, almond, coconut, oat and other drinks), with a 38% increase 
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in the purchase of plant-based drinks in the period 2010-2015 (Chambers 2018). These 
milk-alternatives, however, unless fortified, have a lower iodine content than cow’s milk 
– median 7.3 µg/kg vs 438 µg/kg, respectively (Bath, Hill, et al. 2017). Such changes in 
the pattern of food consumption might jeopardise the iodine status of the UK population.  
This is particularly the case in population groups that are more likely to avoid cow’s milk 
or substitute it with lower-iodine milk-alternatives (e.g., young women, vegans, health-
conscious individuals, or individuals with milk allergy or intolerance) (Chambers 2018), 
without increasing their iodine intake from other dietary sources.  
 
Given the difficulty in meeting the increased iodine requirement of pregnancy and the 
deleterious effects of even maternal mild-to-moderate iodine deficiency on child 
cognition, as demonstrated in Chapter 6 and in previous observational studies (van Mil et 
al. 2012; Bath, Steer, et al. 2013; Hynes et al. 2013; Hynes et al. 2017; Markhus et al. 
2018; Murcia et al. 2018; Levie et al. 2019), iodine supplementation may be necessary in 
this population group. However, the role of iodine supplements in mildly-to-moderately 
iodine-deficient pregnant women is not clear. In Chapter 7, the benefits and safety of 
iodine supplementation in pregnancy on thyroid function and child cognition were 
investigated by reviewing systematically the most up-to-date literature. The evidence on 
iodine supplementation in pregnancy was found to be insufficient to support current 
recommendations in some countries such as New Zealand and Australia (The National 
Health and Medical Research Council 2010). Without confirmation of a beneficial role 
of iodine supplementation in pregnancy and in the absence of salt-iodisation programmes 
in countries such as the UK, it is important that pregnant women are given information 
on how to meet their higher iodine requirements through diet. An RCT administering 
three litres of milk per week to women of childbearing age in Northern Ireland, resulted 
in a significantly higher UIC in the intervention group vs control after six and 12 weeks 
of intervention, and significantly greater changes in UIC from baseline in the intervention 
group compared with the control (O’Kane et al. 2018); this suggests that milk and dairy 
products could be used as a means of targeted interventions to improve iodine intake in 
those populations who can tolerate milk. Considering the potential importance of 
thyroidal iodine stores (Glinoer 2004), the pre-conceptional period may be an important 
window of opportunity to ensure optimal iodine stores in women of childbearing age prior 
to pregnancy. However, lack of awareness of the importance of iodine and poor 
knowledge of its dietary sources have been reported in surveys of pregnant women 
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residing in the UK (Combet et al. 2015), Australia (Charlton et al. 2012) and Norway 
(Garnweidner-Holme et al. 2017). Poor knowledge of iodine nutrition has also been 
reported in women of childbearing age (O’Kane et al. 2016). It is therefore important to 
understand these population groups more in-depth (e.g., their perceptions of available 
dietary advice, attitudes and experiences) and identify the barriers to achieving an 
adequate iodine intake (e.g., the barriers to consumption of good iodine sources such as 
milk and fish). For instance, a recent qualitative study showed that pregnant women found 
the pregnancy dietary guidelines confusing and that there were more barriers to the 
consumption of fish and seafood in pregnancy as compared to the consumption of dairy 
(Bouga et al. 2018). It is important that health professionals working with pregnant 
women and women of childbearing age are aware of the importance of iodine and think 
about iodine intake when discussing foods to avoid during pregnancy. As evidence 
suggests that abrupt increases in iodine intake should be avoided, it is important to ensure 
women of childbearing age enter pregnancy with good iodine stores. This could be 
achieved by public-health campaigns to raise the public profile of iodine and educate 
women of the good iodine food sources and even more importantly, of the food swaps, if 
excluding certain food groups (e.g., those who do not consume or avoid milk and dairy 
should increase their intake of other good source of iodine and/or opt for fortified plant-
based milks; vegans may need to consider fortified foods and dietary supplements).  
 
The apparent low level of awareness is of public-health concern, as the risks of iodine 
deficiency in pregnant women extend to limited potential of their offspring [e.g., lower 
intelligence quotient (IQ) and behavioural disorders] (Bath 2019; Hay et al. 2019). A 
slight decrease in population average IQ has an effect on economic growth; an increase 
in population average IQ by one point was associated with an annual increase of 0.11% 
in gross domestic product (GDP) per person (Jones and Schneider 2006). For instance, 
the GDP per head in the UK was £29,670 in 2017 (Office for National Statistics 2018); 
based on published data, a one-point decrease in a nation’s average IQ would amount to 
a £3,264 lower GDP per person for that year (Jones and Schneider 2006). There is a need 
for public-health strategies aimed at increasing awareness of the importance of iodine 
nutrition and educating pregnant women and women of reproductive age on how to 
achieve adequate iodine intake to ensure optimal development of their children who will 
be contributing to the future economy.  
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While there is not enough evidence in favour of or against iodine supplementation in 
pregnancy, it is clear that iodised-salt programmes are an effective way to ensure adequate 
iodine intake in populations (WHO 2007a). In Chapter 3, the highest median urinary 
iodine concentration (UIC) was observed in pregnant women from the Netherlands, 
followed by women from Spain and the lowest in women from the UK. These differences 
in iodine status could relate to variability in iodised-salt availability and use. Cereal and 
cereal products were found to be a significant determinant of iodine status in the 
Netherlands – an association probably driven by bread which is fortified with iodised salt 
in the Netherlands (Verkaik-Kloosterman et al. 2012). The results also showed that 
iodised-salt intake was the strongest dietary determinant of iodine status in women from 
Spain. By contrast, the UK has never had a salt-iodisation policy (Phillips 1997); 
nowadays, most salt available in the UK does not contain iodine and the iodine 
concentration of the main iodised-salt brand is low (Bath, Button, et al. 2013). The 
findings in Chapter 3 suggest that iodised salt consumed either discretionarily (e.g., as 
table salt in Spain) or as part of processed foods (e.g., in bread in the Netherlands) is an 
important factor with a large influence on iodine status. A push to increase iodised-salt 
supply and availability in the UK is needed, however, given the recommendation for salt-
reduction (WHO 2012), salt should not be solely relied on to meet iodine requirements. 
Furthermore, as in developed countries most of the salt (more than 75%) is consumed 
from processed foods (Brown et al. 2009), commitment from the food industry is key for 
the effective implementation of salt iodisation; this is another challenge (Zimmermann 
2010; WHO 2014). For instance, although iodised salt was strongly associated with 
urinary iodine concentration in women from Spain, the median UIC of that population 
was still lower than that of women from the Netherlands. Iodised salt is available in both 
countries; however only a 16% penetration rate has been reported in Spanish households, 
whereas in the Netherlands, all baked goods are fortified with iodised salt and the iodised-
salt penetration rate both in households and the food industry (mainly bread-making) has 
been estimated as 60% and 70%, respectively (WHO 2007b). Although the addition of 
iodised salt to food does not change its taste and smell (WHO 2014), the food industry 
may be reluctant to use it because of consumer misconceptions. The implementation of 
iodine fortification programmes requires regular monitoring of population iodine status 
and salt consumption since there could be a risk of excessive amounts in some population 
groups (e.g., children with high milk intakes). Taken together these challenges probably 
contribute to the reluctance of countries to introduce iodine fortification programmes.  
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8.1.2 Assessment of iodine status in pregnancy 
Currently, there is no validated biomarker of iodine status in individuals (Pearce and 
Caldwell 2016). As a result of substantial individual variation in day-to-day iodine intake 
and hydration status (Andersen et al. 2008; Vejbjerg et al. 2009; König et al. 2011), the 
most widely used indicator of population iodine status (i.e., UIC) is of limited use for the 
assessment of iodine status in individuals. The lack of an individual biomarker of iodine 
status limits public-health monitoring and research. This issue is particularly important 
for pregnant women who are the most vulnerable to iodine deficiency. Although UIC is 
the most widely used measure of iodine status in public-health monitoring and research, 
the effect of pregnancy on this measure is not clear. In Chapter 4, the gestational changes 
in urinary iodine concentration were explored longitudinally using multiple urinary-
iodine concentration measurements during pregnancy. This study showed that urinary 
iodine concentration [measured as UIC and urinary iodine-to-creatinine ratio (UI/Creat)] 
increased with advancing pregnancy. These findings suggested that one urinary-iodine 
measurement in pregnancy does not reflect iodine status during the entire pregnancy; this 
emphasises the need to make multiple urinary-iodine measurements. Repeat measures of 
urinary iodine concentration could provide information about iodine intake at different 
gestational time-points or, if collected closer together, could improve the accuracy of the 
estimation of individual iodine status. For instance, it has been shown that two 
measurements of spot-UIC will estimate individual iodine status with a 50% precision, 
while 14 repeat spot-UIC measurements will estimate individual iodine status with a 20% 
precision (König et al. 2011). 
 
As a great deal of research is directed towards a better understanding of the effects of 
maternal iodine deficiency on child neurodevelopment, an accurate assessment of 
maternal iodine status in pregnancy would be of great value. In Chapter 6, multiple spot-
urine iodine measurements were used in an attempt to gain a better proxy for pregnancy 
iodine status. Low maternal iodine status at multiple gestational time-points was found to 
be associated with lower child non-verbal IQ at 8 years. These findings were in contrast 
to the results from previous studies that showed an association with verbal, but not with 
non-verbal, IQ (Bath, Steer, et al. 2013; Levie et al. 2019). The previous studies referred 
to were mainly focused on early pregnancy as an important time-window of susceptibility 
to the potential negative effects of maternal iodine deficiency; they also used a single 
spot-urine iodine measurement as the exposure. The difference in findings could be 
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because the multiple measures used in Chapter 6 also carried information about maternal 
iodine intake in the later stages of pregnancy when iodine deficiency may have had an 
effect on cognitive functions other than those affected by deficiency earlier in pregnancy.  
 
A very recent study in adult women has shown that to estimate individual iodine status 
with ±5% precision, around 500 24-hour urine samples are needed from an individual 
(Chen et al. 2019). Collection of a large number of urine samples from each individual 
can be impractical and costly in large studies and could also introduce selection bias. The 
disadvantages of using urinary-iodine measurements to assess iodine status in the general 
population and in pregnancy, coupled with the fact that they provide limited information 
about thyroid function have directed attention to other biomarkers indicative of longer-
term iodine nutrition and thyroid function, such as the thyroid-specific protein, 
thyroglobulin (Tg). In Chapter 5, the usefulness of Tg as a biomarker of iodine status 
during pregnancy was investigated in one iodine-sufficient and one mildly-to-moderately 
iodine-deficient population. In that study, Tg was found to be negatively associated with 
iodine status in pregnancy in each population, with a higher Tg concentration in the 
groups of women with lower UI/Creat. However, the results indicated that Tg measured 
in the first trimester was not able to distinguish between an overall iodine-sufficient 
population and a mildly-to-moderately iodine-deficient population, as the median Tg 
concentration was similar between the two. Considering the important role of thyroidal 
iodine stores with restricted iodine intake in pregnancy, in Chapter 5, it was hypothesised 
that Tg could be a more sensitive measure of iodine status in a group of pregnant women 
if measured later in pregnancy. If iodine intake is low in pregnancy, iodine stores will 
become progressively depleted resulting in a progressive rise in serum Tg concertation 
(Glinoer 2004); this would therefore result in a more apparent difference in median Tg 
between an iodine-sufficient and a mildly-to-moderately iodine-deficient group of 
pregnant women. Indeed, a recent randomised controlled trial (RCT) in mildly-to-
moderately iodine-deficient pregnant women in Italy showed that Tg increased from the 
second trimester onwards in the placebo group but not in the iodine-supplemented group 
(Censi et al. 2019).  
 
Although there is a growing body of evidence that Tg could be a sensitive marker of long-
term iodine nutrition in groups of children (Zimmermann et al. 2013), adults (Chong et 
al. 2015; Ma et al. 2016) and pregnant women (Bath, Pop, et al. 2017; Stinca et al. 2017; 
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Censi et al. 2019), its usefulness for individuals is unknown. In Chapter 5, a very weak 
correlation between serum Tg and spot-UI/Creat was observed; however, as discussed 
above, spot-urine iodine measurements are not indicative of individual long-term iodine 
intake and a single spot-UI/Creat may not be an appropriate measure. It should also be 
noted that Tg is a non-specific marker of iodine nutrition and is also dependent on thyroid 
activity (Laurberg et al. 2007). For instance, in the context of pregnancy, physiological 
changes unrelated to iodine status could increase serum Tg, such as an increased thyroid 
secretory activity and a peak in human chorionic gonadotropin (hCG) at the end of the 
first trimester (Laurberg et al. 2007; Koukkou et al. 2016). The interference from 
thyroglobulin antibodies (Tg-Ab) and the large inter-assay variability, even with the use 
of certified reference materials (CRMs) are other limitations to the use of Tg as a 
biomarker of iodine status (Zimmermann and Andersson 2012). 
 
As there is no validated biomarker of iodine status in an individual and each of the 
currently available methods has its own limitations, a complementary use of the 
biomarkers that are currently available, as well as dietary assessment methods might 
provide more comprehensive information about iodine status, instead of solely relying on 
one biomarker. For instance, several urinary-iodine measurements in pregnancy (e.g., to 
provide some information about overall pregnancy iodine status but also recent iodine 
intake at different gestational time-points), alongside a measurement of Tg and/or a food-
frequency questionnaire (FFQ) (e.g., to provide information about longer-term/habitual 
iodine intake) might be beneficial.  
 
 
8.2 Overall strengths and limitations  
The strengths and limitations of each study in this thesis have been discussed extensively 
in the respective chapters (Chapter 3-7). Briefly, the strengths include: (i) the large sample 
size of pregnant women from three population-based birth cohorts (Chapters 3 and 5); (ii)  
the novel use of multiple urinary-iodine measurements to assess iodine status in 
pregnancy (Chapters 4-6) and its association with child cognition (Chapter 6); iii) the 
longitudinal analyses of the within-subject gestational changes in urinary iodine 
concentration (Chapter 4); (iv) the availability of data on maternal diet during pregnancy 
and other potential determinants of iodine status (Chapters 3); and (v) the analysis of Tg 
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in the same laboratory using the same method (Chapter 5) [important as there is a large 
variation in Tg measurements between laboratories even with the use of CRMs 
(Zimmermann and Andersson 2012)].  
 
Several limitations should be considered when interpreting the findings from this thesis. 
Overall, the observational nature of the studies (Chapters 3-6) is one of the main 
limitations. Despite statistical adjustment for confounding factors, potential residual 
confounding (e.g., due to factors that were not measured or those incompletely measured) 
cannot be excluded and the results cannot infer causality. The reliance on data from cohort 
studies has its limitations. As with all prospective cohort studies, there is a decline in the 
number of individuals followed up over time and selection bias is an issue as attrition is 
often related to specific subject characteristics (i.e., non-participation is not random) 
(Nohr and Liew 2018). This means that findings based on these data may not be 
generalizable to the wider population. Although an effort was made to harmonise the data 
in the studies where more than one cohort was used (Chapters 3 and 5), the issues of 
comparability of the available data should be noted (e.g., the urinary iodine measurements 
performed in different laboratories and the different FFQs). Another limitation was the 
use of casual spot-urine samples throughout; as discussed in Section 8.1.2, spot-urine 
iodine measurements only provide information about recent iodine intake and cannot 
determine individual iodine status. To overcome this limitation to some extent, the urinary 
iodine-to-creatinine ratio (see Chapter 2, Section 2.4.2 ‘Creatinine adjustment’) and 
repeat urinary-iodine measurements were used to gain a better proxy of iodine status in 
pregnancy (Chapters 4-6). The availability of multiple urine samples, however, was 
limited to a small proportion of the initially recruited women and of the women with at 
least one measurement of urinary iodine concentration; this could have led to a selection 
bias in Chapters 4 and 6. Finally, in the studies that used dietary data (Chapters 3-5), diet 
was measured with an FFQ which has its limitations as a dietary assessment method 
(Shim et al. 2014); this method is good for assessment of habitual diet (e.g., can capture 
foods that are rarely consumed such as fish) but it can be an unreliable method to 
accurately assess food consumption and salt intake (Zimmermann and Andersson 2012). 
A food diary would be a better method to assess food and salt intake more accurately but 
repeat dietary assessments will be required to capture the day-to-day variability in iodine 
intake (Zimmermann and Andersson 2012). 
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8.3 Suggestions for future work 
The present thesis gives rise to several areas of potential future work. 
 
1. Firstly, the gestational changes in iodine status during pregnancy need to be explored 
further using repeat urinary-iodine measurements. Repeat measurements need to be 
collected within each trimester for each woman to improve accuracy at that 
gestational time-point and also across pregnancy to track changes with gestational 
age. To assess the underlying dietary changes during pregnancy, repeat measures of 
diet in pregnancy would also be useful; this would provide more information about 
whether the gestational changes are explained by diet or by physiology (e.g., increased 
renal iodide clearance).  
 
2. Secondly, the effects of changes in iodine availability across the stages of pregnancy 
on child neurodevelopment are not well researched and need to be investigated 
further. For instance, it is unclear whether low maternal iodine intake in early 
pregnancy can be compensated for in later pregnancy or what happens if optimal 
iodine status in early pregnancy is followed by low iodine intake in the remaining 
stages of pregnancy. In a previous study, maternal low free thyroxine (FT4) in early 
pregnancy was associated with a delay in infant neurodevelopment; however, this 
negative effect was not seen in women who had a low FT4 concentration in early 
pregnancy followed by improved FT4 in later pregnancy (Pop et al. 2003). 
Furthermore, whether the different patterns of change in iodine nutritional status over 
the course of pregnancy can have a differential effect on child cognitive outcomes is 
not well understood [e.g., iodine deficiency at different gestational time-points could 
affect the development of different neuropsychological functions (Zoeller and Rovet 
2004)]. For instance, in Chapter 6, maternal iodine status beyond early pregnancy was 
associated with non-verbal IQ, while previous studies showed that the development 
of verbal IQ was particularly vulnerable to iodine deficiency in early pregnancy (Bath, 
Steer, et al. 2013; Levie et al. 2019). 
 
3. Thirdly, the results of this thesis showed that maternal Tg concentration might be a 
good complementary indicator of iodine nutrition in groups of pregnant women as it 
was negatively associated with UI/Creat. However, the usefulness of Tg as a 
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biomarker of individual iodine status is not clear. As Tg concentration is thought to 
reflect iodine intake in weeks to months prior to its measurement (Zimmermann and 
Andersson 2012), the association of Tg with repeat urinary-iodine measurements 
collected prior to the Tg measurement should be explored in pregnant women. 
Individual biomarkers of iodine status are still lacking and this has implications for 
iodine-intake monitoring in populations, as well as research.   
 
4. Finally, as shown in Chapter 7, the evidence is still inconclusive as to whether 
maternal iodine supplementation should be recommended in pregnancy in areas of 
mild-to-moderate iodine deficiency. There is an urgent need for a clinical trial with 
child cognitive outcomes in areas of moderate deficiency; however, countries are 
increasingly introducing recommendations for iodine supplementation in pregnancy 
which limits the feasibility of such trial.  
 
 
8.4 Conclusions  
The work presented in this thesis contributes to current iodine research by providing 
valuable insights into several aspects of maternal iodine nutrition and shedding light on 
important knowledge gaps. It particularly highlights the necessity of repeat spot-urine 
iodine measurements to better assess iodine status in pregnancy and the use of other 
complementary biomarkers. As it is unclear whether iodine supplementation in pregnancy 
is beneficial and safe, with the absence of salt-iodisation policies in many European 
countries, there is a need to educate pregnant women and women of childbearing age on 
the importance of iodine and the ways that they can meet iodine requirements through 
diet.  
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Appendices 
Appendix I: Supplemental Tables 
Supplemental Table 3. 1  Overview of the classification of foods into food groups by 
cohort 
Food group   ALSPAC  Generation R  INMA 
Vegetables 
  
green leafy vegetables 
(e.g., cabbage), other 
green vegetables (e.g., 
leeks), carrots, other 
root vegetables (e.g., 
turnip), salad 
vegetables (e.g., 
tomatoes) 
 
leafy (e.g., spinach), 
root (e.g., carrots), 
cabbage, mixed salad 
vegetables, 
mushrooms, allium 
(e.g., onion, garlic), 
stems and sprouts 
(e.g., asparagus), 
fruiting (e.g., 
tomatoes) 
 
leafy (e.g., spinach), 
root (e.g., carrots), 
cruciferous (e.g., 
broccoli), salad 
vegetables (e.g., 
lettuce), allium (e.g., 
onions, leek, garlic), 
fruiting (e.g., 
tomatoes, aubergines, 
peppers) 
Fruit 
  
fresh fruit (e.g., apple, 
grapes, banana) 
 
fresh fruit (e.g., apple, 
grapes, banana), 
olives 
 
fresh fruit (e.g., 
apple, grapes, 
banana) 
Nuts and seeds 
  
nuts, tahini 
 
nuts, seeds, nut spread 
 
almonds, peanuts, 
hazelnuts, pine nuts 
Potatoes 
  
chips, roast potatoes, 
boiled/mashed/ jacket 
potatoes 
 
potatoes and other 
tubers (does not 
include potato crisps) 
 
fried, boiled/roasted 
potatoes, potato 
crisps 
Legumes 
  
pulses (e.g., lentils, 
chickpeas), baked 
beans, peas, 
sweetcorn, broad 
beans 
 
dried lentils, beans 
and peas 
 
lentils, chickpeas, 
beans 
Cereals and 
cereal products 
  
breakfast cereals (e.g., 
oats, cornflakes, bran 
cereals), pasta, rice, 
bread, crispbreads, 
pizza 
 
breakfast cereals, 
pasta, rice, bread, 
pretzels, crispbreads, 
pizza, flour and 
thickeners 
 
breakfast cereals, 
pasta, rice, bread, 
boiled corn 
Cakes, 
confectionery 
and added 
sugar 
  
cakes or buns, 
biscuits, chocolate 
bars (e.g., Mars), 
chocolate (e.g., dairy 
milk), sweets (e.g., 
toffees), pudding (e.g., 
cheesecake, mousse), 
sugar 
 
cakes, pastries, 
biscuits, candy bars, 
chocolate, non-
chocolate sweets (e.g., 
toffees) jam, honey, 
sugar, ice cream, 
syrups, water ice 
 
cakes, pastries, 
biscuits, chocolate, 
jams, honey, sugar 
Added fats 
  
animal fats (e.g., 
butter, ghee), 
vegetable oils and 
spreads  
(e.g., olive oil) 
 
animal fats (e.g., 
butter),vegetable oils 
(e.g., olive oil), 
spreads and 
margarines 
 
animal fats (e.g., 
butter), vegetable oils 
and spreads  
(e.g., olive oil) 
Milk and dairy 
products 
  
milk, cheese 
 
milk, milk drinks, 
evaporated milk, 
yoghurt, fresh cheese 
(e.g., cottage cheese), 
cheese, milk puddings 
(e.g., mouse, cream 
base), cream 
 
fresh milk, condensed 
milk,  yoghurt, 
cheese, custard, ice 
cream, cream 
(continued on next page) 
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Supplemental Table 3. 1  Overview of the classification of foods into food groups by 
cohort (continued) 
Food group  ALSPAC 
 
Generation R 
 
INMA 
Meat and meat 
products 
  
red meat, poultry, 
offal (e.g., liver), 
processed meat (e.g., 
sausages, burgers, 
bacon), pies and 
pasties (e.g., meat 
pies) 
 
red meat, poultry, 
offal (e.g., liver), 
processed meat  
(e.g., sausage, pate) 
 
red meat, white meat 
(e.g., chicken), offal 
(e.g., liver), 
processed meat (e.g., 
sausages, pate, 
bacon) 
Eggs 
  
eggs, quiche 
 
eggs 
 
eggs 
Fish and 
shellfish 
  
white fish (e.g., cod), 
oily fish (e.g., 
salmon), shellfish 
(e.g., prawns) 
 
white fish (e.g., cod), 
oily fish (e.g., 
salmon),  shellfish 
(e.g., prawns), 
processed fish  
(e.g., fish fingers) 
 
boiled/fried/ grilled 
white fish (e.g., cod), 
boiled/fried/ grilled 
oily fish (e.g., 
salmon), seafood and 
shellfish  (e.g., 
oysters, clams, 
lobster) 
Condiments 
and seasoning   
N/A 
 
seasonings (e.g., salt, 
herbs, spices) 
 
salt, including iodised 
salt 
Processed and 
fried foods                                
(e.g., sauces, 
soups, fried 
foods, crisps) 
  
fried food (e.g., 
bacon, eggs, egg fried 
fish), crisps 
 
sauces (e.g., tomato, 
dressings, 
mayonnaise), soups, 
bouillons 
 
vegetable soups, 
tomato sauce, 
chicken croquettes, 
pizza 
Non-alcoholic 
beverages             
(excluding 
coffee and tea) 
  
tinned juice (e.g., 
tomato juice), pure 
fruit juice, soft drinks 
 
fruit and vegetable 
juices, soft drinks, 
isotonic drinks, water 
 
fruit juice, soft 
drinks, unalcoholic 
beer, tap water, 
bottled water 
Alcoholic 
beverages   
N/A 
 
wine, beer, liquors 
and spirits 
 
wine, beer, liquors 
and spirits 
Miscellaneous                 
(e.g., soy 
products, diet 
foods and 
sweeteners) 
  
soy products (e.g., 
TVP, vegeburgers), 
bean curd (e.g., tofu) 
 
diet products, soy 
products, artificial 
sweeteners 
 
N/A 
Abbreviations: N/A, data not available; TVP, texturised vegetable protein 
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Supplemental Table 3. 2  Determinants of urinary iodine-to-creatinine ratio measured at ≤ 18 gestational weeks by cohort 
 ALSPAC (n=2,852)  Generation R (n=2,254)  INMA (n=1,460) 
Determinants n B (95% CI) P 1  n B (95% CI) P 
1  n B (95% CI) P 
1 
Maternal factors                       
Gestational week at urine sampling 2852 0.051 (0.046, 0.057) <0.001   2254 0.007 (-0.006, 0.019) 0.300   1460 0.004 (-0.023, 0.032) 0.755 
Maternal age 2, years 2852 0.014 (0.008, 0.020) <0.001   2254 0.018 (0.012, 0.024) <0.001   1460 0.020 (0.010, 0.030) <0.001 
Pre-pregnancy BMI, kg/m2 2852 -0.013 (-0.019, -0.007) <0.001   2254 -0.011 (-0.017, -0.006) <0.001   1460 -0.013 (-0.022, -0.004) 0.005 
Ethnicity 3                       
    Reference group 2800 Ref.     1095 Ref.     1340 Ref.   
    Non-white 52 -0.018 (-0.203, 0.168) 0.851   N/A . .   N/A . . 
    Non-Dutch N/A . .   1159 (see separate table) 4     N/A . . 
    Non-Spanish N/A . .   N/A . .   120 -0.016 (-0.150, 0.118) 0.810 
Parity                       
    0 1354 Ref.     1279 Ref.     806 Ref.   
    1 965 0.032 (-0.021, 0.085) 0.232   665 -0.001 (-0.057, 0.056) 0.982   544 -0.029 (-0.110, 0.052) 0.481 
    ≥ 2 533 0.040 (-0.029, 0.108) 0.254   310 -0.041 (-0.123, 0.041) 0.327   110 -0.128 (-0.276, 0.020) 0.090 
Smoking status                       
    Never smoked 2169 Ref.     1671 Ref.     1020 Ref.   
    Stopped smoking 333 -0.003 (-0.075, 0.070) 0.943   211 -0.093 (-0.179, -0.007) 0.035   187 -0.060 (-0.172, 0.052) 0.296 
    Continued smoking 350 0.018 (-0.055, 0.092) 0.620   372 -0.008 (-0.083, 0.066) 0.831   253 -0.001 (-0.105, 0.104) 0.990 
Alcohol consumption                       
    No 1350 Ref.     1458 Ref.     1330 Ref.   
    Yes 1502 -0.006 (-0.052, 0.040) 0.795   796 -0.002 (-0.059, 0.055) 0.954   130 -0.051 (-0.181, 0.079) 0.442 
(continued on next page) 
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Supplemental Table 3.2  Determinants of urinary iodine-to-creatinine ratio measured at ≤ 18 gestational weeks by cohort (continued) 
 ALSPAC (n=2,852)  Generation R (n=2,254)  INMA (n=1,460) 
Determinants n B (95% CI) P 1   n B (95% CI) P 1   n B (95% CI) P 1 
Markers of socio-economic status 
Education level                       
    Low 576 Ref.     247 Ref.     337 Ref.   
    Medium 1780 0.005 (-0.056, 0.066) 0.869   995 -0.077 (-0.165, 0.012) 0.089   581 -0.016 (-0.112, 0.079) 0.736 
    High 496 0.026 (-0.055, 0.107) 0.531   1012 -0.057 (-0.159, 0.045) 0.272   542 0.089 (-0.013, 0.190) 0.088 
Net household income  
(€ per month)                       
    Low < €1200 N/A . .   492 Ref.     N/A . . 
    Medium €1200-2200 N/A . .   597 0.022 (-0.063, 0.108) 0.606   N/A . . 
    High > €2200 N/A . .   1165 0.089 (-0.001, 0.179) 0.054   N/A . . 
Home ownership                       
    Owned/mortgaged 2425 Ref.     N/A . .   N/A . . 
    Private/other rented 236 -0.037 (-0.126, 0.053) 0.422   N/A . .   N/A . . 
    Council rented 191 -0.032 (-0.136, 0.072) 0.547   N/A . .   N/A . . 
Crowding index                       
    ≤ 1 person per room 2747 Ref.     N/A . .   N/A . . 
    + 1 person per room 105 0.134 (-0.006, 0.274) 0.060   N/A . .   N/A . . 
Family adversity index                       
    None 0 1395 Ref.     N/A . .   N/A . . 
    Mild 1-2 1124 -0.007 (-0.056, 0.041) 0.765   N/A . .   N/A . . 
    Severe > 3 333 -0.100 (-0.182, -0.018) 0.016   N/A . .   N/A . . 
Life event score 2852 0.007 (-0.001, 0.015) 0.097   N/A . .   N/A . . 
(continued on next page) 
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Supplemental Table 3.2  Determinants of urinary iodine-to-creatinine ratio measured at ≤ 18 gestational weeks by cohort (continued) 
 ALSPAC (n=2,852)  Generation R (n=2,254)  INMA (n=1,460) 
Determinants n B (95% CI) P 1   n B (95% CI) P 1   n B (95% CI) P 1 
Markers of socio-economic status (continued) 
Marital status            
    Never-married 355 Ref.     1136 Ref.      N/A . . 
    Married 2357 0.095 (0.018, 0.171) 0.015   1118 0.030 (-0.025, 0.086) 0.285   N/A . . 
    Other 5 140 0.028 (-0.097, 0.153) 0.666   N/A . .   N/A . . 
Living with a partner                       
    Yes N/A . .   N/A . .   1445 Ref.   
    No N/A . .   N/A . .   15 -0.233 (-0.598, 0.131) 0.209 
Child factors                       
Child’s sex                       
    Male 1405 Ref.     1147 Ref.     737 Ref.   
    Female 1447 -0.025 (-0.070, 0.019) 0.261   1107 -0.026 (-0.073, 0.021) 0.278   723 -0.014 (-0.087, 0.058) 0.700 
Effect estimates (B=unstandardized regression coefficient), their 95% CIs and P-values from multiple linear regression models performed for each cohort with (natural) log-
transformed iodine-to-creatinine ratio (UI/Creat) as the dependent variable and maternal characteristics as independent variables (for full models, see footnote 1). Reported B 
coefficients represent the change in the mean (natural) log of UI/Creat per unit increase in the continuous independent variables and for each category compared to the reference 
for the categorical independent variables. 1 P-values from adjusted Model 1 (adjusted for maternal and pregnancy characteristics): ALSPAC Model 1 (R2=0.123, P < 0.0001): 
gestational week at urine sampling, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, home ownership, 
crowding index, family adversity index, life event score, marital status and child’s sex; Generation R Model 1 (R2=0.086, P < 0.0001): gestational week at urine sampling, 
maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, net household income (€ per month), marital status 
and child’s sex; and INMA Model 1 (R2=0.021, P < 0.0001): gestational week at urine sampling, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking 
status, alcohol consumption, education level, living with a partner and child’s sex . 2 Maternal age at urine sample collection, except in ALSPAC (age at last menstrual period). 
3 Reference group of ethnicity in ALSPAC (Reference group=White), in Generation R (Reference group=Dutch) and in INMA (Reference group=Spanish). 4 Non-Dutch group 
in Generation R presented in detail in Table 3.3. 5 ALSPAC (Other=widowed, divorced, or separated). Abbreviations: BMI, body mass index; 95% CI, confidence interval; 
N/A, data not available or not applicable; Ref, reference category; UI/Creat, urinary iodine-to-creatinine ratio 
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Supplemental Table 3. 3  Determinants of urinary iodine concentration measured at ≤ 18 gestational weeks by cohort 
 ALSPAC (n=2,852)  Generation R (n=2,254)  INMA (n=1,460) 
 Adjusted Model 1 
1 Adjusted Model 2 2   Adjusted Model 1 1 Adjusted Model 2 2   Adjusted Model 1 1 Adjusted Model 2 2 
Determinants n B P n B P  n B P n B P  n B P n B P 
Gestational week at urine sampling 2852 0.033 <0.001 2710 0.034 <0.001   2254 0.014 0.020 1580 0.021 0.004   1460 0.009 0.516 1446 -0.007 0.605 
Maternal age 3, years 2852 0.009 0.002 2710 0.006 0.063   2254 0.011 <0.001 1580 0.010 0.009   1460 0.019 <0.001 1446 0.013 0.008 
Pre-pregnancy BMI, kg/m2 2852 -0.009 0.004 2710 -0.009 0.008   2254 -0.003 0.279 1580 -0.004 0.192   1460 -0.007 0.113 1446 -0.002 0.650 
Family adversity index                                         
    None 0 1395 Ref.   1334 Ref.     N/A . . . . .   N/A . . . . . 
    Mild 1-2 1124 -0.025 0.309 1069 -0.020 0.423   N/A . . . . .   N/A . . . . . 
    Severe > 3 333 -0.112 0.008 307 -0.101 0.019   N/A . . . . .   N/A . . . . . 
Marital status                                         
    Never-married 355 Ref.   320 Ref.     1136 Ref.    825 Ref.     N/A . . . . . 
    Married 2357 0.044 0.257 2269 0.078 0.054   1118 0.034 0.208 755 0.042 0.179   N/A . . . . . 
    Other 4 140 -0.015 0.815 121 0.009 0.889   N/A . . . . .   N/A . . . . . 
Ethnicity                                         
    Reference group 5 2800 Ref.   2674 Ref.      1095 Ref.   930 Ref.     1340 Ref.   1328 Ref.   
    Non-white 52 0.048 0.611 36 0.109 0.284   N/A . . . . .   N/A . . . . . 
    Non-Dutch: N/A . . . . .                 N/A . . . . . 
      Indonesian N/A . . . . .   72 -0.012 0.861 58 -0.026 0.725   N/A . . . . . 
      Cape Verdian N/A . . . . .   87 0.061 0.370 41 0.150 0.112   N/A . . . . . 
      Moroccan N/A . . . . .   165 0.286 <0.001 72 0.242 0.003   N/A . . . . . 
      Dutch Antilles N/A . . . . .   65 -0.064 0.393 37 -0.117 0.245   N/A . . . . . 
      Surinamese N/A . . . . .   196 -0.046 0.327 111 -0.024 0.698   N/A . . . . . 
      Turkish N/A . . . . .   226 0.323 <0.001 103 0.308 <0.001   N/A . . . . . 
      Other, Non-Western N/A . . . . .   107 0.125 0.034 53 0.054 0.502   N/A . . . . . 
      Asian N/A . . . . .   32 0.062 0.544 19 0.022 0.863   N/A . . . . . 
      Other, Western N/A . . . . .   209 0.023 0.575 156 0.050 0.297   N/A . . . . . 
    Non-Spanish N/A . . . . .   N/A . . . . .   120 0.007 0.909 118 0.032 0.627 
(continued on next page) 
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Supplemental Table 3. 3  Determinants of urinary iodine concentration measured at ≤ 18 gestational weeks by cohort (continued) 
 ALSPAC (n=2,852)   Generation R (n=2,254)   INMA (n=1,460) 
 Adjusted Model 1 1 Adjusted Model 2 2  Adjusted Model 1 1 Adjusted Model 2 2  Adjusted Model 1 1 Adjusted Model 2 2 
Determinants n B P n B P  n B P n B P  n B P n B P 
Smoking status                     
    Never smoked 2169 Ref.   2077 Ref.     1671 Ref.   1202 Ref.     1020 Ref.   1011 Ref.   
    Stopped smoking 333 -0.008 0.825 312 -0.015 0.686   211 -0.078 0.065 147 -0.120 0.016   187 -0.097 0.077 186 -0.096 0.076 
    Continued smoking 350 0.005 0.896 321 0.034 0.380   372 0.021 0.557 231 0.039 0.385   253 -0.015 0.765 249 0.010 0.838 
Effect estimates (B=unstandardised regression coefficient) and P-values from multiple linear regression models performed for each cohort with (natural) log-transformed urinary iodine 
concentration (UIC) as the dependent variable and maternal characteristics and dietary intakes as independent variables (for full models, see footnotes 1 and 2). All models were additionally 
adjusted for urinary creatinine concentration (UCreat, g/L). Reported B coefficients represent the change in the mean (natural) log of UIC per unit increase in the continuous independent 
variables and for each category compared to the reference for the categorical independent variables. 1 Adjusted Model 1 (adjusted for maternal and pregnancy characteristics): ALSPAC Model 
1 (R2=0.424, P < 0.0001): gestational week at urine sampling, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, home 
ownership, crowding index, family adversity index, life event score, marital status, child’s sex, UCreat (g/L) and UCreat^2 ; Generation R Model 1 (R2=0.525, P < 0.0001): gestational week 
at urine sampling, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, net household income (€ per month), marital 
status, child’s sex, UCreat (g/L) and UCreat^2; and INMA Model 1 (R2=0.193, P < 0.0001): gestational week at urine sampling, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, 
parity, smoking status, alcohol consumption, education level, living with a partner, child’s sex, UCreat (g/L) and UCreat^2. 2 Adjusted Model 2 (adjusted for maternal and pregnancy 
characteristics + dietary intakes): ALSPAC Model 2 (R2=0.443, P < 0.0001): Model 1 + energy intake (kcal/day) + intake of vegetables (g/day), fruit (g/day), nuts and seeds (g/day), potatoes 
(g/day), legumes (g/day), cereals and cereal products (g/day), cakes, confectionery and added sugar (g/day), added fats (g/day), milk and dairy products (g/day), meat and meat products 
(g/day), eggs (g/day), fish and shellfish (g/day), processed and fried foods (g/day), non-alcoholic beverages (g/day), miscellaneous (g/day); Generation R Model 2 (R2=0.548, P < 0.0001): 
Model 1 + energy intake (kcal/day) + intake of vegetables (g/day), fruit (g/day), nuts and seeds (g/day), potatoes (g/day), legumes (g/day), cereals and cereal products (g/day), cakes, 
confectionery and added sugar (g/day), added fats (g/day), milk and dairy products (g/day), meat and meat products (g/day), eggs (g/day), fish and shellfish (g/day), condiments and seasoning 
(g/day), processed and fried foods (g/day), non-alcoholic beverages (g/day), alcoholic beverages (g/day), miscellaneous (g/day); and INMA Model 2 (R2=0.227, P < 0.0001): Model 1 + 
energy intake (kcal/day) + intake of vegetables (g/day), fruit (g/day), nuts and seeds (g/day), potatoes (g/day), legumes (g/day), cereals and cereal products (g/day), cakes, confectionery and 
added sugar (g/day), added fats (g/day), milk and dairy products (g/day), meat and meat products (g/day), eggs (g/day), fish and shellfish (g/day), condiments and seasoning (e.g., salt) (g/day), 
processed and fried foods (g/day), non-alcoholic beverages (g/day), alcoholic beverages (g/day). 3 Maternal age at urine sample collection, except in ALSPAC (age at last menstrual period). 
4 ALSPAC (Other=widowed, divorced, or separated). 5 Reference group of ethnicity in ALSPAC (Reference group=White), in Generation R (Reference group=Dutch) and in INMA (Reference 
group=Spanish). Abbreviations: BMI, body mass index; N/A, data not available or not applicable; Ref, reference category; UCreat, urinary creatinine concentration; UCreat^2, squared 
urinary creatinine concentration; UIC, urinary iodine concentration 
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Supplemental Table 3. 4  Descriptives of dietary intakes of food groups (g/day) and 
energy intake (kcal/day) estimated from FFQ by cohort 
 
ALSPAC                                       
(n=2,710) 
 Generation R 
(n=1,580) 
 INMA                                                 
(n=1,446) 
Food group (g/day) 1 Mean (±SD)  Mean (±SD)  Mean (±SD) 
Vegetables 117 (±64)  144 (±64)  220 (±114) 
Fruit 100 (±56)  171 (±116)  320 (±200) 
Nuts and seeds 3 (±7)  17 (±12)  6 (±9) 
Potatoes 98 (±49)  52 (±43)  63 (±37) 
Legumes 54 (±32)  4 (±7)  38 (±25) 
Cereals and cereal products 195 (±79)  195 (±71)  184 (±77) 
Cakes, confectionery and 
added sugar 
80 (±55)  98 (±56)  44 (±36) 
Added fats 19 (±11)  25 (±14)  23 (±15) 
Milk and dairy products 391 (±155)  412 (±251)  444 (±233) 
Meat and meat products 71 (±40)  78 (±43)  116 (±50) 
Eggs 21 (±18)  11 (±10)  20 (±9) 
Fish and shellfish 35 (±30)  14 (±13)  69 (±36) 
Condiments and seasoning  
(e.g., salt, iodised salt) N/A  6 (±5)  0.3 (±0.4) 
Processed and fried foods  
(e.g., sauces, soups, fried 
foods, crisps) 
8 (±8)  100 (±90)  101 (±66) 
Non-alcoholic beverages 
(excluding coffee and tea) 2 
175 (±83)  940 (±550)  1488 (±494) 
Alcoholic beverages N/A  6 (±17)  3 (±13) 
Miscellaneous  
(e.g., soy products, diet foods 
and sweeteners) 
2 (±9)  6 (±20)  N/A 
Energy, kcal/day 1743 (±459)  2076 (±520)  2083 (±532) 
1 Dietary intake of food groups presented as mean (±SD) grams per day, energy intake presented as mean 
(±SD) kcal per day. 2 Non-alcoholic beverages food group also included water in INMA and Generation R 
(but not in ALSPAC). Abbreviations: FFQ, food-frequency questionnaire; N/A, data not available; SD, 
standard deviation 
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Supplemental Table 3. 5  Multivariable associations of food-group intakes estimated from FFQ (per 100 g/day) with urinary iodine-to-creatinine ratio 
measured at ≤ 18 gestational weeks by cohort 
 ALSPAC (n=2,710) 
 Generation R (n=1,580)  INMA (n=1,446) 
Food group intakes (per 100 g/day) 1 B (95% CI)  P 2   B (95% CI)  P 3   B (95% CI) P 4 
Vegetables 0.24 (-1.51, 2.06) 0.791   -0.76 (-4.78, 3.46) 0.719   0.48 (-7.07, 8.31) 0.903 
Fruit 2.79 (0.59, 5.09) 0.012   1.13 (-1.12, 3.45) 0.328   -4.38 (-8.91, 0.26) 0.064 
Nuts and seeds 19.30 (-2.05, 51.25) 0.083   51.07 (17.18, 96.03) 0.001  68.80 (-33.30, 230.33) 0.223 
Potatoes 2.66 (-0.20, 5.71) 0.069   5.92 (-1.17, 13.61) 0.104   -16.46 (-36.05, 5.36) 0.134 
Legumes 2.33 (-1.33, 6.29) 0.219   16.98 (-17.38, 68.39) 0.384   28.00 (-5.39, 66.86) 0.105 
Cereals and cereal products 1.42 (-0.92, 3.88) 0.238   12.32 (6.34, 18.69) <0.001  0.21 (-13.90, 15.34) 0.978 
Cakes, confectionery and added sugar 4.90 (0.50, 9.73) 0.028  5.36 (-2.24, 13.64) 0.172   -17.98 (-43.38, 11.33) 0.217 
Added fats 1 0.11 (-0.01, 0.24) 0.082   0.27 (0.04, 0.50) 0.022   -0.42 (-1.13, 0.29) 0.243 
Milk and dairy products 3.73 (2.74, 4.74) <0.001   2.34 (1.00, 3.70) 0.001   6.92 (2.52, 11.41) 0.002 
Meat and meat products 1.27 (-2.30, 5.13) 0.497   2.87 (-4.14, 10.49) 0.433   -32.71 (-50.77, -12.58) 0.002 
Eggs 5.44 (-1.18, 13.06) 0.112   65.32 (26.28, 117.87) <0.001  86.92 (-13.13, 238.12) 0.099 
Fish and shellfish 5.10 (0.89, 9.70) 0.017   2.01 (-16.18, 24.91) 0.845   28.04 (2.73, 56.38) 0.029 
Condiments and seasoning (e.g., salt) 1,5 N/A .   0.27 (-0.30, 0.84) 0.359   31.69 (10.31, 55.16) 0.003 
Processed and fried foods (e.g., sauces, soups, fried foods, crisps) 0.85 (-12.40, 19.47) 0.915   1.88 (-0.98, 4.83) 0.199   0.00 (-11.26, 11.91) 0.999 
Non-alcoholic beverages (excluding coffee and tea) 0.62 (-0.71, 1.99) 0.367   0.40 (-0.07, 0.87) 0.099   -1.46 (-3.05, 0.13) 0.072 
Alcoholic beverages N/A .   13.86 (-1.99, 32.66) 0.090   -34.72 (-85.12, 36.20) 0.297 
Miscellaneous (e.g., soy products, diet foods and sweeteners) 14.61 (-0.70, 35.22) 0.063   8.13 (-4.77, 23.06) 0.230   N/A . 
Effect estimates (B=unstandardised regression coefficient), 95% CIs and P-values from multiple linear regressions performed for each cohort with (natural) log-transformed iodine-to-
creatinine ratio (UI/Creat) as the dependent variable and food-group intakes as the independent variables, adjusted for covariates (see footnotes 2-4). Reported B coefficients represent the 
actual change in the geometric mean of UI/Creat (µg/g) associated with a 100-g increase in intake of a food group. B coefficients and their 95% CIs are calculated by back-transformation 
from logarithmic scale (see ‘Methods’ Section 3.2.8). When calculating the B coefficients all categorical covariates were set to their reference group and the continuous covariates gestational 
week, maternal age, pre-pregnancy BMI and energy intake were centred to their means. 1 Added fats and salt intakes expressed per 1 g/day. 2 P-values from Model 2 in ALSPAC (R2=0.147, 
P < 0.0001): energy (kcal/day) + gestational week, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, home ownership, 
crowding index, family adversity index, life event score, marital status and child’s sex. 3 P-values from Model 2 in  Generation R (R2=0.091, P < 0.0001): energy (kcal/day) + gestational 
week, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, alcohol consumption, education level, net household income (€ per month), marital status and 
child’s sex. 4 P-values from Model 2 in INMA (R2=0.060, P < 0.0001): energy (kcal/day) + gestational week, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking 
status, alcohol consumption, education level, living with a partner and child’s sex. 5 In INMA this food group also included iodised salt. Separate information about the consumption of table 
salt and use of iodine-fortified table salt was collected only in the INMA cohort Abbreviations: BMI, body mass index; 95% CI, confidence interval; FFQ, food-frequency questionnaire; 
N/A, data not available; UI/Creat, urinary iodine-to-creatinine ratio 
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Supplemental Table 4. 1  Descriptives of maternal UIC, Creatinine and UI/Creat at each measurement time-point in pregnancy for all women 
who provided at least one urine sample during pregnancy 
 
First measurement 
(n=3,122) 
 
Second measurement 
(n=486) 
 
Third measurement 
(n=203) 
      
Gestational week at urine sampling 1 12.0 (8.0 - 16.0)  17.0 (16.0 - 19.0)  34.0 (33.0 - 35.0) 
UIC, µg/L 1 95 (57 - 153)  102 (55 - 162)  135 (76 - 207) 
Creatinine, g/L 1 0.81 (0.46 - 1.19)  0.66 (0.32 - 1.00)  0.81 (0.51 - 1.12) 
UI/Creat, µg/g 1 124 (82 - 198)  172 (103 - 266)  161 (109 - 239) 
      
UIC < 150 µg/L, n (%) 2300 (73.7%)  346 (71.2%)  114 (56.2%) 
UI/Creat < 150 µg/g, n (%) 1916 (61.4%)  210 (43.2%)  90 (44.3%) 
1 Data are presented as medians (25-75th percentile). Abbreviations: UI/Creat, iodine-to-creatinine ratio; UIC, urinary iodine concentration 
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Supplemental Table 4. 2  Association of gestational week with maternal UIC, Creatinine and UI/Creat at each measurement time-point in pregnancy for all 
women who provided at least one urine sample during pregnancy 
  First measurement (n=3,037)  Second measurement (n=474)  Third measurement (n=203) 
  B (95% CI) P  B (95% CI) P  B (95% CI) P 
UIC, µg/L          
Model 1 1          
Gestational week (linear)  0.002 (-0.003, 0.007)  0.442  0.018 (0.005, 0.031) 0.008  -0.008 (-0.057, 0.040) 0.734 
Model 2 2          
Gestational week (linear)  -0.030 (-0.046, -0.014) <0.001  0.018 (-0.089, 0.124)  0.748  -0.043 (-0.820, 0.734) 0.913 
Gestational week (squared)  0.001 (0.001, 0.001) <0.001  0.000 (-0.002, 0.002) 0.996  0.001 (-0.011, 0.012) 0.930 
Creatinine, g/L          
Model 1 1          
Gestational week (linear)  -0.010 (-0.012, -0.008) <0.001  0.003 (-0.001, 0.007) 0.089  -0.002 (-0.017, 0.012) 0.757 
Model 2 2          
Gestational week (linear)  -0.037 (-0.043,-0.032) <0.001  0.002 (-0.029, 0.033) 0.904  -0.152 (-0.386, 0.082) 0.204 
Gestational week (squared)  0.001 (0.001, 0.001) <0.001  0.000 (-0.001, 0.001) 0.928  0.002 (-0.001, 0.006) 0.210 
UI/Creat, µg/g          
Model 1 1          
Gestational week (linear)   0.030 (0.026, 0.033) <0.001  0.007 (-0.002, 0.017) 0.140  -0.002 (-0.038, 0.034) 0.921 
Model 2 2          
Gestational week (linear)  0.079 (0.067, 0.091) <0.001  0.026 (-0.053, 0.105) 0.521  0.358 (-0.209, 0.925) 0.216 
Gestational week (squared)  -0.001 (-0.002, -0.001) <0.001  -0.000 (-0.002, 0.001) 0.643  -0.005 (-0.014, 0.003) 0.213 
Model 3 3          
Gestational week (linear)  0.026 (-0.013, 0.064) 0.194  0.483 (0.164, 0.802) 0.003  N/A 
4  
Gestational week (squared)  0.002 (-0.000, 0.004) 0.108  -0.019 (-0.032, -0.006) 0.003    
Gestational week (cubic)  -0.000 (-0.000, -0.000)  0.004  0.000 (0.000, 0.000) 0.004    
1 Effect estimates (B=unstandardised regression coefficients), their 95% CI and P-values are from multiple linear regression models performed for each time-point at urine sampling with 
(natural) log-transformed UIC or Creatinine or UI/Creat as the dependent variable and gestational week at each urine sampling as the independent variable. Models were adjusted for maternal 
age (years), pre-pregnancy BMI (kg/m2), milk intake (g/day), family adversity index and marital status. Reported B coefficients represent the change in the mean (natural) log of UIC (µg/L), 
Creatinine (g/L) and UI/Creat (µg/g) per one week increase in gestational age at urine sampling. 2 Model 1 + gestational age^2 (squared term). 3 Model 2 + gestational age^3 (cubed term). 4 
Model does not fit the data (squared term is automatically excluded from the model). Abbreviations: BMI, body mass index; 95% CI, confidence interval; N/A, not available/applicable; 
UI/Creat, iodine-to-creatinine ratio; UIC, urinary iodine concentration  
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Supplemental Table 5. 1  Proportion of women with elevated thyroglobulin concentration (>40 ng/ml 1 or >55 ng/ml 2) according to maternal 
food-group intake and iodine-containing supplement-use 
 
Generation R (n=2,768)  INMA (n=1,155) 
Elevated Tg Tg > 40 ng/ml 1 Tg > 55 ng/ml 2  Tg > 40 ng/ml 1 Tg > 55 ng/ml 2 
 Total n (%) P 3 n (%) P 3  Total n (%) P 3 n (%) P 3 
Milk intake    0.045 4  0.062 4    0.097  0.003 
    None 148 9 (6.1 %)  6 (4.1%)   111 9 (8.1%)  7 (6.3%)  
    ≤ 1 glass (≤ 200 g/day) 1506 54 (3.6%)  23 (1.5%)   615 22 (3.6%)  10 (1.6%)  
    > 1 glass (> 200 g/day) 1114 28 (2.5%)  15 (1.3%)   429 20 (4.7%)  6 (1.4%)  
Fish and shellfish intake    0.014  0.163    0.972  0.827 
    None 555 28 (5.0%)  13 (2.3%)   N/A     
    Some 2213 63 (2.8%)  31 (1.4%)   N/A     
    < 60 g/day N/A      480 22 (4.6%)  11 (2.3 %)  
    60-120 g/day N/A      561 24 (4.3%)  10 (1.8 %)  
    > 120 g/day N/A      114 5 (4.4 %)  2 (1.8 %)  
Bread intake   0.396  0.877       
    Below median (≤  98 g/day) 1378 50 (3.6%)   21 (1.5%)    N/A     
    Above median (> 98 g/day) 1377 41 (3.0%)  23 (1.7%)   N/A     
Salt intake          0.361  0.356 
    None (0 g/day) N/A      374 20 (5.3%)  10 (2.7%)  
    Some (> 0 g/day) N/A      781 31 (4.0%)  13 (1.7%)  
Iodine-containing supplement-use    0.496 4  1.000 4    0.017  0.144 
    No 72 1 (1.4%)  1 (1.4%)    631 37 (5.9%)  17 (2.7%)  
    Yes 521 20 (3.8%)  7 (1.3%)   537 15 (2.8%)  7 (1.3%)  
1 Cut-off value for elevated Tg based on previous studies in adults and school-aged children (see ‘Methods’ Section 5.2.6). 2 Cut-off value considered elevated from the laboratory 
where the Tg measurements were performed (see ‘Methods’ Section 5.2.3).3 P-values from a Chi-square test (after Continuity Correction for comparisons in 2x2 tables). 4 
Fisher's Exact Test P-value was reported due to some cells (>20%) with expected count < 5. Abbreviations: Tg, thyroglobulin  
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Supplemental Table 6. 1  Comparison between ALSPAC women a single urinary iodine 
measurement and those with multiple urinary iodine measurements 
 ALSPAC cohort  
Characteristics 1 Women with a single  
iodine measurement  
(n=2,628) 
 
Women with multiple  
iodine measurements 
(n=452) 
P 2 
Maternal factors    
 
Maternal age 3 (years), mean (±SD) 28.6 (±4.5)  28.9 (±4.4) 0.190 
Pre-pregnancy BMI (kg/m2), median 
(25-75th) 
22.2 (20.5 - 24.4)  22.5 (20.5 - 24.8) 0.351 
Ethnicity, n (%)    0.610 
    White 2502 (98.7%)  435 (99.1%)  
    Non-white 34 (1.3%)  4 (0.9%)  
Parity, n (%)    0.616 
    0 1188 (47.4%)  213 (49.3%)  
    1 855 (34.1%)  147 (34.0%)  
    ≥ 2 464 (18.5%)  72 (16.7%)  
Smoking status, n (%)    0.047 
    Never smoked 1949 (75.6%)  360 (80.7%)  
    Stopped smoking 307 (11.9%)  38 (8.5%)  
    Continued smoking 323 (12.5%)  48 (10.8%)  
Alcohol consumption, n (%)    0.005 
    No 1164 (45.8%)  233 (53.2%)  
    Yes 1375 (54.2%)  205 (46.8%)  
Markers of socio-economic status     
Maternal education level, n (%)    0.249 
    Low 515 (20.2%)  74 (16.9%)  
    Medium 1583 (62.1%)  287 (65.5%)  
    High 451 (17.7%)  77 (17.6%)  
Paternal education level, n (%)    0.188 
    Low 659 (26.5%)  97 (22.4%)  
    Medium 1249 (50.3%)  228 (52.7%)  
    High 575 (23.2%)  108 (24.9%)  
Home ownership, n (%)    <0.001 
    Owned/mortgaged 2172 (85.1%)  404 (91.2%)  
    Private/other rented 186 (7.3%)  27 (6.1%)  
    Council rented 195 (7.6%)  12 (2.7%)  
Crowding index, n (%)    0.076 
    ≤1 person per room 2444 (96.7%)  435 (98.4%)  
    +1 person per room 83 (3.3%)  7 (1.6%)  
Family adversity index, n (%)    0.020 
    None (0) 1245 (47.9%)  246 (55.0%)  
    Mild (1-2) 1053 (40.5%)  158 (35.4%)  
    Severe (≥3) 301 (11.6%)  43 (9.6%)  
Life event score, median (25-75th) 3.0 (2.0 - 5.0)  3.0 (2.0 - 5.0) 0.308 
(continued on next page) 
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Supplemental Table 6.1  Comparison between ALSPAC women a single urinary 
iodine measurement and those with multiple urinary iodine measurements (continued) 
 ALSPAC cohort  
Characteristics 1 Women with a single  
iodine measurement  
(n=2,628) 
 
Women with multiple  
iodine measurements 
(n=452) 
P 2 
 Markers of socio-economic status (continued) 
Marital status, n (%)    0.488 
    Married 2142 (83.0%)  377 (85.1%)  
    Never-married 325 (12.6%)  47 (10.6%)  
    Other 4 115 (4.4%)  19 (4.3%)  
Living with a partner, n (%)    0.334 
    Yes 2433 (94.9%)  423 (96.1%)  
    No 130 (5.1%)  17 (3.9%)  
Child factors     
Child’s sex, n (%)    0.580 
    Male 1291 (49.1%)  229 (50.7%)  
    Female 1337 (50.9%)  223 (49.3%)  
Birth weight, n (%)    0.714 
    <2500 g 106 (4.0%)  16 (3.5%)  
    ≥2500 g 2522 (96.0%)  436 (96.5%)  
Preterm birth, n (%)    0.251 
    Yes (<37 weeks) 129 (4.9%)  16 (3.5%)  
    No (≥37 weeks) 2499 (95.1%)  436 (96.5%)  
Breastfeeding, n (%)    0.812 
    Yes 2143 (84.1%)  376 (84.7%)  
    No 405 (15.9%)  68 (15.3%)  
1 Data are presented as mean (±SD) for all continuous normally distributed variables, median (25-75th 
percentile) for all continuous non-normally distributed variables and n (%) for the categorical variables. All 
reported values are based on the unimputed data and due to missing values for some variables, the numbers 
may not add up to the total number of women in each sample. Percentages do not take into account the 
missing values and add up to 100%. 2 P-values of the differences in characteristics between ALSPAC 
women with a single urinary iodine measurement only and those with multiple urinary iodine measurements 
are from Independent Samples t-tests (for continuous normally distributed variables), Mann-Whitney U 
tests (for continuous non-normally distributed variables), or Chi-Square tests (for categorical variables). P-
values from Chi-Square tests based on 2x2 contingency tables were reported with Yates’ Continuity 
Correction. All statistical comparisons were performed on the unimputed data. 3 Maternal age at last 
menstrual period. 4 Other=widowed, divorced, or separated. Abbreviations: ALSPAC, Avon Longitudinal 
Study of Parents and Children; BMI, body mass index; SD, standard deviation  
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Supplemental Table 6. 2  Risk of suboptimum verbal, non-verbal and total IQ in children at 8 years (score < 85 points) according to maternal 
mean UI/Creat (<150 µg/g vs ≥150 µg/g) and UI/Creat status (based on two or three UI/Creat measurements), adjusted for potential confounders 
   Suboptimum Verbal IQ 
 
 Suboptimum Non-verbal IQ   Suboptimum Total IQ 
  n OR (95% CI) P 
 
 OR (95% CI) P   OR (95% CI) P 
             
Women with at least two iodine measurements (n=452) 
Mean UI/Creat groups             
    < 150 µg/g  211 1.46 (0.63, 3.34) 0.376   1.73 (1.04, 2.87) 0.034   1.88 (0.96, 3.70) 0.066 
    ≥ 150 µg/g   241 Ref.    Ref.    Ref.  
UI/Creat status             
    Insufficient   121 0.91 (0.23, 3.56) 0.890   2.73 (1.06, 7.04) 0.037   1.74 (0.56, 5.45) 0.340 
    Borderline insufficient  259 1.08 (0.33, 3.56) 0.895   2.40 (0.98, 5.84) 0.055   1.36 (0.47, 3.92) 0.574 
    Sufficient  72 Ref.    Ref.    Ref.  
             
Women with three iodine measurements (n=178) 
Mean UI/Creat groups             
    < 150 µg/g  82 16.60 (1.32, 209.57) 0.030   1.77 (0.72, 4.39) 0.215   2.43 (0.75, 7.94) 0.140 
    ≥ 150 µg/g   96 Ref.    Ref.    Ref.  
UI/Creat status 1   N/A    N/A    N/A  
Effect estimates (OR=odds ratios), their 95% CIs and P-values are from multiple logistic regression models performed for each outcome (i.e., the child IQ measures) and in 
each sample of women (those with at least two and those with three iodine measurements) with child verbal or non-verbal or total IQ [categorised into scores <85 IQ points 
(suboptimum) or ≥85 IQ points] as the dependent variable and mean UI/Creat groups or UI/Creat status as the independent variable. Models were adjusted for mean gestational 
week at urine sampling, maternal age (years), pre-pregnancy BMI (kg/m2), ethnicity, parity, smoking status, education level, family adversity index, marital status and child's 
sex. Reported OR are for child verbal, non-verbal or total IQ <85 points (i.e., suboptimum) when maternal mean UI/Creat <150 µg/g [vs mean UI/Creat ≥150 µg/g (reference 
group)] or maternal UI/Creat status = ’insufficient’ or ‘borderline insufficient’ [vs UI/Creat status = ‘sufficient’ (reference group)]. 1 For women with three iodine measurements 
(n=178), the models using UI/Creat status were not performed due to no/small number of women with children with suboptimum IQ scores (<85 points) in the reference ‘iodine 
sufficient’ group (i.e., n=1 for verbal IQ, n=0 for non-verbal IQ and n=0 for total IQ). Abbreviations: BMI, body mass index; 95% CI, confidence interval; IQ, intelligence 
quotient; N/A, data not available or not applicable; OR, odds ratio; Ref., reference group; UI/Creat, urinary iodine-to-creatinine ratio  
 220 
 
Supplemental Table 7.1  Excluded records after full-text review with reasons for 
exclusions 
Excluded records after 
full-text review 
(first author, year, 
country) 
Reasons for exclusion 
Exclusion 
code 
   
Glinoer, 1995, Belgium  The median UIC was 36 µg/L. Our initial cut-off for 
inclusion was a median UIC in the range of 50-149 µg/L 
(mild-to-moderate iodine deficiency). Although this 
study is often cited as one of the six trials in mild-to-
moderate deficiency and authors have labelled it as a 
study in a setting of mild iodine deficiency, the study was 
excluded as it was outside the pre-defined inclusion 
criteria for baseline UIC.  
Severe 
deficiency 
   
O'Donnell, 2002, China The baseline iodine status of the women was not reported. 
However, the study was conducted in an area of severe 
iodine deficiency in China (Xinjiang Province), therefore, 
it was not our population of interest. 
Severe 
deficiency 
   
Vila, 2008, Spain Only 10 women took iodine-containing supplements in 
the 1st trimester during this study. Only differences in 
UIC and UIC change (between the 1st & 3rd trimesters) 
were reported between supplement-users vs. non-users. 
Thyroid volume (TV) change was reported overall but not 
between supplemented vs. non-supplemented women. 
No 
outcomes 
of interest 
reported 
   
Kusić, 2012, Croatia Survey looking at the effect of iodised salt (IS) 
programme implementation; only reported UIC of 
pregnant women cross-sectionally (i.e., only current 
status at the time of the survey, not before and after IS 
implementation). UIC change before and after IS was 
only reported for school-aged children (SAC). TV was 
also only measured and reported for SAC. Croatia was 
iodine-sufficient at the time of survey, with median UIC 
in pregnant women 159 µg/L. Percentage of women who 
took KI supplements (20%) was reported but no 
differences in any parameters were reported between 
those who used supplements and those who did not. 
No 
outcomes 
of interest 
reported + 
iodine 
sufficiency 
   
Andersen, Nøhr et al., 2013, 
Denmark 
The mean UIC was 41 µg/L. Although the study was 
labelled as conducted 'in the context of mild-moderate 
deficiency', the baseline UIC was outside the pre-defined 
range for inclusion in the study (UIC range: 50-149 µg/L).  
Severe 
deficiency 
   
Andersen, Sørensen et al., 
2013, Denmark  
Only UIC differences between iodine-containing 
supplement users (84.1%) vs. non-users (15.9%) were 
reported. No thyroid function parameters were reported. 
No 
outcomes 
of interest 
reported 
   
Koukkou, 2014, Greece None of the participating women were taking iodine-
containing preparations. Only UIE differences between 
iodised salt users vs. non-users were reported. No other 
thyroid function indices were reported in relation to 
iodised salt use. 
No 
outcomes 
of interest 
(continued on next page) 
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Supplemental Table 7.1  Excluded records after full-text review with reasons for 
exclusions (continued) 
Excluded records after 
full-text review 
(first author, year, 
country) 
Reasons for exclusion 
Exclusion 
code 
   
Sukkhojaiwaratkul, 2014, 
Thailand 
Pregnant women were iodine sufficient at baseline 
(median UIC was 170.6 µg/L). Even after splitting into 
supplement users vs. non-users, both groups were iodine 
sufficient and had medians > 150 µg/L (196.5 vs. 161.1 
µg/L). 
Iodine 
sufficiency 
   
Anees, 2015, Pakistan The study was set in an area of endemic goitre. The 
median UIC of the study sample was not reported. 
Supplementation (iodised oil) was given to women with 
visible goitre, which suggests severe iodine deficiency. 
This study was also classed as one from an area of severe 
deficiency in a previous systematic review by Farebrother 
et al. in 2018 (ref).  
Endemic-
goitre area 
   
Kirkegaard-Klitbo, 2016, 
Denmark  
Only UIC differences between iodine-containing 
supplement users (82.9%) vs. non-users (17.1%) were 
reported. No thyroid function parameters were reported. 
No 
outcomes 
of interest 
reported 
Abbreviations: IS, iodised salt; KI, potassium iodide; Ref., reference; SAC, school-aged children; TV, 
thyroid volume; UIC, urinary iodine concentration; UIE, urinary iodine excretion 
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Supplemental Table 7.2 Summary of the support for risk of bias judgment of included 
randomised controlled trials and other intervention studies 
Study 
(first author, year) 
Support for risk of bias judgement - summary 
RCTs (n=9)  
Silva, 1981 Women were inadequately randomised ‘one of every four women was not treated’; 
allocation concealment mechanisms are not described but due to inadequate 
randomisation, even if done, concealment was probably inadequate; women in the 
intervention group were administered KI drops and those in the control group were 
not, therefore participants likely knew in which group they had been allocated; 
unclear whether personnel were blinded (likely not); unclear about blinding of 
outcome assessors but all outcomes were objective (laboratory measurements) 
(assume low risk of bias); analyses were based only on compliers with the protocol, 
validated by urinary iodine measurements (36 out of 160 complied with 
intervention and ‘similar proportion of controls was lost’); reasons for attrition 
were not reported; 
  
Romano, 1991 It is only stated that women were ‘randomly allotted to groups’ and there is no 
information about the randomisation procedure or allocation concealment; women 
in the intervention group were administered IS and those in the control group were 
not, therefore participants likely knew in which group they had been allocated; 
unclear whether personnel were blinded (likely not); TV assessors were blinded; 
there are no missing data on the outcomes;  
  
Pedersen, 1993 It is only stated that the study was ‘randomised’ but there is no information about 
the randomisation procedure or allocation concealment; women in the intervention 
group were administered KI drops and those in the control group were not, 
therefore participants were probably aware of their group allocation; unclear about 
blinding of personnel; TV was measured by blinded investigators; attrition and 
exclusions from the study are described before and after allocation, the reasons for 
attrition after allocation (e.g., relocation) and the final numbers in analyses are 
balanced between groups; 
  
Liesenkötter, 1996 Inadequate generation of random sequence - women were assigned to intervention 
based on days of the week when they presented in the study unit (i.e., 
Monday=intervention vs. Tuesday=control); allocation concealment mechanisms 
are not described but due to inadequate randomisation, even if done, concealment 
was probably inadequate; no information about blinding is provided; TV 
measurements were done by a blinded investigator; 
  
Nøhr, 2000 It is only stated that the study was ‘randomised’ but there is no information about 
the randomisation procedure or allocation concealment; the trial was double-blind 
and an identical placebo tablet (without iodine) was given to the control group; 
compliance was evaluated with 24-h UIE that showed higher values for the 
intervention group throughout; unclear whether outcome assessors were blinded; 
six women were censored from the study due to no or only one blood test available 
post-partum (in this excluded group there was a higher proportion of smokers vs. 
the included women) - unclear bias effect; half of the women (n=34) were taking 
iodine-containing supplement prior to start of intervention with no difference in 
distribution among the three study groups but when the two intervention groups 
were combined for some analyses, the proportion of prior-supplement-users is 
nearly double in the iodine group vs. control (23 vs. 11); only TPO-Ab+ women 
were selected for the study which limits generalisability but is not a source of bias; 
 
(continued on next page) 
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Supplemental Table 7.2  Summary of the support for risk of bias judgment of included 
randomised controlled trials and other intervention studies (continued) 
Study 
(first author, year) 
Support for risk of bias judgement - summary 
  
Brucker-Davis, 
2013 
Women were adequately randomised into two groups by ‘a method of drawing of 
lots by blocks, using tables of permutation’; there is no information about the 
allocation concealment; the study was open-label, although participants in the 
control group received a placebo tablet (multivitamin without iodine); compliance 
was assessed by hospital pharmacist; TV measurements were performed by two of 
the investigators who were likely not blinded as the trial was open; after attrition, 
there is a larger number of women in the control group as more women from the 
intervention group withdrew from the study (20 vs. 4); the reasons for withdrawal 
from the study are unbalanced between groups (intervention group: 4 miscarriages, 
10 cases with digestive intolerance, 3 cases withdrew consent, one induced 
abortion, 2 missed data collection vs. control group: 1 digestive intolerance and 3 
miscarriages); 
  
Brucker-Davis, 
2015 
Women were adequately randomised into two groups by ‘a method of drawing of 
lots by blocks, using tables of permutation’ (extracted from a previous publication 
by Brucker-Davis et al., 2013 in the same cohort); there is no information about the 
allocation concealment; the study was open-label, although participants in the 
control group received a placebo tablet (multivitamin without iodine) (extracted 
from Brucker-Davis et al., 2013); compliance was assessed by hospital pharmacist; 
neuropsychological assessment was performed by a blinded investigators but only 
one scale of the assessment tool was based on a parent-filled questionnaire (likely 
not blinded as study was open); there is imbalance in the attrition rate and reasons 
for withdrawal, as well as the final numbers for analyses between the study groups 
(for full attrition details see judgment summary for Brucker-Davis, 2013); only 44 
out of 86 children underwent cognitive assessment; reasons for withdrawal per 
study group were not reported; 
  
Zhou, 2015 Women were adequately  randomised ‘in a ratio 1:1 using a web-based 
randomisation service’; likely adequate allocation concealment ‘neither staff, nor 
women were aware of the group allocation’; the trial was started as double-blinded 
and placebo-controlled but it was aborted early due to withdrawal of funding 
support and the study was unblinded at a mean of 33 gestational weeks; unclear 
whether neurodevelopment outcome assessors were blinded; as the trial was 
unblinded early, some women in each group (5 in intervention vs. 18 in control 
group) discontinued the intervention and one woman in the control group started 
taking iodine supplements (likely introduced bias); primary analyses were based 
on the intention-to-treat principle using the initially randomised groups; 
  
Gowachirapant, 
2017 
Women were adequately randomised ‘by simple randomisation (1:1) stratified by 
site, using a computer-generated randomisation sequence’; allocation concealment 
was achieved by externally coding the iodine and placebo supplements and using 
sealed envelopes with the codes; the trial was double-blind and an identical placebo 
tablet (without iodine) was given to the control group; compliance was assessed by 
tablet counting; cognitive testing was done by a clinical psychologist (likely 
blinded, as the study was double-blinded); attrition and exclusion of participants 
for the main outcome are described by study group; the reasons for attrition after 
allocation and the final numbers in analyses are balanced between groups; 
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Supplemental Table 7.2  Summary of the support for risk of bias judgment of included 
randomised controlled trials and other intervention studies (continued) 
Study 
(first author, year) 
Support for risk of bias judgement – summary  
Other intervention studies (n=4) 
Antonangeli, 2002 It is only stated that the women were ‘randomly sub-divided into two groups’ but 
there is no information about the randomisation procedure; there is no description 
of allocation concealment procedure; the study was designed as an open-label trial, 
therefore participants and personnel knew the group allocations; unclear about 
blinding of outcome assessors but all outcomes were objective (laboratory 
measurements) (assume low risk of bias); reported that 7 women withdrew consent 
and 12 dropped out (8 of these had serious gestational events) but it is unclear 
whether these women dropped out before or after they were assigned to the 
intervention (‘67 women completed the study’) and if dropped out after allocation, 
the numbers per group were not reported (unclear risk of bias); there was no 
control/no-treatment group and women in the higher iodine dose group had higher 
baseline UI/Creat (91 vs. 66 µg/g) (assume high risk of other sources of bias);  
  
Berbel, 2009 There is no information about randomisation (all women were assigned the 
intervention at enrolment and study groups were based on gestational age at 
enrolment e.g., first pregnancy visit or at term) but the children of women were 
selected for neurocognitive evaluation based on different baseline maternal 
characteristics for each intervention group (e.g., children of euthyroid women in 
one group and of hypothyroxinaemic women in the other two groups); allocation 
concealment is not applicable, as all women were allocated to the same 
intervention; there is no information about blinding of participants and personnel 
but there were very strict selection criteria for outcome assessment in the different 
groups (i.e., investigators probably knew about the characteristics of women in the 
different groups) and all women were administered the intervention (assume high 
risk); some outcomes were objective (laboratory measurements) and for subjective 
outcomes, outcome assessors were blinded ‘child’s performance during 
neurobehavioral evaluations was carried out masked’ (assume low risk of bias); 
numbers and reasons for exclusion were reported in detail per group but the nature 
of the maternal exclusion criteria (i.e., maternal thyroid function) might introduce 
bias (i.e., child neurocognitive evaluation was done only for women in the group 
with the earliest administration of supplement who were euthyroid during 
pregnancy, while in the other two groups with later administration selected women 
were hypothyroxinaemic, thus, the effect of timing of iodine supplementation 
cannot be distinguished from that of maternal baseline FT4 concentrations); no 
control for confounders in the analyses but strict inclusion criteria was applied to 
obtain comparable groups after enrolment (unclear about the risk of bias); 
  
Velasco, 2009 All women recruited during pregnancy received the intervention (no 
randomisation); the control group was not permitted by ethics and was made up of 
women selected at term; there were some differences in the baseline characteristics 
of the mothers in the intervention and ‘control’ groups and in the age at assessment 
of child outcomes (i.e., neurodevelopment was assessed at an earlier age in the 
intervention group e.g., 5 vs. 12 months in the ‘controls’); allocation concealment 
is not applicable, as all women were allocated to the same intervention; … 
(continued) 
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Supplemental Table 7.2  Summary of the support for risk of bias judgment of included 
randomised controlled trials and other intervention studies (continued) 
Study 
(first author, year) 
Support for risk of bias judgement – summary  
  
Velasco, 2009 
(continued) 
the participants and personnel were not blinded as all women recruited during 
pregnancy (i.e., during the time of the intervention) were supplemented; some 
outcomes were objective (laboratory measurements) and for subjective outcomes 
(i.e., child neurodevelopment), outcome assessors were blinded ‘the psychological 
evaluation was performed by an independent researcher who was unaware of the 
design sequence of the study’ (assume low risk of bias); no information about 
exclusion criteria or attrition was provided;  
  
Santiago, 2013 Women were adequately randomised into groups ‘a sequence of random numbers 
was generated with appropriate software’; there is no information about the 
allocation concealment; no information about blinding is provided but all three 
groups were advised to use IS, two of which were also given KI tablets, thus 
participants might have been aware of their group allocation (likely performance 
bias); compliance with KI and IS intake was asked by phone; some outcomes were 
objective (laboratory measurements) and for subjective outcomes (i.e., child 
neurodevelopment), outcome assessors were blinded ‘the psychological 
assessment was done by an independent investigator blind to the type of the study 
design’ (assume low risk of bias); the reasons for attrition are not reported but 
women who did not complete the study had similar baseline characteristic to 
women who completed the study and were included in the analyses; reasons for 
attrition in terms of infant cognitive assessment are not reported; the study did not 
have a no-treatment control group (women who were recommended IS served as 
the control group) and 32% of women had used IS for at least 1 year prior to study; 
Abbreviations: 24-h UIE, 24-hour urinary iodine excretion (µg/24h); FT4, free thyroxine; IS, iodised salt; 
KI, potassium iodide; TPO-Ab+, positive for thyroid peroxidase antibody; TV, thyroid volume; UI/Creat, 
urinary iodine-to-creatinine ratio (µg/g) 
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Supplemental Table 7.3 Quality assessment of included prospective cohort studies and 
cross-sectional studies using the Newcastle-Ottawa scale 
Study 
(first author, year) 
Selection  
(max 4 stars) 
Comparability 
(max 2 stars) 
Outcome 
assessment 
(max 3 stars) 
Quality 
judgement 1 
Prospective cohort studies (n=8) 
Moleti, 2008 ★★★ ★ ★★ Good 
     
Moleti, 2011 ★★★ ★ ★★ Good 
     
Murcia, 2011 ★★★ ★★ ★★★ Good 
     
Rebagliato, 2013 ★★★ ★★ ★★★ Good 
     
Moleti, 2016 ★★★ ★★ ★★★ Good 
     
Murcia, 2017 ★★★ ★★ ★★ Good 
     
Abel, 2017 ★★★ ★★ ★★ Good 
     
Abel, 2017 ★★★ ★★ ★★½ Good 
     
Cross-sectional studies (n=10) 
Klett, 1999 ★  ★★ Poor 
     
Nøhr, 2000 ★★★ ★ ★★★ Good 
     
Fadeyev, 2003 ★★  ★★★ Poor 
     
Gietka-Czernel, 2010 ★  ★★ Poor 
     
Marco, 2010 ★  ★★ Poor 
     
Rebagliato, 2010 ★★★ ★★ ★★★ Good 
     
Menéndez Torre, 2014 ★★ ★ ★★ Fair 
     
Konrade, 2015 ★★ ★ ★★★ Fair 
     
Zygmunt, 2015 ★  ★★ Poor 
     
Katko, 2017 ★★ ★ ★★★ Fair 
1 Quality Grading: good quality = 3 or 4 stars in selection domain AND 1 or 2 stars in comparability 
domain AND 2 or 3 stars in outcome/exposure domain; fair quality = 2 stars in selection domain AND 1 
or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain; poor quality = 0 or 1 
star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain 
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Appendix II: Supplemental Methods 
Supplemental Methods 1  Abstract screening checklist 
Eligibility criteria  Decision to include 
(i) Does the study address the exposure of interest?  
- Any type, dosage and regimen of iodine 
supplementation during pregnancy 
 
Yes No 
Cannot 
determine 
(ii) Does the study address the population of interest? 
- Pregnant women living in an area of  
mild-to-moderate iodine deficiency  
(median UIC in the range 50-149 μg/L) 1 
 
Yes No 
Cannot 
determine 
(iii) Does the study address any of the outcomes of 
interest? 
- Maternal thyroid function 
- Infant/child thyroid function 
- Child neurodevelopment 
 
Yes No 
Cannot 
determine 
(iv) Does the study have any of the following designs?  
- Observational study 
- Non-randomised/uncontrolled intervention  
- Randomised controlled trial (RCT) 
 
Yes No 
Cannot 
determine 
Exclude studies if:     
- In iodine-sufficient (UIC ≥ 150 μg/L) 2 or severely iodine-deficient  
  (UIC < 50 μg/L; endemic goitre) 1 populations 
- Address supplementation in infants  
- In languages other than English 
- Unpublished  
- Non-peer reviewed (e.g., meeting abstracts, letters) 
- Case-reports 
- Narrative reviews or comment articles 
- Other systematic reviews and/or meta-analyses 
1 Definitions taken/derived from Zimmermann, M. B. (2007) ‘The Adverse Effects of Mild-to-Moderate 
Iodine Deficiency during Pregnancy and Childhood: A Review’, Thyroid, 17(9), pp. 829–835. doi: 
10.1089/thy.2007.0108. 2 Definition taken from WHO (2007) Assessment of iodine deficiency disorders 
and monitoring their elimination. A guide for programme managers. Geneva. Available at: 
http://apps.who.int/iris/bitstream/10665/43781/1/9789241595827_eng.pdf. Abbreviations: RCT, 
randomised controlled trial; UIC, urinary iodine concentration; WHO, World Health Organisation 
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Supplemental Methods 2  Search terms for PubMed  
 
Search code: ((((((((((((((iodine OR iodide OR iodate OR iodis* OR iodiz*))) AND 
((supplement* OR prophylaxis OR treat*)))) AND ((pregnant OR pregnancy)))) AND 
((neurodevelop* OR cognit* OR develop* OR thyroid OR behaviour OR education* OR 
ADHD OR hearing OR brain)))) AND ((deficient OR deficiency)))) AND ((thyroid OR 
thyroid function OR thyroid hormone OR thyroid size)))) AND Humans[Mesh] AND 
English[lang]) 
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Appendix III: Publications and submitted papers 
This section is not included in the electronic version of the thesis. Published papers can be found 
online using the references provided in the list of publications section. 
